{
  "total_files": 32,
  "missing_proposed_files": 0,
  "missing_proposed_pmcids": [],
  "overall_mean_score": 0.24446830303846084,
  "overall_min_score": 0.0062245107073532905,
  "overall_max_score": 0.47532008253743774,
  "individual_results": [
    {
      "pmid": "37332933",
      "pmcid": "PMC10275785",
      "title": "Effect of NLRP3 inflammasome genes polymorphism on disease susceptibility and response to TNF-\u03b1 inhibitors in Iraqi patients with rheumatoid arthritis",
      "benchmarks": {
        "drug_annotations": {
          "total_samples": 2,
          "field_scores": {
            "Variant/Haplotypes": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Gene": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "PMID": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Phenotype Category": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Significance": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Alleles": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Specialty Population": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Metabolizer types": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "isPlural": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Is/Is Not associated": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Direction of effect": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "PD/PK terms": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Multiple drugs And/or": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Population types": {
              "mean_score": 0.8987551331520081,
              "scores": [
                0.8987551331520081,
                0.8987551331520081
              ]
            },
            "Population Phenotypes or diseases": {
              "mean_score": 0.9299848079681396,
              "scores": [
                0.9299848079681396,
                0.9299848079681396
              ]
            },
            "Multiple phenotypes or diseases And/or": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Comparison Allele(s) or Genotype(s)": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Comparison Metabolizer types": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Drug(s)": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            }
          },
          "overall_score": 0.8857231547957972,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "PMID": 0.0,
                "Phenotype Category": 1.0,
                "Significance": 1.0,
                "Alleles": 1.0,
                "Specialty Population": 1.0,
                "Metabolizer types": 1.0,
                "isPlural": 1.0,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "PD/PK terms": 1.0,
                "Multiple drugs And/or": 1.0,
                "Population types": 0.8987551331520081,
                "Population Phenotypes or diseases": 0.9299848079681396,
                "Multiple phenotypes or diseases And/or": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.0,
                "Comparison Metabolizer types": 1.0,
                "Drug(s)": 1.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "rs2043211",
                  "prediction": "rs2043211"
                },
                "Gene": {
                  "ground_truth": "CARD8",
                  "prediction": "CARD8"
                },
                "PMID": {
                  "ground_truth": 37332933,
                  "prediction": null
                },
                "Phenotype Category": {
                  "ground_truth": "Efficacy",
                  "prediction": "efficacy"
                },
                "Significance": {
                  "ground_truth": "yes",
                  "prediction": "yes"
                },
                "Alleles": {
                  "ground_truth": "TT",
                  "prediction": "TT"
                },
                "Specialty Population": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Metabolizer types": {
                  "ground_truth": null,
                  "prediction": null
                },
                "isPlural": {
                  "ground_truth": "Is",
                  "prediction": "Is"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "decreased",
                  "prediction": "decreased"
                },
                "PD/PK terms": {
                  "ground_truth": "response to",
                  "prediction": "response to"
                },
                "Multiple drugs And/or": {
                  "ground_truth": "or",
                  "prediction": "or"
                },
                "Population types": {
                  "ground_truth": "in people with",
                  "prediction": "in patients with"
                },
                "Population Phenotypes or diseases": {
                  "ground_truth": "Other:Rheumatoid arthritis",
                  "prediction": "Disease:Rheumatoid Arthritis"
                },
                "Multiple phenotypes or diseases And/or": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "AA + AT",
                  "prediction": null
                },
                "Comparison Metabolizer types": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Drug(s)": {
                  "ground_truth": "etanercept, infliximab",
                  "prediction": "Etanercept, Infliximab"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "PMID": 0.0,
                "Phenotype Category": 1.0,
                "Significance": 1.0,
                "Alleles": 1.0,
                "Specialty Population": 1.0,
                "Metabolizer types": 1.0,
                "isPlural": 1.0,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "PD/PK terms": 1.0,
                "Multiple drugs And/or": 1.0,
                "Population types": 0.8987551331520081,
                "Population Phenotypes or diseases": 0.9299848079681396,
                "Multiple phenotypes or diseases And/or": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.0,
                "Comparison Metabolizer types": 1.0,
                "Drug(s)": 1.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "rs4612666",
                  "prediction": "rs4612666"
                },
                "Gene": {
                  "ground_truth": "NLRP3",
                  "prediction": "NLRP3"
                },
                "PMID": {
                  "ground_truth": 37332933,
                  "prediction": null
                },
                "Phenotype Category": {
                  "ground_truth": "Efficacy",
                  "prediction": "efficacy"
                },
                "Significance": {
                  "ground_truth": "yes",
                  "prediction": "yes"
                },
                "Alleles": {
                  "ground_truth": "TT",
                  "prediction": "TT"
                },
                "Specialty Population": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Metabolizer types": {
                  "ground_truth": null,
                  "prediction": null
                },
                "isPlural": {
                  "ground_truth": "Is",
                  "prediction": "Is"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "decreased",
                  "prediction": "decreased"
                },
                "PD/PK terms": {
                  "ground_truth": "response to",
                  "prediction": "response to"
                },
                "Multiple drugs And/or": {
                  "ground_truth": "or",
                  "prediction": "or"
                },
                "Population types": {
                  "ground_truth": "in people with",
                  "prediction": "in patients with"
                },
                "Population Phenotypes or diseases": {
                  "ground_truth": "Other:Rheumatoid arthritis",
                  "prediction": "Disease:Rheumatoid Arthritis"
                },
                "Multiple phenotypes or diseases And/or": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "CC + CT",
                  "prediction": null
                },
                "Comparison Metabolizer types": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Drug(s)": {
                  "ground_truth": "etanercept, infliximab",
                  "prediction": "Etanercept, Infliximab"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            }
          ],
          "aligned_variants": [
            "rs2043211",
            "rs4612666"
          ],
          "unmatched_ground_truth": [],
          "unmatched_predictions": []
        },
        "phenotype_annotations": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": []
        },
        "functional_analysis": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "status": "missing_var_fa_ann"
        },
        "study_parameters": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "unmatched_ground_truth": [
            {
              "Study Parameters ID": 1452143368,
              "Variant Annotation ID": 1452143360,
              "Study Type": null,
              "Study Cases": 66.0,
              "Study Controls": 33.0,
              "Characteristics": "Cases = responders, controls = non-responders",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": 0.265,
              "Allele Of Frequency In Cases": "T",
              "Frequency In Controls": 0.647,
              "Allele Of Frequency In Controls": "T",
              "P Value": "< 0.0001",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.183,
              "Confidence Interval Start": 0.063,
              "Confidence Interval Stop": 0.531,
              "Biogeographical Groups": "Near Eastern",
              "Variant Annotation ID_norm": "1452143360"
            },
            {
              "Study Parameters ID": 1452143420,
              "Variant Annotation ID": 1452143400,
              "Study Type": null,
              "Study Cases": 66.0,
              "Study Controls": 33.0,
              "Characteristics": "Cases = responders, controls = non-responders",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": 0.197,
              "Allele Of Frequency In Cases": "T",
              "Frequency In Controls": 0.559,
              "Allele Of Frequency In Controls": "T",
              "P Value": "< 0.0001",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.131,
              "Confidence Interval Start": 0.047,
              "Confidence Interval Stop": 0.36,
              "Biogeographical Groups": "Near Eastern",
              "Variant Annotation ID_norm": "1452143400"
            }
          ],
          "unmatched_predictions": [
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 100.0,
              "Study Controls": 100.0,
              "Characteristics": "Rheumatoid arthritis patients (88 females, 12 males)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "< 0.0001",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Unknown",
              "Variant Annotation ID_norm": null
            },
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 100.0,
              "Study Controls": 100.0,
              "Characteristics": "Patients with CARD8 (rs2043211) TT genotype",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "< 0.0001",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Unknown",
              "Variant Annotation ID_norm": null
            },
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 100.0,
              "Study Controls": 100.0,
              "Characteristics": "Patients with NLRP3 (rs4612666) TT genotype",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "< 0.0001",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Unknown",
              "Variant Annotation ID_norm": null
            },
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 100.0,
              "Study Controls": 100.0,
              "Characteristics": "Elevated TNF-\u03b1 and IL-1\u03b2 serum levels in non-responders",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": 7.84,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": 6.09,
              "Allele Of Frequency In Controls": null,
              "P Value": "0.0005",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Unknown",
              "Variant Annotation ID_norm": null
            },
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 100.0,
              "Study Controls": 100.0,
              "Characteristics": "Patients classified into responders and non-responders based on EULAR criteria",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "< 0.0001",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Unknown",
              "Variant Annotation ID_norm": null
            }
          ]
        }
      },
      "overall_score": 0.26571694643873917,
      "num_benchmarks": 4
    },
    {
      "pmid": "37490620",
      "pmcid": "PMC10399933",
      "title": "Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2, and CYP2C9 variants",
      "benchmarks": {
        "drug_annotations": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Variant/Haplotypes": "c.521C/C",
              "Gene": "SLCO1B1",
              "Drug(s)": "simvastatin",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Hazard ratio (HR) 1.88, 95% CI 1.08-3.25, P = 0.025, associated with simvastatin intolerance.",
              "Sentence": "Genotype c.521C/C is associated with increased toxicity simvastatin in the general adult population.",
              "Alleles": "C/C",
              "Metabolizer types": null,
              "Comparison Allele(s) or Genotype(s)": "T/T",
              "Comparison Metabolizer types": null,
              "Specialty Population": null,
              "Population types": "general adult population",
              "Population Phenotypes or diseases": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "toxicity",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "We confirmed the association of SLCO1B1 c.521C/C genotype with simvastatin intolerance... [hazard ratio (HR) 1.88, 95% confidence interval (CI) 1.08-3.25, P = 0.025]...",
                "The intolerance phenotype derived from statin switching alone or combined with CK measurement appears to be suitable to evaluate statin intolerance.",
                "We included only statin switching in our phenotype, since in our preliminary analyses with simvastatin-*SLCO1B1* statin switching rather than statin discontinuation or statin dose reduction, best-represented statin intolerance."
              ]
            },
            {
              "Variant/Haplotypes": "c.521T>C",
              "Gene": "SLCO1B1",
              "Drug(s)": "pravastatin",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Hazard ratio (HR) 2.11, 95% CI 1.01-4.39, P = 0.047, associated with pravastatin intolerance.",
              "Sentence": "Genotype c.521T>C is associated with increased toxicity pravastatin in the general adult population.",
              "Alleles": "T/C, C/C",
              "Metabolizer types": null,
              "Comparison Allele(s) or Genotype(s)": "T/T",
              "Comparison Metabolizer types": null,
              "Specialty Population": null,
              "Population types": "general adult population",
              "Population Phenotypes or diseases": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "toxicity",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "SLCO1B1 c.521T>C carriers had an increased risk of pravastatin intolerance defined by statin switching when compared to homozygous reference T/T genotype (HR 2.11, 95% CI 1.01-4.39, P = 0.047).",
                "In addition to simvastatin, we observed that heterozygous or homozygous *SLCO1B1* c.521T>C carriers had a higher risk of pravastatin intolerance based on statin switching phenotype when compared to reference allele homozygotes."
              ]
            },
            {
              "Variant/Haplotypes": "c.521T>C",
              "Gene": "SLCO1B1",
              "Drug(s)": "simvastatin",
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "No significant association observed with atorvastatin-induced toxicity.",
              "Sentence": "Genotype c.521T>C is not associated with toxicity simvastatin in the general adult population.",
              "Alleles": "T/C, C/C",
              "Metabolizer types": null,
              "Comparison Allele(s) or Genotype(s)": "T/T",
              "Comparison Metabolizer types": null,
              "Specialty Population": null,
              "Population types": "general adult population",
              "Population Phenotypes or diseases": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "toxicity",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "We confirmed the association of SLCO1B1 c.521C/C genotype with simvastatin intolerance both by using phenotype of switching initial statin to another as a marker of statin intolerance [hazard ratio (HR) 1.88, 95% confidence interval (CI) 1.08-3.25, P = 0.025]",
                "Neither the SLCO1B1 or ABCG2 genotypes nor atorvastatin dose were associated with the statin intolerance phenotypes",
                "Moreover, we observed that heterozygous or homozygous SLCO1B1 c.521T>C carriers had a higher risk of pravastatin intolerance based on statin switching phenotype when compared to reference allele homozygotes."
              ]
            },
            {
              "Variant/Haplotypes": "rs2231142",
              "Gene": "ABCG2",
              "Drug(s)": "rosuvastatin",
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "No significant association for ABCG2 on rosuvastatin-induced toxicity was found.",
              "Sentence": "Variant rs2231142 is not associated with toxicity rosuvastatin in the general adult population.",
              "Alleles": "C/A, C/C",
              "Metabolizer types": null,
              "Comparison Allele(s) or Genotype(s)": "C/C",
              "Comparison Metabolizer types": null,
              "Specialty Population": null,
              "Population types": "general adult population",
              "Population Phenotypes or diseases": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "toxicity",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "No significant association was observed with atorvastatin and rosuvastatin.",
                "The findings are in line with the JUPITER trial in which the *SLCO1B1* genotype was not associated with clinically reported myalgia in a clinical trial setting with rosuvastatin dose of 20 mg.",
                "We observed no statistically significant increase in statin intolerance risk for atorvastatin, fluvastatin or rosuvastatin with the studied genotypes."
              ]
            },
            {
              "Variant/Haplotypes": "rs1057910",
              "Gene": "CYP2C9",
              "Drug(s)": "fluvastatin",
              "Phenotype Category": "toxicity",
              "Significance": "not stated",
              "Notes": "No statistically significant association was observed for fluvastatin.",
              "Sentence": "Variants rs1057910 and rs1799853 are not associated with toxicity fluvastatin in the general adult population.",
              "Alleles": "C/T, T/T",
              "Metabolizer types": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "Specialty Population": null,
              "Population types": "general adult population",
              "Population Phenotypes or diseases": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "toxicity",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "No statistically significant association was found for fluvastatin.",
                "We observed no statistically significant increase in statin intolerance risk for atorvastatin, fluvastatin or rosuvastatin with the studied genotypes.",
                "For fluvastatin, there was a trend towards increased risk of statin intolerance with a point estimate of HR at 1.88 in carriers of 2-4 risk alleles, but perhaps due to low sample size, the finding was not statistically significant."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "rs1799853",
              "Gene": "CYP2C9",
              "Drug(s)": "fluvastatin",
              "Phenotype Category": "toxicity",
              "Significance": "not stated",
              "Notes": "No statistically significant association was observed for fluvastatin.",
              "Sentence": "Variants rs1057910 and rs1799853 are not associated with toxicity fluvastatin in the general adult population.",
              "Alleles": "C/T, T/T",
              "Metabolizer types": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "Specialty Population": null,
              "Population types": "general adult population",
              "Population Phenotypes or diseases": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "toxicity",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "No statistically significant association was found for fluvastatin.",
                "We observed no statistically significant increase in statin intolerance risk for atorvastatin, fluvastatin or rosuvastatin with the studied genotypes.",
                "For fluvastatin, there was a trend towards increased risk of statin intolerance with a point estimate of HR at 1.88 in carriers of 2-4 risk alleles, but perhaps due to low sample size, the finding was not statistically significant."
              ],
              "_expanded_from_multi_variant": true
            }
          ]
        },
        "phenotype_annotations": {
          "total_samples": 7,
          "field_scores": {
            "Variant/Haplotypes": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Gene": {
              "mean_score": 0.2857142857142857,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Drug(s)": {
              "mean_score": 0.2857142857142857,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Phenotype Category": {
              "mean_score": 0.2857142857142857,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Alleles": {
              "mean_score": 0.2529339279447283,
              "scores": [
                0.9050132036209106,
                0.8655242919921875,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Is/Is Not associated": {
              "mean_score": 0.2857142857142857,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Direction of effect": {
              "mean_score": 0.2857142857142857,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Phenotype": {
              "mean_score": 0.24281954765319824,
              "scores": [
                0.8498684167861938,
                0.8498684167861938,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "When treated with/exposed to/when assayed with": {
              "mean_score": 0.2857142857142857,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Comparison Allele(s) or Genotype(s)": {
              "mean_score": 0.2469649314880371,
              "scores": [
                0.8643772602081299,
                0.8643772602081299,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.24742898132119853,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Variant/Haplotypes": 0.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 1.0,
                "Alleles": 0.9050132036209106,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.8498684167861938,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.8643772602081299
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "rs4149056",
                  "prediction": "SLCO1B1"
                },
                "Gene": {
                  "ground_truth": "SLCO1B1",
                  "prediction": "SLCO1B1"
                },
                "Drug(s)": {
                  "ground_truth": "simvastatin",
                  "prediction": "simvastatin"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "CC",
                  "prediction": "C/C"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:Discontinuation",
                  "prediction": "statin intolerance"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "TT",
                  "prediction": "SLCO1B1 c.521T/T"
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Variant/Haplotypes": 0.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 1.0,
                "Alleles": 0.8655242919921875,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.8498684167861938,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.8643772602081299
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "rs4149056",
                  "prediction": "SLCO1B1"
                },
                "Gene": {
                  "ground_truth": "SLCO1B1",
                  "prediction": "SLCO1B1"
                },
                "Drug(s)": {
                  "ground_truth": "pravastatin",
                  "prediction": "pravastatin"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "CC + CT",
                  "prediction": "C/T"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:Discontinuation",
                  "prediction": "statin intolerance"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "TT",
                  "prediction": "SLCO1B1 c.521T/T"
                }
              },
              "dependency_issues": []
            }
          ],
          "aligned_variants": [
            "slco1b1+simvastatin",
            "slco1b1+pravastatin"
          ],
          "unmatched_ground_truth": [
            {
              "Variant Annotation ID": 1452196120,
              "Variant/Haplotypes": "CYP2C9*1",
              "Gene": "CYP2C9",
              "Drug(s)": "fluvastatin",
              "PMID": 37490620,
              "Phenotype Category": "Toxicity",
              "Significance": "no",
              "Notes": "effect is described as \"Statin switch\" as measured by changes in prescription refills in the medical record, and attributed to muscle side effects (therefore tagged as toxicity). \"The sample sizes for fluvastatin and pravastatin were relatively small\"\"No statistically significant association was found for fluvastatin",
              "Sentence": "CYP2C9 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) is not associated with increased risk of discontinuation when treated with fluvastatin as compared to CYP2C9 *1/*1 + *1/*2 + *1/*3 (assigned as intermediate metabolizer and normal metabolizer phenotype) .",
              "Alleles": "*2/*2 + *2/*3 + *3/*3",
              "Specialty Population": null,
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Discontinuation",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": null,
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1 + *1/*2 + *1/*3",
              "Comparison Metabolizer types": "normal metabolizer and intermediate metabolizer",
              "PMID_norm": "37490620",
              "Variant Annotation ID_norm": "1452196120",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1452196120,
              "Variant/Haplotypes": "CYP2C9*2",
              "Gene": "CYP2C9",
              "Drug(s)": "fluvastatin",
              "PMID": 37490620,
              "Phenotype Category": "Toxicity",
              "Significance": "no",
              "Notes": "effect is described as \"Statin switch\" as measured by changes in prescription refills in the medical record, and attributed to muscle side effects (therefore tagged as toxicity). \"The sample sizes for fluvastatin and pravastatin were relatively small\"\"No statistically significant association was found for fluvastatin",
              "Sentence": "CYP2C9 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) is not associated with increased risk of discontinuation when treated with fluvastatin as compared to CYP2C9 *1/*1 + *1/*2 + *1/*3 (assigned as intermediate metabolizer and normal metabolizer phenotype) .",
              "Alleles": "*2/*2 + *2/*3 + *3/*3",
              "Specialty Population": null,
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Discontinuation",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": null,
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1 + *1/*2 + *1/*3",
              "Comparison Metabolizer types": "normal metabolizer and intermediate metabolizer",
              "PMID_norm": "37490620",
              "Variant Annotation ID_norm": "1452196120",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1452196120,
              "Variant/Haplotypes": "CYP2C9*3",
              "Gene": "CYP2C9",
              "Drug(s)": "fluvastatin",
              "PMID": 37490620,
              "Phenotype Category": "Toxicity",
              "Significance": "no",
              "Notes": "effect is described as \"Statin switch\" as measured by changes in prescription refills in the medical record, and attributed to muscle side effects (therefore tagged as toxicity). \"The sample sizes for fluvastatin and pravastatin were relatively small\"\"No statistically significant association was found for fluvastatin",
              "Sentence": "CYP2C9 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) is not associated with increased risk of discontinuation when treated with fluvastatin as compared to CYP2C9 *1/*1 + *1/*2 + *1/*3 (assigned as intermediate metabolizer and normal metabolizer phenotype) .",
              "Alleles": "*2/*2 + *2/*3 + *3/*3",
              "Specialty Population": null,
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Discontinuation",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": null,
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1 + *1/*2 + *1/*3",
              "Comparison Metabolizer types": "normal metabolizer and intermediate metabolizer",
              "PMID_norm": "37490620",
              "Variant Annotation ID_norm": "1452196120",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1452196040,
              "Variant/Haplotypes": "rs4149056",
              "Gene": "SLCO1B1",
              "Drug(s)": "atorvastatin, fluvastatin, rosuvastatin",
              "PMID": 37490620,
              "Phenotype Category": "Toxicity",
              "Significance": "no",
              "Notes": "effect is described as \"Statin switch\" as measured by changes in prescription refills in the medical record, and attributed to muscle side effects (therefore tagged as toxicity). \"No significant association was observed with atorvastatin and rosuvastatin.\" \"The sample sizes for fluvastatin and pravastatin were relatively small\"\"No statistically significant association was found for fluvastatin",
              "Sentence": "Genotypes CC + CT is not associated with increased risk of discontinuation when treated with atorvastatin, fluvastatin or rosuvastatin as compared to genotype TT.",
              "Alleles": "CC + CT",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Discontinuation",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": "or",
              "Population types": null,
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "TT",
              "Comparison Metabolizer types": null,
              "PMID_norm": "37490620",
              "Variant Annotation ID_norm": "1452196040"
            },
            {
              "Variant Annotation ID": 1452196080,
              "Variant/Haplotypes": "rs2231142",
              "Gene": "ABCG2",
              "Drug(s)": "atorvastatin, fluvastatin, rosuvastatin",
              "PMID": 37490620,
              "Phenotype Category": "Toxicity",
              "Significance": "no",
              "Notes": "effect is described as \"Statin switch\" as measured by changes in prescription refills in the medical record, and attributed to muscle side effects (therefore tagged as toxicity). \"No significant association was observed with atorvastatin and rosuvastatin.\" \"The sample sizes for fluvastatin and pravastatin were relatively small\"\"No statistically significant association was found for fluvastatin\" Alleles complemented to plus chromosomal strand.",
              "Sentence": "Genotypes GT + TT is not associated with increased risk of discontinuation when treated with atorvastatin, fluvastatin or rosuvastatin as compared to genotype GG.",
              "Alleles": "GT + TT",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Discontinuation",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": "or",
              "Population types": null,
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "GG",
              "Comparison Metabolizer types": null,
              "PMID_norm": "37490620",
              "Variant Annotation ID_norm": "1452196080"
            }
          ],
          "unmatched_predictions": [
            {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "c.521C/C",
              "Gene": "SLCO1B1",
              "Drug(s)": "simvastatin",
              "PMID": 37490620,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Hazard ratio (HR) 1.88, 95% CI 1.08-3.25, P = 0.025 for statin switching as marker of intolerance",
              "Sentence": "SLCO1B1 c.521C/C is associated with increased risk of statin intolerance when treated with simvastatin in patients initiating therapy.",
              "Alleles": "C/C",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": null,
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "statin intolerance",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": null,
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "SLCO1B1 c.521T/T",
              "Comparison Metabolizer types": null,
              "PMID_norm": 37490620,
              "Variant Annotation ID_norm": "1",
              "Citations": [
                "We confirmed the association of SLCO1B1 c.521C/C genotype with simvastatin intolerance both by using phenotype of switching initial statin to another as a marker of statin intolerance [hazard ratio (HR) 1.88, 95% confidence interval (CI) 1.08-3.25, P = 0.025] and statin switching along with creatine kinase measurement (HR 5.44, 95% CI 1.49-19.9, P = 0.011).",
                "In the Cox proportional hazards model accounting for the statin dose, SLCO1B1 c.521C/C genotype was associated with an increased risk of simvastatin intolerance when compared to homozygous reference T/T genotype using both statin switcher [hazard ratio (HR) 1.88, 95% confidence interval (CI) 1.08-3.25, P = 0.025] and statin switcher with CK measurement (HR 5.44, 95% CI 1.49-19.9, P = 0.011) phenotypes.",
                "The current study has several clinical implications. First, it corroborates the well-characterized association of SLCO1B1 genotype with simvastatin intolerance in a real-world setting."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "c.521T>C",
              "Gene": "SLCO1B1",
              "Drug(s)": "pravastatin",
              "PMID": 37490620,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "HR 2.11, 95% CI 1.01-4.39, P = 0.047 for increased risk of pravastatin intolerance when compared to wild-type genotype",
              "Sentence": "SLCO1B1 c.521T>C is associated with increased risk of statin intolerance when treated with pravastatin in patients initiating therapy.",
              "Alleles": "C/T",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": null,
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "statin intolerance",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": null,
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "SLCO1B1 c.521T/T",
              "Comparison Metabolizer types": null,
              "PMID_norm": 37490620,
              "Variant Annotation ID_norm": "2",
              "Citations": [
                "SLCO1B1 c.521T>C carriers had an increased risk of pravastatin intolerance defined by statin switching when compared to homozygous reference T/T genotype (HR 2.11, 95% CI 1.01-4.39, P = 0.047).",
                "In addition to simvastatin, we observed that heterozygous or homozygous SLCO1B1 c.521T>C carriers had a higher risk of pravastatin intolerance based on statin switching phenotype when compared to reference allele homozygotes."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "ABCG2",
              "Gene": "ABCG2",
              "Drug(s)": "none",
              "PMID": 37490620,
              "Phenotype Category": "other",
              "Significance": "not stated",
              "Notes": "No significant association observed between ABCG2 and atorvastatin tolerance.",
              "Sentence": "ABCG2 c.421C>A is not associated with statin intolerance in patients initiating therapy with atorvastatin.",
              "Alleles": "C/A",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": null,
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "statin intolerance",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": null,
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "ABCG2 c.421C/C",
              "Comparison Metabolizer types": null,
              "PMID_norm": 37490620,
              "Variant Annotation ID_norm": "3",
              "Citations": [
                "Neither the SLCO1B1 or ABCG2 genotypes nor atorvastatin dose were associated with the statin intolerance phenotypes.",
                "No significant association was observed with atorvastatin and rosuvastatin.",
                "We observed no statistically significant increase in statin intolerance risk for atorvastatin, fluvastatin or rosuvastatin with the studied genotypes."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "c.421C>A",
              "Gene": "ABCG2",
              "Drug(s)": "none",
              "PMID": 37490620,
              "Phenotype Category": "other",
              "Significance": "not stated",
              "Notes": "No significant association observed between ABCG2 and atorvastatin tolerance.",
              "Sentence": "ABCG2 c.421C>A is not associated with statin intolerance in patients initiating therapy with atorvastatin.",
              "Alleles": "C/A",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": null,
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "statin intolerance",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": null,
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "ABCG2 c.421C/C",
              "Comparison Metabolizer types": null,
              "PMID_norm": 37490620,
              "Variant Annotation ID_norm": "3",
              "Citations": [
                "Neither the SLCO1B1 or ABCG2 genotypes nor atorvastatin dose were associated with the statin intolerance phenotypes.",
                "No significant association was observed with atorvastatin and rosuvastatin.",
                "We observed no statistically significant increase in statin intolerance risk for atorvastatin, fluvastatin or rosuvastatin with the studied genotypes."
              ],
              "_expanded_from_multi_variant": true
            }
          ]
        },
        "functional_analysis": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "status": "missing_var_fa_ann"
        },
        "study_parameters": {
          "total_samples": 10,
          "field_scores": {
            "Study Type": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Study Cases": {
              "mean_score": 0.1,
              "scores": [
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Study Controls": {
              "mean_score": 0.3,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Characteristics": {
              "mean_score": 0.27143682837486266,
              "scores": [
                0.916503369808197,
                0.9142157435417175,
                0.8836491703987122,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Characteristics Type": {
              "mean_score": 0.3,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Frequency In Cases": {
              "mean_score": 0.3,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Allele Of Frequency In Cases": {
              "mean_score": 0.3,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Frequency In Controls": {
              "mean_score": 0.3,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Allele Of Frequency In Controls": {
              "mean_score": 0.3,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "P Value": {
              "mean_score": 0.3,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Ratio Stat Type": {
              "mean_score": 0.3,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Ratio Stat": {
              "mean_score": 0.3,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Confidence Interval Start": {
              "mean_score": 0.3,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Confidence Interval Stop": {
              "mean_score": 0.3,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Biogeographical Groups": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.24476245522499082,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.916503369808197,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 1.0,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1452195960,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1452195947,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": null,
                  "prediction": "cohort"
                },
                "Study Cases": {
                  "ground_truth": 92.0,
                  "prediction": 92
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "Statin switch",
                  "prediction": "Pravastatin intolerance defined by statin switching"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.047",
                  "prediction": "= 0.047"
                },
                "Ratio Stat Type": {
                  "ground_truth": "HR",
                  "prediction": "HR"
                },
                "Ratio Stat": {
                  "ground_truth": 2.11,
                  "prediction": 2.11
                },
                "Confidence Interval Start": {
                  "ground_truth": 1.01,
                  "prediction": 1.01
                },
                "Confidence Interval Stop": {
                  "ground_truth": 4.39,
                  "prediction": 4.39
                },
                "Biogeographical Groups": {
                  "ground_truth": "European",
                  "prediction": "Unknown"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 0.0,
                "Study Controls": 1.0,
                "Characteristics": 0.9142157435417175,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 1.0,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1452195946,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1452195940,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": null,
                  "prediction": "cohort"
                },
                "Study Cases": {
                  "ground_truth": 916.0,
                  "prediction": 2042
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "Statin switch",
                  "prediction": "Statin switchers with CK measurement for simvastatin"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.011",
                  "prediction": "= 0.011"
                },
                "Ratio Stat Type": {
                  "ground_truth": "HR",
                  "prediction": "HR"
                },
                "Ratio Stat": {
                  "ground_truth": 5.44,
                  "prediction": 5.44
                },
                "Confidence Interval Start": {
                  "ground_truth": 1.49,
                  "prediction": 1.49
                },
                "Confidence Interval Stop": {
                  "ground_truth": 19.9,
                  "prediction": 19.9
                },
                "Biogeographical Groups": {
                  "ground_truth": "European",
                  "prediction": "Unknown"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 2,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 0.0,
                "Study Controls": 1.0,
                "Characteristics": 0.8836491703987122,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 1.0,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1452195945,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1452195940,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": null,
                  "prediction": "cohort"
                },
                "Study Cases": {
                  "ground_truth": 916.0,
                  "prediction": 2042
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "Statin switch",
                  "prediction": "Patients initiating statin therapy; including simvastatin users, heterozygous or homozygous SLCO1B1 c.521T>C carriers, and pravastatin users"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.025",
                  "prediction": "= 0.025"
                },
                "Ratio Stat Type": {
                  "ground_truth": "HR",
                  "prediction": "HR"
                },
                "Ratio Stat": {
                  "ground_truth": 1.88,
                  "prediction": 1.88
                },
                "Confidence Interval Start": {
                  "ground_truth": 1.08,
                  "prediction": 1.08
                },
                "Confidence Interval Stop": {
                  "ground_truth": 3.25,
                  "prediction": 3.25
                },
                "Biogeographical Groups": {
                  "ground_truth": "European",
                  "prediction": "Unknown"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            }
          ],
          "aligned_variants": [
            "None:Statin switch",
            "None:Statin switch",
            "None:Statin switch"
          ],
          "unmatched_ground_truth": [
            {
              "Study Parameters ID": 1452196130,
              "Variant Annotation ID": 1452196120,
              "Study Type": null,
              "Study Cases": 70.0,
              "Study Controls": null,
              "Characteristics": "Statin switch, fluvastatin",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.394",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": "1452196120"
            },
            {
              "Study Parameters ID": 1452196046,
              "Variant Annotation ID": 1452196040,
              "Study Type": null,
              "Study Cases": 184.0,
              "Study Controls": null,
              "Characteristics": "Statin switch, rosuvastatin",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.301",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": "1452196040"
            },
            {
              "Study Parameters ID": 1452196045,
              "Variant Annotation ID": 1452196040,
              "Study Type": null,
              "Study Cases": 70.0,
              "Study Controls": null,
              "Characteristics": "Statin switch, fluvastatin",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.36",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": "1452196040"
            },
            {
              "Study Parameters ID": 1452196060,
              "Variant Annotation ID": 1452196040,
              "Study Type": null,
              "Study Cases": 780.0,
              "Study Controls": null,
              "Characteristics": "Statin switch, atorvastatin",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.759",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": "1452196040"
            },
            {
              "Study Parameters ID": 1452196085,
              "Variant Annotation ID": 1452196080,
              "Study Type": null,
              "Study Cases": 70.0,
              "Study Controls": null,
              "Characteristics": "Statin switch, fluvastatin",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.113",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": "1452196080"
            },
            {
              "Study Parameters ID": 1452196100,
              "Variant Annotation ID": 1452196080,
              "Study Type": null,
              "Study Cases": 184.0,
              "Study Controls": null,
              "Characteristics": "Statin switch, rosuvastatin",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.660",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": "1452196080"
            },
            {
              "Study Parameters ID": 1452196101,
              "Variant Annotation ID": 1452196080,
              "Study Type": null,
              "Study Cases": 780.0,
              "Study Controls": null,
              "Characteristics": "Statin switch, atorvastatin",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.877",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": "1452196080"
            }
          ],
          "unmatched_predictions": []
        }
      },
      "overall_score": 0.12318118544135773,
      "num_benchmarks": 4
    },
    {
      "pmid": "38216550",
      "pmcid": "PMC10786722",
      "title": "Integrating rare genetic variants into DPYD pharmacogenetic testing may help preventing fluoropyrimidine-induced toxicity",
      "benchmarks": {
        "drug_annotations": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Variant/Haplotypes": "c.1679T>G",
              "Gene": "DPYD",
              "Drug(s)": "fluoropyrimidine",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Significant association with low DPD activity.",
              "Sentence": "Genotype c.1679T>G is associated with increased toxicity to fluoropyrimidine in patients with cancer.",
              "Alleles": "c.1679T>G",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "wild-type",
              "Specialty Population": "",
              "Population types": "in patients with cancer",
              "Population Phenotypes or diseases": "Other: advanced solid tumors",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "toxicity of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Dose adjustment based on pretreatment screening for the most clinically relevant DPYD defective variants, i.e. c.1679T>G (DPYD*13, rs55886062), c.1905+1G>A (DPYD*2A, rs3918290) and c.2846A>T (p.Asp949Val or rs67376798), has been shown to improve the safety of chemotherapy regimens based on fluorouracil.",
                "Our data showed a significant association between each of these genetic variants and low DPD activity.",
                "Overall, our results indicate that rare DPYD genetic variants account for a significative part of the interindividual variability of DPD activity."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "(DPYD*13",
              "Gene": "DPYD",
              "Drug(s)": "fluoropyrimidine",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Significant association with low DPD activity.",
              "Sentence": "Genotype c.1679T>G is associated with increased toxicity to fluoropyrimidine in patients with cancer.",
              "Alleles": "c.1679T>G",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "wild-type",
              "Specialty Population": "",
              "Population types": "in patients with cancer",
              "Population Phenotypes or diseases": "Other: advanced solid tumors",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "toxicity of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Dose adjustment based on pretreatment screening for the most clinically relevant DPYD defective variants, i.e. c.1679T>G (DPYD*13, rs55886062), c.1905+1G>A (DPYD*2A, rs3918290) and c.2846A>T (p.Asp949Val or rs67376798), has been shown to improve the safety of chemotherapy regimens based on fluorouracil.",
                "Our data showed a significant association between each of these genetic variants and low DPD activity.",
                "Overall, our results indicate that rare DPYD genetic variants account for a significative part of the interindividual variability of DPD activity."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "rs55886062)",
              "Gene": "DPYD",
              "Drug(s)": "fluoropyrimidine",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Significant association with low DPD activity.",
              "Sentence": "Genotype c.1679T>G is associated with increased toxicity to fluoropyrimidine in patients with cancer.",
              "Alleles": "c.1679T>G",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "wild-type",
              "Specialty Population": "",
              "Population types": "in patients with cancer",
              "Population Phenotypes or diseases": "Other: advanced solid tumors",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "toxicity of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Dose adjustment based on pretreatment screening for the most clinically relevant DPYD defective variants, i.e. c.1679T>G (DPYD*13, rs55886062), c.1905+1G>A (DPYD*2A, rs3918290) and c.2846A>T (p.Asp949Val or rs67376798), has been shown to improve the safety of chemotherapy regimens based on fluorouracil.",
                "Our data showed a significant association between each of these genetic variants and low DPD activity.",
                "Overall, our results indicate that rare DPYD genetic variants account for a significative part of the interindividual variability of DPD activity."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "c.1905+1G>A",
              "Gene": "DPYD",
              "Drug(s)": "fluoropyrimidine",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Significant adverse drug reactions linked to this variant.",
              "Sentence": "Genotype c.1905+1G>A is associated with increased toxicity to fluoropyrimidine in patients with cancer.",
              "Alleles": "c.1905+1G>A",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "wild-type",
              "Specialty Population": "",
              "Population types": "in patients with cancer",
              "Population Phenotypes or diseases": "Other: advanced solid tumors",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "toxicity of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Dose adjustment based on pretreatment screening for the most clinically relevant *DPYD* defective variants, i.e. c.1679T>G (*DPYD*13*), c.1905+1G>A (*DPYD*2A*), and c.2846A>T (p.Asp949Val or rs67376798), has been shown to improve the safety of chemotherapy regimens based on fluorouracil.",
                "This is in agreement with results from sequencing data established in large distinct populations, which showed that the vast majority of variants among pharmacogenes are rare (MAF < 1%) or very rare (MAF \u2264 0.1%) and non-synonymous, with an estimated 30-40% of functional variability likely attributed to these rare variants.",
                "Overall, our results indicate that rare *DPYD* genetic variants account for a significative part of the interindividual variability of DPD activity."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "(DPYD*2A",
              "Gene": "DPYD",
              "Drug(s)": "fluoropyrimidine",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Significant adverse drug reactions linked to this variant.",
              "Sentence": "Genotype c.1905+1G>A is associated with increased toxicity to fluoropyrimidine in patients with cancer.",
              "Alleles": "c.1905+1G>A",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "wild-type",
              "Specialty Population": "",
              "Population types": "in patients with cancer",
              "Population Phenotypes or diseases": "Other: advanced solid tumors",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "toxicity of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Dose adjustment based on pretreatment screening for the most clinically relevant *DPYD* defective variants, i.e. c.1679T>G (*DPYD*13*), c.1905+1G>A (*DPYD*2A*), and c.2846A>T (p.Asp949Val or rs67376798), has been shown to improve the safety of chemotherapy regimens based on fluorouracil.",
                "This is in agreement with results from sequencing data established in large distinct populations, which showed that the vast majority of variants among pharmacogenes are rare (MAF < 1%) or very rare (MAF \u2264 0.1%) and non-synonymous, with an estimated 30-40% of functional variability likely attributed to these rare variants.",
                "Overall, our results indicate that rare *DPYD* genetic variants account for a significative part of the interindividual variability of DPD activity."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "rs3918290)",
              "Gene": "DPYD",
              "Drug(s)": "fluoropyrimidine",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Significant adverse drug reactions linked to this variant.",
              "Sentence": "Genotype c.1905+1G>A is associated with increased toxicity to fluoropyrimidine in patients with cancer.",
              "Alleles": "c.1905+1G>A",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "wild-type",
              "Specialty Population": "",
              "Population types": "in patients with cancer",
              "Population Phenotypes or diseases": "Other: advanced solid tumors",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "toxicity of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Dose adjustment based on pretreatment screening for the most clinically relevant *DPYD* defective variants, i.e. c.1679T>G (*DPYD*13*), c.1905+1G>A (*DPYD*2A*), and c.2846A>T (p.Asp949Val or rs67376798), has been shown to improve the safety of chemotherapy regimens based on fluorouracil.",
                "This is in agreement with results from sequencing data established in large distinct populations, which showed that the vast majority of variants among pharmacogenes are rare (MAF < 1%) or very rare (MAF \u2264 0.1%) and non-synonymous, with an estimated 30-40% of functional variability likely attributed to these rare variants.",
                "Overall, our results indicate that rare *DPYD* genetic variants account for a significative part of the interindividual variability of DPD activity."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "c.2846A>T",
              "Gene": "DPYD",
              "Drug(s)": "fluoropyrimidine",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Affects DPD activity and toxicity risk in fluoropyrimidine treatment.",
              "Sentence": "Genotype c.2846A>T is associated with increased toxicity to fluoropyrimidine in patients with cancer.",
              "Alleles": "c.2846A>T",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "wild-type",
              "Specialty Population": "",
              "Population types": "in patients with cancer",
              "Population Phenotypes or diseases": "Other: advanced solid tumors",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "toxicity of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Dose adjustment based on pretreatment screening for the most clinically relevant *DPYD* defective variants, i.e. c.2846A>T (p.Asp949Val or rs67376798), has been shown to improve the safety of chemotherapy regimens based on fluorouracil.",
                "As expected, our data showed a significant association between each of these genetic variants and low DPD activity.",
                "Overall, our results indicate that rare *DPYD* genetic variants account for a significative part of the interindividual variability of DPD activity."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "(rs67376798)",
              "Gene": "DPYD",
              "Drug(s)": "fluoropyrimidine",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Affects DPD activity and toxicity risk in fluoropyrimidine treatment.",
              "Sentence": "Genotype c.2846A>T is associated with increased toxicity to fluoropyrimidine in patients with cancer.",
              "Alleles": "c.2846A>T",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "wild-type",
              "Specialty Population": "",
              "Population types": "in patients with cancer",
              "Population Phenotypes or diseases": "Other: advanced solid tumors",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "toxicity of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Dose adjustment based on pretreatment screening for the most clinically relevant *DPYD* defective variants, i.e. c.2846A>T (p.Asp949Val or rs67376798), has been shown to improve the safety of chemotherapy regimens based on fluorouracil.",
                "As expected, our data showed a significant association between each of these genetic variants and low DPD activity.",
                "Overall, our results indicate that rare *DPYD* genetic variants account for a significative part of the interindividual variability of DPD activity."
              ],
              "_expanded_from_multi_variant": true
            }
          ]
        },
        "phenotype_annotations": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": []
        },
        "functional_analysis": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "unmatched_ground_truth": [
            {
              "Variant Annotation ID": 1452352260,
              "Variant/Haplotypes": "rs56038477",
              "Gene": "DPYD",
              "Drug(s)": null,
              "PMID": 38216550,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "Consistent with previous reports, the c.1236G>A (rs56038477) which is included in the risk haplotype B3 was significantly associated with low DPD activity [30, 31]. Nevertheless, compared to the most clinically relevant DPYD defective variants, the association of these three variants with DPD activity was rather modest (Fig. 2).\" NOTE: the HapB has two variants, and c.1129-5923C>G rs75017182 is the causative variant, a recent study has shown they are not in perfect LD in all populations [PMID: 38129972].",
              "Sentence": "Genotypes CT + TT is associated with decreased activity of DPYD as compared to genotype CC.",
              "Alleles": "CT + TT",
              "Specialty Population": null,
              "Assay type": "plasma dihydrouracil/uracil",
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Functional terms": "activity of",
              "Gene/gene product": "DPYD",
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "CC",
              "Comparison Metabolizer types": null,
              "PMID_norm": "38216550",
              "Variant Annotation ID_norm": "1452352260"
            },
            {
              "Variant Annotation ID": 1452352325,
              "Variant/Haplotypes": "rs1801160",
              "Gene": "DPYD",
              "Drug(s)": null,
              "PMID": 38216550,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "The association between common DPYD genetic variants (MAF \u2265 1%) and DPD activity is summarized in Fig. 2. Among the seven genetic variants identified, three variants (c.1236G>A or rs56038477 p.Glu412Glu ; c.496A>G or rs2297595 p.Met166Val; DPYD*6 c.2194G>A or rs1801160 p.Val732Ile) were significantly more frequent in the group of patients exhibiting partial DPD deficiency. Consistent with previous reports, the c.1236G>A (rs56038477) which is included in the risk haplotype B3 was significantly associated with low DPD activity [30, 31]. Nevertheless, compared to the most clinically relevant DPYD defective variants, the association of these three variants with DPD activity was rather modest (Fig. 2).",
              "Sentence": "Genotypes CT + TT is associated with decreased activity of DPYD as compared to genotype CC.",
              "Alleles": "CT + TT",
              "Specialty Population": null,
              "Assay type": "plasma dihydrouracil/uracil",
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Functional terms": "activity of",
              "Gene/gene product": "DPYD",
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "CC",
              "Comparison Metabolizer types": null,
              "PMID_norm": "38216550",
              "Variant Annotation ID_norm": "1452352325"
            },
            {
              "Variant Annotation ID": 1452352320,
              "Variant/Haplotypes": "rs2297595",
              "Gene": "DPYD",
              "Drug(s)": null,
              "PMID": 38216550,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "The association between common DPYD genetic variants (MAF \u2265 1%) and DPD activity is summarized in Fig. 2. Among the seven genetic variants identified, three variants (c.1236G>A or rs56038477 p.Glu412Glu ; c.496A>G or rs2297595 p.Met166Val; DPYD*6 c.2194G>A or rs1801160 p.Val732Ile) were significantly more frequent in the group of patients exhibiting partial DPD deficiency. Consistent with previous reports, the c.1236G>A (rs56038477) which is included in the risk haplotype B3 was significantly associated with low DPD activity [30, 31]. Nevertheless, compared to the most clinically relevant DPYD defective variants, the association of these three variants with DPD activity was rather modest (Fig. 2).",
              "Sentence": "Genotypes CC + CT is associated with decreased activity of DPYD as compared to genotype TT.",
              "Alleles": "CC + CT",
              "Specialty Population": null,
              "Assay type": "plasma dihydrouracil/uracil",
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Functional terms": "activity of",
              "Gene/gene product": "DPYD",
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "TT",
              "Comparison Metabolizer types": null,
              "PMID_norm": "38216550",
              "Variant Annotation ID_norm": "1452352320"
            }
          ],
          "unmatched_predictions": [
            {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "c.1905+1G>A",
              "Gene": "DPYD",
              "Drug(s)": "5-fluorouracil",
              "PMID": 38216550,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Patients with this variant experienced severe toxicity during treatment with 5-fluorouracil.",
              "Sentence": "c.1905+1G>A (DPYD*2A) is associated with increased risk of severe toxicity when treated with 5-fluorouracil as compared to wild-type DPYD.",
              "Alleles": "",
              "Specialty Population": "",
              "Assay type": "Next Generation Sequencing",
              "Cell type": "plasma samples",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Functional terms": "risk of",
              "Gene/gene product": "DPD",
              "When treated with/exposed to/when assayed with": "",
              "Multiple drugs And/or": "",
              "Comparison Allele(s) or Genotype(s)": "wild-type DPYD",
              "Comparison Metabolizer types": "",
              "PMID_norm": "38216550",
              "Variant Annotation ID_norm": "1",
              "Citations": [
                "Dose adjustment based on pretreatment screening for the most clinically relevant *DPYD* defective variants, i.e. c.1679T>G (*DPYD*13*), c.1905+1G>A (*DPYD*2A*), and c.2846A>T (p.Asp949Val or rs67376798), has been shown to improve the safety of chemotherapy regimens based on fluorouracil.",
                "As expected, our data showed a significant association between each of these genetic variants and low DPD activity.",
                "Overall, our results indicate that rare *DPYD* genetic variants account for a significative part of the interindividual variability of DPD activity."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "(DPYD*2A)",
              "Gene": "DPYD",
              "Drug(s)": "5-fluorouracil",
              "PMID": 38216550,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Patients with this variant experienced severe toxicity during treatment with 5-fluorouracil.",
              "Sentence": "c.1905+1G>A (DPYD*2A) is associated with increased risk of severe toxicity when treated with 5-fluorouracil as compared to wild-type DPYD.",
              "Alleles": "",
              "Specialty Population": "",
              "Assay type": "Next Generation Sequencing",
              "Cell type": "plasma samples",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Functional terms": "risk of",
              "Gene/gene product": "DPD",
              "When treated with/exposed to/when assayed with": "",
              "Multiple drugs And/or": "",
              "Comparison Allele(s) or Genotype(s)": "wild-type DPYD",
              "Comparison Metabolizer types": "",
              "PMID_norm": "38216550",
              "Variant Annotation ID_norm": "1",
              "Citations": [
                "Dose adjustment based on pretreatment screening for the most clinically relevant *DPYD* defective variants, i.e. c.1679T>G (*DPYD*13*), c.1905+1G>A (*DPYD*2A*), and c.2846A>T (p.Asp949Val or rs67376798), has been shown to improve the safety of chemotherapy regimens based on fluorouracil.",
                "As expected, our data showed a significant association between each of these genetic variants and low DPD activity.",
                "Overall, our results indicate that rare *DPYD* genetic variants account for a significative part of the interindividual variability of DPD activity."
              ],
              "_expanded_from_multi_variant": true
            }
          ],
          "status": "no_overlap_after_alignment"
        },
        "study_parameters": {
          "total_samples": 3,
          "field_scores": {
            "Study Type": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            },
            "Study Cases": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0
              ]
            },
            "Study Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            },
            "Characteristics": {
              "mean_score": 0.8726030786832174,
              "scores": [
                0.8998017311096191,
                0.8618435263633728,
                0.8561639785766602
              ]
            },
            "Characteristics Type": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            },
            "Frequency In Cases": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            },
            "Allele Of Frequency In Cases": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            },
            "Frequency In Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            },
            "Allele Of Frequency In Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            },
            "P Value": {
              "mean_score": 0.3333333333333333,
              "scores": [
                0.0,
                0.0,
                1.0
              ]
            },
            "Ratio Stat Type": {
              "mean_score": 0.6666666666666666,
              "scores": [
                1.0,
                1.0,
                0.0
              ]
            },
            "Ratio Stat": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            },
            "Confidence Interval Start": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            },
            "Confidence Interval Stop": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            },
            "Biogeographical Groups": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.7915068719122146,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 1.0,
                "Study Cases": 0.0,
                "Study Controls": 1.0,
                "Characteristics": 0.8998017311096191,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.0,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1452352264,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1452352260,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Study Cases": {
                  "ground_truth": 855.0,
                  "prediction": 628
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "plasma dihydrouracil/uracil",
                  "prediction": "patients with DPD deficiency identified by [U] and UH2/U ratio"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "< 0.05",
                  "prediction": null
                },
                "Ratio Stat Type": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "Unknown",
                  "prediction": "European"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 1.0,
                "Study Cases": 0.0,
                "Study Controls": 1.0,
                "Characteristics": 0.8618435263633728,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.0,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1452352360,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1452352325,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Study Cases": {
                  "ground_truth": 1055.0,
                  "prediction": 2928
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "plasma dihydrouracil/uracil",
                  "prediction": "All patients (non-deficient DPD)"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "< 0.01",
                  "prediction": null
                },
                "Ratio Stat Type": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "Unknown",
                  "prediction": "European"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 2,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 1.0,
                "Study Cases": 0.0,
                "Study Controls": 1.0,
                "Characteristics": 0.8561639785766602,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 1.0,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1452352324,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1452352320,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Study Cases": {
                  "ground_truth": 1265.0,
                  "prediction": 180
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "plasma dihydrouracil/uracil",
                  "prediction": "patients who may exhibit low DPD activity"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "< 0.01",
                  "prediction": "< 0.01"
                },
                "Ratio Stat Type": {
                  "ground_truth": null,
                  "prediction": "Unknown"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "Unknown",
                  "prediction": "European"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            }
          ],
          "aligned_variants": [
            "None:plasma dihydrouracil",
            "None:plasma dihydrouracil",
            "None:plasma dihydrouracil"
          ],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 2972,
              "Study Controls": null,
              "Characteristics": "patients eligible for an uracil analog-based chemotherapy",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": null,
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            },
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": null,
              "Study Cases": 580,
              "Study Controls": null,
              "Characteristics": "partial DPD deficiency (UH2/U plasma ratio \u2264 10)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "< 0.00001",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          ]
        }
      },
      "overall_score": 0.1583013743824429,
      "num_benchmarks": 4
    },
    {
      "pmid": "38377518",
      "pmcid": "PMC10880264",
      "title": "Pharmacogenetic Factors Influence Escitalopram Pharmacokinetics and Adverse Events in Youth with a Family History of Bipolar Disorder: A Preliminary Study",
      "benchmarks": {
        "drug_annotations": {
          "total_samples": 3,
          "field_scores": {
            "Variant/Haplotypes": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                0.0,
                0.0
              ]
            },
            "Gene": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                0.0,
                0.0
              ]
            },
            "PMID": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0
              ]
            },
            "Phenotype Category": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                0.0,
                0.0
              ]
            },
            "Significance": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                0.0,
                0.0
              ]
            },
            "Alleles": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0
              ]
            },
            "Specialty Population": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                0.0,
                0.0
              ]
            },
            "Metabolizer types": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                0.0,
                0.0
              ]
            },
            "isPlural": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                0.0,
                0.0
              ]
            },
            "Is/Is Not associated": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                0.0,
                0.0
              ]
            },
            "Direction of effect": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                0.0,
                0.0
              ]
            },
            "PD/PK terms": {
              "mean_score": 0.29640263319015503,
              "scores": [
                0.8892078995704651,
                0.0,
                0.0
              ]
            },
            "Multiple drugs And/or": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0
              ]
            },
            "Population types": {
              "mean_score": 0.29346684614817303,
              "scores": [
                0.880400538444519,
                0.0,
                0.0
              ]
            },
            "Population Phenotypes or diseases": {
              "mean_score": 0.2926830053329468,
              "scores": [
                0.8780490159988403,
                0.0,
                0.0
              ]
            },
            "Multiple phenotypes or diseases And/or": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0
              ]
            },
            "Comparison Allele(s) or Genotype(s)": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0
              ]
            },
            "Comparison Metabolizer types": {
              "mean_score": 0.29397936662038165,
              "scores": [
                0.881938099861145,
                0.0,
                0.0
              ]
            },
            "Drug(s)": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.2373613255065784,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "PMID": 0.0,
                "Phenotype Category": 1.0,
                "Significance": 1.0,
                "Alleles": 0.0,
                "Specialty Population": 1.0,
                "Metabolizer types": 1.0,
                "isPlural": 1.0,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "PD/PK terms": 0.8892078995704651,
                "Multiple drugs And/or": 0.0,
                "Population types": 0.880400538444519,
                "Population Phenotypes or diseases": 0.8780490159988403,
                "Multiple phenotypes or diseases And/or": 0.0,
                "Comparison Allele(s) or Genotype(s)": 0.0,
                "Comparison Metabolizer types": 0.881938099861145,
                "Drug(s)": 1.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "CYP2C19",
                  "prediction": "CYP2C19"
                },
                "Gene": {
                  "ground_truth": "CYP2C19",
                  "prediction": "CYP2C19"
                },
                "PMID": {
                  "ground_truth": 38377518,
                  "prediction": null
                },
                "Phenotype Category": {
                  "ground_truth": "Metabolism/PK",
                  "prediction": "metabolism/PK"
                },
                "Significance": {
                  "ground_truth": "yes",
                  "prediction": "yes"
                },
                "Alleles": {
                  "ground_truth": null,
                  "prediction": ""
                },
                "Specialty Population": {
                  "ground_truth": "Pediatric",
                  "prediction": "Pediatric"
                },
                "Metabolizer types": {
                  "ground_truth": "intermediate metabolizer",
                  "prediction": "intermediate metabolizer"
                },
                "isPlural": {
                  "ground_truth": "Is",
                  "prediction": "Is"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "PD/PK terms": {
                  "ground_truth": "dose-adjusted trough concentrations of",
                  "prediction": "AUC0-24"
                },
                "Multiple drugs And/or": {
                  "ground_truth": null,
                  "prediction": ""
                },
                "Population types": {
                  "ground_truth": "in children with",
                  "prediction": "in youth with a first-degree relative with bipolar I disorder"
                },
                "Population Phenotypes or diseases": {
                  "ground_truth": "Other:Depression, Other:Anxiety Disorders",
                  "prediction": "Disease:bipolar disorder"
                },
                "Multiple phenotypes or diseases And/or": {
                  "ground_truth": "or",
                  "prediction": ""
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": null,
                  "prediction": ""
                },
                "Comparison Metabolizer types": {
                  "ground_truth": "normal metabolizer",
                  "prediction": ""
                },
                "Drug(s)": {
                  "ground_truth": "escitalopram",
                  "prediction": "escitalopram"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            }
          ],
          "aligned_variants": [
            "cyp2c19"
          ],
          "unmatched_ground_truth": [
            {
              "Variant Annotation ID": 1452390346,
              "Variant/Haplotypes": "intermediate",
              "Gene": "CYP2C19",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CPIC guidelines used to assign CYP2C19  metabolizer phenotypes based on CYP2C19: *1, *2,*3, *4, *5, *6, *7, *8, *17. \"CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0-24 (p = 0.025), Ctrough (p = 0.013), and t1/2 (p = 0.0008) of escitalopram (Fig. 1).\" \"CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n = 17), normal metabolizer (NM n = 31), or intermediate metabolizer (IM n = 17), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs).",
              "Sentence": "CYP2C19 intermediate metabolizer is associated with increased dose-adjusted trough concentrations of escitalopram in children with Depression or Anxiety Disorders as compared to CYP2C19 normal metabolizer.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "intermediate metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "dose-adjusted trough concentrations of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Other:Depression, Other:Anxiety Disorders",
              "Multiple phenotypes or diseases And/or": "or",
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": "normal metabolizer",
              "PMID_norm": "38377518",
              "Variant Annotation ID_norm": "1452390346",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1452390346,
              "Variant/Haplotypes": "metabolizer",
              "Gene": "CYP2C19",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CPIC guidelines used to assign CYP2C19  metabolizer phenotypes based on CYP2C19: *1, *2,*3, *4, *5, *6, *7, *8, *17. \"CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0-24 (p = 0.025), Ctrough (p = 0.013), and t1/2 (p = 0.0008) of escitalopram (Fig. 1).\" \"CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n = 17), normal metabolizer (NM n = 31), or intermediate metabolizer (IM n = 17), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs).",
              "Sentence": "CYP2C19 intermediate metabolizer is associated with increased dose-adjusted trough concentrations of escitalopram in children with Depression or Anxiety Disorders as compared to CYP2C19 normal metabolizer.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "intermediate metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "dose-adjusted trough concentrations of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Other:Depression, Other:Anxiety Disorders",
              "Multiple phenotypes or diseases And/or": "or",
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": "normal metabolizer",
              "PMID_norm": "38377518",
              "Variant Annotation ID_norm": "1452390346",
              "_expanded_from_multi_variant": true
            }
          ],
          "unmatched_predictions": [
            {
              "Variant/Haplotypes": "IM",
              "Gene": "CYP2C19",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "Slower CYP2C19 metabolizers had greater dose-normalized AUC0-24, trough concentrations, and elimination half-lives.",
              "Sentence": "CYP2C19 IM is associated with increased AUC0-24 in youth treated with escitalopram with a family history of bipolar disorder.",
              "Alleles": "",
              "Metabolizer types": "intermediate metabolizer",
              "Comparison Allele(s) or Genotype(s)": "",
              "Comparison Metabolizer types": "",
              "Specialty Population": "Pediatric",
              "Population types": "in youth with a first-degree relative with bipolar I disorder",
              "Population Phenotypes or diseases": "Disease:bipolar disorder",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "AUC0-24",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0-24; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001).",
                "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0-24 (p = 0.025)"
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "CYP2C19",
              "Gene": "CYP2C19",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "Slower CYP2C19 metabolizers had greater dose-normalized AUC0-24, trough concentrations, and elimination half-lives.",
              "Sentence": "CYP2C19 IM is associated with increased AUC0-24 in youth treated with escitalopram with a family history of bipolar disorder.",
              "Alleles": "",
              "Metabolizer types": "intermediate metabolizer",
              "Comparison Allele(s) or Genotype(s)": "",
              "Comparison Metabolizer types": "",
              "Specialty Population": "Pediatric",
              "Population types": "in youth with a first-degree relative with bipolar I disorder",
              "Population Phenotypes or diseases": "Disease:bipolar disorder",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "AUC0-24",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0-24; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001).",
                "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0-24 (p = 0.025)"
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "NM",
              "Gene": "CYP2C19",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "Slower CYP2C19 metabolizers had greater dose-normalized AUC0-24, trough concentrations, and elimination half-lives.",
              "Sentence": "CYP2C19 IM is associated with increased AUC0-24 in youth treated with escitalopram with a family history of bipolar disorder.",
              "Alleles": "",
              "Metabolizer types": "intermediate metabolizer",
              "Comparison Allele(s) or Genotype(s)": "",
              "Comparison Metabolizer types": "",
              "Specialty Population": "Pediatric",
              "Population types": "in youth with a first-degree relative with bipolar I disorder",
              "Population Phenotypes or diseases": "Disease:bipolar disorder",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "AUC0-24",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0-24; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001).",
                "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0-24 (p = 0.025)"
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "CYP2C19",
              "Gene": "CYP2C19",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "Slower CYP2C19 metabolizers had greater dose-normalized AUC0-24, trough concentrations, and elimination half-lives.",
              "Sentence": "CYP2C19 IM is associated with increased AUC0-24 in youth treated with escitalopram with a family history of bipolar disorder.",
              "Alleles": "",
              "Metabolizer types": "intermediate metabolizer",
              "Comparison Allele(s) or Genotype(s)": "",
              "Comparison Metabolizer types": "",
              "Specialty Population": "Pediatric",
              "Population types": "in youth with a first-degree relative with bipolar I disorder",
              "Population Phenotypes or diseases": "Disease:bipolar disorder",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "AUC0-24",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0-24; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001).",
                "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0-24 (p = 0.025)"
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "RM",
              "Gene": "CYP2C19",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "Slower CYP2C19 metabolizers had greater dose-normalized AUC0-24, trough concentrations, and elimination half-lives.",
              "Sentence": "CYP2C19 IM is associated with increased AUC0-24 in youth treated with escitalopram with a family history of bipolar disorder.",
              "Alleles": "",
              "Metabolizer types": "intermediate metabolizer",
              "Comparison Allele(s) or Genotype(s)": "",
              "Comparison Metabolizer types": "",
              "Specialty Population": "Pediatric",
              "Population types": "in youth with a first-degree relative with bipolar I disorder",
              "Population Phenotypes or diseases": "Disease:bipolar disorder",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "AUC0-24",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0-24; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001).",
                "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0-24 (p = 0.025)"
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "CYP2C19",
              "Gene": "CYP2C19",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "Slower CYP2C19 metabolizers had greater dose-normalized AUC0-24, trough concentrations, and elimination half-lives.",
              "Sentence": "CYP2C19 IM is associated with increased AUC0-24 in youth treated with escitalopram with a family history of bipolar disorder.",
              "Alleles": "",
              "Metabolizer types": "intermediate metabolizer",
              "Comparison Allele(s) or Genotype(s)": "",
              "Comparison Metabolizer types": "",
              "Specialty Population": "Pediatric",
              "Population types": "in youth with a first-degree relative with bipolar I disorder",
              "Population Phenotypes or diseases": "Disease:bipolar disorder",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "AUC0-24",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0-24; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001).",
                "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0-24 (p = 0.025)"
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "UM",
              "Gene": "CYP2C19",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "Slower CYP2C19 metabolizers had greater dose-normalized AUC0-24, trough concentrations, and elimination half-lives.",
              "Sentence": "CYP2C19 IM is associated with increased AUC0-24 in youth treated with escitalopram with a family history of bipolar disorder.",
              "Alleles": "",
              "Metabolizer types": "intermediate metabolizer",
              "Comparison Allele(s) or Genotype(s)": "",
              "Comparison Metabolizer types": "",
              "Specialty Population": "Pediatric",
              "Population types": "in youth with a first-degree relative with bipolar I disorder",
              "Population Phenotypes or diseases": "Disease:bipolar disorder",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "AUC0-24",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0-24; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001).",
                "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0-24 (p = 0.025)"
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "CYP2D6",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Slower CYP2D6 metabolizers had increased TEASAP akathisia scores.",
              "Sentence": "CYP2D6 IM is associated with increased akathisia in youth treated with escitalopram with a family history of bipolar disorder.",
              "Alleles": "",
              "Metabolizer types": "intermediate metabolizer",
              "Comparison Allele(s) or Genotype(s)": "",
              "Comparison Metabolizer types": "",
              "Specialty Population": "Pediatric",
              "Population types": "in youth with a first-degree relative with bipolar I disorder",
              "Population Phenotypes or diseases": "Disease:bipolar disorder",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "TEASAP scores",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Slower CYP2D6 metabolizers had increased TEASAP akathisia (p = 0.015) scores.",
                "Individuals with slower CYP2D6 phenotypes may be at increased risk of experiencing akathisia or worsening impulsivity.",
                "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0-24 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50)."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "IM",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Slower CYP2D6 metabolizers had increased TEASAP akathisia scores.",
              "Sentence": "CYP2D6 IM is associated with increased akathisia in youth treated with escitalopram with a family history of bipolar disorder.",
              "Alleles": "",
              "Metabolizer types": "intermediate metabolizer",
              "Comparison Allele(s) or Genotype(s)": "",
              "Comparison Metabolizer types": "",
              "Specialty Population": "Pediatric",
              "Population types": "in youth with a first-degree relative with bipolar I disorder",
              "Population Phenotypes or diseases": "Disease:bipolar disorder",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "TEASAP scores",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Slower CYP2D6 metabolizers had increased TEASAP akathisia (p = 0.015) scores.",
                "Individuals with slower CYP2D6 phenotypes may be at increased risk of experiencing akathisia or worsening impulsivity.",
                "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0-24 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50)."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "CYP2D6",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Slower CYP2D6 metabolizers had increased TEASAP akathisia scores.",
              "Sentence": "CYP2D6 IM is associated with increased akathisia in youth treated with escitalopram with a family history of bipolar disorder.",
              "Alleles": "",
              "Metabolizer types": "intermediate metabolizer",
              "Comparison Allele(s) or Genotype(s)": "",
              "Comparison Metabolizer types": "",
              "Specialty Population": "Pediatric",
              "Population types": "in youth with a first-degree relative with bipolar I disorder",
              "Population Phenotypes or diseases": "Disease:bipolar disorder",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "TEASAP scores",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Slower CYP2D6 metabolizers had increased TEASAP akathisia (p = 0.015) scores.",
                "Individuals with slower CYP2D6 phenotypes may be at increased risk of experiencing akathisia or worsening impulsivity.",
                "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0-24 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50)."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "NM",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Slower CYP2D6 metabolizers had increased TEASAP akathisia scores.",
              "Sentence": "CYP2D6 IM is associated with increased akathisia in youth treated with escitalopram with a family history of bipolar disorder.",
              "Alleles": "",
              "Metabolizer types": "intermediate metabolizer",
              "Comparison Allele(s) or Genotype(s)": "",
              "Comparison Metabolizer types": "",
              "Specialty Population": "Pediatric",
              "Population types": "in youth with a first-degree relative with bipolar I disorder",
              "Population Phenotypes or diseases": "Disease:bipolar disorder",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "TEASAP scores",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Slower CYP2D6 metabolizers had increased TEASAP akathisia (p = 0.015) scores.",
                "Individuals with slower CYP2D6 phenotypes may be at increased risk of experiencing akathisia or worsening impulsivity.",
                "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0-24 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50)."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "HTR2A",
              "Gene": "HTR2A",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "HTR2A A/A and A/G genotypes were associated with increased TEASAP 'self-injury, suicidality, and harm to others' subscale scores.",
              "Sentence": "Genotype HTR2A A/A is associated with increased self-injury, suicidality, and harm to others in youth treated with escitalopram with a family history of bipolar disorder.",
              "Alleles": "A/A, A/G",
              "Metabolizer types": "",
              "Comparison Allele(s) or Genotype(s)": "G/G",
              "Comparison Metabolizer types": "",
              "Specialty Population": "Pediatric",
              "Population types": "in youth with a first-degree relative with bipolar I disorder",
              "Population Phenotypes or diseases": "Other:self-injury",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "subscale scores",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "*HTR2A A/A* and *A/G* genotypes were associated with increased TEASAP 'self-injury, suicidality, and harm to others' subscale scores (*p* = 0.017).",
                "Participants with *HTR2A A/A* or *A/G* genotypes had a greater increase in TEASAP 'Self-injury, Suicidality, and Harm to Others' subscale scores relative to those with *HTR2A G/G* genotypes (*p* = 0.017).",
                "Emergence of adverse events was determined by study clinicians, and symptoms were tracked using the Treatment-Emergent Activation and Suicidality Assessment Profile (TEASAP) and Pediatric Adverse Events Rating Scale."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "A/A",
              "Gene": "HTR2A",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "HTR2A A/A and A/G genotypes were associated with increased TEASAP 'self-injury, suicidality, and harm to others' subscale scores.",
              "Sentence": "Genotype HTR2A A/A is associated with increased self-injury, suicidality, and harm to others in youth treated with escitalopram with a family history of bipolar disorder.",
              "Alleles": "A/A, A/G",
              "Metabolizer types": "",
              "Comparison Allele(s) or Genotype(s)": "G/G",
              "Comparison Metabolizer types": "",
              "Specialty Population": "Pediatric",
              "Population types": "in youth with a first-degree relative with bipolar I disorder",
              "Population Phenotypes or diseases": "Other:self-injury",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "subscale scores",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "*HTR2A A/A* and *A/G* genotypes were associated with increased TEASAP 'self-injury, suicidality, and harm to others' subscale scores (*p* = 0.017).",
                "Participants with *HTR2A A/A* or *A/G* genotypes had a greater increase in TEASAP 'Self-injury, Suicidality, and Harm to Others' subscale scores relative to those with *HTR2A G/G* genotypes (*p* = 0.017).",
                "Emergence of adverse events was determined by study clinicians, and symptoms were tracked using the Treatment-Emergent Activation and Suicidality Assessment Profile (TEASAP) and Pediatric Adverse Events Rating Scale."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "HTR2A",
              "Gene": "HTR2A",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "HTR2A A/A and A/G genotypes were associated with increased TEASAP 'self-injury, suicidality, and harm to others' subscale scores.",
              "Sentence": "Genotype HTR2A A/A is associated with increased self-injury, suicidality, and harm to others in youth treated with escitalopram with a family history of bipolar disorder.",
              "Alleles": "A/A, A/G",
              "Metabolizer types": "",
              "Comparison Allele(s) or Genotype(s)": "G/G",
              "Comparison Metabolizer types": "",
              "Specialty Population": "Pediatric",
              "Population types": "in youth with a first-degree relative with bipolar I disorder",
              "Population Phenotypes or diseases": "Other:self-injury",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "subscale scores",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "*HTR2A A/A* and *A/G* genotypes were associated with increased TEASAP 'self-injury, suicidality, and harm to others' subscale scores (*p* = 0.017).",
                "Participants with *HTR2A A/A* or *A/G* genotypes had a greater increase in TEASAP 'Self-injury, Suicidality, and Harm to Others' subscale scores relative to those with *HTR2A G/G* genotypes (*p* = 0.017).",
                "Emergence of adverse events was determined by study clinicians, and symptoms were tracked using the Treatment-Emergent Activation and Suicidality Assessment Profile (TEASAP) and Pediatric Adverse Events Rating Scale."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "A/G",
              "Gene": "HTR2A",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "HTR2A A/A and A/G genotypes were associated with increased TEASAP 'self-injury, suicidality, and harm to others' subscale scores.",
              "Sentence": "Genotype HTR2A A/A is associated with increased self-injury, suicidality, and harm to others in youth treated with escitalopram with a family history of bipolar disorder.",
              "Alleles": "A/A, A/G",
              "Metabolizer types": "",
              "Comparison Allele(s) or Genotype(s)": "G/G",
              "Comparison Metabolizer types": "",
              "Specialty Population": "Pediatric",
              "Population types": "in youth with a first-degree relative with bipolar I disorder",
              "Population Phenotypes or diseases": "Other:self-injury",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "subscale scores",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "*HTR2A A/A* and *A/G* genotypes were associated with increased TEASAP 'self-injury, suicidality, and harm to others' subscale scores (*p* = 0.017).",
                "Participants with *HTR2A A/A* or *A/G* genotypes had a greater increase in TEASAP 'Self-injury, Suicidality, and Harm to Others' subscale scores relative to those with *HTR2A G/G* genotypes (*p* = 0.017).",
                "Emergence of adverse events was determined by study clinicians, and symptoms were tracked using the Treatment-Emergent Activation and Suicidality Assessment Profile (TEASAP) and Pediatric Adverse Events Rating Scale."
              ],
              "_expanded_from_multi_variant": true
            }
          ]
        },
        "phenotype_annotations": {
          "total_samples": 7,
          "field_scores": {
            "Variant/Haplotypes": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Gene": {
              "mean_score": 0.8871978095599583,
              "scores": [
                1.0,
                0.8632352352142334,
                0.8632352352142334,
                0.8632352352142334,
                0.8735596537590027,
                0.8735596537590027,
                0.8735596537590027
              ]
            },
            "Drug(s)": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Phenotype Category": {
              "mean_score": 0.5714285714285714,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Alleles": {
              "mean_score": 0.8503295608929226,
              "scores": [
                0.85505211353302,
                0.8439474701881409,
                0.8439474701881409,
                0.8439474701881409,
                0.8551374673843384,
                0.8551374673843384,
                0.8551374673843384
              ]
            },
            "Is/Is Not associated": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Direction of effect": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Phenotype": {
              "mean_score": 0.8691556624003819,
              "scores": [
                0.9304036498069763,
                0.8501980304718018,
                0.8501980304718018,
                0.8501980304718018,
                0.8676972985267639,
                0.8676972985267639,
                0.8676972985267639
              ]
            },
            "When treated with/exposed to/when assayed with": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Comparison Allele(s) or Genotype(s)": {
              "mean_score": 0.8247031228882926,
              "scores": [
                0.8289949893951416,
                0.8283377885818481,
                0.8283377885818481,
                0.8283377885818481,
                0.8196378350257874,
                0.8196378350257874,
                0.8196378350257874
              ]
            }
          },
          "overall_score": 0.8342850736918903,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Variant/Haplotypes": 0.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 1.0,
                "Alleles": 0.85505211353302,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.9304036498069763,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.8289949893951416
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "rs6311",
                  "prediction": "HTR2A"
                },
                "Gene": {
                  "ground_truth": "HTR2A",
                  "prediction": "HTR2A"
                },
                "Drug(s)": {
                  "ground_truth": "escitalopram",
                  "prediction": "escitalopram"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "CT + TT",
                  "prediction": "A/G, A/A"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm",
                  "prediction": "self-injury, suicidality"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "CC",
                  "prediction": "HTR2A G/G"
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Variant/Haplotypes": 0.0,
                "Gene": 0.8632352352142334,
                "Drug(s)": 1.0,
                "Phenotype Category": 1.0,
                "Alleles": 0.8439474701881409,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.8501980304718018,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.8283377885818481
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "rs6311",
                  "prediction": "CYP2D6"
                },
                "Gene": {
                  "ground_truth": "HTR2A",
                  "prediction": "CYP2D6"
                },
                "Drug(s)": {
                  "ground_truth": "escitalopram",
                  "prediction": "escitalopram"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "CT + TT",
                  "prediction": "IM, PM"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm",
                  "prediction": "akathisia"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "CC",
                  "prediction": "CYP2D6 NM"
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 2,
              "field_scores": {
                "Variant/Haplotypes": 0.0,
                "Gene": 0.8632352352142334,
                "Drug(s)": 1.0,
                "Phenotype Category": 1.0,
                "Alleles": 0.8439474701881409,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.8501980304718018,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.8283377885818481
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "rs6311",
                  "prediction": "IM"
                },
                "Gene": {
                  "ground_truth": "HTR2A",
                  "prediction": "CYP2D6"
                },
                "Drug(s)": {
                  "ground_truth": "escitalopram",
                  "prediction": "escitalopram"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "CT + TT",
                  "prediction": "IM, PM"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm",
                  "prediction": "akathisia"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "CC",
                  "prediction": "CYP2D6 NM"
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 3,
              "field_scores": {
                "Variant/Haplotypes": 0.0,
                "Gene": 0.8632352352142334,
                "Drug(s)": 1.0,
                "Phenotype Category": 1.0,
                "Alleles": 0.8439474701881409,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.8501980304718018,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.8283377885818481
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "rs6311",
                  "prediction": "PM"
                },
                "Gene": {
                  "ground_truth": "HTR2A",
                  "prediction": "CYP2D6"
                },
                "Drug(s)": {
                  "ground_truth": "escitalopram",
                  "prediction": "escitalopram"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "CT + TT",
                  "prediction": "IM, PM"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm",
                  "prediction": "akathisia"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "CC",
                  "prediction": "CYP2D6 NM"
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 4,
              "field_scores": {
                "Variant/Haplotypes": 0.0,
                "Gene": 0.8735596537590027,
                "Drug(s)": 1.0,
                "Phenotype Category": 0.0,
                "Alleles": 0.8551374673843384,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.8676972985267639,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.8196378350257874
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "rs6311",
                  "prediction": "CYP2C19"
                },
                "Gene": {
                  "ground_truth": "HTR2A",
                  "prediction": "CYP2C19"
                },
                "Drug(s)": {
                  "ground_truth": "escitalopram",
                  "prediction": "escitalopram"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "metabolism/PK"
                },
                "Alleles": {
                  "ground_truth": "CT + TT",
                  "prediction": "IM, NM, RM"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm",
                  "prediction": "serum escitalopram levels"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "CC",
                  "prediction": "CYP2C19 PM"
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 5,
              "field_scores": {
                "Variant/Haplotypes": 0.0,
                "Gene": 0.8735596537590027,
                "Drug(s)": 1.0,
                "Phenotype Category": 0.0,
                "Alleles": 0.8551374673843384,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.8676972985267639,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.8196378350257874
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "rs6311",
                  "prediction": "RM"
                },
                "Gene": {
                  "ground_truth": "HTR2A",
                  "prediction": "CYP2C19"
                },
                "Drug(s)": {
                  "ground_truth": "escitalopram",
                  "prediction": "escitalopram"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "metabolism/PK"
                },
                "Alleles": {
                  "ground_truth": "CT + TT",
                  "prediction": "IM, NM, RM"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm",
                  "prediction": "serum escitalopram levels"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "CC",
                  "prediction": "CYP2C19 PM"
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 6,
              "field_scores": {
                "Variant/Haplotypes": 0.0,
                "Gene": 0.8735596537590027,
                "Drug(s)": 1.0,
                "Phenotype Category": 0.0,
                "Alleles": 0.8551374673843384,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.8676972985267639,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.8196378350257874
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "rs6311",
                  "prediction": "IM"
                },
                "Gene": {
                  "ground_truth": "HTR2A",
                  "prediction": "CYP2C19"
                },
                "Drug(s)": {
                  "ground_truth": "escitalopram",
                  "prediction": "escitalopram"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "metabolism/PK"
                },
                "Alleles": {
                  "ground_truth": "CT + TT",
                  "prediction": "IM, NM, RM"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm",
                  "prediction": "serum escitalopram levels"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "CC",
                  "prediction": "CYP2C19 PM"
                }
              },
              "dependency_issues": []
            }
          ],
          "aligned_variants": [
            "cyp2d6",
            "cyp2c19",
            "intermediate",
            "cyp2d6+escitalopram",
            "cyp2d6+escitalopram",
            "cyp2c19+escitalopram",
            "htr2a+escitalopram"
          ],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "NM",
              "Gene": "CYP2C19",
              "Drug(s)": "escitalopram",
              "PMID": "38377518",
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "Slower CYP2C19 metabolizers had significantly higher dose-normalized AUC0-24, trough concentrations, and elimination half-lives.",
              "Sentence": "CYP2C19 IM, NM, RM is associated with increased metabolism of escitalopram in youth with a family history of bipolar disorder.",
              "Alleles": "IM, NM, RM",
              "Specialty Population": "Pediatric",
              "Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "metabolism",
              "Phenotype": "serum escitalopram levels",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": "not stated",
              "Population types": "in youth with",
              "Population Phenotypes or diseases": "bipolar disorder",
              "Multiple phenotypes or diseases And/or": "not stated",
              "Comparison Allele(s) or Genotype(s)": "CYP2C19 PM",
              "Comparison Metabolizer types": "poor metabolizer",
              "PMID_norm": "38377518",
              "Variant Annotation ID_norm": "1",
              "Citations": [
                "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0-24; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001).",
                "We hypothesized that CYP450 enzyme metabolizer phenotypes (CYP2C19, CYP2D6) would predict dose-normalized pharmacokinetic parameters and that slower CYP2C19 metabolizers would confer increased risk of escitalopram-related adverse events.",
                "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0-24 (p = 0.025), Ctrough (p = 0.013), and t1/2 (p = 0.0008) of escitalopram."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "A/G",
              "Gene": "HTR2A",
              "Drug(s)": "escitalopram",
              "PMID": "38377518",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "HTR2A A/A and A/G genotypes were associated with increased TEASAP self-injury, suicidality scores.",
              "Sentence": "HTR2A A/G, A/A is associated with increased risk of self-injury, suicidality when treated with escitalopram.",
              "Alleles": "A/G, A/A",
              "Specialty Population": "Pediatric",
              "Metabolizer types": "not applicable",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "self-injury, suicidality",
              "Multiple phenotypes And/or": "not stated",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": "not stated",
              "Population types": "in youth with",
              "Population Phenotypes or diseases": "bipolar disorder",
              "Multiple phenotypes or diseases And/or": "not stated",
              "Comparison Allele(s) or Genotype(s)": "HTR2A G/G",
              "Comparison Metabolizer types": "not applicable",
              "PMID_norm": "38377518",
              "Variant Annotation ID_norm": "3",
              "Citations": [
                "*HTR2A A/A* and *A/G* genotypes were associated with increased TEASAP \"self-injury, suicidality, and harm to others\" subscale scores (*p* = 0.017).",
                "Participants with *HTR2A A/A* or *A/G* genotypes had a greater increase in TEASAP \"Self-injury, Suicidality, and Harm to Others\" subscale scores relative to those with *HTR2A G/G* genotypes (*p* = 0.017)."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "A/A",
              "Gene": "HTR2A",
              "Drug(s)": "escitalopram",
              "PMID": "38377518",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "HTR2A A/A and A/G genotypes were associated with increased TEASAP self-injury, suicidality scores.",
              "Sentence": "HTR2A A/G, A/A is associated with increased risk of self-injury, suicidality when treated with escitalopram.",
              "Alleles": "A/G, A/A",
              "Specialty Population": "Pediatric",
              "Metabolizer types": "not applicable",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "self-injury, suicidality",
              "Multiple phenotypes And/or": "not stated",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": "not stated",
              "Population types": "in youth with",
              "Population Phenotypes or diseases": "bipolar disorder",
              "Multiple phenotypes or diseases And/or": "not stated",
              "Comparison Allele(s) or Genotype(s)": "HTR2A G/G",
              "Comparison Metabolizer types": "not applicable",
              "PMID_norm": "38377518",
              "Variant Annotation ID_norm": "3",
              "Citations": [
                "*HTR2A A/A* and *A/G* genotypes were associated with increased TEASAP \"self-injury, suicidality, and harm to others\" subscale scores (*p* = 0.017).",
                "Participants with *HTR2A A/A* or *A/G* genotypes had a greater increase in TEASAP \"Self-injury, Suicidality, and Harm to Others\" subscale scores relative to those with *HTR2A G/G* genotypes (*p* = 0.017)."
              ],
              "_expanded_from_multi_variant": true
            }
          ]
        },
        "functional_analysis": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "status": "missing_var_fa_ann"
        },
        "study_parameters": {
          "total_samples": 4,
          "field_scores": {
            "Study Type": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Study Cases": {
              "mean_score": 0.725,
              "scores": [
                1.0,
                1.0,
                0.9,
                0.0
              ]
            },
            "Study Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Characteristics": {
              "mean_score": 0.9597177505493164,
              "scores": [
                0.9587251543998718,
                0.9587251543998718,
                0.9581674933433533,
                0.9632532000541687
              ]
            },
            "Characteristics Type": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Frequency In Cases": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Allele Of Frequency In Cases": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Frequency In Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Allele Of Frequency In Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "P Value": {
              "mean_score": 0.625,
              "scores": [
                1.0,
                0.5,
                0.5,
                0.5
              ]
            },
            "Ratio Stat Type": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Ratio Stat": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Confidence Interval Start": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Confidence Interval Stop": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Biogeographical Groups": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.7539811833699545,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.9587251543998718,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 1.0,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1452390361,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1452390352,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": null,
                  "prediction": "clinical trial"
                },
                "Study Cases": {
                  "ground_truth": 66.0,
                  "prediction": 66
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "Outpatient youth aged 12-17 years who had at least one first-degree relative with bipolar I disorder; TEASAP subscale Self-injury, suicidality and harm to others",
                  "prediction": "Youth aged 12-17 years with a first-degree relative with bipolar I disorder treated with escitalopram."
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.017",
                  "prediction": "= 0.017"
                },
                "Ratio Stat Type": {
                  "ground_truth": null,
                  "prediction": "Unknown"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "Multiple groups, Non-Hispanic Caucasian n=44, Hispanic Caucasian n=7, Black or African n = 7, Multiple or other n=8",
                  "prediction": "Unknown"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.9587251543998718,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.5,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1452390309,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1452390301,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": null,
                  "prediction": "clinical trial"
                },
                "Study Cases": {
                  "ground_truth": 66.0,
                  "prediction": 66
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "Outpatient youth aged 12-17 years who had at least one first-degree relative with bipolar I disorder; TEASAP subscale Self-injury, suicidality and harm to others",
                  "prediction": "Youth aged 12-17 years with a first-degree relative with bipolar I disorder treated with escitalopram."
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.09",
                  "prediction": "= 0.025"
                },
                "Ratio Stat Type": {
                  "ground_truth": null,
                  "prediction": "HR"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "Multiple groups, Non-Hispanic Caucasian n=44, Hispanic Caucasian n=7, Black or African n = 7, Multiple or other n=8",
                  "prediction": "Unknown"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 2,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 0.9,
                "Study Controls": 1.0,
                "Characteristics": 0.9581674933433533,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.5,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1452390397,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1452390389,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": null,
                  "prediction": "clinical trial"
                },
                "Study Cases": {
                  "ground_truth": 64.0,
                  "prediction": 66
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "Outpatient youth aged 12-17 years who had at least one first-degree relative with bipolar I disorder; TEASAP subscale Akathisia, hyperkinesis and somatic anxiety",
                  "prediction": "Youth aged 12-17 years with a first-degree relative with bipolar I disorder treated with escitalopram."
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.017",
                  "prediction": "= 0.013"
                },
                "Ratio Stat Type": {
                  "ground_truth": null,
                  "prediction": "HR"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "Multiple groups, Non-Hispanic Caucasian n=44, Hispanic Caucasian n=7, Black or African n = 7, Multiple or other n=8",
                  "prediction": "Unknown"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 3,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 0.0,
                "Study Controls": 1.0,
                "Characteristics": 0.9632532000541687,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.5,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1452390351,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1452390346,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": null,
                  "prediction": "clinical trial"
                },
                "Study Cases": {
                  "ground_truth": 48.0,
                  "prediction": 66
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "Outpatient youth aged 12-17 years who had at least one first-degree relative with bipolar I disorder; dose-normalized AUC0-24",
                  "prediction": "Youth aged 12-17 years with a first-degree relative with bipolar I disorder treated with escitalopram."
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.025",
                  "prediction": "= 0.015"
                },
                "Ratio Stat Type": {
                  "ground_truth": null,
                  "prediction": "Unknown"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "Multiple groups, Non-Hispanic Caucasian n=33, Hispanic Caucasian n=6, Black or African n = 6, Multiple or other n=6",
                  "prediction": "Unknown"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            }
          ],
          "aligned_variants": [
            "None:Outpatient youth age",
            "None:Outpatient youth age",
            "None:Outpatient youth age",
            "None:Outpatient youth age"
          ],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 66,
              "Study Controls": null,
              "Characteristics": "Youth aged 12-17 years with a first-degree relative with bipolar I disorder treated with escitalopram.",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "< 0.001",
              "Ratio Stat Type": "HR",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Unknown",
              "Variant Annotation ID_norm": null
            }
          ]
        }
      },
      "overall_score": 0.47229015643353145,
      "num_benchmarks": 4
    },
    {
      "pmid": "38497131",
      "pmcid": "PMC10946077",
      "title": "Individual Irinotecan Therapy Under the Guidance of Pre-Treated UGT1A1*6 Genotyping in Gastric Cancer",
      "benchmarks": {
        "drug_annotations": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Variant/Haplotypes": "UGT1A1*6",
              "Gene": "UGT1A1",
              "Drug(s)": "irinotecan",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Patients with AA genotype had significantly higher grade 3/4 diarrhea (100%), neutropenia (100%), and leukopenia (100%) compared to GA and GG genotypes.",
              "Standardized Sentence": "UGT1A1*6 is associated with increased toxicity of irinotecan in patients with gastric cancer.",
              "Alleles": "AA",
              "Metabolizer types": "poor metabolizer",
              "Specialty Population": "",
              "Population types": "in patients with gastric cancer",
              "Population Phenotypes or diseases": "Disease:gastric cancer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "toxicity of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "The administration of intravenous irinotecan occurred every 3 weeks, with the selection of irinotecan dosage based on the polymorphism of UGT1A1 gene. This gene was categorized into 3 groups: UGT1A1*6 wild-type (GG type) with a dosage of 125 mg/m2, d1, d8, UGT1A1*6 mutant heterozygosity (GA type) with a dosage of 100 mg/m2, d1, d8 and UGT1A1*6 homozygosity mutation (AA type) with a dosage of 75 mg/m2, d1, d8 or paclitaxel 125 mg/m2, d1, d8.",
                "Additionally, grade 3/4 diarrhea, neutropenia, and leukopenia were significantly more common in AA genotype patients compared to GG (2%, 19%, and 24%) or GA (23%, 31%, and 31%) genotype patients, suggesting that patients with the AA genotype could not tolerate severe toxicity even with reduced doses of irinotecan.",
                "There was a significant difference in the risk of delayed diarrhea (p = 0.000), leukopenia (p = 0.003) and neutropenia (p = 0.000) in patients with different UGT1A1*6 genotypes."
              ]
            },
            {
              "Variant/Haplotypes": "UGT1A1*6",
              "Gene": "UGT1A1",
              "Drug(s)": "irinotecan",
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "No significant difference in progression-free survival (PFS) and overall survival (OS) among GG, GA, and AA genotypes after dose adjustment.",
              "Standardized Sentence": "UGT1A1*6 is not associated with decreased efficacy of irinotecan in patients with gastric cancer.",
              "Alleles": "GG/GA/AA",
              "Metabolizer types": "",
              "Specialty Population": "",
              "Population types": "in patients with gastric cancer",
              "Population Phenotypes or diseases": "Disease:gastric cancer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "",
              "PD/PK terms": "efficacy of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Among 107 patients, there were no significant differences in PFS (4.8 m vs 4.9 m vs 4.4 m; p = 0.5249) and OS (9.3 m vs 9.3 m vs NA; p = 0.6821) among patients with GG/GA/AA subtypes after dose adjustment.",
                "There are no significant differences in PFS and OS among patients with different alleles or after dose adjustment (p > 0.05).",
                "It proved that individual irinotecan treatment can have a good effect in patients with non-AA subtype under the guidance of UGT1A1*6 gene polymorphism."
              ]
            }
          ]
        },
        "phenotype_annotations": {
          "total_samples": 7,
          "field_scores": {
            "Variant/Haplotypes": {
              "mean_score": 0.14285714285714285,
              "scores": [
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Gene": {
              "mean_score": 0.14285714285714285,
              "scores": [
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Drug(s)": {
              "mean_score": 0.14285714285714285,
              "scores": [
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Phenotype Category": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Alleles": {
              "mean_score": 0.12084452595029559,
              "scores": [
                0.8459116816520691,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Is/Is Not associated": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Direction of effect": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Phenotype": {
              "mean_score": 0.1209284918648856,
              "scores": [
                0.8464994430541992,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "When treated with/exposed to/when assayed with": {
              "mean_score": 0.14285714285714285,
              "scores": [
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Comparison Allele(s) or Genotype(s)": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.08287936200698216,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 0.0,
                "Alleles": 0.8459116816520691,
                "Is/Is Not associated": 0.0,
                "Direction of effect": 0.0,
                "Phenotype": 0.8464994430541992,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "UGT1A1*6",
                  "prediction": "UGT1A1*6"
                },
                "Gene": {
                  "ground_truth": "UGT1A1",
                  "prediction": "UGT1A1"
                },
                "Drug(s)": {
                  "ground_truth": "irinotecan",
                  "prediction": "irinotecan"
                },
                "Phenotype Category": {
                  "ground_truth": "Efficacy",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "*6 + *28",
                  "prediction": "AA, GA, GG"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Not associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "decreased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Efficacy:Overall survival, Efficacy:Progression-free survival",
                  "prediction": "delayed diarrhea, leukopenia, neutropenia"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "*1",
                  "prediction": null
                }
              },
              "dependency_issues": []
            }
          ],
          "aligned_variants": [
            "ugt1a1*6"
          ],
          "unmatched_ground_truth": [
            {
              "Variant Annotation ID": 1452426860,
              "Variant/Haplotypes": "UGT1A1*1",
              "Gene": "UGT1A1",
              "Drug(s)": "irinotecan",
              "PMID": 38497131,
              "Phenotype Category": "Efficacy",
              "Significance": "no",
              "Notes": "In this study, we calculated irinotecan dose according to UGT1A1*6 gene polymorphism based on BSA. For patients with GG type, irinotecan was used in full dose. For patients with GA type, irinotecan was used by 20% reduction. For patients with AA type, irinotecan was used by 40% reduction.\" \"Of the 8 patients with UGT1A1*6 AA subtype, 5 had severe toxicity and were subsequently switched to paclitaxel in the following treatment. Three patients received paclitaxel treatment directly.\" \"In the present study, univariable and multivariate analysis revealed no relation between PFS and UGT1A1*6 or UGT1A1*28",
              "Sentence": "UGT1A1 *6 + *28 is not associated with decreased likelihood of overall survival or progression-free survival when treated with irinotecan in people with Stomach Neoplasms as compared to UGT1A1 *1.",
              "Alleles": "*6 + *28",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "decreased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Efficacy:Overall survival, Efficacy:Progression-free survival",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Other:Stomach Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "38497131",
              "Variant Annotation ID_norm": "1452426860",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1452426860,
              "Variant/Haplotypes": "UGT1A1*28",
              "Gene": "UGT1A1",
              "Drug(s)": "irinotecan",
              "PMID": 38497131,
              "Phenotype Category": "Efficacy",
              "Significance": "no",
              "Notes": "In this study, we calculated irinotecan dose according to UGT1A1*6 gene polymorphism based on BSA. For patients with GG type, irinotecan was used in full dose. For patients with GA type, irinotecan was used by 20% reduction. For patients with AA type, irinotecan was used by 40% reduction.\" \"Of the 8 patients with UGT1A1*6 AA subtype, 5 had severe toxicity and were subsequently switched to paclitaxel in the following treatment. Three patients received paclitaxel treatment directly.\" \"In the present study, univariable and multivariate analysis revealed no relation between PFS and UGT1A1*6 or UGT1A1*28",
              "Sentence": "UGT1A1 *6 + *28 is not associated with decreased likelihood of overall survival or progression-free survival when treated with irinotecan in people with Stomach Neoplasms as compared to UGT1A1 *1.",
              "Alleles": "*6 + *28",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "decreased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Efficacy:Overall survival, Efficacy:Progression-free survival",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Other:Stomach Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "38497131",
              "Variant Annotation ID_norm": "1452426860",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1452426882,
              "Variant/Haplotypes": "UGT1A1*1",
              "Gene": "UGT1A1",
              "Drug(s)": "irinotecan",
              "PMID": 38497131,
              "Phenotype Category": "Toxicity",
              "Significance": "no",
              "Notes": "there were no significant differences in diarrhea (p = 0.136), neutropenia (p = 0.991), and leukopenia (p = 0.857) in UGT1A1*28 subgroups.\" \"The frequencies of TA6/TA6, TA6/TA7, TA7/TA7 for UGT1A1*28 and GG, GA, AA genotypes for UGT1A1*6 were 70.9%, 25.5%, 3.6% and 60.9%, 31.8%, 7.3%, respectively (Table 2). Three patients (2.7%) carried double heterozygosity (GA and TA6/TA7). No concurrent homozygous mutations were detected.",
              "Sentence": "UGT1A1 *28 is not associated with increased severity of Neutropenia, Leukopenia or Diarrhea when treated with irinotecan in people with Stomach Neoplasms as compared to UGT1A1 *1.",
              "Alleles": "*28",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "severity of",
              "Phenotype": "Side Effect:Neutropenia, Side Effect:Leukopenia, Side Effect:Diarrhea",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Other:Stomach Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "38497131",
              "Variant Annotation ID_norm": "1452426882",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1452426882,
              "Variant/Haplotypes": "UGT1A1*28",
              "Gene": "UGT1A1",
              "Drug(s)": "irinotecan",
              "PMID": 38497131,
              "Phenotype Category": "Toxicity",
              "Significance": "no",
              "Notes": "there were no significant differences in diarrhea (p = 0.136), neutropenia (p = 0.991), and leukopenia (p = 0.857) in UGT1A1*28 subgroups.\" \"The frequencies of TA6/TA6, TA6/TA7, TA7/TA7 for UGT1A1*28 and GG, GA, AA genotypes for UGT1A1*6 were 70.9%, 25.5%, 3.6% and 60.9%, 31.8%, 7.3%, respectively (Table 2). Three patients (2.7%) carried double heterozygosity (GA and TA6/TA7). No concurrent homozygous mutations were detected.",
              "Sentence": "UGT1A1 *28 is not associated with increased severity of Neutropenia, Leukopenia or Diarrhea when treated with irinotecan in people with Stomach Neoplasms as compared to UGT1A1 *1.",
              "Alleles": "*28",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "severity of",
              "Phenotype": "Side Effect:Neutropenia, Side Effect:Leukopenia, Side Effect:Diarrhea",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Other:Stomach Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "38497131",
              "Variant Annotation ID_norm": "1452426882",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1452426961,
              "Variant/Haplotypes": "UGT1A1*1",
              "Gene": "UGT1A1",
              "Drug(s)": "irinotecan",
              "PMID": 38497131,
              "Phenotype Category": "Toxicity",
              "Significance": "yes",
              "Notes": "diarrhea (p = 0.000), neutropenia (p = 0.000), and leukopenia (p = 0.003) were significantly different among UGT1A1*6 subgroups (Table 3). Additionally, grade 3/4 diarrhea, neutropenia, and leukopenia were significantly more common in AA genotype patients compared to GG (2%, 19%, and 24%) or GA (23%, 31%, and 31%) genotype patients, suggesting that that patients with the AA genotype could not tolerate severe toxicity even with reduced doses of irinotecan.diarrhea (p = 0.000), neutropenia (p = 0.000), and leukopenia (p = 0.003) were significantly different among UGT1A1*6 subgroups (Table 3). Additionally, grade 3/4 diarrhea, neutropenia, and leukopenia were significantly more common in AA genotype patients compared to GG (2%, 19%, and 24%) or GA (23%, 31%, and 31%) genotype patients, suggesting that that patients with the AA genotype could not tolerate severe toxicity even with reduced doses of irinotecan.\" \"The frequencies of TA6/TA6, TA6/TA7, TA7/TA7 for UGT1A1*28 and GG, GA, AA genotypes for UGT1A1*6 were 70.9%, 25.5%, 3.6% and 60.9%, 31.8%, 7.3%, respectively (Table 2). Three patients (2.7%) carried double heterozygosity (GA and TA6/TA7). No concurrent homozygous mutations were detected.",
              "Sentence": "UGT1A1 *6 is associated with increased severity of Neutropenia, Leukopenia or Diarrhea when treated with irinotecan in people with Stomach Neoplasms as compared to UGT1A1 *1.",
              "Alleles": "*6",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "severity of",
              "Phenotype": "Side Effect:Neutropenia, Side Effect:Leukopenia, Side Effect:Diarrhea",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Other:Stomach Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "38497131",
              "Variant Annotation ID_norm": "1452426961",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1452426961,
              "Variant/Haplotypes": "UGT1A1*6",
              "Gene": "UGT1A1",
              "Drug(s)": "irinotecan",
              "PMID": 38497131,
              "Phenotype Category": "Toxicity",
              "Significance": "yes",
              "Notes": "diarrhea (p = 0.000), neutropenia (p = 0.000), and leukopenia (p = 0.003) were significantly different among UGT1A1*6 subgroups (Table 3). Additionally, grade 3/4 diarrhea, neutropenia, and leukopenia were significantly more common in AA genotype patients compared to GG (2%, 19%, and 24%) or GA (23%, 31%, and 31%) genotype patients, suggesting that that patients with the AA genotype could not tolerate severe toxicity even with reduced doses of irinotecan.diarrhea (p = 0.000), neutropenia (p = 0.000), and leukopenia (p = 0.003) were significantly different among UGT1A1*6 subgroups (Table 3). Additionally, grade 3/4 diarrhea, neutropenia, and leukopenia were significantly more common in AA genotype patients compared to GG (2%, 19%, and 24%) or GA (23%, 31%, and 31%) genotype patients, suggesting that that patients with the AA genotype could not tolerate severe toxicity even with reduced doses of irinotecan.\" \"The frequencies of TA6/TA6, TA6/TA7, TA7/TA7 for UGT1A1*28 and GG, GA, AA genotypes for UGT1A1*6 were 70.9%, 25.5%, 3.6% and 60.9%, 31.8%, 7.3%, respectively (Table 2). Three patients (2.7%) carried double heterozygosity (GA and TA6/TA7). No concurrent homozygous mutations were detected.",
              "Sentence": "UGT1A1 *6 is associated with increased severity of Neutropenia, Leukopenia or Diarrhea when treated with irinotecan in people with Stomach Neoplasms as compared to UGT1A1 *1.",
              "Alleles": "*6",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "severity of",
              "Phenotype": "Side Effect:Neutropenia, Side Effect:Leukopenia, Side Effect:Diarrhea",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Other:Stomach Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "38497131",
              "Variant Annotation ID_norm": "1452426961",
              "_expanded_from_multi_variant": true
            }
          ],
          "unmatched_predictions": []
        },
        "functional_analysis": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "status": "missing_var_fa_ann"
        },
        "study_parameters": {
          "total_samples": 7,
          "field_scores": {
            "Study Type": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Study Cases": {
              "mean_score": 0.5428571428571428,
              "scores": [
                1.0,
                1.0,
                0.9,
                0.9,
                0.0,
                0.0,
                0.0
              ]
            },
            "Study Controls": {
              "mean_score": 0.7142857142857143,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0
              ]
            },
            "Characteristics": {
              "mean_score": 0.615860104560852,
              "scores": [
                0.827975869178772,
                0.8539823293685913,
                0.8767160177230835,
                0.8653979897499084,
                0.8869485259056091,
                0.0,
                0.0
              ]
            },
            "Characteristics Type": {
              "mean_score": 0.7142857142857143,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0
              ]
            },
            "Frequency In Cases": {
              "mean_score": 0.7142857142857143,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0
              ]
            },
            "Allele Of Frequency In Cases": {
              "mean_score": 0.7142857142857143,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0
              ]
            },
            "Frequency In Controls": {
              "mean_score": 0.7142857142857143,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0
              ]
            },
            "Allele Of Frequency In Controls": {
              "mean_score": 0.7142857142857143,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0
              ]
            },
            "P Value": {
              "mean_score": 0.35000000000000003,
              "scores": [
                0.95,
                0.5,
                0.5,
                0.5,
                0.0,
                0.0,
                0.0
              ]
            },
            "Ratio Stat Type": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Ratio Stat": {
              "mean_score": 0.7142857142857143,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0
              ]
            },
            "Confidence Interval Start": {
              "mean_score": 0.7142857142857143,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0
              ]
            },
            "Confidence Interval Stop": {
              "mean_score": 0.7142857142857143,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0
              ]
            },
            "Biogeographical Groups": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.5291525783992949,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.827975869178772,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.95,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1452426880,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1452426860,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": null,
                  "prediction": "retrospective"
                },
                "Study Cases": {
                  "ground_truth": 110.0,
                  "prediction": 110
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "OS for *6",
                  "prediction": "Patients treated with irinotecan, differentiated by UGT1A1 genotype."
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.703",
                  "prediction": "= 0.6821"
                },
                "Ratio Stat Type": {
                  "ground_truth": null,
                  "prediction": "HR"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "Unknown",
                  "prediction": "East Asian"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.8539823293685913,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.5,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1452426890,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1452426882,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": null,
                  "prediction": "retrospective"
                },
                "Study Cases": {
                  "ground_truth": 110.0,
                  "prediction": 110
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "Leukopenia grade 3-4",
                  "prediction": "Patients with advanced gastric cancer receiving irinotecan treatment based on UGT1A1 genotype."
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.857",
                  "prediction": "= 0.5249"
                },
                "Ratio Stat Type": {
                  "ground_truth": null,
                  "prediction": "HR"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "Unknown",
                  "prediction": "East Asian"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 2,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 0.9,
                "Study Controls": 1.0,
                "Characteristics": 0.8767160177230835,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.5,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1452426980,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1452426961,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": null,
                  "prediction": "retrospective"
                },
                "Study Cases": {
                  "ground_truth": 110.0,
                  "prediction": 107
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "Neutropenia grade 3-4",
                  "prediction": "Patients with UGT1A1 genotype receiving irinotecan treatment and analysis of adverse events."
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "< 0.001",
                  "prediction": "< 0.000"
                },
                "Ratio Stat Type": {
                  "ground_truth": null,
                  "prediction": "Unknown"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "Unknown",
                  "prediction": "East Asian"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 3,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 0.9,
                "Study Controls": 1.0,
                "Characteristics": 0.8653979897499084,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.5,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1452426968,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1452426961,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": null,
                  "prediction": "retrospective"
                },
                "Study Cases": {
                  "ground_truth": 110.0,
                  "prediction": 107
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "Leukopenia grade 3-4",
                  "prediction": "Patients with UGT1A1 genotype receiving irinotecan treatment and analysis of adverse events."
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.003",
                  "prediction": "< 0.003"
                },
                "Ratio Stat Type": {
                  "ground_truth": null,
                  "prediction": "Unknown"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "Unknown",
                  "prediction": "East Asian"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 4,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 0.0,
                "Study Controls": 1.0,
                "Characteristics": 0.8869485259056091,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.0,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1452426889,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1452426882,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": null,
                  "prediction": "retrospective"
                },
                "Study Cases": {
                  "ground_truth": 110.0,
                  "prediction": 5
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "Neutopenia grade 3-4",
                  "prediction": "Patients with UGT1A1*6 AA genotype switched to paclitaxel due to severe adverse events."
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.136",
                  "prediction": null
                },
                "Ratio Stat Type": {
                  "ground_truth": null,
                  "prediction": "Unknown"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "Unknown",
                  "prediction": "East Asian"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            }
          ],
          "aligned_variants": [
            "None:OS for *6",
            "None:Leukopenia grade 3-4",
            "None:Neutropenia grade 3-",
            "None:Leukopenia grade 3-4",
            "None:Neutopenia grade 3-4"
          ],
          "unmatched_ground_truth": [
            {
              "Study Parameters ID": 1452426891,
              "Variant Annotation ID": 1452426882,
              "Study Type": null,
              "Study Cases": 110.0,
              "Study Controls": null,
              "Characteristics": "Diarrhea grade 3-4",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.136",
              "Ratio Stat Type": null,
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Unknown",
              "Variant Annotation ID_norm": "1452426882"
            },
            {
              "Study Parameters ID": 1452426969,
              "Variant Annotation ID": 1452426961,
              "Study Type": null,
              "Study Cases": 110.0,
              "Study Controls": null,
              "Characteristics": "Diarrhea grade 3-4",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "< 0.001",
              "Ratio Stat Type": null,
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Unknown",
              "Variant Annotation ID_norm": "1452426961"
            }
          ],
          "unmatched_predictions": []
        }
      },
      "overall_score": 0.13069432428195363,
      "num_benchmarks": 4
    },
    {
      "pmid": "38568509",
      "pmcid": "PMC10993165",
      "title": "Human Leukocyte Antigens and Sulfamethoxazole/Cotrimoxazole-Induced Severe Cutaneous Adverse Reactions: A Systematic Review and Meta-Analysis",
      "benchmarks": {
        "drug_annotations": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Variant/Haplotypes": "HLA-A*11:01",
              "Gene": "HLA-A",
              "Drug(s)": "sulfamethoxazole,cotrimoxazole",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "HLA-A*11:01 was significantly associated with SMX/CTX-induced SCARs (OR, 2.10; 95% CI, 1.11-4.00) compared to tolerant controls.",
              "Sentence": "HLA-A*11:01 is associated with increased risk of severe cutaneous adverse reactions in patients receiving sulfamethoxazole and cotrimoxazole.",
              "Alleles": "HLA-A*11:01",
              "Specialty Population": "",
              "Population types": "in people with SCARs",
              "Population Phenotypes or diseases": "Disease:Severe Cutaneous Adverse Reactions",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "In this systematic review and meta-analysis of 6 studies involving 322 patients with SCARs, significant associations were identified between the HLA-A*11:01, HLA-B*13:01, HLA-B*15:02, HLA-B*38:02, and HLA-C*08:01 genotypes and SMX/CTX-induced SCARs.",
                "Significant associations were found in HLA-A*11:01 (OR, 2.10; 95% CI, 1.11-4.00) compared with tolerant controls.",
                "The results of this systematic review and meta-analysis suggest that multiple HLA alleles (HLA-A*11:01, HLA-B*13:01, HLA-B*15:02, HLA-B*38:02, and HLA-C*08:01) are associated with SMX/CTX-induced SCARs."
              ]
            },
            {
              "Variant/Haplotypes": "HLA-B*13:01",
              "Gene": "HLA-B",
              "Drug(s)": "sulfamethoxazole,cotrimoxazole",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "HLA-B*13:01 showed a strong association with SMX/CTX-induced SCARs (OR, 5.96; 95% CI, 1.58-22.56) compared to tolerant controls.",
              "Sentence": "HLA-B*13:01 is associated with increased risk of severe cutaneous adverse reactions in patients receiving sulfamethoxazole and cotrimoxazole.",
              "Alleles": "HLA-B*13:01",
              "Specialty Population": "",
              "Population types": "in people with SCARs",
              "Population Phenotypes or diseases": "Disease:Severe Cutaneous Adverse Reactions",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "the HLA-B*13:01 allele showed an association with SMX/CTX-induced SJS/TEN and drug reaction with eosinophilia and systemic symptoms.",
                "Significant associations were found in HLA-A*11:01 (OR, 2.10; 95% CI, 1.11-4.00), HLA-B*13:01 (OR, 5.96; 95% CI, 1.58-22.56), HLA-B*15:02 (OR, 2.23; 95% CI, 1.20-4.14), HLA-B*38:02 (OR, 3.47; 95% CI, 1.42-8.48), and HLA-C*08:01 (OR, 2.63; 95% CI, 1.07-6.44) compared with tolerant controls.",
                "The results of this systematic review and meta-analysis suggest that multiple HLA alleles (HLA-A*11:01, HLA-B*13:01, HLA-B*15:02, HLA-B*38:02, and HLA-C*08:01) are associated with SMX/CTX-induced SCARs."
              ]
            },
            {
              "Variant/Haplotypes": "HLA-B*15:02",
              "Gene": "HLA-B",
              "Drug(s)": "sulfamethoxazole,cotrimoxazole",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "HLA-B*15:02 was significantly associated with SMX/CTX-induced SJS/TEN (OR, 3.01; 95% CI, 1.56-5.80) compared to tolerant controls.",
              "Sentence": "HLA-B*15:02 is associated with increased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in patients receiving sulfamethoxazole and cotrimoxazole.",
              "Alleles": "HLA-B*15:02",
              "Specialty Population": "",
              "Population types": "in people with SCARs",
              "Population Phenotypes or diseases": "Disease:Stevens-Johnson Syndrome",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "The HLA-B*15:02 and HLA-B*38:02 genotypes were significantly associated with SMX/CTX-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), while...",
                "In the Stevens-Johnson syndrome/toxic epidermal necrolysis subgroup, significant associations were found in HLA-B*15:02 (OR, 3.01; 95% CI, 1.56-5.80)...",
                "...significant associations were found in HLA-B*15:02 (OR, 2.23; 95% CI, 1.20-4.14) compared with tolerant controls."
              ]
            },
            {
              "Variant/Haplotypes": "HLA-B*38:02",
              "Gene": "HLA-B",
              "Drug(s)": "sulfamethoxazole,cotrimoxazole",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "HLA-B*38:02 was significantly associated with SMX/CTX-induced SJS/TEN (OR, 5.13; 95% CI, 1.96-13.47).",
              "Sentence": "HLA-B*38:02 is associated with increased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in patients receiving sulfamethoxazole and cotrimoxazole.",
              "Alleles": "HLA-B*38:02",
              "Specialty Population": "",
              "Population types": "in people with SCARs",
              "Population Phenotypes or diseases": "Disease:Stevens-Johnson Syndrome",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "The HLA-B*15:02 and HLA-B*38:02 genotypes were significantly associated with SMX/CTX-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN)...in the Stevens-Johnson syndrome/toxic epidermal necrolysis subgroup, significant associations were found in HLA-B*15:02 (OR, 3.01; 95% CI, 1.56-5.80) and HLA-B*38:02 (OR, 5.13; 95% CI, 1.96-13.47).",
                "...the HLA-B*38:02 genotype was significantly associated with SMX/CTX-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), while the HLA-A*68:01 and HLA-B*39:01 genotypes were associated with SMX/CTX-induced drug reaction with eosinophilia and systemic symptoms.",
                "...significant associations were found in HLA-B*38:02 (OR, 3.47; 95% CI, 1.42-8.48), and in the drug reaction with eosinophilia and systemic symptoms subgroup, significant associations were found in HLA-B*13:01 (OR, 23.09; 95% CI, 3.31-161.00)..."
              ]
            },
            {
              "Variant/Haplotypes": "HLA-C*08:01",
              "Gene": "HLA-C",
              "Drug(s)": "sulfamethoxazole,cotrimoxazole",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "HLA-C*08:01 was associated with increased risk of SCARs (OR, 2.63; 95% CI, 1.07-6.44) compared to tolerant controls.",
              "Sentence": "HLA-C*08:01 is associated with increased risk of severe cutaneous adverse reactions in patients receiving sulfamethoxazole and cotrimoxazole.",
              "Alleles": "HLA-C*08:01",
              "Specialty Population": "",
              "Population types": "in people with SCARs",
              "Population Phenotypes or diseases": "Disease:Severe Cutaneous Adverse Reactions",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "significant associations were identified between the *HLA-C*08:01* genotypes and SMX/CTX-induced SCARs.",
                "HLA-C*08:01* was associated with increased risk of SCARs (OR, 2.63; 95% CI, 1.07-6.44) compared to tolerant controls.",
                "In the results, we identified significant associations between the *HLA-C*08:01* genotype and SMX/CTX-induced SCARs."
              ]
            },
            {
              "Variant/Haplotypes": "HLA-A*68:01",
              "Gene": "HLA-A",
              "Drug(s)": "sulfamethoxazole,cotrimoxazole",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "HLA-A*68:01 was significantly associated with SMX/CTX-induced DRESS (OR, 12.86; 95% CI, 1.09-151.34) compared to tolerant controls.",
              "Sentence": "HLA-A*68:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms in patients receiving sulfamethoxazole and cotrimoxazole.",
              "Alleles": "HLA-A*68:01",
              "Specialty Population": "",
              "Population types": "in people with SCARs",
              "Population Phenotypes or diseases": "Disease:Drug Reaction with Eosinophilia and Systemic Symptoms",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "the *HLA-A*68:01* and *HLA-B*39:01* genotypes were associated with SMX/CTX-induced drug reaction with eosinophilia and systemic symptoms;",
                "the *HLA-A*68:01* (OR, 12.86; 95% CI, 1.09-151.34), *HLA-B*13:01* (OR, 23.09; 95% CI, 3.31-161.00), *HLA-B*39:01* (OR, 4.56; 95% CI, 1.31-15.82)",
                "the results of this systematic review and meta-analysis suggest that multiple HLA alleles (*HLA-A*11:01*, *HLA-B*13:01*, *HLA-B*15:02*, *HLA-B*38:02*, and *HLA-C*08:01*) are associated with SMX/CTX-induced SCARs."
              ]
            },
            {
              "Variant/Haplotypes": "HLA-B*39:01",
              "Gene": "HLA-B",
              "Drug(s)": "sulfamethoxazole,cotrimoxazole",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "HLA-B*39:01 was associated with SMX/CTX-induced DRESS (OR, 4.56; 95% CI, 1.31-15.82).",
              "Sentence": "HLA-B*39:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms in patients receiving sulfamethoxazole and cotrimoxazole.",
              "Alleles": "HLA-B*39:01",
              "Specialty Population": "",
              "Population types": "in people with SCARs",
              "Population Phenotypes or diseases": "Disease:Drug Reaction with Eosinophilia and Systemic Symptoms",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "the HLA-A*68:01 and HLA-B*39:01 genotypes were associated with SMX/CTX-induced drug reaction with eosinophilia and systemic symptoms;",
                "In the drug reaction with eosinophilia and systemic symptoms subgroup, significant associations were found in HLA-A*68:01 (OR, 12.86; 95% CI, 1.09-151.34), HLA-B*39:01 (OR, 4.56; 95% CI, 1.31-15.82).",
                "The results of this systematic review and meta-analysis suggest that multiple HLA alleles (HLA-B*39:01) are associated with SMX/CTX-induced SCARs."
              ]
            }
          ]
        },
        "phenotype_annotations": {
          "total_samples": 3,
          "field_scores": {
            "Variant/Haplotypes": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            },
            "Gene": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            },
            "Drug(s)": {
              "mean_score": 0.9615678191184998,
              "scores": [
                0.9615678191184998,
                0.9615678191184998,
                0.9615678191184998
              ]
            },
            "Phenotype Category": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            },
            "Alleles": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0
              ]
            },
            "Is/Is Not associated": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            },
            "Direction of effect": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            },
            "Phenotype": {
              "mean_score": 0.9425883094469706,
              "scores": [
                0.9728982448577881,
                0.9728982448577881,
                0.8819684386253357
              ]
            },
            "When treated with/exposed to/when assayed with": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            },
            "Comparison Allele(s) or Genotype(s)": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            }
          },
          "overall_score": 0.8606273622976409,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "Drug(s)": 0.9615678191184998,
                "Phenotype Category": 1.0,
                "Alleles": 0.0,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.9728982448577881,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 1.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "HLA-B*15:02",
                  "prediction": "HLA-B*15:02"
                },
                "Gene": {
                  "ground_truth": "HLA-B",
                  "prediction": "HLA-B"
                },
                "Drug(s)": {
                  "ground_truth": "sulfamethoxazole, sulfamethoxazole / trimethoprim",
                  "prediction": "sulfamethoxazole, cotrimoxazole"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "*15:02",
                  "prediction": null
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis, Side Effect:Severe Cutaneous Adverse Reactions",
                  "prediction": "Stevens-Johnson syndrome/toxic epidermal necrolysis"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": null,
                  "prediction": null
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "Drug(s)": 0.9615678191184998,
                "Phenotype Category": 1.0,
                "Alleles": 0.0,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.9728982448577881,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 1.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "HLA-B*38:02",
                  "prediction": "HLA-B*38:02"
                },
                "Gene": {
                  "ground_truth": "HLA-B",
                  "prediction": "HLA-B"
                },
                "Drug(s)": {
                  "ground_truth": "sulfamethoxazole, sulfamethoxazole / trimethoprim",
                  "prediction": "sulfamethoxazole, cotrimoxazole"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "*38:02",
                  "prediction": null
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis, Side Effect:Severe Cutaneous Adverse Reactions",
                  "prediction": "Stevens-Johnson syndrome/toxic epidermal necrolysis"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": null,
                  "prediction": null
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 2,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "Drug(s)": 0.9615678191184998,
                "Phenotype Category": 1.0,
                "Alleles": 0.0,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.8819684386253357,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 1.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "HLA-B*13:01",
                  "prediction": "HLA-B*13:01"
                },
                "Gene": {
                  "ground_truth": "HLA-B",
                  "prediction": "HLA-B"
                },
                "Drug(s)": {
                  "ground_truth": "sulfamethoxazole, sulfamethoxazole / trimethoprim",
                  "prediction": "sulfamethoxazole, cotrimoxazole"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "*13:01",
                  "prediction": null
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:Severe Cutaneous Adverse Reactions",
                  "prediction": "Stevens-Johnson syndrome/toxic epidermal necrolysis"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": null,
                  "prediction": null
                }
              },
              "dependency_issues": []
            }
          ],
          "aligned_variants": [
            "hla-b*15:02",
            "hla-b*13:01",
            "hla-b*38:02"
          ],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "HLA-A*11:01",
              "Gene": "HLA-A",
              "Drug(s)": "sulfamethoxazole, cotrimoxazole",
              "PMID": 38568509,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Significantly associated with severe cutaneous adverse reactions (SCARs) in the Japanese population.",
              "Sentence": "HLA-A *11:01 is associated with increased likelihood of severe cutaneous adverse reactions when treated with sulfamethoxazole/cotrimoxazole in people of Japanese descent.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "severe cutaneous adverse reactions",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people of Japanese descent",
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "38568509",
              "Variant Annotation ID_norm": "1",
              "Citations": [
                "Among Japanese individuals, a significant association has been identified between the HLA-A*11:01 allele and SMX-induced SCARs.",
                "Significant associations were found in HLA-A*11:01 (OR, 2.10; 95% CI, 1.11-4.00) compared with tolerant controls.",
                "The results of this systematic review and meta-analysis suggest that multiple HLA alleles (HLA-A*11:01, HLA-B*13:01, HLA-B*15:02, HLA-B*38:02, and HLA-C*08:01) are associated with SMX/CTX-induced SCARs."
              ]
            },
            {
              "Variant Annotation ID": 5,
              "Variant/Haplotypes": "HLA-C*08:01",
              "Gene": "HLA-C",
              "Drug(s)": "sulfamethoxazole, cotrimoxazole",
              "PMID": 38568509,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Associated with DRESS and SJS in Asian populations.",
              "Sentence": "HLA-C *08:01 is associated with increased likelihood of DRESS when treated with sulfamethoxazole/cotrimoxazole in people of Asian descent.",
              "Alleles": null,
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "drug reaction with eosinophilia and systemic symptoms (DRESS)",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people of Asian descent",
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "38568509",
              "Variant Annotation ID_norm": "5",
              "Citations": [
                "the *HLA-C*08:01* genotype and SMX/CTX-induced SCARs.",
                "significant associations were found in *HLA-C*08:01* (OR, 2.63; 95% CI, 1.07-6.44) compared with tolerant controls.",
                "In Thai populations, significant associations were found in *HLA-C*08:01* (OR, 2.63; 95% CI, 1.07-6.44) compared with tolerant controls."
              ]
            },
            {
              "Variant Annotation ID": 6,
              "Variant/Haplotypes": "HLA-A*68:01",
              "Gene": "HLA-A",
              "Drug(s)": "sulfamethoxazole, cotrimoxazole",
              "PMID": 38568509,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Significantly associated with DRESS in patients tolerant to SMX/CTX.",
              "Sentence": "HLA-A *68:01 is associated with increased likelihood of DRESS when treated with sulfamethoxazole/cotrimoxazole.",
              "Alleles": null,
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "drug reaction with eosinophilia and systemic symptoms",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "null",
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "38568509",
              "Variant Annotation ID_norm": "6",
              "Citations": [
                "the HLA-A*68:01 and HLA-B*39:01 genotypes were associated with SMX/CTX-induced drug reaction with eosinophilia and systemic symptoms;",
                "In the drug reaction with eosinophilia and systemic symptoms subgroup, significant associations were found in HLA-A*68:01 (OR, 12.86; 95% CI, 1.09-151.34)",
                "The results of this systematic review and meta-analysis suggest that multiple HLA alleles (HLA-A*11:01, HLA-B*13:01, HLA-B*15:02, HLA-B*38:02, and HLA-C*08:01) are associated with SMX/CTX-induced SCARs."
              ]
            },
            {
              "Variant Annotation ID": 7,
              "Variant/Haplotypes": "HLA-B*39:01",
              "Gene": "HLA-B",
              "Drug(s)": "sulfamethoxazole, cotrimoxazole",
              "PMID": 38568509,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Significantly associated with DRESS in several populations.",
              "Sentence": "HLA-B *39:01 is associated with increased likelihood of DRESS when treated with sulfamethoxazole/cotrimoxazole in Asian patients.",
              "Alleles": null,
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "drug reaction with eosinophilia and systemic symptoms (DRESS)",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in Asian patients",
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "38568509",
              "Variant Annotation ID_norm": "7",
              "Citations": [
                "... the HLA-A*68:01 and HLA-B*39:01 genotypes were associated with SMX/CTX-induced drug reaction with eosinophilia and systemic symptoms; the HLA-B*13:01 allele showed an association with SMX/CTX-induced SJS/TEN and drug reaction with eosinophilia and systemic symptoms.",
                "In the drug reaction with eosinophilia and systemic symptoms subgroup, significant associations were found in HLA-A*68:01 (OR, 12.86; 95% CI, 1.09-151.34), HLA-B*13:01 (OR, 23.09; 95% CI, 3.31-161.00), HLA-B*39:01 (OR, 4.56; 95% CI, 1.31-15.82).",
                "... the HLA-B*39:01 allele was significantly associated with SMX/CTX-induced DRESS."
              ]
            }
          ]
        },
        "functional_analysis": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "status": "missing_var_fa_ann"
        },
        "study_parameters": {
          "total_samples": 5,
          "field_scores": {
            "Study Type": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Study Cases": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Study Controls": {
              "mean_score": 0.4,
              "scores": [
                1.0,
                0.0,
                0.0,
                1.0,
                0.0
              ]
            },
            "Characteristics": {
              "mean_score": 0.8491875886917114,
              "scores": [
                0.833801805973053,
                0.8576934933662415,
                0.8755479454994202,
                0.8392849564552307,
                0.8396097421646118
              ]
            },
            "Characteristics Type": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Frequency In Cases": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Allele Of Frequency In Cases": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Frequency In Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Allele Of Frequency In Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "P Value": {
              "mean_score": 0.1,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.5,
                0.0
              ]
            },
            "Ratio Stat Type": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Ratio Stat": {
              "mean_score": 0.74,
              "scores": [
                1.0,
                1.0,
                0.8,
                0.9,
                0.0
              ]
            },
            "Confidence Interval Start": {
              "mean_score": 0.5599999999999999,
              "scores": [
                1.0,
                1.0,
                0.8,
                0.0,
                0.0
              ]
            },
            "Confidence Interval Stop": {
              "mean_score": 0.58,
              "scores": [
                1.0,
                1.0,
                0.9,
                0.0,
                0.0
              ]
            },
            "Biogeographical Groups": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0
              ]
            }
          },
          "overall_score": 0.7486125059127808,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 1.0,
                "Study Cases": 0.0,
                "Study Controls": 1.0,
                "Characteristics": 0.833801805973053,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.0,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 1.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1452438990,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1452439000,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "meta-analysis",
                  "prediction": "meta-analysis"
                },
                "Study Cases": {
                  "ground_truth": null,
                  "prediction": 322
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "2 studies, SJS/TEN v tolerant controls",
                  "prediction": "HLA-B*38:02"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": null,
                  "prediction": "< .001"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": 5.13,
                  "prediction": 5.13
                },
                "Confidence Interval Start": {
                  "ground_truth": 1.96,
                  "prediction": 1.96
                },
                "Confidence Interval Stop": {
                  "ground_truth": 13.47,
                  "prediction": 13.47
                },
                "Biogeographical Groups": {
                  "ground_truth": "Multiple groups",
                  "prediction": "Multiple Groups"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 1.0,
                "Study Cases": 0.0,
                "Study Controls": 0.0,
                "Characteristics": 0.8576934933662415,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.0,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 1.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1452438988,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1452438980,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "meta-analysis",
                  "prediction": "meta-analysis"
                },
                "Study Cases": {
                  "ground_truth": 158.0,
                  "prediction": 236
                },
                "Study Controls": {
                  "ground_truth": 226.0,
                  "prediction": 8448
                },
                "Characteristics": {
                  "ground_truth": "2 studies, SCAR v tolerant controls",
                  "prediction": "Patients with SJS/TEN"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.01",
                  "prediction": "< .001"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": 5.96,
                  "prediction": 5.96
                },
                "Confidence Interval Start": {
                  "ground_truth": 1.58,
                  "prediction": 1.58
                },
                "Confidence Interval Stop": {
                  "ground_truth": 22.56,
                  "prediction": 22.56
                },
                "Biogeographical Groups": {
                  "ground_truth": "Multiple groups",
                  "prediction": "Multiple Groups"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 2,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 1.0,
                "Study Cases": 0.0,
                "Study Controls": 0.0,
                "Characteristics": 0.8755479454994202,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.0,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 0.8,
                "Confidence Interval Start": 0.8,
                "Confidence Interval Stop": 0.9,
                "Biogeographical Groups": 1.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1452437426,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1452437420,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "meta-analysis",
                  "prediction": "meta-analysis"
                },
                "Study Cases": {
                  "ground_truth": 158.0,
                  "prediction": 322
                },
                "Study Controls": {
                  "ground_truth": 226.0,
                  "prediction": 8448
                },
                "Characteristics": {
                  "ground_truth": "2 studies, SCAR v tolerant controls",
                  "prediction": "Patients with SCARs caused by SMX/CTX"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.01",
                  "prediction": null
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": 2.23,
                  "prediction": 2.1
                },
                "Confidence Interval Start": {
                  "ground_truth": 1.2,
                  "prediction": 1.11
                },
                "Confidence Interval Stop": {
                  "ground_truth": 4.14,
                  "prediction": 4.0
                },
                "Biogeographical Groups": {
                  "ground_truth": "Multiple groups",
                  "prediction": "Multiple Groups"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 3,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 1.0,
                "Study Cases": 0.0,
                "Study Controls": 1.0,
                "Characteristics": 0.8392849564552307,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.5,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 0.9,
                "Confidence Interval Start": 0.0,
                "Confidence Interval Stop": 0.0,
                "Biogeographical Groups": 1.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1452437520,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1452437420,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "meta-analysis",
                  "prediction": "meta-analysis"
                },
                "Study Cases": {
                  "ground_truth": null,
                  "prediction": 322
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "2 studies, SJS/TEN v tolerant controls",
                  "prediction": "HLA-B*15:02"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.001",
                  "prediction": "< .001"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": 3.01,
                  "prediction": 3.09
                },
                "Confidence Interval Start": {
                  "ground_truth": 1.56,
                  "prediction": 1.9
                },
                "Confidence Interval Stop": {
                  "ground_truth": 5.8,
                  "prediction": 5.02
                },
                "Biogeographical Groups": {
                  "ground_truth": "Multiple groups",
                  "prediction": "Multiple Groups"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 4,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 1.0,
                "Study Cases": 0.0,
                "Study Controls": 0.0,
                "Characteristics": 0.8396097421646118,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.0,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 0.0,
                "Confidence Interval Start": 0.0,
                "Confidence Interval Stop": 0.0,
                "Biogeographical Groups": 1.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1452438989,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1452439000,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "meta-analysis",
                  "prediction": "meta-analysis"
                },
                "Study Cases": {
                  "ground_truth": 158.0,
                  "prediction": 86
                },
                "Study Controls": {
                  "ground_truth": 226.0,
                  "prediction": 8448
                },
                "Characteristics": {
                  "ground_truth": "2 studies, SCAR v tolerant controls",
                  "prediction": "Patients with DRESS"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.01",
                  "prediction": "< .001"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": 3.47,
                  "prediction": 23.09
                },
                "Confidence Interval Start": {
                  "ground_truth": 1.42,
                  "prediction": 3.31
                },
                "Confidence Interval Stop": {
                  "ground_truth": 8.48,
                  "prediction": 161.0
                },
                "Biogeographical Groups": {
                  "ground_truth": "Multiple groups",
                  "prediction": "Multiple Groups"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            }
          ],
          "aligned_variants": [
            "meta-analysis:2 studies, SJS/TEN v",
            "meta-analysis:2 studies, SCAR v to",
            "meta-analysis:2 studies, SCAR v to",
            "meta-analysis:2 studies, SJS/TEN v",
            "meta-analysis:2 studies, SCAR v to"
          ],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "meta-analysis",
              "Study Cases": 322,
              "Study Controls": null,
              "Characteristics": "HLA-C*08:01",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.63,
              "Confidence Interval Start": 1.07,
              "Confidence Interval Stop": 6.44,
              "Biogeographical Groups": "Multiple Groups",
              "Variant Annotation ID_norm": null
            }
          ]
        }
      },
      "overall_score": 0.40791070987184846,
      "num_benchmarks": 4
    },
    {
      "pmid": "38707740",
      "pmcid": "PMC11062152",
      "title": "Risk Factors for Adverse Events of Nanoliposomal Irinotecan Plus 5-Fluorouracil and L-leucovorin",
      "benchmarks": {
        "drug_annotations": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Variant/Haplotypes": "UGT1A1*6",
              "Gene": "UGT1A1",
              "Drug(s)": "nanoliposomal irinotecan, 5-fluorouracil, L-leucovorin",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Genotype of UGT1A1*6 or *28 (+/+) was significantly associated with decreased white blood cell count (p=0.009) and neutrophil count (p=0.017).",
              "Standardized Sentence": "Genotype *28/+ is associated with decreased leukopenia during nal-IRI/FL treatment in patients with metastatic pancreatic cancer.",
              "Alleles": "(+/+)",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "UGT1A1*6 or *28 (+/-), UGT1A1*6 or *28 (-/-)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "",
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:metastatic pancreatic cancer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "counts of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Patients with UGT1A1*6 or *28 (+/+) exhibited significantly lower nadir counts of white blood cells (p=0.033) and neutrophils (p=0.043).",
                "Multiple regression analyses revealed that the decreased white blood cell count was significantly associated with the genotype of UGT1A1*6 or *28 (+/+) (p=0.009)... decreased neutrophil count was significantly related to the genotype of UGT1A1*6 or *28 (+/+) (p=0.017).",
                "Patients with UGT1A1*6 or *28 (+/+) should be especially concerned about neutropenia and leukopenia during nal-IRI/FL treatment."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "or",
              "Gene": "UGT1A1",
              "Drug(s)": "nanoliposomal irinotecan, 5-fluorouracil, L-leucovorin",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Genotype of UGT1A1*6 or *28 (+/+) was significantly associated with decreased white blood cell count (p=0.009) and neutrophil count (p=0.017).",
              "Standardized Sentence": "Genotype *28/+ is associated with decreased leukopenia during nal-IRI/FL treatment in patients with metastatic pancreatic cancer.",
              "Alleles": "(+/+)",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "UGT1A1*6 or *28 (+/-), UGT1A1*6 or *28 (-/-)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "",
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:metastatic pancreatic cancer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "counts of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Patients with UGT1A1*6 or *28 (+/+) exhibited significantly lower nadir counts of white blood cells (p=0.033) and neutrophils (p=0.043).",
                "Multiple regression analyses revealed that the decreased white blood cell count was significantly associated with the genotype of UGT1A1*6 or *28 (+/+) (p=0.009)... decreased neutrophil count was significantly related to the genotype of UGT1A1*6 or *28 (+/+) (p=0.017).",
                "Patients with UGT1A1*6 or *28 (+/+) should be especially concerned about neutropenia and leukopenia during nal-IRI/FL treatment."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "*28",
              "Gene": "UGT1A1",
              "Drug(s)": "nanoliposomal irinotecan, 5-fluorouracil, L-leucovorin",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Genotype of UGT1A1*6 or *28 (+/+) was significantly associated with decreased white blood cell count (p=0.009) and neutrophil count (p=0.017).",
              "Standardized Sentence": "Genotype *28/+ is associated with decreased leukopenia during nal-IRI/FL treatment in patients with metastatic pancreatic cancer.",
              "Alleles": "(+/+)",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "UGT1A1*6 or *28 (+/-), UGT1A1*6 or *28 (-/-)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "",
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:metastatic pancreatic cancer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "counts of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Patients with UGT1A1*6 or *28 (+/+) exhibited significantly lower nadir counts of white blood cells (p=0.033) and neutrophils (p=0.043).",
                "Multiple regression analyses revealed that the decreased white blood cell count was significantly associated with the genotype of UGT1A1*6 or *28 (+/+) (p=0.009)... decreased neutrophil count was significantly related to the genotype of UGT1A1*6 or *28 (+/+) (p=0.017).",
                "Patients with UGT1A1*6 or *28 (+/+) should be especially concerned about neutropenia and leukopenia during nal-IRI/FL treatment."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "(+/+)",
              "Gene": "UGT1A1",
              "Drug(s)": "nanoliposomal irinotecan, 5-fluorouracil, L-leucovorin",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Genotype of UGT1A1*6 or *28 (+/+) was significantly associated with decreased white blood cell count (p=0.009) and neutrophil count (p=0.017).",
              "Standardized Sentence": "Genotype *28/+ is associated with decreased leukopenia during nal-IRI/FL treatment in patients with metastatic pancreatic cancer.",
              "Alleles": "(+/+)",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "UGT1A1*6 or *28 (+/-), UGT1A1*6 or *28 (-/-)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "",
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:metastatic pancreatic cancer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "counts of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Patients with UGT1A1*6 or *28 (+/+) exhibited significantly lower nadir counts of white blood cells (p=0.033) and neutrophils (p=0.043).",
                "Multiple regression analyses revealed that the decreased white blood cell count was significantly associated with the genotype of UGT1A1*6 or *28 (+/+) (p=0.009)... decreased neutrophil count was significantly related to the genotype of UGT1A1*6 or *28 (+/+) (p=0.017).",
                "Patients with UGT1A1*6 or *28 (+/+) should be especially concerned about neutropenia and leukopenia during nal-IRI/FL treatment."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "UGT1A1*6",
              "Gene": "UGT1A1",
              "Drug(s)": "nanoliposomal irinotecan, 5-fluorouracil, L-leucovorin",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Genotype of UGT1A1*6 or *28 (+/+) was significantly associated with decreased white blood cell count (p=0.009) and neutrophil count (p=0.017).",
              "Standardized Sentence": "Genotype *28/+ is associated with decreased leukopenia during nal-IRI/FL treatment in patients with metastatic pancreatic cancer.",
              "Alleles": "(+/+)",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "UGT1A1*6 or *28 (+/-), UGT1A1*6 or *28 (-/-)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "",
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:metastatic pancreatic cancer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "counts of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Patients with UGT1A1*6 or *28 (+/+) exhibited significantly lower nadir counts of white blood cells (p=0.033) and neutrophils (p=0.043).",
                "Multiple regression analyses revealed that the decreased white blood cell count was significantly associated with the genotype of UGT1A1*6 or *28 (+/+) (p=0.009)... decreased neutrophil count was significantly related to the genotype of UGT1A1*6 or *28 (+/+) (p=0.017).",
                "Patients with UGT1A1*6 or *28 (+/+) should be especially concerned about neutropenia and leukopenia during nal-IRI/FL treatment."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "or",
              "Gene": "UGT1A1",
              "Drug(s)": "nanoliposomal irinotecan, 5-fluorouracil, L-leucovorin",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Genotype of UGT1A1*6 or *28 (+/+) was significantly associated with decreased white blood cell count (p=0.009) and neutrophil count (p=0.017).",
              "Standardized Sentence": "Genotype *28/+ is associated with decreased leukopenia during nal-IRI/FL treatment in patients with metastatic pancreatic cancer.",
              "Alleles": "(+/+)",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "UGT1A1*6 or *28 (+/-), UGT1A1*6 or *28 (-/-)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "",
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:metastatic pancreatic cancer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "counts of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Patients with UGT1A1*6 or *28 (+/+) exhibited significantly lower nadir counts of white blood cells (p=0.033) and neutrophils (p=0.043).",
                "Multiple regression analyses revealed that the decreased white blood cell count was significantly associated with the genotype of UGT1A1*6 or *28 (+/+) (p=0.009)... decreased neutrophil count was significantly related to the genotype of UGT1A1*6 or *28 (+/+) (p=0.017).",
                "Patients with UGT1A1*6 or *28 (+/+) should be especially concerned about neutropenia and leukopenia during nal-IRI/FL treatment."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "*28",
              "Gene": "UGT1A1",
              "Drug(s)": "nanoliposomal irinotecan, 5-fluorouracil, L-leucovorin",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Genotype of UGT1A1*6 or *28 (+/+) was significantly associated with decreased white blood cell count (p=0.009) and neutrophil count (p=0.017).",
              "Standardized Sentence": "Genotype *28/+ is associated with decreased leukopenia during nal-IRI/FL treatment in patients with metastatic pancreatic cancer.",
              "Alleles": "(+/+)",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "UGT1A1*6 or *28 (+/-), UGT1A1*6 or *28 (-/-)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "",
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:metastatic pancreatic cancer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "counts of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Patients with UGT1A1*6 or *28 (+/+) exhibited significantly lower nadir counts of white blood cells (p=0.033) and neutrophils (p=0.043).",
                "Multiple regression analyses revealed that the decreased white blood cell count was significantly associated with the genotype of UGT1A1*6 or *28 (+/+) (p=0.009)... decreased neutrophil count was significantly related to the genotype of UGT1A1*6 or *28 (+/+) (p=0.017).",
                "Patients with UGT1A1*6 or *28 (+/+) should be especially concerned about neutropenia and leukopenia during nal-IRI/FL treatment."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "(+/-)",
              "Gene": "UGT1A1",
              "Drug(s)": "nanoliposomal irinotecan, 5-fluorouracil, L-leucovorin",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Genotype of UGT1A1*6 or *28 (+/+) was significantly associated with decreased white blood cell count (p=0.009) and neutrophil count (p=0.017).",
              "Standardized Sentence": "Genotype *28/+ is associated with decreased leukopenia during nal-IRI/FL treatment in patients with metastatic pancreatic cancer.",
              "Alleles": "(+/+)",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "UGT1A1*6 or *28 (+/-), UGT1A1*6 or *28 (-/-)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "",
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:metastatic pancreatic cancer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "counts of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Patients with UGT1A1*6 or *28 (+/+) exhibited significantly lower nadir counts of white blood cells (p=0.033) and neutrophils (p=0.043).",
                "Multiple regression analyses revealed that the decreased white blood cell count was significantly associated with the genotype of UGT1A1*6 or *28 (+/+) (p=0.009)... decreased neutrophil count was significantly related to the genotype of UGT1A1*6 or *28 (+/+) (p=0.017).",
                "Patients with UGT1A1*6 or *28 (+/+) should be especially concerned about neutropenia and leukopenia during nal-IRI/FL treatment."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "UGT1A1*6",
              "Gene": "UGT1A1",
              "Drug(s)": "nanoliposomal irinotecan, 5-fluorouracil, L-leucovorin",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Genotype of UGT1A1*6 or *28 (+/+) was significantly associated with decreased white blood cell count (p=0.009) and neutrophil count (p=0.017).",
              "Standardized Sentence": "Genotype *28/+ is associated with decreased leukopenia during nal-IRI/FL treatment in patients with metastatic pancreatic cancer.",
              "Alleles": "(+/+)",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "UGT1A1*6 or *28 (+/-), UGT1A1*6 or *28 (-/-)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "",
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:metastatic pancreatic cancer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "counts of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Patients with UGT1A1*6 or *28 (+/+) exhibited significantly lower nadir counts of white blood cells (p=0.033) and neutrophils (p=0.043).",
                "Multiple regression analyses revealed that the decreased white blood cell count was significantly associated with the genotype of UGT1A1*6 or *28 (+/+) (p=0.009)... decreased neutrophil count was significantly related to the genotype of UGT1A1*6 or *28 (+/+) (p=0.017).",
                "Patients with UGT1A1*6 or *28 (+/+) should be especially concerned about neutropenia and leukopenia during nal-IRI/FL treatment."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "or",
              "Gene": "UGT1A1",
              "Drug(s)": "nanoliposomal irinotecan, 5-fluorouracil, L-leucovorin",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Genotype of UGT1A1*6 or *28 (+/+) was significantly associated with decreased white blood cell count (p=0.009) and neutrophil count (p=0.017).",
              "Standardized Sentence": "Genotype *28/+ is associated with decreased leukopenia during nal-IRI/FL treatment in patients with metastatic pancreatic cancer.",
              "Alleles": "(+/+)",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "UGT1A1*6 or *28 (+/-), UGT1A1*6 or *28 (-/-)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "",
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:metastatic pancreatic cancer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "counts of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Patients with UGT1A1*6 or *28 (+/+) exhibited significantly lower nadir counts of white blood cells (p=0.033) and neutrophils (p=0.043).",
                "Multiple regression analyses revealed that the decreased white blood cell count was significantly associated with the genotype of UGT1A1*6 or *28 (+/+) (p=0.009)... decreased neutrophil count was significantly related to the genotype of UGT1A1*6 or *28 (+/+) (p=0.017).",
                "Patients with UGT1A1*6 or *28 (+/+) should be especially concerned about neutropenia and leukopenia during nal-IRI/FL treatment."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "*28",
              "Gene": "UGT1A1",
              "Drug(s)": "nanoliposomal irinotecan, 5-fluorouracil, L-leucovorin",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Genotype of UGT1A1*6 or *28 (+/+) was significantly associated with decreased white blood cell count (p=0.009) and neutrophil count (p=0.017).",
              "Standardized Sentence": "Genotype *28/+ is associated with decreased leukopenia during nal-IRI/FL treatment in patients with metastatic pancreatic cancer.",
              "Alleles": "(+/+)",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "UGT1A1*6 or *28 (+/-), UGT1A1*6 or *28 (-/-)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "",
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:metastatic pancreatic cancer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "counts of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Patients with UGT1A1*6 or *28 (+/+) exhibited significantly lower nadir counts of white blood cells (p=0.033) and neutrophils (p=0.043).",
                "Multiple regression analyses revealed that the decreased white blood cell count was significantly associated with the genotype of UGT1A1*6 or *28 (+/+) (p=0.009)... decreased neutrophil count was significantly related to the genotype of UGT1A1*6 or *28 (+/+) (p=0.017).",
                "Patients with UGT1A1*6 or *28 (+/+) should be especially concerned about neutropenia and leukopenia during nal-IRI/FL treatment."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "(-/-)",
              "Gene": "UGT1A1",
              "Drug(s)": "nanoliposomal irinotecan, 5-fluorouracil, L-leucovorin",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Genotype of UGT1A1*6 or *28 (+/+) was significantly associated with decreased white blood cell count (p=0.009) and neutrophil count (p=0.017).",
              "Standardized Sentence": "Genotype *28/+ is associated with decreased leukopenia during nal-IRI/FL treatment in patients with metastatic pancreatic cancer.",
              "Alleles": "(+/+)",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "UGT1A1*6 or *28 (+/-), UGT1A1*6 or *28 (-/-)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "",
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:metastatic pancreatic cancer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "counts of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Patients with UGT1A1*6 or *28 (+/+) exhibited significantly lower nadir counts of white blood cells (p=0.033) and neutrophils (p=0.043).",
                "Multiple regression analyses revealed that the decreased white blood cell count was significantly associated with the genotype of UGT1A1*6 or *28 (+/+) (p=0.009)... decreased neutrophil count was significantly related to the genotype of UGT1A1*6 or *28 (+/+) (p=0.017).",
                "Patients with UGT1A1*6 or *28 (+/+) should be especially concerned about neutropenia and leukopenia during nal-IRI/FL treatment."
              ],
              "_expanded_from_multi_variant": true
            }
          ]
        },
        "phenotype_annotations": {
          "total_samples": 6,
          "field_scores": {
            "Variant/Haplotypes": {
              "mean_score": 0.8333333333333334,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0
              ]
            },
            "Gene": {
              "mean_score": 0.8333333333333334,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0
              ]
            },
            "Drug(s)": {
              "mean_score": 0.795893669128418,
              "scores": [
                0.9550724029541016,
                0.9550724029541016,
                0.9550724029541016,
                0.9550724029541016,
                0.9550724029541016,
                0.0
              ]
            },
            "Phenotype Category": {
              "mean_score": 0.6666666666666666,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0
              ]
            },
            "Alleles": {
              "mean_score": 0.6027973095575968,
              "scores": [
                0.9041959643363953,
                0.9041959643363953,
                0.9041959643363953,
                0.9041959643363953,
                0.0,
                0.0
              ]
            },
            "Is/Is Not associated": {
              "mean_score": 0.8333333333333334,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0
              ]
            },
            "Direction of effect": {
              "mean_score": 0.16666666666666666,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                1.0,
                0.0
              ]
            },
            "Phenotype": {
              "mean_score": 0.7835380733013153,
              "scores": [
                0.9623125195503235,
                0.9623125195503235,
                0.9623125195503235,
                0.9623125195503235,
                0.8519783616065979,
                0.0
              ]
            },
            "When treated with/exposed to/when assayed with": {
              "mean_score": 0.8333333333333334,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0
              ]
            },
            "Comparison Allele(s) or Genotype(s)": {
              "mean_score": 0.6103620529174805,
              "scores": [
                0.9155430793762207,
                0.9155430793762207,
                0.9155430793762207,
                0.9155430793762207,
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.6549006667402055,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "Drug(s)": 0.9550724029541016,
                "Phenotype Category": 1.0,
                "Alleles": 0.9041959643363953,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 0.0,
                "Phenotype": 0.9623125195503235,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.9155430793762207
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "UGT1A1*6",
                  "prediction": "UGT1A1*6"
                },
                "Gene": {
                  "ground_truth": "UGT1A1",
                  "prediction": "UGT1A1"
                },
                "Drug(s)": {
                  "ground_truth": "fluorouracil, irinotecan, leucovorin",
                  "prediction": "Nanoliposomal irinotecan, 5-fluorouracil, L-leucovorin"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "*6/*6 + *28/*28 + *6/*28",
                  "prediction": "(+/+), (-/-), (+/-)"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "decreased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:Neutropenia, Side Effect:Leukopenia",
                  "prediction": "leukopenia, neutropenia"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "*1/*1",
                  "prediction": "(-/-), (+/-)"
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "Drug(s)": 0.9550724029541016,
                "Phenotype Category": 1.0,
                "Alleles": 0.9041959643363953,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 0.0,
                "Phenotype": 0.9623125195503235,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.9155430793762207
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "UGT1A1*28",
                  "prediction": "*28"
                },
                "Gene": {
                  "ground_truth": "UGT1A1",
                  "prediction": "UGT1A1"
                },
                "Drug(s)": {
                  "ground_truth": "fluorouracil, irinotecan, leucovorin",
                  "prediction": "Nanoliposomal irinotecan, 5-fluorouracil, L-leucovorin"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "*6/*6 + *28/*28 + *6/*28",
                  "prediction": "(+/+), (-/-), (+/-)"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "decreased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:Neutropenia, Side Effect:Leukopenia",
                  "prediction": "leukopenia, neutropenia"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "*1/*1",
                  "prediction": "(-/-), (+/-)"
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 2,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "Drug(s)": 0.9550724029541016,
                "Phenotype Category": 1.0,
                "Alleles": 0.9041959643363953,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 0.0,
                "Phenotype": 0.9623125195503235,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.9155430793762207
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "UGT1A1*6",
                  "prediction": "UGT1A1*6"
                },
                "Gene": {
                  "ground_truth": "UGT1A1",
                  "prediction": "UGT1A1"
                },
                "Drug(s)": {
                  "ground_truth": "fluorouracil, irinotecan, leucovorin",
                  "prediction": "Nanoliposomal irinotecan, 5-fluorouracil, L-leucovorin"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "*6/*6 + *28/*28 + *6/*28",
                  "prediction": "(+/+), (-/-), (+/-)"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "decreased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:Neutropenia, Side Effect:Leukopenia",
                  "prediction": "leukopenia, neutropenia"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "*1/*1",
                  "prediction": "(-/-), (+/-)"
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 3,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "Drug(s)": 0.9550724029541016,
                "Phenotype Category": 1.0,
                "Alleles": 0.9041959643363953,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 0.0,
                "Phenotype": 0.9623125195503235,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.9155430793762207
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "UGT1A1*28",
                  "prediction": "*28"
                },
                "Gene": {
                  "ground_truth": "UGT1A1",
                  "prediction": "UGT1A1"
                },
                "Drug(s)": {
                  "ground_truth": "fluorouracil, irinotecan, leucovorin",
                  "prediction": "Nanoliposomal irinotecan, 5-fluorouracil, L-leucovorin"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "*6/*6 + *28/*28 + *6/*28",
                  "prediction": "(+/+), (-/-), (+/-)"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "decreased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:Neutropenia, Side Effect:Leukopenia",
                  "prediction": "leukopenia, neutropenia"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "*1/*1",
                  "prediction": "(-/-), (+/-)"
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 4,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "Drug(s)": 0.9550724029541016,
                "Phenotype Category": 0.0,
                "Alleles": 0.0,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.8519783616065979,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "UGT1A1*6",
                  "prediction": "UGT1A1"
                },
                "Gene": {
                  "ground_truth": "UGT1A1",
                  "prediction": "UGT1A1"
                },
                "Drug(s)": {
                  "ground_truth": "fluorouracil, irinotecan, leucovorin",
                  "prediction": "Nanoliposomal irinotecan, 5-fluorouracil, L-leucovorin"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "dosage"
                },
                "Alleles": {
                  "ground_truth": "*6/*6 + *28/*28 + *6/*28",
                  "prediction": null
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:Neutropenia, Side Effect:Leukopenia",
                  "prediction": "dosage requirements"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "*1/*1",
                  "prediction": null
                }
              },
              "dependency_issues": []
            }
          ],
          "aligned_variants": [
            "ugt1a1*1",
            "ugt1a1*6",
            "ugt1a1*28",
            "ugt1a1*6",
            "ugt1a1*28"
          ],
          "unmatched_ground_truth": [
            {
              "Variant Annotation ID": 1452474678,
              "Variant/Haplotypes": "UGT1A1*1",
              "Gene": "UGT1A1",
              "Drug(s)": "fluorouracil, irinotecan, leucovorin",
              "PMID": 38707740,
              "Phenotype Category": "Toxicity",
              "Significance": "no",
              "Notes": "Grade 3 or 4 leukopenia and neutropenia in the UGT1A1*6 or *28 (+/+) group demonstrated an incidence rate of 50.0%, indicating a higher tendency than those in UGT1A1*6 or *28 (-/-) and (+/-) groups at 7.1% and 12.5%, respectively (p=0.085 for each) (Figure 2C and D). Multiple regression analyses revealed that the UGT1A1*6 or *28 (+/+) genotype, high AST value before the nal-IRI/FL therapy, and pancreatic head cancer were significantly associated with decreased white blood cell count (p=0.009, 0.019, and 0.030, respectively) (Table III), and that of UGT1A1*6 or *28 (+/+) was significantly related to decreased neutrophil count (p=0.017)",
              "Sentence": "UGT1A1 *6/*6 + *28/*28 + *6/*28 is associated with increased risk of Neutropenia or Leukopenia when treated with fluorouracil, irinotecan and leucovorin in people with Pancreatic Neoplasms and Neoplasm Metastasis as compared to UGT1A1 *1/*1.",
              "Alleles": "*6/*6 + *28/*28 + *6/*28",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Neutropenia, Side Effect:Leukopenia",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": "and",
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Other:Pancreatic Neoplasms, Other:Metastatic neoplasm",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "38707740",
              "Variant Annotation ID_norm": "1452474678",
              "_expanded_from_multi_variant": true
            }
          ],
          "unmatched_predictions": [
            {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "or",
              "Gene": "UGT1A1",
              "Drug(s)": "Nanoliposomal irinotecan, 5-fluorouracil, L-leucovorin",
              "PMID": 38707740,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Patients with UGT1A1*6 or *28 (+/+) exhibited significantly lower nadir counts of white blood cells and neutrophils.",
              "Sentence": "UGT1A1*6 or *28 (+/+) is associated with decreased white blood cell count and neutrophil count when treated with nanoliposomal irinotecan plus 5-fluorouracil and L-leucovorin in people with metastatic pancreatic cancer.",
              "Alleles": "(+/+), (-/-), (+/-)",
              "Specialty Population": null,
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "leukopenia, neutropenia",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "metastatic pancreatic cancer",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "(-/-), (+/-)",
              "Comparison Metabolizer types": null,
              "PMID_norm": null,
              "Variant Annotation ID_norm": null,
              "Citations": [
                "Patients with UGT1A1*6 or *28 (+/+) exhibited significantly lower nadir counts of white blood cells (p=0.033) and neutrophils (p=0.043).",
                "Multiple regression analyses revealed that the decreased white blood cell count was significantly associated with the genotype of UGT1A1*6 or *28 (+/+) (p=0.009)... and that of UGT1A1*6 or *28 (+/+) was significantly related to decreased neutrophil count (p=0.017).",
                "Patients with UGT1A1*6 or *28 (+/+) should be especially concerned about neutropenia and leukopenia during nal-IRI/FL treatment."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "(+/+)",
              "Gene": "UGT1A1",
              "Drug(s)": "Nanoliposomal irinotecan, 5-fluorouracil, L-leucovorin",
              "PMID": 38707740,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Patients with UGT1A1*6 or *28 (+/+) exhibited significantly lower nadir counts of white blood cells and neutrophils.",
              "Sentence": "UGT1A1*6 or *28 (+/+) is associated with decreased white blood cell count and neutrophil count when treated with nanoliposomal irinotecan plus 5-fluorouracil and L-leucovorin in people with metastatic pancreatic cancer.",
              "Alleles": "(+/+), (-/-), (+/-)",
              "Specialty Population": null,
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "leukopenia, neutropenia",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "metastatic pancreatic cancer",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "(-/-), (+/-)",
              "Comparison Metabolizer types": null,
              "PMID_norm": null,
              "Variant Annotation ID_norm": null,
              "Citations": [
                "Patients with UGT1A1*6 or *28 (+/+) exhibited significantly lower nadir counts of white blood cells (p=0.033) and neutrophils (p=0.043).",
                "Multiple regression analyses revealed that the decreased white blood cell count was significantly associated with the genotype of UGT1A1*6 or *28 (+/+) (p=0.009)... and that of UGT1A1*6 or *28 (+/+) was significantly related to decreased neutrophil count (p=0.017).",
                "Patients with UGT1A1*6 or *28 (+/+) should be especially concerned about neutropenia and leukopenia during nal-IRI/FL treatment."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "or",
              "Gene": "UGT1A1",
              "Drug(s)": "Nanoliposomal irinotecan, 5-fluorouracil, L-leucovorin",
              "PMID": 38707740,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Patients with UGT1A1*6 or *28 (+/+) exhibited significantly lower nadir counts of white blood cells and neutrophils.",
              "Sentence": "UGT1A1*6 or *28 (+/+) is associated with decreased white blood cell count and neutrophil count when treated with nanoliposomal irinotecan plus 5-fluorouracil and L-leucovorin in people with metastatic pancreatic cancer.",
              "Alleles": "(+/+), (-/-), (+/-)",
              "Specialty Population": null,
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "leukopenia, neutropenia",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "metastatic pancreatic cancer",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "(-/-), (+/-)",
              "Comparison Metabolizer types": null,
              "PMID_norm": null,
              "Variant Annotation ID_norm": null,
              "Citations": [
                "Patients with UGT1A1*6 or *28 (+/+) exhibited significantly lower nadir counts of white blood cells (p=0.033) and neutrophils (p=0.043).",
                "Multiple regression analyses revealed that the decreased white blood cell count was significantly associated with the genotype of UGT1A1*6 or *28 (+/+) (p=0.009)... and that of UGT1A1*6 or *28 (+/+) was significantly related to decreased neutrophil count (p=0.017).",
                "Patients with UGT1A1*6 or *28 (+/+) should be especially concerned about neutropenia and leukopenia during nal-IRI/FL treatment."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "(-/-)",
              "Gene": "UGT1A1",
              "Drug(s)": "Nanoliposomal irinotecan, 5-fluorouracil, L-leucovorin",
              "PMID": 38707740,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Patients with UGT1A1*6 or *28 (+/+) exhibited significantly lower nadir counts of white blood cells and neutrophils.",
              "Sentence": "UGT1A1*6 or *28 (+/+) is associated with decreased white blood cell count and neutrophil count when treated with nanoliposomal irinotecan plus 5-fluorouracil and L-leucovorin in people with metastatic pancreatic cancer.",
              "Alleles": "(+/+), (-/-), (+/-)",
              "Specialty Population": null,
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "leukopenia, neutropenia",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "metastatic pancreatic cancer",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "(-/-), (+/-)",
              "Comparison Metabolizer types": null,
              "PMID_norm": null,
              "Variant Annotation ID_norm": null,
              "Citations": [
                "Patients with UGT1A1*6 or *28 (+/+) exhibited significantly lower nadir counts of white blood cells (p=0.033) and neutrophils (p=0.043).",
                "Multiple regression analyses revealed that the decreased white blood cell count was significantly associated with the genotype of UGT1A1*6 or *28 (+/+) (p=0.009)... and that of UGT1A1*6 or *28 (+/+) was significantly related to decreased neutrophil count (p=0.017).",
                "Patients with UGT1A1*6 or *28 (+/+) should be especially concerned about neutropenia and leukopenia during nal-IRI/FL treatment."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "UGT1A1*6",
              "Gene": "UGT1A1",
              "Drug(s)": "Nanoliposomal irinotecan, 5-fluorouracil, L-leucovorin",
              "PMID": 38707740,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Patients with UGT1A1*6 or *28 (+/+) exhibited significantly lower nadir counts of white blood cells and neutrophils.",
              "Sentence": "UGT1A1*6 or *28 (+/+) is associated with decreased white blood cell count and neutrophil count when treated with nanoliposomal irinotecan plus 5-fluorouracil and L-leucovorin in people with metastatic pancreatic cancer.",
              "Alleles": "(+/+), (-/-), (+/-)",
              "Specialty Population": null,
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "leukopenia, neutropenia",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "metastatic pancreatic cancer",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "(-/-), (+/-)",
              "Comparison Metabolizer types": null,
              "PMID_norm": null,
              "Variant Annotation ID_norm": null,
              "Citations": [
                "Patients with UGT1A1*6 or *28 (+/+) exhibited significantly lower nadir counts of white blood cells (p=0.033) and neutrophils (p=0.043).",
                "Multiple regression analyses revealed that the decreased white blood cell count was significantly associated with the genotype of UGT1A1*6 or *28 (+/+) (p=0.009)... and that of UGT1A1*6 or *28 (+/+) was significantly related to decreased neutrophil count (p=0.017).",
                "Patients with UGT1A1*6 or *28 (+/+) should be especially concerned about neutropenia and leukopenia during nal-IRI/FL treatment."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "or",
              "Gene": "UGT1A1",
              "Drug(s)": "Nanoliposomal irinotecan, 5-fluorouracil, L-leucovorin",
              "PMID": 38707740,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Patients with UGT1A1*6 or *28 (+/+) exhibited significantly lower nadir counts of white blood cells and neutrophils.",
              "Sentence": "UGT1A1*6 or *28 (+/+) is associated with decreased white blood cell count and neutrophil count when treated with nanoliposomal irinotecan plus 5-fluorouracil and L-leucovorin in people with metastatic pancreatic cancer.",
              "Alleles": "(+/+), (-/-), (+/-)",
              "Specialty Population": null,
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "leukopenia, neutropenia",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "metastatic pancreatic cancer",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "(-/-), (+/-)",
              "Comparison Metabolizer types": null,
              "PMID_norm": null,
              "Variant Annotation ID_norm": null,
              "Citations": [
                "Patients with UGT1A1*6 or *28 (+/+) exhibited significantly lower nadir counts of white blood cells (p=0.033) and neutrophils (p=0.043).",
                "Multiple regression analyses revealed that the decreased white blood cell count was significantly associated with the genotype of UGT1A1*6 or *28 (+/+) (p=0.009)... and that of UGT1A1*6 or *28 (+/+) was significantly related to decreased neutrophil count (p=0.017).",
                "Patients with UGT1A1*6 or *28 (+/+) should be especially concerned about neutropenia and leukopenia during nal-IRI/FL treatment."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "*28",
              "Gene": "UGT1A1",
              "Drug(s)": "Nanoliposomal irinotecan, 5-fluorouracil, L-leucovorin",
              "PMID": 38707740,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Patients with UGT1A1*6 or *28 (+/+) exhibited significantly lower nadir counts of white blood cells and neutrophils.",
              "Sentence": "UGT1A1*6 or *28 (+/+) is associated with decreased white blood cell count and neutrophil count when treated with nanoliposomal irinotecan plus 5-fluorouracil and L-leucovorin in people with metastatic pancreatic cancer.",
              "Alleles": "(+/+), (-/-), (+/-)",
              "Specialty Population": null,
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "leukopenia, neutropenia",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "metastatic pancreatic cancer",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "(-/-), (+/-)",
              "Comparison Metabolizer types": null,
              "PMID_norm": null,
              "Variant Annotation ID_norm": null,
              "Citations": [
                "Patients with UGT1A1*6 or *28 (+/+) exhibited significantly lower nadir counts of white blood cells (p=0.033) and neutrophils (p=0.043).",
                "Multiple regression analyses revealed that the decreased white blood cell count was significantly associated with the genotype of UGT1A1*6 or *28 (+/+) (p=0.009)... and that of UGT1A1*6 or *28 (+/+) was significantly related to decreased neutrophil count (p=0.017).",
                "Patients with UGT1A1*6 or *28 (+/+) should be especially concerned about neutropenia and leukopenia during nal-IRI/FL treatment."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "(+/-)",
              "Gene": "UGT1A1",
              "Drug(s)": "Nanoliposomal irinotecan, 5-fluorouracil, L-leucovorin",
              "PMID": 38707740,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Patients with UGT1A1*6 or *28 (+/+) exhibited significantly lower nadir counts of white blood cells and neutrophils.",
              "Sentence": "UGT1A1*6 or *28 (+/+) is associated with decreased white blood cell count and neutrophil count when treated with nanoliposomal irinotecan plus 5-fluorouracil and L-leucovorin in people with metastatic pancreatic cancer.",
              "Alleles": "(+/+), (-/-), (+/-)",
              "Specialty Population": null,
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "leukopenia, neutropenia",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "metastatic pancreatic cancer",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "(-/-), (+/-)",
              "Comparison Metabolizer types": null,
              "PMID_norm": null,
              "Variant Annotation ID_norm": null,
              "Citations": [
                "Patients with UGT1A1*6 or *28 (+/+) exhibited significantly lower nadir counts of white blood cells (p=0.033) and neutrophils (p=0.043).",
                "Multiple regression analyses revealed that the decreased white blood cell count was significantly associated with the genotype of UGT1A1*6 or *28 (+/+) (p=0.009)... and that of UGT1A1*6 or *28 (+/+) was significantly related to decreased neutrophil count (p=0.017).",
                "Patients with UGT1A1*6 or *28 (+/+) should be especially concerned about neutropenia and leukopenia during nal-IRI/FL treatment."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "polymorphism",
              "Gene": "UGT1A1",
              "Drug(s)": "Nanoliposomal irinotecan, 5-fluorouracil, L-leucovorin",
              "PMID": 38707740,
              "Phenotype Category": "dosage",
              "Significance": "yes",
              "Notes": "Decreased white blood cell count was significantly associated with high AST values before therapy and pancreatic head cancer.",
              "Sentence": "UGT1A1 polymorphism is associated with dosage requirements of nanoliposomal irinotecan when treated with 5-fluorouracil and L-leucovorin in people with metastatic pancreatic cancer.",
              "Alleles": null,
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": null,
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "dosage",
              "Phenotype": "dosage requirements",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": "and",
              "Population types": "in people with",
              "Population Phenotypes or diseases": "metastatic pancreatic cancer",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": null,
              "Variant Annotation ID_norm": null,
              "Citations": [
                "Patients with UGT1A1*6 or *28 (+/+) exhibited significantly lower nadir counts of white blood cells (p=0.033) and neutrophils (p=0.043).",
                "Multiple regression analyses revealed that the decreased white blood cell count was significantly associated with the genotype of UGT1A1*6 or *28 (+/+) (p=0.009)",
                "Patients with UGT1A1*6 or *28 (+/+) should be especially concerned about neutropenia and leukopenia during nal-IRI/FL treatment."
              ],
              "_expanded_from_multi_variant": true
            }
          ]
        },
        "functional_analysis": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "status": "missing_var_fa_ann"
        },
        "study_parameters": {
          "total_samples": 3,
          "field_scores": {
            "Study Type": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            },
            "Study Cases": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                0.0,
                0.0
              ]
            },
            "Study Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            },
            "Characteristics": {
              "mean_score": 0.8882995049158732,
              "scores": [
                0.9087681770324707,
                0.8776070475578308,
                0.8785232901573181
              ]
            },
            "Characteristics Type": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            },
            "Frequency In Cases": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            },
            "Allele Of Frequency In Cases": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            },
            "Frequency In Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            },
            "Allele Of Frequency In Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            },
            "P Value": {
              "mean_score": 0.5,
              "scores": [
                0.0,
                1.0,
                0.5
              ]
            },
            "Ratio Stat Type": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                0.0,
                0.0
              ]
            },
            "Ratio Stat": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            },
            "Confidence Interval Start": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            },
            "Confidence Interval Stop": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            },
            "Biogeographical Groups": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.803664411438836,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 1.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.9087681770324707,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.0,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1452474677,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1452474670,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Study Cases": {
                  "ground_truth": 29.0,
                  "prediction": 29
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "diarrhea greater than grade 1 during Nanoliposomal irinotecan +  5-fluorouracil (5-FU) and leucovorin treatment",
                  "prediction": "Patients with metastatic pancreatic cancer; incidence of grade \u22651 diarrhea"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.943",
                  "prediction": null
                },
                "Ratio Stat Type": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "East Asian",
                  "prediction": "Unknown"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 1.0,
                "Study Cases": 0.0,
                "Study Controls": 1.0,
                "Characteristics": 0.8776070475578308,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 1.0,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1452474729,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1452474678,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Study Cases": {
                  "ground_truth": 31.0,
                  "prediction": 36
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "predictive factors for leukopenia (multiple regression) during Nanoliposomal irinotecan +  5-fluorouracil (5-FU) and leucovorin treatment",
                  "prediction": "Patients with metastatic pancreatic cancer; UGT1A1 homozygous (+/+) genotype"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.009",
                  "prediction": "= 0.009"
                },
                "Ratio Stat Type": {
                  "ground_truth": null,
                  "prediction": "Unknown"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "East Asian",
                  "prediction": "Unknown"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 2,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 1.0,
                "Study Cases": 0.0,
                "Study Controls": 1.0,
                "Characteristics": 0.8785232901573181,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.5,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1452474688,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1452474678,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Study Cases": {
                  "ground_truth": 31.0,
                  "prediction": 36
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "predictive factors for neutropenia (multiple regression) during Nanoliposomal irinotecan +  5-fluorouracil (5-FU) and leucovorin treatment",
                  "prediction": "Patients with metastatic pancreatic cancer; UGT1A1 genotypes (wild-type, heterozygous, homozygous)"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.017",
                  "prediction": "= 0.033"
                },
                "Ratio Stat Type": {
                  "ground_truth": null,
                  "prediction": "Unknown"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "East Asian",
                  "prediction": "Unknown"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            }
          ],
          "aligned_variants": [
            "None:diarrhea greater tha",
            "None:predictive factors f",
            "None:predictive factors f"
          ],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": null,
              "Study Cases": 36,
              "Study Controls": null,
              "Characteristics": "Patients with metastatic pancreatic cancer; high AST value before therapy",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.019",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Unknown",
              "Variant Annotation ID_norm": null
            },
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": null,
              "Study Cases": 36,
              "Study Controls": null,
              "Characteristics": "Patients with metastatic pancreatic cancer; pancreatic head cancer",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.030",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Unknown",
              "Variant Annotation ID_norm": null
            }
          ]
        }
      },
      "overall_score": 0.3572030823098289,
      "num_benchmarks": 4
    },
    {
      "pmid": "39346054",
      "pmcid": "PMC11430164",
      "title": "The effect of gene polymorphism on ticagrelor metabolism: an in vitro study of 22 CYP3A4 variants in Chinese Han population",
      "benchmarks": {
        "drug_annotations": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Variant/Haplotypes": "CYP3A4*11",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4*11 exhibited significantly higher intrinsic clearance compared to wild-type CYP3A4*1.",
              "Sentence": "CYP3A4*11 is associated with increased metabolism of ticagrelor in individuals of Chinese Han population.",
              "Alleles": "*11",
              "Metabolizer types": "extensive metabolizer",
              "Comparison Allele(s) or Genotype(s)": "CYP3A4*1",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "",
              "Population types": "in individuals of Chinese Han population",
              "Population Phenotypes or diseases": "",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "metabolism of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "The intrinsic clearance of CYP3A4*11, *18 and *33 was much higher than that of wild-type;",
                "CYP3A4*11 exhibited significantly higher intrinsic clearance compared to wild-type CYP3A4*1,",
                "CYP3A4*11, *18, and *33 show significantly higher catalytic activities compared to the wild-type."
              ]
            },
            {
              "Variant/Haplotypes": "CYP3A4*18",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4*18 displayed significantly higher intrinsic clearance than wild-type.",
              "Sentence": "CYP3A4*18 is associated with increased metabolism of ticagrelor in individuals of Chinese Han population.",
              "Alleles": "*18",
              "Metabolizer types": "extensive metabolizer",
              "Comparison Allele(s) or Genotype(s)": "CYP3A4*1",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "",
              "Population types": "in individuals of Chinese Han population",
              "Population Phenotypes or diseases": "",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "metabolism of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "The intrinsic clearance of CYP3A4*11, *18 and *33 was much higher than that of wild-type... CYP3A4*18 displayed significantly higher intrinsic clearance than wild-type.",
                "CYP3A4 gene polymorphism is an important factor in drug metabolism... We hope that these results will help to identify PMs, expand the existing database on CYP3A4 gene polymorphisms, facilitate the development of metabolic models, and provide valuable reference for predicting in vivo ticagrelor concentration.",
                "The results suggested that there is allele-specific activity towards ticagrelor in vitro."
              ]
            },
            {
              "Variant/Haplotypes": "CYP3A4*33",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4*33 showed significantly higher intrinsic clearance compared to wild-type.",
              "Sentence": "CYP3A4*33 is associated with increased metabolism of ticagrelor in individuals of Chinese Han population.",
              "Alleles": "*33",
              "Metabolizer types": "extensive metabolizer",
              "Comparison Allele(s) or Genotype(s)": "CYP3A4*1",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "",
              "Population types": "in individuals of Chinese Han population",
              "Population Phenotypes or diseases": "",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "metabolism of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "The intrinsic clearance of CYP3A4*11, *18 and *33 was much higher than that of wild-type;...",
                "CYP3A4*33 showed significantly higher intrinsic clearance compared to wild-type.",
                "...we evaluated the effect of CYP3A4*1G and 22 CYP3A4 variants, including seven new variants that specifically distributed in Chinese Han population, on ticagrelor metabolism..."
              ]
            },
            {
              "Variant/Haplotypes": "CYP3A4*2",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4*2 displayed significantly lower intrinsic clearance compared to wild-type.",
              "Sentence": "CYP3A4*2 is associated with decreased metabolism of ticagrelor in individuals of Chinese Han population.",
              "Alleles": "*2",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "CYP3A4*1",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "",
              "Population types": "in individuals of Chinese Han population",
              "Population Phenotypes or diseases": "",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "metabolism of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "CYP3A4*2 exhibits a 74.48% decrease in intrinsic clearance for ticagrelor when compared to the wild-type.",
                "The remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type.",
                "This study aimed to evaluate the catalytic characteristics of 22 CYP3A4 alleles identified in the Chinese Han population on the metabolism of ticagrelor in vitro, focusing on the effect of CYP3A4 polymorphism on ticagrelor metabolism."
              ]
            },
            {
              "Variant/Haplotypes": "CYP3A4*3",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4*3 exhibited significantly lower intrinsic clearance than wild-type.",
              "Sentence": "CYP3A4*3 is associated with decreased metabolism of ticagrelor in individuals of Chinese Han population.",
              "Alleles": "*3",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "CYP3A4*1",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "",
              "Population types": "in individuals of Chinese Han population",
              "Population Phenotypes or diseases": "",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "metabolism of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "The remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type.",
                "CYP3A4*3 was first identified in Chinese subject from Shanghai... This study confirmed this point: the increase in Km is larger than that of Vmax, resulting in a 64.99% decrease in CLint for CYP3A4*3 compared with CYP3A4*1.",
                "In this study, we evaluated the effect of CYP3A4*1G and 22 CYP3A4 variants, including seven new variants that specifically distributed in Chinese Han population, on ticagrelor metabolism."
              ]
            },
            {
              "Variant/Haplotypes": "CYP3A4*24",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4*24 demonstrated severely reduced activity in ticagrelor metabolism.",
              "Sentence": "CYP3A4*24 is associated with decreased metabolism of ticagrelor in individuals of Chinese Han population.",
              "Alleles": "*24",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "CYP3A4*1",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "",
              "Population types": "in individuals of Chinese Han population",
              "Population Phenotypes or diseases": "",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "metabolism of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "CYP3A4*24 (Q200H) involves an A \u2192T nucleotide substitution in exon 7, which causes a change from glutamine to histidine at position 220. In this study, CYP3A4*24 showed feeble catalytic activity towards ticagrelor, with only 1.48% relative clearance.",
                "CYP3A4*17 (F189S) and *24 (Q200H) exhibit severely reduced activity in the metabolism of ticagrelor, with over 90% decreased CLint compared to the wild-type."
              ]
            },
            {
              "Variant/Haplotypes": "CYP3A4*30",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "Phenotype Category": "Metabolism/PK",
              "Significance": "not stated",
              "Notes": "CYP3A4*30 displayed weak or no activity.",
              "Sentence": "CYP3A4*30 is not associated with effective metabolism of ticagrelor in individuals of Chinese Han population.",
              "Alleles": "*30",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "CYP3A4*1",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "",
              "Population types": "in individuals of Chinese Han population",
              "Population Phenotypes or diseases": "",
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "",
              "PD/PK terms": "metabolism of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "CYP3A4*30 displayed weak or no activity.",
                "CYP3A4*30 (R130STOP) could not be determined because of no detectable enzymatic activity toward ticagrelor.",
                "Our results provide some support for this prediction, indicating that CYP3A4*30 exhibits a markedly reduced Clint for ticagrelor, achieving only 4.72% of the activity observed in the wild-type."
              ]
            },
            {
              "Variant/Haplotypes": "CYP3A4*17",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4*17 showed significantly lower intrinsic clearance compared to wild-type.",
              "Sentence": "CYP3A4*17 is associated with decreased metabolism of ticagrelor in individuals of Chinese Han population.",
              "Alleles": "*17",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "CYP3A4*1",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "",
              "Population types": "in individuals of Chinese Han population",
              "Population Phenotypes or diseases": "",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "metabolism of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "CYP3A4*17 (F189S) and *24 (Q200H) exhibit severely reduced activity in the metabolism of ticagrelor, with over 90% decreased CLint compared to the wild-type.",
                "CYP3A4*17 exhibits a markedly reduced Clint for ticagrelor, achieving only 4.72% of the activity observed in the wild-type.",
                "The remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type."
              ]
            }
          ]
        },
        "phenotype_annotations": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": []
        },
        "functional_analysis": {
          "total_samples": 19,
          "field_scores": {
            "Variant/Haplotypes": {
              "mean_score": 0.049999999999999996,
              "scores": [
                0.95,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Gene": {
              "mean_score": 0.05263157894736842,
              "scores": [
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Drug(s)": {
              "mean_score": 0.05263157894736842,
              "scores": [
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "PMID": {
              "mean_score": 0.05263157894736842,
              "scores": [
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Phenotype Category": {
              "mean_score": 0.05263157894736842,
              "scores": [
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Significance": {
              "mean_score": 0.05263157894736842,
              "scores": [
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Alleles": {
              "mean_score": 0.046135281261644866,
              "scores": [
                0.8765703439712524,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Specialty Population": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Assay type": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Metabolizer types": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "isPlural": {
              "mean_score": 0.05263157894736842,
              "scores": [
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Is/Is Not associated": {
              "mean_score": 0.05263157894736842,
              "scores": [
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Direction of effect": {
              "mean_score": 0.05263157894736842,
              "scores": [
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Functional terms": {
              "mean_score": 0.05263157894736842,
              "scores": [
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Gene/gene product": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "When treated with/exposed to/when assayed with": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Multiple drugs And/or": {
              "mean_score": 0.05263157894736842,
              "scores": [
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Cell type": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Comparison Allele(s) or Genotype(s)": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Comparison Metabolizer types": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.03112255353676645,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Variant/Haplotypes": 0.95,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "PMID": 1.0,
                "Phenotype Category": 1.0,
                "Significance": 1.0,
                "Alleles": 0.8765703439712524,
                "Specialty Population": 0.0,
                "Assay type": 0.0,
                "Metabolizer types": 0.0,
                "isPlural": 1.0,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Functional terms": 1.0,
                "Gene/gene product": 0.0,
                "When treated with/exposed to/when assayed with": 0.0,
                "Multiple drugs And/or": 1.0,
                "Cell type": 0.0,
                "Comparison Allele(s) or Genotype(s)": 0.0,
                "Comparison Metabolizer types": 0.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "CYP3A4*1",
                  "prediction": "CYP3A4*1G"
                },
                "Gene": {
                  "ground_truth": "CYP3A4",
                  "prediction": "CYP3A4"
                },
                "Drug(s)": {
                  "ground_truth": "ticagrelor",
                  "prediction": "ticagrelor"
                },
                "PMID": {
                  "ground_truth": 39346054,
                  "prediction": 39346054
                },
                "Phenotype Category": {
                  "ground_truth": "Metabolism/PK",
                  "prediction": "metabolism/PK"
                },
                "Significance": {
                  "ground_truth": "yes",
                  "prediction": "yes"
                },
                "Alleles": {
                  "ground_truth": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
                  "prediction": "*1G"
                },
                "Specialty Population": {
                  "ground_truth": null,
                  "prediction": ""
                },
                "Assay type": {
                  "ground_truth": null,
                  "prediction": "insect cells"
                },
                "Metabolizer types": {
                  "ground_truth": null,
                  "prediction": ""
                },
                "isPlural": {
                  "ground_truth": "Is",
                  "prediction": "Is"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "decreased",
                  "prediction": "decreased"
                },
                "Functional terms": {
                  "ground_truth": "clearance of",
                  "prediction": "clearance of"
                },
                "Gene/gene product": {
                  "ground_truth": null,
                  "prediction": "CYP3A4"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": null,
                  "prediction": "when assayed with"
                },
                "Multiple drugs And/or": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Cell type": {
                  "ground_truth": null,
                  "prediction": "in insect microsomes"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "*1",
                  "prediction": null
                },
                "Comparison Metabolizer types": {
                  "ground_truth": null,
                  "prediction": ""
                }
              },
              "dependency_issues": [
                "Invalid star allele format: CYP3A4*1G"
              ],
              "penalty_info": {
                "total_penalty": 0.05,
                "penalized_fields": {
                  "Variant/Haplotypes": {
                    "original_score": 1.0,
                    "penalized_score": 0.95,
                    "penalty_percentage": 5.0
                  }
                },
                "issues_by_field": {
                  "Variant/Haplotypes": [
                    "Invalid star allele format: CYP3A4*1G"
                  ]
                }
              }
            }
          ],
          "aligned_variants": [
            "cyp3a4*1"
          ],
          "unmatched_ground_truth": [
            {
              "Variant Annotation ID": 1452626580,
              "Variant/Haplotypes": "CYP3A4*2",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "PMID": 39346054,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type",
              "Sentence": "CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
              "Alleles": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
              "Specialty Population": null,
              "Assay type": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Functional terms": "clearance of",
              "Gene/gene product": null,
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "39346054",
              "Variant Annotation ID_norm": "1452626580",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1452626580,
              "Variant/Haplotypes": "CYP3A4*3",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "PMID": 39346054,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type",
              "Sentence": "CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
              "Alleles": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
              "Specialty Population": null,
              "Assay type": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Functional terms": "clearance of",
              "Gene/gene product": null,
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "39346054",
              "Variant Annotation ID_norm": "1452626580",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1452626580,
              "Variant/Haplotypes": "CYP3A4*4",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "PMID": 39346054,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type",
              "Sentence": "CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
              "Alleles": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
              "Specialty Population": null,
              "Assay type": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Functional terms": "clearance of",
              "Gene/gene product": null,
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "39346054",
              "Variant Annotation ID_norm": "1452626580",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1452626580,
              "Variant/Haplotypes": "CYP3A4*5",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "PMID": 39346054,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type",
              "Sentence": "CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
              "Alleles": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
              "Specialty Population": null,
              "Assay type": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Functional terms": "clearance of",
              "Gene/gene product": null,
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "39346054",
              "Variant Annotation ID_norm": "1452626580",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1452626580,
              "Variant/Haplotypes": "CYP3A4*9",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "PMID": 39346054,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type",
              "Sentence": "CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
              "Alleles": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
              "Specialty Population": null,
              "Assay type": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Functional terms": "clearance of",
              "Gene/gene product": null,
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "39346054",
              "Variant Annotation ID_norm": "1452626580",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1452626580,
              "Variant/Haplotypes": "CYP3A4*14",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "PMID": 39346054,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type",
              "Sentence": "CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
              "Alleles": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
              "Specialty Population": null,
              "Assay type": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Functional terms": "clearance of",
              "Gene/gene product": null,
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "39346054",
              "Variant Annotation ID_norm": "1452626580",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1452626580,
              "Variant/Haplotypes": "CYP3A4*15",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "PMID": 39346054,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type",
              "Sentence": "CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
              "Alleles": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
              "Specialty Population": null,
              "Assay type": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Functional terms": "clearance of",
              "Gene/gene product": null,
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "39346054",
              "Variant Annotation ID_norm": "1452626580",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1452626580,
              "Variant/Haplotypes": "CYP3A4*16",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "PMID": 39346054,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type",
              "Sentence": "CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
              "Alleles": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
              "Specialty Population": null,
              "Assay type": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Functional terms": "clearance of",
              "Gene/gene product": null,
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "39346054",
              "Variant Annotation ID_norm": "1452626580",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1452626580,
              "Variant/Haplotypes": "CYP3A4*17",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "PMID": 39346054,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type",
              "Sentence": "CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
              "Alleles": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
              "Specialty Population": null,
              "Assay type": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Functional terms": "clearance of",
              "Gene/gene product": null,
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "39346054",
              "Variant Annotation ID_norm": "1452626580",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1452626580,
              "Variant/Haplotypes": "CYP3A4*19",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "PMID": 39346054,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type",
              "Sentence": "CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
              "Alleles": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
              "Specialty Population": null,
              "Assay type": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Functional terms": "clearance of",
              "Gene/gene product": null,
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "39346054",
              "Variant Annotation ID_norm": "1452626580",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1452626580,
              "Variant/Haplotypes": "CYP3A4*24",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "PMID": 39346054,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type",
              "Sentence": "CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
              "Alleles": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
              "Specialty Population": null,
              "Assay type": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Functional terms": "clearance of",
              "Gene/gene product": null,
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "39346054",
              "Variant Annotation ID_norm": "1452626580",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1452626580,
              "Variant/Haplotypes": "CYP3A4*28",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "PMID": 39346054,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type",
              "Sentence": "CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
              "Alleles": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
              "Specialty Population": null,
              "Assay type": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Functional terms": "clearance of",
              "Gene/gene product": null,
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "39346054",
              "Variant Annotation ID_norm": "1452626580",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1452626580,
              "Variant/Haplotypes": "CYP3A4*29",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "PMID": 39346054,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type",
              "Sentence": "CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
              "Alleles": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
              "Specialty Population": null,
              "Assay type": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Functional terms": "clearance of",
              "Gene/gene product": null,
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "39346054",
              "Variant Annotation ID_norm": "1452626580",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1452626580,
              "Variant/Haplotypes": "CYP3A4*31",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "PMID": 39346054,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type",
              "Sentence": "CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
              "Alleles": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
              "Specialty Population": null,
              "Assay type": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Functional terms": "clearance of",
              "Gene/gene product": null,
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "39346054",
              "Variant Annotation ID_norm": "1452626580",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1452626560,
              "Variant/Haplotypes": "CYP3A4*1",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "PMID": 39346054,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type",
              "Sentence": "CYP3A4 *11 + *18 + *33 is associated with increased clearance of ticagrelor as compared to CYP3A4 *1.",
              "Alleles": "*11 + *18 + *33",
              "Specialty Population": null,
              "Assay type": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Functional terms": "clearance of",
              "Gene/gene product": null,
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "39346054",
              "Variant Annotation ID_norm": "1452626560",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1452626560,
              "Variant/Haplotypes": "CYP3A4*11",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "PMID": 39346054,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type",
              "Sentence": "CYP3A4 *11 + *18 + *33 is associated with increased clearance of ticagrelor as compared to CYP3A4 *1.",
              "Alleles": "*11 + *18 + *33",
              "Specialty Population": null,
              "Assay type": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Functional terms": "clearance of",
              "Gene/gene product": null,
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "39346054",
              "Variant Annotation ID_norm": "1452626560",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1452626560,
              "Variant/Haplotypes": "CYP3A4*18",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "PMID": 39346054,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type",
              "Sentence": "CYP3A4 *11 + *18 + *33 is associated with increased clearance of ticagrelor as compared to CYP3A4 *1.",
              "Alleles": "*11 + *18 + *33",
              "Specialty Population": null,
              "Assay type": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Functional terms": "clearance of",
              "Gene/gene product": null,
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "39346054",
              "Variant Annotation ID_norm": "1452626560",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1452626560,
              "Variant/Haplotypes": "CYP3A4*33",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "PMID": 39346054,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type",
              "Sentence": "CYP3A4 *11 + *18 + *33 is associated with increased clearance of ticagrelor as compared to CYP3A4 *1.",
              "Alleles": "*11 + *18 + *33",
              "Specialty Population": null,
              "Assay type": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Functional terms": "clearance of",
              "Gene/gene product": null,
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "39346054",
              "Variant Annotation ID_norm": "1452626560",
              "_expanded_from_multi_variant": true
            }
          ],
          "unmatched_predictions": [],
          "status": "ok"
        },
        "study_parameters": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": null,
              "Study Cases": 22,
              "Study Controls": null,
              "Characteristics": "22 CYP3A4 variants in Chinese Han population",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": null,
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Chinese Han",
              "Variant Annotation ID_norm": null
            },
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": null,
              "Study Cases": 22,
              "Study Controls": null,
              "Characteristics": "CYP3A4*11, higher intrinsic clearance compared to wild-type",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "< 0.01",
              "Ratio Stat Type": "CLint",
              "Ratio Stat": 2.6473,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Chinese Han",
              "Variant Annotation ID_norm": null
            },
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": null,
              "Study Cases": 22,
              "Study Controls": null,
              "Characteristics": "CYP3A4*18, increased intrinsic clearance compared to wild-type",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "< 0.01",
              "Ratio Stat Type": "CLint",
              "Ratio Stat": 1.2249,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Chinese Han",
              "Variant Annotation ID_norm": null
            },
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": null,
              "Study Cases": 22,
              "Study Controls": null,
              "Characteristics": "CYP3A4*33, higher intrinsic clearance compared to wild-type",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "< 0.01",
              "Ratio Stat Type": "CLint",
              "Ratio Stat": 9.4029,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Chinese Han",
              "Variant Annotation ID_norm": null
            },
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": null,
              "Study Cases": 22,
              "Study Controls": null,
              "Characteristics": "CYP3A4*30, weak or no activity",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": null,
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Chinese Han",
              "Variant Annotation ID_norm": null
            },
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": null,
              "Study Cases": 22,
              "Study Controls": null,
              "Characteristics": "CYP3A4*24, low intrinsic clearance compared to wild-type",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "< 0.01",
              "Ratio Stat Type": "CLint",
              "Ratio Stat": 0.0148,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Chinese Han",
              "Variant Annotation ID_norm": null
            }
          ]
        }
      },
      "overall_score": 0.0062245107073532905,
      "num_benchmarks": 4
    },
    {
      "pmid": "39604537",
      "pmcid": "PMC11603346",
      "title": "Association between the CYP2B6 polymorphisms and nonnucleoside reverse transcriptase inhibitors drug-induced liver injury: a systematic review and meta-analysis",
      "benchmarks": {
        "drug_annotations": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Variant/Haplotypes": "CYP2B6*6",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "CYP2B6*6 carriers were significantly more susceptible to EFV-induced liver injury with an odds ratio (OR) of 1.83 (1.15-2.90).",
              "Sentence": "CYP2B6*6 is associated with increased risk of liver injury in efavirenz context in PLHIV.",
              "Alleles": "CYP2B6*6",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "CYP2B6*1/*1",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "",
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Other: HIV",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "toxicity of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "CYP2B6 *6* carriers were significantly more susceptible to EFV-induced liver injury, with an odds ratio (OR) of 1.83 (1.15-2.90),...",
                "The results illustrated that the ARVDILI was primarily involved in xenobiotic metabolism. Interestingly, the STRING database indicates that CYP2D6, CYP1A1, and CYP2B6 seem to be the center of the interaction among those proteins...",
                "Our findings demonstrated that a genotype known as CYP2B6 *6*, which is related with a decreased ability to metabolize drugs, was linked to an increased risk of ARVDILI in PLHIV patients who were using EFV."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "(rs3745274",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "CYP2B6*6 carriers were significantly more susceptible to EFV-induced liver injury with an odds ratio (OR) of 1.83 (1.15-2.90).",
              "Sentence": "CYP2B6*6 is associated with increased risk of liver injury in efavirenz context in PLHIV.",
              "Alleles": "CYP2B6*6",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "CYP2B6*1/*1",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "",
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Other: HIV",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "toxicity of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "CYP2B6 *6* carriers were significantly more susceptible to EFV-induced liver injury, with an odds ratio (OR) of 1.83 (1.15-2.90),...",
                "The results illustrated that the ARVDILI was primarily involved in xenobiotic metabolism. Interestingly, the STRING database indicates that CYP2D6, CYP1A1, and CYP2B6 seem to be the center of the interaction among those proteins...",
                "Our findings demonstrated that a genotype known as CYP2B6 *6*, which is related with a decreased ability to metabolize drugs, was linked to an increased risk of ARVDILI in PLHIV patients who were using EFV."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "rs2279343)",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "CYP2B6*6 carriers were significantly more susceptible to EFV-induced liver injury with an odds ratio (OR) of 1.83 (1.15-2.90).",
              "Sentence": "CYP2B6*6 is associated with increased risk of liver injury in efavirenz context in PLHIV.",
              "Alleles": "CYP2B6*6",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "CYP2B6*1/*1",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "",
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Other: HIV",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "toxicity of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "CYP2B6 *6* carriers were significantly more susceptible to EFV-induced liver injury, with an odds ratio (OR) of 1.83 (1.15-2.90),...",
                "The results illustrated that the ARVDILI was primarily involved in xenobiotic metabolism. Interestingly, the STRING database indicates that CYP2D6, CYP1A1, and CYP2B6 seem to be the center of the interaction among those proteins...",
                "Our findings demonstrated that a genotype known as CYP2B6 *6*, which is related with a decreased ability to metabolize drugs, was linked to an increased risk of ARVDILI in PLHIV patients who were using EFV."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "CYP2B6*1/*6",
              "Gene": "CYP2B6",
              "Drug(s)": "nevirapine",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "CYP2B6*1/*6 and *6/*6 genotypes showed a reduced susceptibility to nevirapine-induced liver injury with an OR of 0.44 (0.22-0.91).",
              "Sentence": "CYP2B6*1/*6 is associated with decreased risk of liver injury in nevirapine context in PLHIV.",
              "Alleles": "CYP2B6*1/*6",
              "Metabolizer types": "intermediate metabolizer",
              "Comparison Allele(s) or Genotype(s)": "CYP2B6*1/*1",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "",
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Other: HIV",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "toxicity of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Meta-analysis showed that *CYP2B6* *1/*6* allele and combination of *1/*6 and *6/*6 alleles were significantly associated with a reduction in susceptibility to NVP-induced liver injury, compared with normal metabolizer, with pooled OR and 95% CI of 0.44 (0.22-0.91) and 0.42 (0.21-0.84), respectively, as well as *P* value less than 0.05.",
                "In contrast to the above findings, other previous studies unveiled no correlation between *CYP2B6*6* polymorphisms and susceptibility to ARVDILI due to efavirenz as well as nevirapine.",
                "CYP2B6 *6* haplotype is characterized by the existence of two variants, G516T (rs3745274) and A785G (rs2279343), with or without promoter variants."
              ]
            }
          ]
        },
        "phenotype_annotations": {
          "total_samples": 4,
          "field_scores": {
            "Variant/Haplotypes": {
              "mean_score": 0.25,
              "scores": [
                0.0,
                1.0,
                0.0,
                0.0
              ]
            },
            "Gene": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0
              ]
            },
            "Drug(s)": {
              "mean_score": 0.4649048447608948,
              "scores": [
                0.9704786539077759,
                0.8891407251358032,
                0.0,
                0.0
              ]
            },
            "Phenotype Category": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0
              ]
            },
            "Alleles": {
              "mean_score": 0.4842963218688965,
              "scores": [
                0.9890725016593933,
                0.9481127858161926,
                0.0,
                0.0
              ]
            },
            "Is/Is Not associated": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0
              ]
            },
            "Direction of effect": {
              "mean_score": 0.25,
              "scores": [
                1.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Phenotype": {
              "mean_score": 0.473078191280365,
              "scores": [
                0.94615638256073,
                0.94615638256073,
                0.0,
                0.0
              ]
            },
            "When treated with/exposed to/when assayed with": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0
              ]
            },
            "Comparison Allele(s) or Genotype(s)": {
              "mean_score": 0.4561042785644531,
              "scores": [
                0.9122085571289062,
                0.9122085571289062,
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.42300520092248917,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Variant/Haplotypes": 0.0,
                "Gene": 1.0,
                "Drug(s)": 0.9704786539077759,
                "Phenotype Category": 1.0,
                "Alleles": 0.9890725016593933,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.94615638256073,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.9122085571289062
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "CYP2B6*1",
                  "prediction": "CYP2B6*1/*6"
                },
                "Gene": {
                  "ground_truth": "CYP2B6",
                  "prediction": "CYP2B6"
                },
                "Drug(s)": {
                  "ground_truth": "nevirapine",
                  "prediction": "Nevirapine (NVP)"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "*1/*6 + *6/*6",
                  "prediction": "*1/*6"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "decreased",
                  "prediction": "decreased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:Drug-induced liver injury",
                  "prediction": "liver injury"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "*1/*1",
                  "prediction": "CYP2B6*1/*1"
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "Drug(s)": 0.8891407251358032,
                "Phenotype Category": 1.0,
                "Alleles": 0.9481127858161926,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 0.0,
                "Phenotype": 0.94615638256073,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.9122085571289062
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "CYP2B6*6",
                  "prediction": "CYP2B6*6"
                },
                "Gene": {
                  "ground_truth": "CYP2B6",
                  "prediction": "CYP2B6"
                },
                "Drug(s)": {
                  "ground_truth": "nevirapine",
                  "prediction": "Efavirenz (EFV)"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "*1/*6 + *6/*6",
                  "prediction": "*6"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "decreased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:Drug-induced liver injury",
                  "prediction": "liver injury"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "*1/*1",
                  "prediction": "CYP2B6*1/*1"
                }
              },
              "dependency_issues": []
            }
          ],
          "aligned_variants": [
            "cyp2b6*1",
            "cyp2b6*6"
          ],
          "unmatched_ground_truth": [
            {
              "Variant Annotation ID": 1452721001,
              "Variant/Haplotypes": "CYP2B6*1",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz",
              "PMID": 39604537,
              "Phenotype Category": "Toxicity",
              "Significance": "yes",
              "Notes": "Compared with normal metabolizers, CYP2B6 *6 carriers were significantly more susceptible to EFV-induced liver injury, with an odds ratio (OR) and 95% confidence interval (CI) of 1.83 (1.15-2.90), 2.48 (1.28-4.79), and 1.94 (1.24-3.01) for heterozygous, homozygous, and combination of both alleles, respectively, as well as P value less than 0.05 (Table 2).",
              "Sentence": "CYP2B6 *1/*6 + *6/*6 is associated with increased likelihood of Drug-induced liver injury when treated with efavirenz in people with HIV infectious disease as compared to CYP2B6 *1/*1.",
              "Alleles": "*1/*6 + *6/*6",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Side Effect:Drug-induced liver injury",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Other:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "39604537",
              "Variant Annotation ID_norm": "1452721001",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1452721001,
              "Variant/Haplotypes": "CYP2B6*6",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz",
              "PMID": 39604537,
              "Phenotype Category": "Toxicity",
              "Significance": "yes",
              "Notes": "Compared with normal metabolizers, CYP2B6 *6 carriers were significantly more susceptible to EFV-induced liver injury, with an odds ratio (OR) and 95% confidence interval (CI) of 1.83 (1.15-2.90), 2.48 (1.28-4.79), and 1.94 (1.24-3.01) for heterozygous, homozygous, and combination of both alleles, respectively, as well as P value less than 0.05 (Table 2).",
              "Sentence": "CYP2B6 *1/*6 + *6/*6 is associated with increased likelihood of Drug-induced liver injury when treated with efavirenz in people with HIV infectious disease as compared to CYP2B6 *1/*1.",
              "Alleles": "*1/*6 + *6/*6",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Side Effect:Drug-induced liver injury",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Other:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "39604537",
              "Variant Annotation ID_norm": "1452721001",
              "_expanded_from_multi_variant": true
            }
          ],
          "unmatched_predictions": [
            {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "(rs3745274",
              "Gene": "CYP2B6",
              "Drug(s)": "Efavirenz (EFV)",
              "PMID": 39604537,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "CYP2B6*6 carriers demonstrated increased susceptibility to EFV-induced liver injury in PLHIV, with OR of 1.83.",
              "Sentence": "CYP2B6*6 is associated with increased likelihood of efavirenz-induced liver injury when treated with efavirenz in people living with HIV.",
              "Alleles": "*6",
              "Specialty Population": null,
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "liver injury",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "HIV",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "CYP2B6*1/*1",
              "Comparison Metabolizer types": "normal metabolizer",
              "PMID_norm": "39604537",
              "Variant Annotation ID_norm": "1",
              "Citations": [
                "According to several findings from previous studies as a putative mediator for liver disease in PLHIV, CYP2B6 is the most promising of numerous intriguing genes associated with ARVDILI. It is responsible for several drugs metabolism and synthesizing cholesterol, steroids, and other lipids. Interestingly, CYP2B6 enzymes are also the primary metabolizers of nevirapine and efavirenz.",
                "Our findings demonstrated that a genotype known as CYP2B6*6, which is related with a decreased ability to metabolize drugs, was linked to an increased risk of ARVDILI in PLHIV patients who were using EFV.",
                "The pooled effects of CYP2B6 polymorphisms on EFV-induced liver injury occurrences in PLHIV are summarized... Compared with normal metabolizers, CYP2B6 *6 carriers were significantly more susceptible to EFV-induced liver injury, with an odds ratio (OR) and 95% confidence interval (CI) of 1.83 (1.15-2.90), 2.48 (1.28-4.79), and 1.94 (1.24-3.01) for heterozygous, homozygous, and combination of both alleles, respectively, as well as P value less than 0.05."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "rs2279343)",
              "Gene": "CYP2B6",
              "Drug(s)": "Efavirenz (EFV)",
              "PMID": 39604537,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "CYP2B6*6 carriers demonstrated increased susceptibility to EFV-induced liver injury in PLHIV, with OR of 1.83.",
              "Sentence": "CYP2B6*6 is associated with increased likelihood of efavirenz-induced liver injury when treated with efavirenz in people living with HIV.",
              "Alleles": "*6",
              "Specialty Population": null,
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "liver injury",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "HIV",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "CYP2B6*1/*1",
              "Comparison Metabolizer types": "normal metabolizer",
              "PMID_norm": "39604537",
              "Variant Annotation ID_norm": "1",
              "Citations": [
                "According to several findings from previous studies as a putative mediator for liver disease in PLHIV, CYP2B6 is the most promising of numerous intriguing genes associated with ARVDILI. It is responsible for several drugs metabolism and synthesizing cholesterol, steroids, and other lipids. Interestingly, CYP2B6 enzymes are also the primary metabolizers of nevirapine and efavirenz.",
                "Our findings demonstrated that a genotype known as CYP2B6*6, which is related with a decreased ability to metabolize drugs, was linked to an increased risk of ARVDILI in PLHIV patients who were using EFV.",
                "The pooled effects of CYP2B6 polymorphisms on EFV-induced liver injury occurrences in PLHIV are summarized... Compared with normal metabolizers, CYP2B6 *6 carriers were significantly more susceptible to EFV-induced liver injury, with an odds ratio (OR) and 95% confidence interval (CI) of 1.83 (1.15-2.90), 2.48 (1.28-4.79), and 1.94 (1.24-3.01) for heterozygous, homozygous, and combination of both alleles, respectively, as well as P value less than 0.05."
              ],
              "_expanded_from_multi_variant": true
            }
          ]
        },
        "functional_analysis": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "status": "missing_var_fa_ann"
        },
        "study_parameters": {
          "total_samples": 2,
          "field_scores": {
            "Study Type": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Study Cases": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Study Controls": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Characteristics": {
              "mean_score": 0.8468464612960815,
              "scores": [
                0.837369441986084,
                0.8563234806060791
              ]
            },
            "Characteristics Type": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Frequency In Cases": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Allele Of Frequency In Cases": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Frequency In Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Allele Of Frequency In Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "P Value": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Ratio Stat Type": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Ratio Stat": {
              "mean_score": 0.9,
              "scores": [
                1.0,
                0.8
              ]
            },
            "Confidence Interval Start": {
              "mean_score": 0.9,
              "scores": [
                1.0,
                0.8
              ]
            },
            "Confidence Interval Stop": {
              "mean_score": 0.95,
              "scores": [
                1.0,
                0.9
              ]
            },
            "Biogeographical Groups": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.7064564307530721,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 1.0,
                "Study Cases": 0.0,
                "Study Controls": 0.0,
                "Characteristics": 0.837369441986084,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.0,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1452720988,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1452720980,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "meta-analysis",
                  "prediction": "meta-analysis"
                },
                "Study Cases": {
                  "ground_truth": 504.0,
                  "prediction": 38
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": 782
                },
                "Characteristics": {
                  "ground_truth": "2 studies (Carr, Giacomelli): DILI",
                  "prediction": "CYP2B6 polymorphisms associated with nevirapine-induced liver injury"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "study cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.01",
                  "prediction": "< 0.05"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": 0.42,
                  "prediction": 0.42
                },
                "Confidence Interval Start": {
                  "ground_truth": 0.21,
                  "prediction": 0.21
                },
                "Confidence Interval Stop": {
                  "ground_truth": 0.84,
                  "prediction": 0.84
                },
                "Biogeographical Groups": {
                  "ground_truth": "Multiple groups, \"The meta-analysis of the link between CYP2B6 genotypes and EFV-induced liver injury was only derived from the African population, as well as NVP-induced liver injury were obtained from only African and Caucasian populations. ",
                  "prediction": "African/Caucasian"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 1.0,
                "Study Cases": 0.0,
                "Study Controls": 0.0,
                "Characteristics": 0.8563234806060791,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.0,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 0.8,
                "Confidence Interval Start": 0.8,
                "Confidence Interval Stop": 0.9,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1452721009,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1452721001,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "meta-analysis",
                  "prediction": "meta-analysis"
                },
                "Study Cases": {
                  "ground_truth": 795.0,
                  "prediction": 106
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": 795
                },
                "Characteristics": {
                  "ground_truth": "3 studies (Yimer 2011, Mugusi, Yimer 2012): DILI",
                  "prediction": "CYP2B6 polymorphisms associated with efavirenz-induced liver injury"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "study cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.003",
                  "prediction": "< 0.05"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": 1.94,
                  "prediction": 1.83
                },
                "Confidence Interval Start": {
                  "ground_truth": 1.24,
                  "prediction": 1.15
                },
                "Confidence Interval Stop": {
                  "ground_truth": 3.01,
                  "prediction": 2.9
                },
                "Biogeographical Groups": {
                  "ground_truth": "Sub-Saharan African",
                  "prediction": "African"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            }
          ],
          "aligned_variants": [
            "meta-analysis:2 studies (Carr, Gia",
            "meta-analysis:3 studies (Yimer 201"
          ],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "meta-analysis",
              "Study Cases": 41,
              "Study Controls": 160,
              "Characteristics": "CYP2B6 polymorphisms associated with nevirapine-induced liver injury",
              "Characteristics Type": "study cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "< 0.05",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.44,
              "Confidence Interval Start": 0.22,
              "Confidence Interval Stop": 0.91,
              "Biogeographical Groups": "African",
              "Variant Annotation ID_norm": null
            }
          ]
        }
      },
      "overall_score": 0.2681928464273612,
      "num_benchmarks": 4
    },
    {
      "pmid": "40184070",
      "pmcid": "PMC11971672",
      "title": "Cytochrome P450 2C19 Genotypes and Clopidogrel in Patients With Ischemic Stroke: A Nonrandomized Clinical Trial",
      "benchmarks": {
        "drug_annotations": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Variant/Haplotypes": "CYP2C19",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "Phenotype Category": "efficacy",
              "Significance": "yes",
              "Notes": "Patients who were carriers of the loss-of-function CYP2C19 allele exhibited a higher likelihood of experiencing cardiovascular events.",
              "Sentence": "CYP2C19 LOF allele is associated with increased cardiovascular events clopidogrel patients with acute ischemic stroke.",
              "Alleles": "CYP2C19 LOF allele",
              "Metabolizer types": "poor metabolizers, intermediate metabolizers",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "response to",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "patients who were carriers of the loss-of-function CYP2C19 allele exhibited a higher likelihood of experiencing cardiovascular events.",
                "The primary outcome occurred more frequently in carriers of the LOF CYP2C19 allele than in noncarriers (2.7% [49 of 1785] vs 1.6% [18 of 1125]; log-rank P = .048).",
                "In this prospective nonrandomized clinical trial, carriers of the CYP2C19 LOF allele genotype exhibited a higher likelihood of experiencing cardiovascular events."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "LOF",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "Phenotype Category": "efficacy",
              "Significance": "yes",
              "Notes": "Patients who were carriers of the loss-of-function CYP2C19 allele exhibited a higher likelihood of experiencing cardiovascular events.",
              "Sentence": "CYP2C19 LOF allele is associated with increased cardiovascular events clopidogrel patients with acute ischemic stroke.",
              "Alleles": "CYP2C19 LOF allele",
              "Metabolizer types": "poor metabolizers, intermediate metabolizers",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "response to",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "patients who were carriers of the loss-of-function CYP2C19 allele exhibited a higher likelihood of experiencing cardiovascular events.",
                "The primary outcome occurred more frequently in carriers of the LOF CYP2C19 allele than in noncarriers (2.7% [49 of 1785] vs 1.6% [18 of 1125]; log-rank P = .048).",
                "In this prospective nonrandomized clinical trial, carriers of the CYP2C19 LOF allele genotype exhibited a higher likelihood of experiencing cardiovascular events."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "allele",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "Phenotype Category": "efficacy",
              "Significance": "yes",
              "Notes": "Patients who were carriers of the loss-of-function CYP2C19 allele exhibited a higher likelihood of experiencing cardiovascular events.",
              "Sentence": "CYP2C19 LOF allele is associated with increased cardiovascular events clopidogrel patients with acute ischemic stroke.",
              "Alleles": "CYP2C19 LOF allele",
              "Metabolizer types": "poor metabolizers, intermediate metabolizers",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "response to",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "patients who were carriers of the loss-of-function CYP2C19 allele exhibited a higher likelihood of experiencing cardiovascular events.",
                "The primary outcome occurred more frequently in carriers of the LOF CYP2C19 allele than in noncarriers (2.7% [49 of 1785] vs 1.6% [18 of 1125]; log-rank P = .048).",
                "In this prospective nonrandomized clinical trial, carriers of the CYP2C19 LOF allele genotype exhibited a higher likelihood of experiencing cardiovascular events."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "CYP2C19*1/*1",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "Phenotype Category": "efficacy",
              "Significance": "yes",
              "Notes": "Noncarriers of the CYP2C19 LOF allele had a lower incidence of cardiovascular events compared to carriers.",
              "Sentence": "CYP2C19*1/*1 is associated with decreased cardiovascular events in patients treated with clopidogrel after acute ischemic stroke.",
              "Alleles": "CYP2C19*1/*1",
              "Metabolizer types": "extensive metabolizers",
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "response to",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "In this nonrandomized clinical trial that included 2925 patients with acute ischemic stroke treated with clopidogrel, patients who were carriers of the loss-of-function *CYP2C19* allele exhibited a higher likelihood of experiencing cardiovascular events.",
                "The primary outcome of composite cardiovascular events occurred significantly more in the LOF allele carrier group (49 of 1785 [2.7%]) compared with the noncarrier group (18 of 1125 [1.6%]) (HR, 0.58; 95% CI, 0.34-1.00; *P* = .048 for log-rank test)."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "CYP2C19*1/*17",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "Phenotype Category": "efficacy",
              "Significance": "yes",
              "Notes": "Noncarriers of the CYP2C19 LOF allele had a lower incidence of cardiovascular events compared to carriers.",
              "Sentence": "CYP2C19*1/*1 is associated with decreased cardiovascular events in patients treated with clopidogrel after acute ischemic stroke.",
              "Alleles": "CYP2C19*1/*1",
              "Metabolizer types": "extensive metabolizers",
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "response to",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "In this nonrandomized clinical trial that included 2925 patients with acute ischemic stroke treated with clopidogrel, patients who were carriers of the loss-of-function *CYP2C19* allele exhibited a higher likelihood of experiencing cardiovascular events.",
                "The primary outcome of composite cardiovascular events occurred significantly more in the LOF allele carrier group (49 of 1785 [2.7%]) compared with the noncarrier group (18 of 1125 [1.6%]) (HR, 0.58; 95% CI, 0.34-1.00; *P* = .048 for log-rank test)."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "CYP2C19*17/*17",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "Phenotype Category": "efficacy",
              "Significance": "yes",
              "Notes": "Noncarriers of the CYP2C19 LOF allele had a lower incidence of cardiovascular events compared to carriers.",
              "Sentence": "CYP2C19*1/*1 is associated with decreased cardiovascular events in patients treated with clopidogrel after acute ischemic stroke.",
              "Alleles": "CYP2C19*1/*1",
              "Metabolizer types": "extensive metabolizers",
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "response to",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "In this nonrandomized clinical trial that included 2925 patients with acute ischemic stroke treated with clopidogrel, patients who were carriers of the loss-of-function *CYP2C19* allele exhibited a higher likelihood of experiencing cardiovascular events.",
                "The primary outcome of composite cardiovascular events occurred significantly more in the LOF allele carrier group (49 of 1785 [2.7%]) compared with the noncarrier group (18 of 1125 [1.6%]) (HR, 0.58; 95% CI, 0.34-1.00; *P* = .048 for log-rank test)."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "(extensive",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "Phenotype Category": "efficacy",
              "Significance": "yes",
              "Notes": "Noncarriers of the CYP2C19 LOF allele had a lower incidence of cardiovascular events compared to carriers.",
              "Sentence": "CYP2C19*1/*1 is associated with decreased cardiovascular events in patients treated with clopidogrel after acute ischemic stroke.",
              "Alleles": "CYP2C19*1/*1",
              "Metabolizer types": "extensive metabolizers",
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "response to",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "In this nonrandomized clinical trial that included 2925 patients with acute ischemic stroke treated with clopidogrel, patients who were carriers of the loss-of-function *CYP2C19* allele exhibited a higher likelihood of experiencing cardiovascular events.",
                "The primary outcome of composite cardiovascular events occurred significantly more in the LOF allele carrier group (49 of 1785 [2.7%]) compared with the noncarrier group (18 of 1125 [1.6%]) (HR, 0.58; 95% CI, 0.34-1.00; *P* = .048 for log-rank test)."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "metabolizers)",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "Phenotype Category": "efficacy",
              "Significance": "yes",
              "Notes": "Noncarriers of the CYP2C19 LOF allele had a lower incidence of cardiovascular events compared to carriers.",
              "Sentence": "CYP2C19*1/*1 is associated with decreased cardiovascular events in patients treated with clopidogrel after acute ischemic stroke.",
              "Alleles": "CYP2C19*1/*1",
              "Metabolizer types": "extensive metabolizers",
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "response to",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "In this nonrandomized clinical trial that included 2925 patients with acute ischemic stroke treated with clopidogrel, patients who were carriers of the loss-of-function *CYP2C19* allele exhibited a higher likelihood of experiencing cardiovascular events.",
                "The primary outcome of composite cardiovascular events occurred significantly more in the LOF allele carrier group (49 of 1785 [2.7%]) compared with the noncarrier group (18 of 1125 [1.6%]) (HR, 0.58; 95% CI, 0.34-1.00; *P* = .048 for log-rank test)."
              ],
              "_expanded_from_multi_variant": true
            }
          ]
        },
        "phenotype_annotations": {
          "total_samples": 4,
          "field_scores": {
            "Variant/Haplotypes": {
              "mean_score": 0.25,
              "scores": [
                1.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Gene": {
              "mean_score": 0.75,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0
              ]
            },
            "Drug(s)": {
              "mean_score": 0.75,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0
              ]
            },
            "Phenotype Category": {
              "mean_score": 0.75,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0
              ]
            },
            "Alleles": {
              "mean_score": 0.6268844604492188,
              "scores": [
                0.835845947265625,
                0.835845947265625,
                0.835845947265625,
                0.0
              ]
            },
            "Is/Is Not associated": {
              "mean_score": 0.75,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0
              ]
            },
            "Direction of effect": {
              "mean_score": 0.75,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0
              ]
            },
            "Phenotype": {
              "mean_score": 0.6573778241872787,
              "scores": [
                0.8765037655830383,
                0.8765037655830383,
                0.8765037655830383,
                0.0
              ]
            },
            "When treated with/exposed to/when assayed with": {
              "mean_score": 0.75,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0
              ]
            },
            "Comparison Allele(s) or Genotype(s)": {
              "mean_score": 0.6301545649766922,
              "scores": [
                0.8402060866355896,
                0.8402060866355896,
                0.8402060866355896,
                0.0
              ]
            }
          },
          "overall_score": 0.6675197420020899,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 1.0,
                "Alleles": 0.835845947265625,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.8765037655830383,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.8402060866355896
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "CYP2C19*1",
                  "prediction": "CYP2C19"
                },
                "Gene": {
                  "ground_truth": "CYP2C19",
                  "prediction": "CYP2C19"
                },
                "Drug(s)": {
                  "ground_truth": "clopidogrel",
                  "prediction": "clopidogrel"
                },
                "Phenotype Category": {
                  "ground_truth": "Efficacy",
                  "prediction": "efficacy"
                },
                "Alleles": {
                  "ground_truth": "*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3",
                  "prediction": "LOF allele"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Efficacy:Stroke, Efficacy:Myocardial Infarction, Efficacy:Death",
                  "prediction": "cardiovascular events"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "*1/*1 + *1/*17 + *17/*17",
                  "prediction": "noncarrier of LOF allele"
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Variant/Haplotypes": 0.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 1.0,
                "Alleles": 0.835845947265625,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.8765037655830383,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.8402060866355896
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "CYP2C19*1",
                  "prediction": "LOF"
                },
                "Gene": {
                  "ground_truth": "CYP2C19",
                  "prediction": "CYP2C19"
                },
                "Drug(s)": {
                  "ground_truth": "clopidogrel",
                  "prediction": "clopidogrel"
                },
                "Phenotype Category": {
                  "ground_truth": "Efficacy",
                  "prediction": "efficacy"
                },
                "Alleles": {
                  "ground_truth": "*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3",
                  "prediction": "LOF allele"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Efficacy:Stroke, Efficacy:Myocardial Infarction, Efficacy:Death",
                  "prediction": "cardiovascular events"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "*1/*1 + *1/*17 + *17/*17",
                  "prediction": "noncarrier of LOF allele"
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 2,
              "field_scores": {
                "Variant/Haplotypes": 0.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 1.0,
                "Alleles": 0.835845947265625,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.8765037655830383,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.8402060866355896
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "CYP2C19*1",
                  "prediction": "allele"
                },
                "Gene": {
                  "ground_truth": "CYP2C19",
                  "prediction": "CYP2C19"
                },
                "Drug(s)": {
                  "ground_truth": "clopidogrel",
                  "prediction": "clopidogrel"
                },
                "Phenotype Category": {
                  "ground_truth": "Efficacy",
                  "prediction": "efficacy"
                },
                "Alleles": {
                  "ground_truth": "*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3",
                  "prediction": "LOF allele"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Efficacy:Stroke, Efficacy:Myocardial Infarction, Efficacy:Death",
                  "prediction": "cardiovascular events"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "*1/*1 + *1/*17 + *17/*17",
                  "prediction": "noncarrier of LOF allele"
                }
              },
              "dependency_issues": []
            }
          ],
          "aligned_variants": [
            "cyp2c19*1",
            "cyp2c19+clopidogrel",
            "cyp2c19+clopidogrel"
          ],
          "unmatched_ground_truth": [
            {
              "Variant Annotation ID": 1453096120,
              "Variant/Haplotypes": "CYP2C19*17",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40184070,
              "Phenotype Category": "Efficacy",
              "Significance": "yes",
              "Notes": "Overall, 49 of 1785 LOF allele carriers (2.7%) and 18 of 1125 LOF allele noncarriers (1.6%) experienced cardiovascular events, defined as a composite of recurrent stroke, myocardial infarction, and all-cause mortality at 180 days...The primary outcome of composite cardiovascular events occurred significantly more in the LOF allele carrier group (49 of 1785 [2.7%]) compared with the noncarrier group (18 of 1125 [1.6%]) (HR, 0.58; 95% CI, 0.34-1.00; P = .048 for log-rank test).",
              "Sentence": "CYP2C19 *1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3 (assigned as intermediate metabolizer and poor metabolizer phenotype) is associated with increased likelihood of Stroke, Myocardial Infarction or Death when treated with clopidogrel in people with Stroke as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17 (assigned as normal metabolizer phenotype) .",
              "Alleles": "*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3",
              "Specialty Population": null,
              "Metabolizer types": "intermediate metabolizer and poor metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Efficacy:Stroke, Efficacy:Myocardial Infarction, Efficacy:Death",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Other:Stroke",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1 + *1/*17 + *17/*17",
              "Comparison Metabolizer types": "normal metabolizer",
              "PMID_norm": "40184070",
              "Variant Annotation ID_norm": "1453096120",
              "_expanded_from_multi_variant": true
            }
          ],
          "unmatched_predictions": []
        },
        "functional_analysis": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "status": "missing_var_fa_ann"
        },
        "study_parameters": {
          "total_samples": 2,
          "field_scores": {
            "Study Type": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Study Cases": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Study Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Characteristics": {
              "mean_score": 0.8997842669487,
              "scores": [
                0.9112827777862549,
                0.888285756111145
              ]
            },
            "Characteristics Type": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Frequency In Cases": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Allele Of Frequency In Cases": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Frequency In Controls": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Allele Of Frequency In Controls": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "P Value": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Ratio Stat Type": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Ratio Stat": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Confidence Interval Start": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Confidence Interval Stop": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Biogeographical Groups": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.65998561779658,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 1.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.9112827777862549,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 0.0,
                "Allele Of Frequency In Cases": 0.0,
                "Frequency In Controls": 0.0,
                "Allele Of Frequency In Controls": 0.0,
                "P Value": 1.0,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1453096116,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1453096120,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "clinical trial",
                  "prediction": "clinical trial"
                },
                "Study Cases": {
                  "ground_truth": 2910.0,
                  "prediction": 2910
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "PLATELET trial, composite outcome (recurrent stroke, myocardial infarction, and all-cause mortality at 180 days)",
                  "prediction": "Patients with acute ischemic stroke treated with clopidogrel; 1785 LOF allele carriers and 1125 noncarriers"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": 0.027
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": "LOF allele carriers"
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": 0.016
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": "LOF allele noncarriers"
                },
                "P Value": {
                  "ground_truth": "= 0.048",
                  "prediction": "= 0.048"
                },
                "Ratio Stat Type": {
                  "ground_truth": "HR",
                  "prediction": "HR"
                },
                "Ratio Stat": {
                  "ground_truth": 0.58,
                  "prediction": 0.58
                },
                "Confidence Interval Start": {
                  "ground_truth": 0.34,
                  "prediction": 0.34
                },
                "Confidence Interval Stop": {
                  "ground_truth": 1.0,
                  "prediction": 1.0
                },
                "Biogeographical Groups": {
                  "ground_truth": "Unknown",
                  "prediction": "Asian"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 1.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.888285756111145,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 0.0,
                "Allele Of Frequency In Cases": 0.0,
                "Frequency In Controls": 0.0,
                "Allele Of Frequency In Controls": 0.0,
                "P Value": 1.0,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1453096140,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1453096120,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "clinical trial",
                  "prediction": "clinical trial"
                },
                "Study Cases": {
                  "ground_truth": 2910.0,
                  "prediction": 2910
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "PLATELET trial, Recurrent stroke",
                  "prediction": "Recurrent stroke incidences; LOF allele carriers vs noncarriers"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": 0.025
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": "LOF allele carriers"
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": 0.014
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": "LOF allele noncarriers"
                },
                "P Value": {
                  "ground_truth": "= 0.047",
                  "prediction": "= 0.047"
                },
                "Ratio Stat Type": {
                  "ground_truth": "HR",
                  "prediction": "HR"
                },
                "Ratio Stat": {
                  "ground_truth": 0.56,
                  "prediction": 0.56
                },
                "Confidence Interval Start": {
                  "ground_truth": 0.32,
                  "prediction": 0.32
                },
                "Confidence Interval Stop": {
                  "ground_truth": 1.0,
                  "prediction": 1.0
                },
                "Biogeographical Groups": {
                  "ground_truth": "Unknown",
                  "prediction": "Asian"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            }
          ],
          "aligned_variants": [
            "clinical trial:PLATELET trial, comp",
            "clinical trial:PLATELET trial, Recu"
          ],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 2910,
              "Study Controls": null,
              "Characteristics": "Patients with acute ischemic stroke treated with clopidogrel; major bleeding events",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": 0.006,
              "Allele Of Frequency In Cases": "LOF allele carriers",
              "Frequency In Controls": 0.008,
              "Allele Of Frequency In Controls": "LOF allele noncarriers",
              "P Value": "= 0.56",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 1.29,
              "Confidence Interval Start": 0.53,
              "Confidence Interval Stop": 3.13,
              "Biogeographical Groups": "Asian",
              "Variant Annotation ID_norm": null
            },
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 2910,
              "Study Controls": null,
              "Characteristics": "Patients with acute ischemic stroke treated with clopidogrel; all-cause mortality",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": 0.003,
              "Allele Of Frequency In Cases": "LOF allele carriers",
              "Frequency In Controls": 0.001,
              "Allele Of Frequency In Controls": "LOF allele noncarriers",
              "P Value": "= 0.27",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 0.31,
              "Confidence Interval Start": 0.04,
              "Confidence Interval Stop": 2.71,
              "Biogeographical Groups": "Asian",
              "Variant Annotation ID_norm": null
            },
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 2910,
              "Study Controls": null,
              "Characteristics": "Ischemic stroke events; patients treated with clopidogrel",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": 0.024,
              "Allele Of Frequency In Cases": "LOF allele carriers",
              "Frequency In Controls": 0.014,
              "Allele Of Frequency In Controls": "LOF allele noncarriers",
              "P Value": "= 0.06",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Asian",
              "Variant Annotation ID_norm": null
            }
          ]
        }
      },
      "overall_score": 0.33225304615994294,
      "num_benchmarks": 4
    },
    {
      "pmid": "40099566",
      "pmcid": "PMC12035587",
      "title": "Severe myelosuppression and alopecia after thiopurine initiation in a patient with NUDT15 deficiency",
      "benchmarks": {
        "drug_annotations": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Variant/Haplotypes": "*3/*3",
              "Gene": "NUDT15",
              "Drug(s)": "mercaptopurine",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "The patient exhibited severe myelosuppression, hepatotoxicity and alopecia due to thiopurine toxicity associated with homozygous loss-of-function NUDT15 alleles.",
              "Standardized Sentence": "Genotype *3/*3 is associated with increased toxicity from mercaptopurine in a South Asian female with acute promyelocytic leukaemia.",
              "Alleles": "*3/*3",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "",
              "Comparison Metabolizer types": "",
              "Specialty Population": "",
              "Population types": "in a South Asian female with acute promyelocytic leukaemia",
              "Population Phenotypes or diseases": "Disease:acute promyelocytic leukaemia",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "toxicity of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "the patient exhibited severe myelosuppression, hepatotoxicity and alopecia in an individual with homozygous *3/*3 loss\u2010of\u2010function alleles in the NUDT15 gene.",
                "the patient was found to have wildtype alleles in the thiopurine\u2010S\u2010methyltransferase (*TPMT*) gene, but homozygous loss\u2010of\u2010function alleles in the *NUDT15* gene (c.415C > T; *3/*3), resulting in complete loss of NUDT15 protein function.",
                "this was favoured to be a less likely explanation for the patient's clinical presentation."
              ]
            }
          ]
        },
        "phenotype_annotations": {
          "total_samples": 1,
          "field_scores": {
            "Variant/Haplotypes": {
              "mean_score": 1.0,
              "scores": [
                1.0
              ]
            },
            "Gene": {
              "mean_score": 1.0,
              "scores": [
                1.0
              ]
            },
            "Drug(s)": {
              "mean_score": 1.0,
              "scores": [
                1.0
              ]
            },
            "Phenotype Category": {
              "mean_score": 1.0,
              "scores": [
                1.0
              ]
            },
            "Alleles": {
              "mean_score": 1.0,
              "scores": [
                1.0
              ]
            },
            "Is/Is Not associated": {
              "mean_score": 1.0,
              "scores": [
                1.0
              ]
            },
            "Direction of effect": {
              "mean_score": 1.0,
              "scores": [
                1.0
              ]
            },
            "Phenotype": {
              "mean_score": 0.9641420245170593,
              "scores": [
                0.9641420245170593
              ]
            },
            "When treated with/exposed to/when assayed with": {
              "mean_score": 1.0,
              "scores": [
                1.0
              ]
            },
            "Comparison Allele(s) or Genotype(s)": {
              "mean_score": 0.0,
              "scores": [
                0.0
              ]
            }
          },
          "overall_score": 0.9106903374195099,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 1.0,
                "Alleles": 1.0,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.9641420245170593,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "NUDT15*3",
                  "prediction": "NUDT15"
                },
                "Gene": {
                  "ground_truth": "NUDT15",
                  "prediction": "NUDT15"
                },
                "Drug(s)": {
                  "ground_truth": "mercaptopurine",
                  "prediction": "mercaptopurine"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "*3/*3",
                  "prediction": "*3/*3"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:Myelosuppression, Side Effect:Toxic liver disease, Side Effect:Alopecia",
                  "prediction": "severe myelosuppression, hepatotoxicity, alopecia"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": null,
                  "prediction": ""
                }
              },
              "dependency_issues": []
            }
          ],
          "aligned_variants": [
            "nudt15*3"
          ],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "*3/*3",
              "Gene": "NUDT15",
              "Drug(s)": "mercaptopurine",
              "PMID": 40099566,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Severe myelosuppression, hepatotoxicity, and alopecia were observed in patient with homozygous *3/*3 loss\u2010of\u2010function alleles in the NUDT15 gene.",
              "Sentence": "NUDT15 *3/*3 is associated with increased risk of severe myelosuppression, hepatotoxicity, and alopecia when treated with mercaptopurine in South Asian patients.",
              "Alleles": "*3/*3",
              "Specialty Population": "adult",
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "severe myelosuppression, hepatotoxicity, alopecia",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": "",
              "Population types": "in South Asian patients",
              "Population Phenotypes or diseases": "",
              "Multiple phenotypes or diseases And/or": "",
              "Comparison Allele(s) or Genotype(s)": "",
              "Comparison Metabolizer types": "",
              "PMID_norm": "40099566",
              "Variant Annotation ID_norm": "1",
              "Citations": [
                "we present a case of thiopurine toxicity resulting in severe myelosuppression, hepatotoxicity and alopecia in an individual with homozygous *3/*3 loss\u2010of\u2010function alleles in the NUDT15 gene.",
                "The patient underwent genetic testing and was found to have wildtype alleles in the thiopurine\u2010S\u2010methyltransferase (*TPMT*) gene, but homozygous loss\u2010of\u2010function alleles in the *NUDT15* gene (c.415C > T; *3/*3), resulting in complete loss of NUDT15 protein function.",
                "We present a patient with severe myelosuppression, hepatotoxicity and alopecia following mercaptopurine initiation who was found to have homozygous *3/*3 loss\u2010of\u2010function alleles in the *NUDT15* gene."
              ],
              "_expanded_from_multi_variant": true
            }
          ]
        },
        "functional_analysis": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "status": "missing_var_fa_ann"
        },
        "study_parameters": {
          "total_samples": 1,
          "field_scores": {
            "Study Type": {
              "mean_score": 0.0,
              "scores": [
                0.0
              ]
            },
            "Study Cases": {
              "mean_score": 0.0,
              "scores": [
                0.0
              ]
            },
            "Study Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0
              ]
            },
            "Characteristics": {
              "mean_score": 0.9718648791313171,
              "scores": [
                0.9718648791313171
              ]
            },
            "Characteristics Type": {
              "mean_score": 1.0,
              "scores": [
                1.0
              ]
            },
            "Frequency In Cases": {
              "mean_score": 1.0,
              "scores": [
                1.0
              ]
            },
            "Allele Of Frequency In Cases": {
              "mean_score": 1.0,
              "scores": [
                1.0
              ]
            },
            "Frequency In Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0
              ]
            },
            "Allele Of Frequency In Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0
              ]
            },
            "P Value": {
              "mean_score": 1.0,
              "scores": [
                1.0
              ]
            },
            "Ratio Stat Type": {
              "mean_score": 1.0,
              "scores": [
                1.0
              ]
            },
            "Ratio Stat": {
              "mean_score": 1.0,
              "scores": [
                1.0
              ]
            },
            "Confidence Interval Start": {
              "mean_score": 1.0,
              "scores": [
                1.0
              ]
            },
            "Confidence Interval Stop": {
              "mean_score": 1.0,
              "scores": [
                1.0
              ]
            },
            "Biogeographical Groups": {
              "mean_score": 0.0,
              "scores": [
                0.0
              ]
            }
          },
          "overall_score": 0.7981243252754211,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 0.0,
                "Study Controls": 1.0,
                "Characteristics": 0.9718648791313171,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 1.0,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1453076188,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1453076180,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "case series",
                  "prediction": null
                },
                "Study Cases": {
                  "ground_truth": 0.0,
                  "prediction": 1.0
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "41-year-old South Asian female, severe mercaptopurine toxicity secondary to an inherited NUDT15 protein deficiency, resulting in myelosuppression, hepatotoxicity and alopecia.",
                  "prediction": "41-year-old South Asian female with homozygous NUDT15 *3/*3 loss-of-function alleles, diagnosed with high-risk acute promyelocytic leukaemia, treated with mercaptopurine"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Ratio Stat Type": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "Central/South Asian",
                  "prediction": "South Asian"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            }
          ],
          "aligned_variants": [
            "case series:41-year-old South As"
          ],
          "unmatched_ground_truth": [],
          "unmatched_predictions": []
        }
      },
      "overall_score": 0.43283196628093723,
      "num_benchmarks": 4
    },
    {
      "pmid": "40295977",
      "pmcid": "PMC12036300",
      "title": "The frequencies of CYP2C19*2, *3, and *17 alleles and their impact on the clinical efficacy of doubled maintenance dose of clopidogrel in Syrian patients with coronary artery disease",
      "benchmarks": {
        "drug_annotations": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Variant/Haplotypes": "CYP2C19*2",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "No association observed between CYP2C19*2 allele and recurrent ischemic events or CYP2C19*17 allele and bleeding complications after treatment with a doubled maintenance dose of clopidogrel.",
              "Sentence": "CYP2C19*2 and CYP2C19*17 alleles are not associated with increased ischemic events or bleeding complications in patients treated with clopidogrel after percutaneous coronary intervention in Syrian patients.",
              "Alleles": "*2, *17",
              "Metabolizer types": "intermediate metabolizer, normal metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "",
              "PD/PK terms": "response to",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "No association was found between the CYP2C19*2 allele and recurrent ischemic events or between the CYP2C19*17 allele and bleeding complications in patients treated with a doubled maintenance dose of clopidogrel.",
                "The frequency of the CYP2C19*2 allele in our study population (8%) was found to be compatible with that of other populations... But the present study did not confirm an association between MACE incidence and the carrier status of the non-functional CYP2C19*2 allele...",
                "In Syrian patients undergoing PCI, a doubled maintenance dose of clopidogrel (150 mg/day) may help mitigate variability in response due to CYP2C19*2 carrier status, offering potential benefits in optimizing antiplatelet therapy."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "CYP2C19*17",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "No association observed between CYP2C19*2 allele and recurrent ischemic events or CYP2C19*17 allele and bleeding complications after treatment with a doubled maintenance dose of clopidogrel.",
              "Sentence": "CYP2C19*2 and CYP2C19*17 alleles are not associated with increased ischemic events or bleeding complications in patients treated with clopidogrel after percutaneous coronary intervention in Syrian patients.",
              "Alleles": "*2, *17",
              "Metabolizer types": "intermediate metabolizer, normal metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "",
              "PD/PK terms": "response to",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "No association was found between the CYP2C19*2 allele and recurrent ischemic events or between the CYP2C19*17 allele and bleeding complications in patients treated with a doubled maintenance dose of clopidogrel.",
                "The frequency of the CYP2C19*2 allele in our study population (8%) was found to be compatible with that of other populations... But the present study did not confirm an association between MACE incidence and the carrier status of the non-functional CYP2C19*2 allele...",
                "In Syrian patients undergoing PCI, a doubled maintenance dose of clopidogrel (150 mg/day) may help mitigate variability in response due to CYP2C19*2 carrier status, offering potential benefits in optimizing antiplatelet therapy."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "CYP2C19*3",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "Phenotype Category": "efficacy",
              "Significance": "not stated",
              "Notes": "CYP2C19*3 allele was absent in the study population.",
              "Sentence": "CYP2C19*3 is not associated with decreased response to clopidogrel in patients undergoing percutaneous coronary intervention in Syrian patients.",
              "Alleles": "",
              "Metabolizer types": "",
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "",
              "PD/PK terms": "",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "The allele frequencies were 8% for CYP2C19*2, 0% for CYP2C19*3, and 17% for CYP2C19*17.",
                "The *CYP2C19*3* allele was absent in our study population, which aligns with the low or diminished frequencies reported in European and Middle Eastern populations.",
                "Overall, two of the 41 patients who were followed up in the study experienced at least one MACE after PCI. One case was from the *CYP2C19*2* allele carrier group and the other was from the non-carrier group."
              ]
            },
            {
              "Variant/Haplotypes": "CYP2C19*17",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "No significant association found between CYP2C19*17 allele and increased bleeding complications in patients treated with clopidogrel after PCI.",
              "Sentence": "CYP2C19*17 is not associated with increased bleeding events in patients treated with clopidogrel in Syrian patients.",
              "Alleles": "",
              "Metabolizer types": "",
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "",
              "PD/PK terms": "bleeding events",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "No association was found between the CYP2C19*2 allele and recurrent ischemic events or between the CYP2C19*17 allele and bleeding complications in patients treated with a doubled maintenance dose of clopidogrel.",
                "The frequency of CYP2C19*17 allele was found to be (17%), which is close to that reported in European and Middle Eastern populations but higher than those found in other studies on Asians (from 0.3% in Koreans to 1.3% in Japanese).",
                "Despite 30% of the individuals carrying the gain-of-function CYP2C19*17 allele and receiving a double maintenance dose of clopidogrel after stent placement, the occurrence of hemorrhagic events remained relatively low, not exceeding (9.7%)."
              ]
            }
          ]
        },
        "phenotype_annotations": {
          "total_samples": 6,
          "field_scores": {
            "Variant/Haplotypes": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Gene": {
              "mean_score": 0.6666666666666666,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0
              ]
            },
            "Drug(s)": {
              "mean_score": 0.6486031214396158,
              "scores": [
                0.9729046821594238,
                0.9729046821594238,
                0.9729046821594238,
                0.9729046821594238,
                0.0,
                0.0
              ]
            },
            "Phenotype Category": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                0.0,
                1.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Alleles": {
              "mean_score": 0.6488762597242991,
              "scores": [
                0.9719905853271484,
                0.9709437489509583,
                0.9719905853271484,
                0.9783326387405396,
                0.0,
                0.0
              ]
            },
            "Is/Is Not associated": {
              "mean_score": 0.6666666666666666,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0
              ]
            },
            "Direction of effect": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Phenotype": {
              "mean_score": 0.6173241833845774,
              "scores": [
                0.9549291133880615,
                0.8794723153114319,
                0.9549291133880615,
                0.9146145582199097,
                0.0,
                0.0
              ]
            },
            "When treated with/exposed to/when assayed with": {
              "mean_score": 0.6666666666666666,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0
              ]
            },
            "Comparison Allele(s) or Genotype(s)": {
              "mean_score": 0.5976212819417318,
              "scores": [
                0.8964319229125977,
                0.8964319229125977,
                0.8964319229125977,
                0.8964319229125977,
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.4954296155936187,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "Drug(s)": 0.9729046821594238,
                "Phenotype Category": 1.0,
                "Alleles": 0.9719905853271484,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 0.0,
                "Phenotype": 0.9549291133880615,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.8964319229125977
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "CYP2C19*2",
                  "prediction": "CYP2C19*2"
                },
                "Gene": {
                  "ground_truth": "CYP2C19",
                  "prediction": "CYP2C19"
                },
                "Drug(s)": {
                  "ground_truth": "clopidogrel",
                  "prediction": "Clopidogrel"
                },
                "Phenotype Category": {
                  "ground_truth": "Efficacy",
                  "prediction": "efficacy"
                },
                "Alleles": {
                  "ground_truth": "*1/*2 + *2/*2 + *2/*17",
                  "prediction": "*1/*2"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Not associated with",
                  "prediction": "Not associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": null
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:Major Adverse Cardiac Events (MACE)",
                  "prediction": "major adverse cardiovascular events"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "*1/*1",
                  "prediction": "CYP2C19*1 (wild-type)"
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "Drug(s)": 0.9729046821594238,
                "Phenotype Category": 0.0,
                "Alleles": 0.9709437489509583,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 0.0,
                "Phenotype": 0.8794723153114319,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.8964319229125977
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "CYP2C19*17",
                  "prediction": "CYP2C19*17"
                },
                "Gene": {
                  "ground_truth": "CYP2C19",
                  "prediction": "CYP2C19"
                },
                "Drug(s)": {
                  "ground_truth": "clopidogrel",
                  "prediction": "Clopidogrel"
                },
                "Phenotype Category": {
                  "ground_truth": "Efficacy",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "*1/*2 + *2/*2 + *2/*17",
                  "prediction": "*1/*17"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Not associated with",
                  "prediction": "Not associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": null
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:Major Adverse Cardiac Events (MACE)",
                  "prediction": "bleeding events"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "*1/*1",
                  "prediction": "CYP2C19*1 (wild-type)"
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 2,
              "field_scores": {
                "Variant/Haplotypes": 0.0,
                "Gene": 1.0,
                "Drug(s)": 0.9729046821594238,
                "Phenotype Category": 1.0,
                "Alleles": 0.9719905853271484,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 0.0,
                "Phenotype": 0.9549291133880615,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.8964319229125977
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "CYP2C19*1",
                  "prediction": "(rs4244285)"
                },
                "Gene": {
                  "ground_truth": "CYP2C19",
                  "prediction": "CYP2C19"
                },
                "Drug(s)": {
                  "ground_truth": "clopidogrel",
                  "prediction": "Clopidogrel"
                },
                "Phenotype Category": {
                  "ground_truth": "Efficacy",
                  "prediction": "efficacy"
                },
                "Alleles": {
                  "ground_truth": "*1/*2 + *2/*2 + *2/*17",
                  "prediction": "*1/*2"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Not associated with",
                  "prediction": "Not associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": null
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:Major Adverse Cardiac Events (MACE)",
                  "prediction": "major adverse cardiovascular events"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "*1/*1",
                  "prediction": "CYP2C19*1 (wild-type)"
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 3,
              "field_scores": {
                "Variant/Haplotypes": 0.0,
                "Gene": 1.0,
                "Drug(s)": 0.9729046821594238,
                "Phenotype Category": 0.0,
                "Alleles": 0.9783326387405396,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 0.0,
                "Phenotype": 0.9146145582199097,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.8964319229125977
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "CYP2C19*1",
                  "prediction": "(rs12248560)"
                },
                "Gene": {
                  "ground_truth": "CYP2C19",
                  "prediction": "CYP2C19"
                },
                "Drug(s)": {
                  "ground_truth": "clopidogrel",
                  "prediction": "Clopidogrel"
                },
                "Phenotype Category": {
                  "ground_truth": "Efficacy",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "*1/*17 + *17/*17 + *2/*17",
                  "prediction": "*1/*17"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Not associated with",
                  "prediction": "Not associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": null
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:Hemorrhage",
                  "prediction": "bleeding events"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "*1/*1",
                  "prediction": "CYP2C19*1 (wild-type)"
                }
              },
              "dependency_issues": []
            }
          ],
          "aligned_variants": [
            "cyp2c19*1",
            "cyp2c19*2",
            "cyp2c19+clopidogrel",
            "cyp2c19+clopidogrel"
          ],
          "unmatched_ground_truth": [
            {
              "Variant Annotation ID": 1454052160,
              "Variant/Haplotypes": "CYP2C19*2",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40295977,
              "Phenotype Category": "Efficacy",
              "Significance": "no",
              "Notes": "Our results indicated that carriers of the CYP2C19*17 variant experienced a higher incidence of bleeding events (16.67%) compared to non-carriers (6.9%). Despite this observed difference, it is important to note that the statistical analysis found no significant difference between the two groups (P = 0.567; see Table 7). Similarly, there was no statistically significant difference in bleeding events between CYP2C19*2 carriers and non-carriers (P = 0.0952; see Table 7), although a higher proportion of bleeding events was observed among carriers.",
              "Sentence": "CYP2C19 *1/*17 + *17/*17 + *2/*17 is not associated with increased likelihood of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1/*1.",
              "Alleles": "*1/*17 + *17/*17 + *2/*17",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Side Effect:Hemorrhage",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": null,
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "40295977",
              "Variant Annotation ID_norm": "1454052160",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1454052160,
              "Variant/Haplotypes": "CYP2C19*17",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40295977,
              "Phenotype Category": "Efficacy",
              "Significance": "no",
              "Notes": "Our results indicated that carriers of the CYP2C19*17 variant experienced a higher incidence of bleeding events (16.67%) compared to non-carriers (6.9%). Despite this observed difference, it is important to note that the statistical analysis found no significant difference between the two groups (P = 0.567; see Table 7). Similarly, there was no statistically significant difference in bleeding events between CYP2C19*2 carriers and non-carriers (P = 0.0952; see Table 7), although a higher proportion of bleeding events was observed among carriers.",
              "Sentence": "CYP2C19 *1/*17 + *17/*17 + *2/*17 is not associated with increased likelihood of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1/*1.",
              "Alleles": "*1/*17 + *17/*17 + *2/*17",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Side Effect:Hemorrhage",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": null,
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "40295977",
              "Variant Annotation ID_norm": "1454052160",
              "_expanded_from_multi_variant": true
            }
          ],
          "unmatched_predictions": []
        },
        "functional_analysis": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "status": "missing_var_fa_ann"
        },
        "study_parameters": {
          "total_samples": 2,
          "field_scores": {
            "Study Type": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Study Cases": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Study Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Characteristics": {
              "mean_score": 0.9470909833908081,
              "scores": [
                0.9619601368904114,
                0.9322218298912048
              ]
            },
            "Characteristics Type": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Frequency In Cases": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                0.0
              ]
            },
            "Allele Of Frequency In Cases": {
              "mean_score": 0.4670591354370117,
              "scores": [
                0.9341182708740234,
                0.0
              ]
            },
            "Frequency In Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Allele Of Frequency In Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "P Value": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Ratio Stat Type": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Ratio Stat": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Confidence Interval Start": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Confidence Interval Stop": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Biogeographical Groups": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.6609433412551879,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 0.0,
                "Study Controls": 1.0,
                "Characteristics": 0.9619601368904114,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 0.9341182708740234,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 1.0,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1454052180,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1454052160,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": null,
                  "prediction": "cohort"
                },
                "Study Cases": {
                  "ground_truth": 41.0,
                  "prediction": 50
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "Bleeding events, DAPT with a double maintenance dose of clopidogrel 150 mg/day (for at least one month after PCI).",
                  "prediction": "Syrian CAD patients treated with dual antiplatelet therapy (DAPT) using a doubled maintenance dose of clopidogrel (150 mg/day) after PCI"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": 0.17,
                  "prediction": 0.17
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": "*17",
                  "prediction": "CYP2C19*17"
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.567",
                  "prediction": "= 0.567"
                },
                "Ratio Stat Type": {
                  "ground_truth": null,
                  "prediction": "Unknown"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "Near Eastern",
                  "prediction": "Unknown"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 0.0,
                "Study Controls": 1.0,
                "Characteristics": 0.9322218298912048,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 0.0,
                "Allele Of Frequency In Cases": 0.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 1.0,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1454052120,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1454052100,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": null,
                  "prediction": "cohort"
                },
                "Study Cases": {
                  "ground_truth": 41.0,
                  "prediction": 50
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "MACE, DAPT with a double maintenance dose of clopidogrel 150 mg/day (for at least one month after PCI).",
                  "prediction": "MAPC and bleeding complications in Syrian CAD patients treated with a doubled maintenance dose of clopidogrel"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": 0.08,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": "*2",
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.2744",
                  "prediction": "= 0.2744"
                },
                "Ratio Stat Type": {
                  "ground_truth": null,
                  "prediction": "Unknown"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "Near Eastern",
                  "prediction": "Unknown"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            }
          ],
          "aligned_variants": [
            "None:Bleeding events, DAP",
            "None:MACE, DAPT with a do"
          ],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 50,
              "Study Controls": null,
              "Characteristics": "Syrian CAD patients treated with dual antiplatelet therapy (DAPT) using a doubled maintenance dose of clopidogrel (150 mg/day) after PCI",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": 0.08,
              "Allele Of Frequency In Cases": "CYP2C19*2",
              "Frequency In Controls": 0,
              "Allele Of Frequency In Controls": "CYP2C19*3",
              "P Value": "> 0.9999",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Unknown",
              "Variant Annotation ID_norm": null
            }
          ]
        }
      },
      "overall_score": 0.2808175529291232,
      "num_benchmarks": 4
    },
    {
      "pmid": "40297930",
      "pmcid": "PMC12038368",
      "title": "Impacts of Pharmacokinetic Gene Polymorphisms on Steady\u2010State Plasma Concentrations of Simvastatin in Thai Population",
      "benchmarks": {
        "drug_annotations": {
          "total_samples": 2,
          "field_scores": {
            "Variant/Haplotypes": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                0.0
              ]
            },
            "Gene": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                0.0
              ]
            },
            "PMID": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Phenotype Category": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                0.0
              ]
            },
            "Significance": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                0.0
              ]
            },
            "Alleles": {
              "mean_score": 0.46971458196640015,
              "scores": [
                0.9394291639328003,
                0.0
              ]
            },
            "Specialty Population": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Metabolizer types": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "isPlural": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                0.0
              ]
            },
            "Is/Is Not associated": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                0.0
              ]
            },
            "Direction of effect": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                0.0
              ]
            },
            "PD/PK terms": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                0.0
              ]
            },
            "Multiple drugs And/or": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Population types": {
              "mean_score": 0.4433504343032837,
              "scores": [
                0.8867008686065674,
                0.0
              ]
            },
            "Population Phenotypes or diseases": {
              "mean_score": 0.45727601647377014,
              "scores": [
                0.9145520329475403,
                0.0
              ]
            },
            "Multiple phenotypes or diseases And/or": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Comparison Allele(s) or Genotype(s)": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                0.0
              ]
            },
            "Comparison Metabolizer types": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Drug(s)": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.30896531751281336,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "PMID": 0.0,
                "Phenotype Category": 1.0,
                "Significance": 1.0,
                "Alleles": 0.9394291639328003,
                "Specialty Population": 0.0,
                "Metabolizer types": 0.0,
                "isPlural": 1.0,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "PD/PK terms": 1.0,
                "Multiple drugs And/or": 0.0,
                "Population types": 0.8867008686065674,
                "Population Phenotypes or diseases": 0.9145520329475403,
                "Multiple phenotypes or diseases And/or": 0.0,
                "Comparison Allele(s) or Genotype(s)": 1.0,
                "Comparison Metabolizer types": 0.0,
                "Drug(s)": 0.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "rs4149056",
                  "prediction": "rs4149056"
                },
                "Gene": {
                  "ground_truth": "SLCO1B1",
                  "prediction": "SLCO1B1"
                },
                "PMID": {
                  "ground_truth": 40297930,
                  "prediction": null
                },
                "Phenotype Category": {
                  "ground_truth": "Metabolism/PK",
                  "prediction": "metabolism/PK"
                },
                "Significance": {
                  "ground_truth": "yes",
                  "prediction": "yes"
                },
                "Alleles": {
                  "ground_truth": "CC + CT",
                  "prediction": "TC/CC"
                },
                "Specialty Population": {
                  "ground_truth": null,
                  "prediction": ""
                },
                "Metabolizer types": {
                  "ground_truth": null,
                  "prediction": "decreased function"
                },
                "isPlural": {
                  "ground_truth": "Is",
                  "prediction": "Is"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "PD/PK terms": {
                  "ground_truth": "concentrations of",
                  "prediction": "concentrations of"
                },
                "Multiple drugs And/or": {
                  "ground_truth": null,
                  "prediction": ""
                },
                "Population types": {
                  "ground_truth": "in people with",
                  "prediction": "in patients with dyslipidemia or coronary artery disease"
                },
                "Population Phenotypes or diseases": {
                  "ground_truth": "Other:Cardiovascular Disease, Other:Dyslipidaemia",
                  "prediction": "Disease: coronary artery disease"
                },
                "Multiple phenotypes or diseases And/or": {
                  "ground_truth": "or",
                  "prediction": ""
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "TT",
                  "prediction": "TT"
                },
                "Comparison Metabolizer types": {
                  "ground_truth": null,
                  "prediction": "normal metabolizer"
                },
                "Drug(s)": {
                  "ground_truth": "simvastatin acid",
                  "prediction": "simvastatin"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            }
          ],
          "aligned_variants": [
            "rs4149056"
          ],
          "unmatched_ground_truth": [
            {
              "Variant Annotation ID": 1454052282,
              "Variant/Haplotypes": "rs2306283",
              "Gene": "SLCO1B1",
              "Drug(s)": "simvastatin acid",
              "PMID": 40297930,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "Additionally, SLCO1B1 rs2306283 was associated with significantly higher SVA levels in patients carrying the G allele (AG+GG genotype) at the same dose (3.63 vs. 1.59 ng/mL, p = 0.04). ",
              "Sentence": "Genotypes AG + GG is associated with increased concentrations of simvastatin acid in people with Cardiovascular Disease or Dyslipidaemia as compared to genotype AA.",
              "Alleles": "AG + GG",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "concentrations of",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Other:Cardiovascular Disease, Other:Dyslipidaemia",
              "Multiple phenotypes or diseases And/or": "or",
              "Comparison Allele(s) or Genotype(s)": "AA",
              "Comparison Metabolizer types": null,
              "PMID_norm": "40297930",
              "Variant Annotation ID_norm": "1454052282"
            }
          ],
          "unmatched_predictions": [
            {
              "Variant/Haplotypes": "c.521T>C",
              "Gene": "SLCO1B1",
              "Drug(s)": "simvastatin",
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "The study confirms the association of SLCO1B1 rs4149056 with higher simvastatin plasma levels in Thai patients.",
              "Standardized Sentence": "Genotype TC is associated with increased simvastatin acid levels in patients with dyslipidemia or coronary artery disease.",
              "Alleles": "TC/CC",
              "Metabolizer types": "decreased function",
              "Comparison Allele(s) or Genotype(s)": "TT",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "",
              "Population types": "in patients with dyslipidemia or coronary artery disease",
              "Population Phenotypes or diseases": "Disease: coronary artery disease",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "concentrations of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "These findings suggest that SLCO1B1 c.521T>C, alone or with c.388A>G (SLCO1B1*1b/*15), reduces OATP1B1 function, leading to elevated simvastatin acid levels and increased myotoxicity risk.",
                "This study confirms the association of SLCO1B1 rs4149056 (c.521T>C) with higher simvastatin plasma levels in Thai patients.",
                "Patients with the SLCO1B1*1b/*15 genotype were associated with higher simvastatin acid levels than SLCO1B1*1a/*1a (0.58 vs. 0.16 ng/mL, p < 0.001)."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "or",
              "Gene": "SLCO1B1",
              "Drug(s)": "simvastatin",
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "The study confirms the association of SLCO1B1 rs4149056 with higher simvastatin plasma levels in Thai patients.",
              "Standardized Sentence": "Genotype TC is associated with increased simvastatin acid levels in patients with dyslipidemia or coronary artery disease.",
              "Alleles": "TC/CC",
              "Metabolizer types": "decreased function",
              "Comparison Allele(s) or Genotype(s)": "TT",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "",
              "Population types": "in patients with dyslipidemia or coronary artery disease",
              "Population Phenotypes or diseases": "Disease: coronary artery disease",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "concentrations of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "These findings suggest that SLCO1B1 c.521T>C, alone or with c.388A>G (SLCO1B1*1b/*15), reduces OATP1B1 function, leading to elevated simvastatin acid levels and increased myotoxicity risk.",
                "This study confirms the association of SLCO1B1 rs4149056 (c.521T>C) with higher simvastatin plasma levels in Thai patients.",
                "Patients with the SLCO1B1*1b/*15 genotype were associated with higher simvastatin acid levels than SLCO1B1*1a/*1a (0.58 vs. 0.16 ng/mL, p < 0.001)."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "*1b/*15",
              "Gene": "SLCO1B1",
              "Drug(s)": "simvastatin",
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "The study confirms the association of SLCO1B1 rs4149056 with higher simvastatin plasma levels in Thai patients.",
              "Standardized Sentence": "Genotype TC is associated with increased simvastatin acid levels in patients with dyslipidemia or coronary artery disease.",
              "Alleles": "TC/CC",
              "Metabolizer types": "decreased function",
              "Comparison Allele(s) or Genotype(s)": "TT",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "",
              "Population types": "in patients with dyslipidemia or coronary artery disease",
              "Population Phenotypes or diseases": "Disease: coronary artery disease",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "concentrations of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "These findings suggest that SLCO1B1 c.521T>C, alone or with c.388A>G (SLCO1B1*1b/*15), reduces OATP1B1 function, leading to elevated simvastatin acid levels and increased myotoxicity risk.",
                "This study confirms the association of SLCO1B1 rs4149056 (c.521T>C) with higher simvastatin plasma levels in Thai patients.",
                "Patients with the SLCO1B1*1b/*15 genotype were associated with higher simvastatin acid levels than SLCO1B1*1a/*1a (0.58 vs. 0.16 ng/mL, p < 0.001)."
              ],
              "_expanded_from_multi_variant": true
            }
          ]
        },
        "phenotype_annotations": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": []
        },
        "functional_analysis": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "status": "missing_var_fa_ann"
        },
        "study_parameters": {
          "total_samples": 2,
          "field_scores": {
            "Study Type": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Study Cases": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Study Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Characteristics": {
              "mean_score": 0.8801729083061218,
              "scores": [
                0.9087350368499756,
                0.8516107797622681
              ]
            },
            "Characteristics Type": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Frequency In Cases": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Allele Of Frequency In Cases": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Frequency In Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Allele Of Frequency In Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "P Value": {
              "mean_score": 0.75,
              "scores": [
                1.0,
                0.5
              ]
            },
            "Ratio Stat Type": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Ratio Stat": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Confidence Interval Start": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Confidence Interval Stop": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Biogeographical Groups": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.7753448605537414,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.9087350368499756,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 1.0,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1454052280,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1454052260,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": null,
                  "prediction": "cohort"
                },
                "Study Cases": {
                  "ground_truth": 89.0,
                  "prediction": 89
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "12h simvastatin acid concentrations",
                  "prediction": "Thai patients with dyslipidemia or coronary artery disease on simvastatin treatment for at least 2 weeks"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "study cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.03",
                  "prediction": "= 0.03"
                },
                "Ratio Stat Type": {
                  "ground_truth": null,
                  "prediction": "HR"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "East Asian",
                  "prediction": "Asian"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.8516107797622681,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.5,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1454052320,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1454052282,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": null,
                  "prediction": "cohort"
                },
                "Study Cases": {
                  "ground_truth": 89.0,
                  "prediction": 89
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "12h simvastatin acid concentrations",
                  "prediction": "Patients with SLCO1B1 c.521TC+CC genotype"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "study cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.04",
                  "prediction": "= 0.07"
                },
                "Ratio Stat Type": {
                  "ground_truth": null,
                  "prediction": "Unknown"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "East Asian",
                  "prediction": "Asian"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            }
          ],
          "aligned_variants": [
            "None:12h simvastatin acid",
            "None:12h simvastatin acid"
          ],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 89,
              "Study Controls": null,
              "Characteristics": "Patients with SLCO1B1*1b/*15 genotype",
              "Characteristics Type": "study cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "< 0.001",
              "Ratio Stat Type": "HR",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Asian",
              "Variant Annotation ID_norm": null
            }
          ]
        }
      },
      "overall_score": 0.24775856736459229,
      "num_benchmarks": 4
    },
    {
      "pmid": "40761554",
      "pmcid": "PMC12319246",
      "title": "Pharmacogenetics association with long-term clinical evolution in a kidney transplant patients cohort",
      "benchmarks": {
        "drug_annotations": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "ABCB1_rs9282564",
              "Gene": "ABCB1",
              "Drug(s)": "tacrolimus",
              "PMID": 40761554,
              "Phenotype Category": "other",
              "Significance": "yes",
              "Notes": "Donor's AA variant associated with reduced risk of exitus during the follow-up (p-value: 0.029)",
              "Sentence": "Donor's AA genotype in ABCB1 rs9282564 is associated with reduced risk of exitus in kidney transplant patients.",
              "Alleles": "AA",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "risk of",
              "Multiple drugs And/or": null,
              "Population types": null,
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "40761554",
              "Variant Annotation ID_norm": "1",
              "Citations": [
                "The AA variant in the rs9282564 SNP of the donor's ABCB1 gene was significantly associated (p-value: 0.029) with a reduced risk (OR: 0.116) of exitus during the follow-up period.",
                "To confirm the effect of the associated gene variants on patient survival during the 12-year follow-up, Kaplan-Meier curves were plotted.",
                "Our findings indicate that the presence of associations between pharmacogene variants and clinical outcomes, including survival, renal function, and tumor occurrence."
              ]
            },
            {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "ABCC2_rs2273697",
              "Gene": "ABCC2",
              "Drug(s)": "tacrolimus",
              "PMID": 40761554,
              "Phenotype Category": "other",
              "Significance": "yes",
              "Notes": "Recipient's GA variant associated with increased risk of exitus during the follow-up (p-value: 0.021)",
              "Sentence": "Recipient's GA genotype in ABCC2 rs2273697 is associated with increased risk of exitus in kidney transplant patients.",
              "Alleles": "GA",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of",
              "Multiple drugs And/or": null,
              "Population types": null,
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "40761554",
              "Variant Annotation ID_norm": "2",
              "Citations": [
                "Conversely, patients receiving a graft from a donor with the GA genotype in rs2273697 of ABCC2 were significantly associated (p-value: 0.021) with an increased risk (OR: 4.133) of exitus during the follow-up period.",
                "The potential association between exitus during the follow-up period, regardless of the precise moment, and any of the pharmacogene variants determined was evaluated by multivariate logistic regression, including all variants in the analysis.",
                "To confirm the effect of the associated gene variants on patient survival during the 12-year follow-up, Kaplan-Meier curves were plotted."
              ]
            },
            {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "CYP3A5_rs776746",
              "Gene": "CYP3A5",
              "Drug(s)": "tacrolimus",
              "PMID": 40761554,
              "Phenotype Category": "metabolism/PK",
              "Significance": "not stated",
              "Notes": "CYP3A5 genotype's effect on tacrolimus pharmacokinetics was examined, but no significant association with exitus was found (p-value: 0.138)",
              "Sentence": "CYP3A5 genotype rs776746 is not associated with exitus risk in kidney transplant patients.",
              "Alleles": "*1/*3, *3/*3",
              "Specialty Population": null,
              "Metabolizer types": "extensive metabolizer, poor metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "pharmacokinetics of",
              "Multiple drugs And/or": null,
              "Population types": null,
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "40761554",
              "Variant Annotation ID_norm": "3",
              "Citations": [
                "The potential association between exitus during the follow-up period, regardless of the precise moment, and any of the pharmacogene variants determined was evaluated by multivariate logistic regression, including all variants in the analysis. [...] Although the CYP3A5 rs776746 did not show a significant association with survival in logistic regression, the Kaplan-Meier curve was also represented due to its special relevance and clinical evidence on the response to tacrolimus. No significant difference was observed by log-rank either, but it should not be discarded that the GG variant (\u22173/\u22173) could offer an advantage, especially at late post-transplantation stages.",
                "Kaplan-Meier analysis of variants significantly associated with survival showed that only ABCB1 rs9282564 (log-rank: 0.042) and ABCC2 rs2273697 (log-rank: 0.005) in donors had significant differences in survival rates. To evaluate the effect of CYP3A5 rs776746, a frequently associated variant with tacrolimus, Kaplan-Meier analysis was performed on our cohort subdivided into \u22171/\u22173 and \u22173/\u22173 CYP3A5 haplotypes. We did not observe statistically significant differences (log-rank: 0.138) between haplotypes; however, CYP3A5 \u22171/\u22173 recipients had reduced survival probability compared with \u22173/\u22173 patients in the later stages of follow-up, suggesting a potential long-term effect on patient outcomes."
              ]
            },
            {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "CYP2B6_rs3745274",
              "Gene": "CYP2B6",
              "Drug(s)": "tacrolimus",
              "PMID": 40761554,
              "Phenotype Category": "other",
              "Significance": "yes",
              "Notes": "Recipient's GT variant associated with reduced tumor incidence (OR: 0.099; p-value: 0.048)",
              "Sentence": "Recipient's GT genotype in CYP2B6 rs3745274 is associated with reduced tumor incidence in kidney transplant patients.",
              "Alleles": "GT",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "risk of",
              "Multiple drugs And/or": null,
              "Population types": null,
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "40761554",
              "Variant Annotation ID_norm": "4",
              "Citations": [
                "Increased tumor risk correlated with ABCC2 variants in donors and decreased risk with CYP2B6 rs3745274 in recipients.",
                "Recipients carrying the GT heterozygous genotype in CYP2B6 rs3745274 could present an advantage (OR: 0.099; p-value: 0.048).",
                "Our results show that... tumor occurrence linked to CYP2B6 rs3745274..."
              ]
            },
            {
              "Variant Annotation ID": 5,
              "Variant/Haplotypes": "CYP2C19_rs4244285",
              "Gene": "CYP2C19",
              "Drug(s)": "tacrolimus",
              "PMID": 40761554,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Recipient's AA variant associated with increased nephrotoxicity (OR: 11.65; p-value: 0.026)",
              "Sentence": "Recipient's AA genotype in CYP2C19 rs4244285 is associated with increased nephrotoxicity risk in kidney transplant patients.",
              "Alleles": "AA",
              "Specialty Population": null,
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of",
              "Multiple drugs And/or": null,
              "Population types": null,
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "40761554",
              "Variant Annotation ID_norm": "5",
              "Citations": [
                "Increased nephrotoxicity risk was associated with CYP2C19 rs4244285 and reduced by SLCO1B1 rs2306283 AA and AG variants.",
                "We found a strong association (p-value: 0.026) with a substantial increase in nephrotoxicity risk (OR: 11.6) in patients with the AA variant in CYP2C19 rs4244285.",
                "The AA variant in CYP2C19 rs4244285 is associated with increased nephrotoxicity risk in kidney transplant patients."
              ]
            }
          ]
        },
        "phenotype_annotations": {
          "total_samples": 8,
          "field_scores": {
            "Variant/Haplotypes": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Gene": {
              "mean_score": 0.6128570809960365,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                0.9028566479682922,
                0.0,
                0.0,
                0.0
              ]
            },
            "Drug(s)": {
              "mean_score": 0.61224564909935,
              "scores": [
                0.97959303855896,
                0.97959303855896,
                0.97959303855896,
                0.97959303855896,
                0.97959303855896,
                0.0,
                0.0,
                0.0
              ]
            },
            "Phenotype Category": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Alleles": {
              "mean_score": 0.5805682316422462,
              "scores": [
                1.0,
                1.0,
                0.9154993295669556,
                0.884587287902832,
                0.8444592356681824,
                0.0,
                0.0,
                0.0
              ]
            },
            "Is/Is Not associated": {
              "mean_score": 0.625,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Direction of effect": {
              "mean_score": 0.625,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Phenotype": {
              "mean_score": 0.5371762812137604,
              "scores": [
                0.9629747867584229,
                0.8325313329696655,
                0.8091927170753479,
                0.8270606994628906,
                0.8656507134437561,
                0.0,
                0.0,
                0.0
              ]
            },
            "When treated with/exposed to/when assayed with": {
              "mean_score": 0.625,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Comparison Allele(s) or Genotype(s)": {
              "mean_score": 0.375,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                1.0,
                0.0,
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.565744205377996,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "Drug(s)": 0.97959303855896,
                "Phenotype Category": 1.0,
                "Alleles": 1.0,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.9629747867584229,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 1.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "rs4244285",
                  "prediction": "rs4244285"
                },
                "Gene": {
                  "ground_truth": "CYP2C19",
                  "prediction": "CYP2C19"
                },
                "Drug(s)": {
                  "ground_truth": "tacrolimus",
                  "prediction": "Tacrolimus"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "AA",
                  "prediction": "AA"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:Nephrotoxicity",
                  "prediction": "nephrotoxicity"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": null,
                  "prediction": null
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "Drug(s)": 0.97959303855896,
                "Phenotype Category": 1.0,
                "Alleles": 1.0,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.8325313329696655,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 1.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "rs3745274",
                  "prediction": "rs3745274"
                },
                "Gene": {
                  "ground_truth": "CYP2B6",
                  "prediction": "CYP2B6"
                },
                "Drug(s)": {
                  "ground_truth": "tacrolimus",
                  "prediction": "Tacrolimus"
                },
                "Phenotype Category": {
                  "ground_truth": "Efficacy",
                  "prediction": "efficacy"
                },
                "Alleles": {
                  "ground_truth": "GT",
                  "prediction": "GT"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "decreased",
                  "prediction": "decreased"
                },
                "Phenotype": {
                  "ground_truth": "Efficacy:Transplant rejection",
                  "prediction": "tumor occurrence"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": null,
                  "prediction": null
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 2,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "Drug(s)": 0.97959303855896,
                "Phenotype Category": 1.0,
                "Alleles": 0.9154993295669556,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.8091927170753479,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "rs2273697",
                  "prediction": "rs2273697"
                },
                "Gene": {
                  "ground_truth": "ABCC2",
                  "prediction": "ABCC2"
                },
                "Drug(s)": {
                  "ground_truth": "tacrolimus",
                  "prediction": "Tacrolimus"
                },
                "Phenotype Category": {
                  "ground_truth": "Efficacy",
                  "prediction": "efficacy"
                },
                "Alleles": {
                  "ground_truth": "GG",
                  "prediction": "GA"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Efficacy:Overall survival",
                  "prediction": "exitus"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "AA + AG",
                  "prediction": null
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 3,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "Drug(s)": 0.97959303855896,
                "Phenotype Category": 1.0,
                "Alleles": 0.884587287902832,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.8270606994628906,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "rs9282564",
                  "prediction": "rs9282564"
                },
                "Gene": {
                  "ground_truth": "ABCB1",
                  "prediction": "ABCB1"
                },
                "Drug(s)": {
                  "ground_truth": "tacrolimus",
                  "prediction": "Tacrolimus"
                },
                "Phenotype Category": {
                  "ground_truth": "Efficacy",
                  "prediction": "efficacy"
                },
                "Alleles": {
                  "ground_truth": "TT",
                  "prediction": "AA"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "decreased",
                  "prediction": "decreased"
                },
                "Phenotype": {
                  "ground_truth": "Efficacy:Death",
                  "prediction": "exitus"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "CC + CT",
                  "prediction": null
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 4,
              "field_scores": {
                "Variant/Haplotypes": 0.0,
                "Gene": 0.9028566479682922,
                "Drug(s)": 0.97959303855896,
                "Phenotype Category": 0.0,
                "Alleles": 0.8444592356681824,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.8656507134437561,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 1.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "rs4244285",
                  "prediction": "CYP3A5"
                },
                "Gene": {
                  "ground_truth": "CYP2C19",
                  "prediction": "CYP3A5"
                },
                "Drug(s)": {
                  "ground_truth": "tacrolimus",
                  "prediction": "Tacrolimus"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "metabolism/PK"
                },
                "Alleles": {
                  "ground_truth": "AA",
                  "prediction": "*3/*3"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:Nephrotoxicity",
                  "prediction": "tacrolimus"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": null,
                  "prediction": null
                }
              },
              "dependency_issues": []
            }
          ],
          "aligned_variants": [
            "rs3745274",
            "rs9282564",
            "rs2273697",
            "rs4244285",
            "cyp3a5+tacrolimus"
          ],
          "unmatched_ground_truth": [
            {
              "Variant Annotation ID": 1454211330,
              "Variant/Haplotypes": "rs2740574",
              "Gene": "CYP3A4",
              "Drug(s)": "tacrolimus",
              "PMID": 40761554,
              "Phenotype Category": "Efficacy",
              "Significance": "yes",
              "Notes": "Regarding acute rejection, statistical analysis showed that the CYP3A4 rs2740574 AA variant in the recipient could offer a protective effect (OR: 0.080; p-value: 0.047) compared to other variants at that location. \" Alleles complemented.",
              "Sentence": "Genotype TT is associated with decreased likelihood of Transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes CC + CT.",
              "Alleles": "TT",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Efficacy:Transplant rejection",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Other:Kidney Transplantation",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "CC + CT",
              "Comparison Metabolizer types": null,
              "PMID_norm": "40761554",
              "Variant Annotation ID_norm": "1454211330"
            },
            {
              "Variant Annotation ID": 1454211400,
              "Variant/Haplotypes": "rs2306283",
              "Gene": "SLCO1B1",
              "Drug(s)": "tacrolimus",
              "PMID": 40761554,
              "Phenotype Category": "Toxicity",
              "Significance": "yes",
              "Notes": "From Table 3. AA and AG genotype of Recipient and AG genotype of donor were association with lower odds of nephrotoxicity",
              "Sentence": "Genotypes AA + AG is associated with decreased likelihood of Nephrotoxicity when treated with tacrolimus in people with Kidney Transplantation.",
              "Alleles": "AA + AG",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Side Effect:Nephrotoxicity",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Other:Kidney Transplantation",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "40761554",
              "Variant Annotation ID_norm": "1454211400"
            },
            {
              "Variant Annotation ID": 1454211340,
              "Variant/Haplotypes": "rs4149056",
              "Gene": "SLCO1B1",
              "Drug(s)": "tacrolimus",
              "PMID": 40761554,
              "Phenotype Category": "Efficacy",
              "Significance": "yes",
              "Notes": "The presence of the TT variant in SLCO1B1 rs4149056 in the recipient and the GT variant in CYP2B6 rs3745274 in the donor were also statistically associated with a reduced risk (OR: 0.16 and 0.2, respectively) of acute rejection.\" \"Recipients with the TT variant in SLCO1B1 rs4149056 showed higher dose-adjusted tacrolimus concentrations, possibly mediating a greater immunosuppressive effect and protecting against rejection, consistent with our logistic regression results (OR: 0.157). ",
              "Sentence": "Genotype TT is associated with decreased likelihood of Transplant rejection when treated with tacrolimus in people with Kidney Transplantation.",
              "Alleles": "TT",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Efficacy:Transplant rejection",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Other:Kidney Transplantation",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "40761554",
              "Variant Annotation ID_norm": "1454211340"
            }
          ],
          "unmatched_predictions": [
            {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "*3/*3",
              "Gene": "CYP3A5",
              "Drug(s)": "Tacrolimus",
              "PMID": 40761554,
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A5 *3/*3 genotype associated with higher tacrolimus concentration/dose ratio (C/D) over time",
              "Sentence": "CYP3A5 *3/*3 is associated with increased tacrolimus concentration/dose ratio when treated with tacrolimus in kidney transplant recipients.",
              "Alleles": "*3/*3",
              "Specialty Population": "Adult",
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "concentration of",
              "Phenotype": "tacrolimus",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in adult",
              "Population Phenotypes or diseases": "kidney transplantation",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": 40761554,
              "Variant Annotation ID_norm": 1,
              "Citations": [
                "Patients with the \u22173/\u22173 haplotype, known as non-expressers, exhibit increased tacrolimus concentrations due to impaired drug metabolism.",
                "homozygous patients for this variant (\u22173/\u22173) presented increasing C/D ratios of tacrolimus during the follow-up, reaching levels that exceed 200 [(ng/ml)/(mg/kg)], which was significantly (p-value <0.001) higher than in heterozygous (\u22171/\u22173) patients.",
                "We examined these associations in relation to the most frequent clinical parameters observed during a 12-year follow-up."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "ABCB1",
              "Gene": "ABCB1",
              "Drug(s)": "Tacrolimus",
              "PMID": 40761554,
              "Phenotype Category": "efficacy",
              "Significance": "yes",
              "Notes": "The AA variant in ABCB1 rs9282564 was associated with lower risk of exitus during the follow-up period",
              "Sentence": "ABCB1 rs9282564 AA is associated with decreased risk of exitus when treated with tacrolimus in kidney transplant recipients.",
              "Alleles": "AA",
              "Specialty Population": "Adult",
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "exitus",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in adult",
              "Population Phenotypes or diseases": "kidney transplantation",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": 40761554,
              "Variant Annotation ID_norm": 2,
              "Citations": [
                "The AA variant in the rs9282564 SNP of the donor's ABCB1 gene was significantly associated (p-value: 0.029) with a reduced risk (OR: 0.116) of exitus during the follow-up period.",
                "Patients receiving a graft from a donor with the AA variant in ABCB1 rs9282564 had significantly better survival outcomes compared to those with other genotypes, as indicated by the Kaplan-Meier analysis (p-value: 0.042).",
                "Our findings indicate the presence of associations between pharmacogene variants and clinical outcomes, including survival, renal function, and tumor occurrence, specifically highlighting that the AA variant of ABCB1 rs9282564 is connected to reduced exitus risk."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "ABCC2",
              "Gene": "ABCC2",
              "Drug(s)": "Tacrolimus",
              "PMID": 40761554,
              "Phenotype Category": "efficacy",
              "Significance": "yes",
              "Notes": "The GA variant in ABCC2 rs2273697 was associated with higher risk of exitus during the follow-up period",
              "Sentence": "ABCC2 rs2273697 GA is associated with increased risk of exitus when treated with tacrolimus in kidney transplant recipients.",
              "Alleles": "GA",
              "Specialty Population": "Adult",
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "exitus",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in adult",
              "Population Phenotypes or diseases": "kidney transplantation",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": 40761554,
              "Variant Annotation ID_norm": 3,
              "Citations": [
                "Conversely, patients receiving a graft from a donor with the GA genotype in rs2273697 of ABCC2 were significantly associated (p-value: 0.021) with an increased risk (OR: 4.133) of exitus.",
                "Kaplan-Meier curves were plotted. The genotype in the donor's ABCC2 rs2273697 could significantly (p-value: 0.003; log-rank) affect survival.",
                "Our findings indicate the presence of associations between pharmacogene variants and clinical outcomes, including survival, renal function, and tumor occurrence."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "CYP2B6",
              "Gene": "CYP2B6",
              "Drug(s)": "Tacrolimus",
              "PMID": 40761554,
              "Phenotype Category": "efficacy",
              "Significance": "yes",
              "Notes": "GT heterozygous genotype in recipients was associated with decreased risk of tumor occurrence",
              "Sentence": "CYP2B6 rs3745274 GT is associated with decreased risk of tumor occurrence when treated with tacrolimus in kidney transplant recipients.",
              "Alleles": "GT",
              "Specialty Population": "Adult",
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "tumor occurrence",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in adult",
              "Population Phenotypes or diseases": "kidney transplantation",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": 40761554,
              "Variant Annotation ID_norm": 4,
              "Citations": [
                "Increased tumor risk correlated with ABCC2 variants in donors and decreased risk with CYP2B6 rs3745274 in recipients.",
                "Our results show that... decreased risk was observed in recipients with the GT variant in CYP2B6 rs3745274.",
                "Multivariate logistic regression using all pharmacogene variants showed that recipients carrying the GT heterozygous genotype in CYP2B6 rs3745274 could present an advantage (OR: 0.099; p-value: 0.048)."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 5,
              "Variant/Haplotypes": "CYP2C19",
              "Gene": "CYP2C19",
              "Drug(s)": "Tacrolimus",
              "PMID": 40761554,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "The AA variant was associated with increased risk of nephrotoxicity",
              "Sentence": "CYP2C19 rs4244285 AA is associated with increased risk of nephrotoxicity when treated with tacrolimus in kidney transplant recipients.",
              "Alleles": "AA",
              "Specialty Population": "Adult",
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "nephrotoxicity",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in adult",
              "Population Phenotypes or diseases": "kidney transplantation",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": 40761554,
              "Variant Annotation ID_norm": 5,
              "Citations": [
                "Increased nephrotoxicity risk was associated with CYP2C19 rs4244285 and reduced by SLCO1B1 rs2306283 AA and AG variants.",
                "Our results confirm that variants in CYP2C19 (\u22172, rs4244285) affect the risk of nephrotoxicity in kidney transplant patients, with an odds ratio of 11.652 for the AA variant.",
                "An increased risk of nephrotoxicity was observed in patients receiving grafts carrying the AA variant in CYP2C19 rs4244285."
              ],
              "_expanded_from_multi_variant": true
            }
          ]
        },
        "functional_analysis": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "status": "missing_var_fa_ann"
        },
        "study_parameters": {
          "total_samples": 8,
          "field_scores": {
            "Study Type": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Study Cases": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Study Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Characteristics": {
              "mean_score": 0.8861278742551804,
              "scores": [
                0.8876385688781738,
                0.8483831286430359,
                0.8523847460746765,
                0.88640296459198,
                0.932835578918457,
                0.9256520867347717,
                0.9170963168144226,
                0.8386296033859253
              ]
            },
            "Characteristics Type": {
              "mean_score": 0.25,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Frequency In Cases": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Allele Of Frequency In Cases": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Frequency In Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Allele Of Frequency In Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "P Value": {
              "mean_score": 0.66875,
              "scores": [
                0.5,
                1.0,
                1.0,
                0.85,
                0.5,
                0.5,
                0.5,
                0.5
              ]
            },
            "Ratio Stat Type": {
              "mean_score": 0.125,
              "scores": [
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Ratio Stat": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Confidence Interval Start": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Confidence Interval Stop": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Biogeographical Groups": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0
              ]
            }
          },
          "overall_score": 0.595325191617012,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.8876385688781738,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.5,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 0.0,
                "Confidence Interval Start": 0.0,
                "Confidence Interval Stop": 0.0,
                "Biogeographical Groups": 1.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1454211329,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1454211323,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": null,
                  "prediction": "retrospective"
                },
                "Study Cases": {
                  "ground_truth": 79.0,
                  "prediction": 79
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "nephrotoxicity during 12-year follow-up",
                  "prediction": "Adult kidney transplant recipients treated with tacrolimus"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.026",
                  "prediction": "= 0.021"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": 11.652,
                  "prediction": 4.133
                },
                "Confidence Interval Start": {
                  "ground_truth": 1.509,
                  "prediction": 1.301
                },
                "Confidence Interval Stop": {
                  "ground_truth": 89.957,
                  "prediction": 13.125
                },
                "Biogeographical Groups": {
                  "ground_truth": "Unknown",
                  "prediction": "Unknown"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.8483831286430359,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 1.0,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 0.0,
                "Confidence Interval Start": 0.0,
                "Confidence Interval Stop": 0.0,
                "Biogeographical Groups": 1.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1454211266,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1454211260,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": null,
                  "prediction": "retrospective"
                },
                "Study Cases": {
                  "ground_truth": 79.0,
                  "prediction": 79
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "exitus during 12-year follow-up",
                  "prediction": "Adult kidney transplant recipients treated with tacrolimus"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.029",
                  "prediction": "= 0.029"
                },
                "Ratio Stat Type": {
                  "ground_truth": null,
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": 0.116
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": 0.019
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": 0.726
                },
                "Biogeographical Groups": {
                  "ground_truth": "Unknown",
                  "prediction": "Unknown"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 2,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.8523847460746765,
                "Characteristics Type": 0.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 1.0,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 0.0,
                "Confidence Interval Start": 0.0,
                "Confidence Interval Stop": 0.0,
                "Biogeographical Groups": 1.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1454211277,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1454211271,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": null,
                  "prediction": "retrospective"
                },
                "Study Cases": {
                  "ground_truth": 79.0,
                  "prediction": 79
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "survival during 12-year follow-up",
                  "prediction": "Infection incidence in kidney transplant recipients"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "disease"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.003",
                  "prediction": "= 0.003"
                },
                "Ratio Stat Type": {
                  "ground_truth": null,
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": 0.087
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": 0.019
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": 0.393
                },
                "Biogeographical Groups": {
                  "ground_truth": "Unknown",
                  "prediction": "Unknown"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 3,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.88640296459198,
                "Characteristics Type": 0.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.85,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 0.0,
                "Confidence Interval Start": 0.0,
                "Confidence Interval Stop": 0.0,
                "Biogeographical Groups": 1.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1454211336,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1454211330,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": null,
                  "prediction": "retrospective"
                },
                "Study Cases": {
                  "ground_truth": 79.0,
                  "prediction": 79
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "acute rejection during 12-year follow-up, recipient",
                  "prediction": "Tumor occurrence in kidney transplant recipients"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "disease"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.047",
                  "prediction": "= 0.043"
                },
                "Ratio Stat Type": {
                  "ground_truth": null,
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": 13.091
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": 1.241
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": 138.105
                },
                "Biogeographical Groups": {
                  "ground_truth": "Unknown",
                  "prediction": "Unknown"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 4,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.932835578918457,
                "Characteristics Type": 0.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.5,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 0.0,
                "Confidence Interval Start": 0.0,
                "Confidence Interval Stop": 0.0,
                "Biogeographical Groups": 1.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1454211346,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1454211340,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": null,
                  "prediction": "retrospective"
                },
                "Study Cases": {
                  "ground_truth": 79.0,
                  "prediction": 79
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "acute rejection during 12-year follow-up, recipient",
                  "prediction": "Acute rejection risk in kidney transplant recipients"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "disease"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.024",
                  "prediction": "= 0.035"
                },
                "Ratio Stat Type": {
                  "ground_truth": null,
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": 0.08
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": 0.008
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": 0.833
                },
                "Biogeographical Groups": {
                  "ground_truth": "Unknown",
                  "prediction": "Unknown"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 5,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.9256520867347717,
                "Characteristics Type": 0.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.5,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 0.0,
                "Confidence Interval Start": 0.0,
                "Confidence Interval Stop": 0.0,
                "Biogeographical Groups": 1.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1454211406,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1454211400,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": null,
                  "prediction": "retrospective"
                },
                "Study Cases": {
                  "ground_truth": 79.0,
                  "prediction": 79
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "nephrotoxicity during 12-year follow-up, donor",
                  "prediction": "Nephrotoxicity risk in kidney transplant recipients"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "disease"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.024",
                  "prediction": "= 0.009"
                },
                "Ratio Stat Type": {
                  "ground_truth": "Unknown",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": 0.076
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": 0.012
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": 0.492
                },
                "Biogeographical Groups": {
                  "ground_truth": "Unknown",
                  "prediction": "Unknown"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 6,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.9170963168144226,
                "Characteristics Type": 0.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.5,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 0.0,
                "Confidence Interval Start": 0.0,
                "Confidence Interval Stop": 0.0,
                "Biogeographical Groups": 1.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1454211353,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1454211347,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": null,
                  "prediction": "retrospective"
                },
                "Study Cases": {
                  "ground_truth": 79.0,
                  "prediction": 79
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "acute rejection during 12-year follow-up, donor",
                  "prediction": "Chronic rejection risk in kidney transplant recipients"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "disease"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.027",
                  "prediction": "= 0.012"
                },
                "Ratio Stat Type": {
                  "ground_truth": null,
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": 0.133
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": 0.028
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": 0.643
                },
                "Biogeographical Groups": {
                  "ground_truth": "Unknown",
                  "prediction": "Unknown"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 7,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.8386296033859253,
                "Characteristics Type": 0.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.5,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 0.0,
                "Confidence Interval Start": 0.0,
                "Confidence Interval Stop": 0.0,
                "Biogeographical Groups": 1.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1454211300,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1454211280,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": null,
                  "prediction": "retrospective"
                },
                "Study Cases": {
                  "ground_truth": 79.0,
                  "prediction": 79
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "survival during 12-year follow-up",
                  "prediction": "Diabetes mellitus risk in kidney transplant recipients"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "disease"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.138",
                  "prediction": "= 0.056"
                },
                "Ratio Stat Type": {
                  "ground_truth": null,
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": 0.273
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": 0.072
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": 1.033
                },
                "Biogeographical Groups": {
                  "ground_truth": "Unknown",
                  "prediction": "Unknown"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            }
          ],
          "aligned_variants": [
            "None:nephrotoxicity durin",
            "None:exitus during 12-yea",
            "None:survival during 12-y",
            "None:acute rejection duri",
            "None:acute rejection duri",
            "None:nephrotoxicity durin",
            "None:acute rejection duri",
            "None:survival during 12-y"
          ],
          "unmatched_ground_truth": [],
          "unmatched_predictions": []
        }
      },
      "overall_score": 0.28878829993680116,
      "num_benchmarks": 4
    },
    {
      "pmid": "40786508",
      "pmcid": "PMC12331468",
      "title": "Genetic variants and clinical determinants affecting the response to 5-Fluorouracil-based treatment in Chilean patients with advanced colorectal cancer",
      "benchmarks": {
        "drug_annotations": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Variant/Haplotypes": "rs1801265",
              "Gene": "DPYD",
              "Drug(s)": "5-fluorouracil",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "The C allele of DPYD (rs1801265) was linked to a higher neuropathy risk (OR = 4.58; p = 0.05).",
              "Sentence": "The C allele is associated with increased risk of neuropathy in patients receiving 5-fluorouracil treatment.",
              "Alleles": "C",
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "response to",
              "Comparison Allele(s) or Genotype(s": "T/T",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "",
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:colorectal cancer",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "The C allele of DPYD (rs1801265) was linked to a higher neuropathy risk (OR = 4.58; p = 0.05).",
                "Further analysis of ungrouped ADRs indicated a higher risk of neuropathy in patients carrying the C allele of the DPYD rs1801265 polymorphism (codominant model T/C genotype OR = 30.0, p-value = 0.0049, dominant model OR = 4.583, p-value = 0.05).",
                "This study aimed to establish a correlation between the patient's genotype and the risk of ADR in Chilean advanced CRC patients."
              ]
            },
            {
              "Variant/Haplotypes": "rs1695",
              "Gene": "GSTP1",
              "Drug(s)": "5-fluorouracil",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "The G allele of GSTP1 (rs1695) was protective against neuropathy (OR = 0.147; p = 0.012) but increased mucositis risk (OR = 2.27; p = 0.036).",
              "Sentence": "The G allele is associated with decreased risk of neuropathy but increased risk of mucositis in patients receiving 5-fluorouracil treatment.",
              "Alleles": "G",
              "Metabolizer types": "",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased,increased",
              "PD/PK terms": "response to",
              "Comparison Allele(s) or Genotype(s": "A",
              "Comparison Metabolizer types": "",
              "Specialty Population": "",
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:colorectal cancer",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "The G allele of GSTP1 (rs1695) was protective against neuropathy (OR = 0.147; p = 0.012) but increased mucositis risk (OR = 2.27; p = 0.036).",
                "Among the 16 variants analyzed in 82 patients, key findings included: The G allele of GSTP1 (rs1695) was protective against neuropathy (OR = 0.147; p = 0.012) but increased mucositis risk (OR = 2.27; p = 0.036).",
                "The G allele of the GSTP1 rs1695 polymorphism was correlated with a lower risk of hematological and nervous system disorders in treated patients, including a reduced risk of neuropathy."
              ]
            },
            {
              "Variant/Haplotypes": "rs11280056",
              "Gene": "TYMS",
              "Drug(s)": "5-fluorouracil",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "The TYMS deletion genotype (rs11280056) conferred protection against hematological adverse reactions (OR = 0.029; p = 0.001).",
              "Sentence": "The deletion genotype is associated with decreased risk of hematological adverse reactions in patients receiving 5-fluorouracil treatment.",
              "Alleles": "del/del",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "response to",
              "Comparison Allele(s) or Genotype(s": "",
              "Comparison Metabolizer types": "",
              "Specialty Population": "",
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:colorectal cancer",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "The TYMS deletion genotype (rs11280056) conferred protection against hematological adverse reactions (OR = 0.029; p = 0.001).",
                "We identified a protective correlation between the 6bp deletion of the TYMS 3'UTR region (rs11280056) and a lower risk of gastrointestinal and hematological disorders in chemotherapy patients.",
                "When analyzing the risk of grouped ADR while considering only severe reactions (Grade III-IV), we found that only the TYMS 3'UTR 6bp deletion (rs11280056) was the only polymorphism associated with a lower risk of severe hematological disorders (dominant model OR = 0,098, CI 95% 0.013 - 0.441, p-value =0.005)."
              ]
            },
            {
              "Variant/Haplotypes": "rs45445694",
              "Gene": "TYMS",
              "Drug(s)": "5-fluorouracil",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "The 3R genotype of TYMS 5'UTR (rs45445694) is associated as a risk factor for skin and subcutaneous tissue disorders (OR = 6.40; p = 0.029).",
              "Sentence": "The 3R genotype is associated with increased risk of skin and subcutaneous tissue disorders in patients receiving 5-fluorouracil treatment.",
              "Alleles": "3R/3R",
              "Metabolizer types": "",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "response to",
              "Comparison Allele(s) or Genotype(s": "",
              "Comparison Metabolizer types": "",
              "Specialty Population": "",
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:colorectal cancer",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "On the other hand, the 3R genotype of TYMS 5'UTR (rs45445694) is associated as a risk factor for skin and subcutaneous tissue disorders (OR = 6.40; p = 0.029).",
                "This study provides a foundation for developing pharmacogenetic-based predictive models for adverse reactions associated with 5-FU, including...skin and subcutaneous tissue disorders.",
                "A retrospective nested case-control study was conducted on 82 advanced colorectal cancer patients. Sixteen genetic variants were analyzed to assess their association with adverse reactions and their severity using logistic regression."
              ]
            }
          ]
        },
        "phenotype_annotations": {
          "total_samples": 5,
          "field_scores": {
            "Variant/Haplotypes": {
              "mean_score": 0.6,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0,
                0.0
              ]
            },
            "Gene": {
              "mean_score": 0.768479835987091,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.8423991799354553,
                0.0
              ]
            },
            "Drug(s)": {
              "mean_score": 0.7176769256591797,
              "scores": [
                0.8970961570739746,
                0.8970961570739746,
                0.8970961570739746,
                0.8970961570739746,
                0.0
              ]
            },
            "Phenotype Category": {
              "mean_score": 0.8,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                0.0
              ]
            },
            "Alleles": {
              "mean_score": 0.681645393371582,
              "scores": [
                0.8444317579269409,
                0.8589097857475281,
                0.8306638598442078,
                0.8742215633392334,
                0.0
              ]
            },
            "Is/Is Not associated": {
              "mean_score": 0.8,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                0.0
              ]
            },
            "Direction of effect": {
              "mean_score": 0.8,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                0.0
              ]
            },
            "Phenotype": {
              "mean_score": 0.7125120639801026,
              "scores": [
                0.9030094146728516,
                0.8724660873413086,
                0.9016036987304688,
                0.8854811191558838,
                0.0
              ]
            },
            "When treated with/exposed to/when assayed with": {
              "mean_score": 0.8,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                0.0
              ]
            },
            "Comparison Allele(s) or Genotype(s)": {
              "mean_score": 0.6,
              "scores": [
                1.0,
                1.0,
                0.0,
                1.0,
                0.0
              ]
            }
          },
          "overall_score": 0.7243739535411199,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "Drug(s)": 0.8970961570739746,
                "Phenotype Category": 1.0,
                "Alleles": 0.8444317579269409,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.9030094146728516,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 1.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "rs11280056",
                  "prediction": "rs11280056"
                },
                "Gene": {
                  "ground_truth": "TYMS",
                  "prediction": "TYMS"
                },
                "Drug(s)": {
                  "ground_truth": "FOLFOX, XELOX",
                  "prediction": "5-fluorouracil"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "TTA/TTA + TTA/TTAAAGTTA",
                  "prediction": "del/ins"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "decreased",
                  "prediction": "decreased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:Peripheral Nervous System Diseases, Side Effect:Myelosuppression",
                  "prediction": "hematological adverse reactions"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": null,
                  "prediction": null
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "Drug(s)": 0.8970961570739746,
                "Phenotype Category": 1.0,
                "Alleles": 0.8589097857475281,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.8724660873413086,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 1.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "rs45445694",
                  "prediction": "rs45445694"
                },
                "Gene": {
                  "ground_truth": "TYMS",
                  "prediction": "TYMS"
                },
                "Drug(s)": {
                  "ground_truth": "FOLFOX, XELOX",
                  "prediction": "5-fluorouracil"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3",
                  "prediction": "3R/2R"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:Hand-foot syndrome, Side Effect:Exanthema, Side Effect:Drug Toxicity",
                  "prediction": "skin and subcutaneous tissue disorders"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": null,
                  "prediction": null
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 2,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "Drug(s)": 0.8970961570739746,
                "Phenotype Category": 1.0,
                "Alleles": 0.8306638598442078,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.9016036987304688,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "rs1801265",
                  "prediction": "rs1801265"
                },
                "Gene": {
                  "ground_truth": "DPYD",
                  "prediction": "DPYD"
                },
                "Drug(s)": {
                  "ground_truth": "FOLFOX, XELOX",
                  "prediction": "5-fluorouracil"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "AG + GG",
                  "prediction": "C/T"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:Peripheral Nervous System Diseases",
                  "prediction": "neuropathy"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "AA",
                  "prediction": null
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 3,
              "field_scores": {
                "Variant/Haplotypes": 0.0,
                "Gene": 0.8423991799354553,
                "Drug(s)": 0.8970961570739746,
                "Phenotype Category": 1.0,
                "Alleles": 0.8742215633392334,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.8854811191558838,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 1.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "rs45445694",
                  "prediction": "rs1695"
                },
                "Gene": {
                  "ground_truth": "TYMS",
                  "prediction": "GSTP1"
                },
                "Drug(s)": {
                  "ground_truth": "FOLFOX, XELOX",
                  "prediction": "5-fluorouracil"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3",
                  "prediction": "G/A"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:Hand-foot syndrome, Side Effect:Exanthema, Side Effect:Drug Toxicity",
                  "prediction": "neuropathy, mucositis"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": null,
                  "prediction": null
                }
              },
              "dependency_issues": []
            }
          ],
          "aligned_variants": [
            "rs1801265",
            "rs1695",
            "rs11280056",
            "rs45445694"
          ],
          "unmatched_ground_truth": [
            {
              "Variant Annotation ID": 1454223701,
              "Variant/Haplotypes": "rs1695",
              "Gene": "GSTP1",
              "Drug(s)": "FOLFOX, XELOX",
              "PMID": 40786508,
              "Phenotype Category": "Toxicity",
              "Significance": "yes",
              "Notes": "The G allele of the GSTP1 rs1695 polymorphism was correlated with a lower risk of hematological and nervous system disorders in treated patients, including a reduced risk of neuropathy. This was observed through the analysis of individual ADR using univariate logistic regression without CTCAE v5.0 grouping ( Supplementary Table 3 , OR = 0.01, p-value = 0.008). However, we observed a higher risk of mucositis in patients carrying this polymorphism ( Supplementary Table 3 , OR = 2.27, p-value = 0.036).",
              "Sentence": "Genotype GG is associated with increased likelihood of Mucositis when treated with FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotypes AA + AG.",
              "Alleles": "GG",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Side Effect:Mucositis",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": "or",
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Other:Colorectal Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "AA + AG",
              "Comparison Metabolizer types": null,
              "PMID_norm": "40786508",
              "Variant Annotation ID_norm": "1454223701"
            }
          ],
          "unmatched_predictions": []
        },
        "functional_analysis": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "status": "missing_var_fa_ann"
        },
        "study_parameters": {
          "total_samples": 6,
          "field_scores": {
            "Study Type": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Study Cases": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Study Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Characteristics": {
              "mean_score": 0.8678298691908518,
              "scores": [
                0.8161100149154663,
                0.8540969491004944,
                0.9072026610374451,
                0.8998762965202332,
                0.8720298409461975,
                0.8576634526252747
              ]
            },
            "Characteristics Type": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Frequency In Cases": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Allele Of Frequency In Cases": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Frequency In Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Allele Of Frequency In Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "P Value": {
              "mean_score": 0.6416666666666667,
              "scores": [
                0.85,
                0.5,
                1.0,
                0.5,
                0.5,
                0.5
              ]
            },
            "Ratio Stat Type": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Ratio Stat": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Confidence Interval Start": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Confidence Interval Stop": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Biogeographical Groups": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.7228553246127235,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.8161100149154663,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.85,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1454223659,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1454223625,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": null,
                  "prediction": "case/control"
                },
                "Study Cases": {
                  "ground_truth": 82.0,
                  "prediction": 82.0
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "Skin and subcutaneous tissue disorders (recessive)",
                  "prediction": "Multivariate model predicting anemia"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.029",
                  "prediction": "= 0.027"
                },
                "Ratio Stat Type": {
                  "ground_truth": null,
                  "prediction": "Unknown"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "Latino",
                  "prediction": "Unknown"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.8540969491004944,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.5,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1454223681,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1454223701,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": null,
                  "prediction": "case/control"
                },
                "Study Cases": {
                  "ground_truth": 82.0,
                  "prediction": 82.0
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "Mucositis",
                  "prediction": "Multivariate model predicting pain with MTHFR and ERCC2 variants"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.036",
                  "prediction": "= 0.01"
                },
                "Ratio Stat Type": {
                  "ground_truth": null,
                  "prediction": "Unknown"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "Latino",
                  "prediction": "Unknown"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 2,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.9072026610374451,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 1.0,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 0.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1454223606,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1454223600,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": null,
                  "prediction": "case/control"
                },
                "Study Cases": {
                  "ground_truth": 82.0,
                  "prediction": 82.0
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "neuropathy",
                  "prediction": "C allele of DPYD variant rs1801265 linked to neuropathy risk"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.05",
                  "prediction": "= 0.05"
                },
                "Ratio Stat Type": {
                  "ground_truth": null,
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": 4.58
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "Latino",
                  "prediction": "Unknown"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 3,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.8998762965202332,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.5,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 0.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1454223622,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1454223640,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": null,
                  "prediction": "case/control"
                },
                "Study Cases": {
                  "ground_truth": 82.0,
                  "prediction": 82.0
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "Hematological disorders",
                  "prediction": "TYMS deletion genotype associated with protection against hematological adverse reactions"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.0005",
                  "prediction": "= 0.001"
                },
                "Ratio Stat Type": {
                  "ground_truth": null,
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": 0.029
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "Latino",
                  "prediction": "Unknown"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 4,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.8720298409461975,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.5,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 0.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1454223623,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1454223652,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": null,
                  "prediction": "case/control"
                },
                "Study Cases": {
                  "ground_truth": 82.0,
                  "prediction": 82.0
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "Hematological disorders",
                  "prediction": "5-FU treatment causing mucositis"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.005",
                  "prediction": "= 0.036"
                },
                "Ratio Stat Type": {
                  "ground_truth": null,
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": 2.27
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "Latino",
                  "prediction": "Unknown"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 5,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.8576634526252747,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.5,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 0.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1454223621,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1454223640,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": null,
                  "prediction": "case/control"
                },
                "Study Cases": {
                  "ground_truth": 82.0,
                  "prediction": 82.0
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "neuropathy",
                  "prediction": "3R genotype of TYMS 5'UTR linked to skin and subcutaneous tissue disorders"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.02",
                  "prediction": "= 0.029"
                },
                "Ratio Stat Type": {
                  "ground_truth": null,
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": 6.4
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "Latino",
                  "prediction": "Unknown"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            }
          ],
          "aligned_variants": [
            "None:Skin and subcutaneou",
            "None:Mucositis",
            "None:neuropathy",
            "None:Hematological disord",
            "None:Hematological disord",
            "None:neuropathy"
          ],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 82.0,
              "Study Controls": null,
              "Characteristics": "Advanced colorectal cancer patients receiving 5-FU-based chemotherapy",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.012",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.147,
              "Confidence Interval Start": 0.007,
              "Confidence Interval Stop": 0.991,
              "Biogeographical Groups": "Unknown",
              "Variant Annotation ID_norm": null
            }
          ]
        }
      },
      "overall_score": 0.3618832509848807,
      "num_benchmarks": 4
    },
    {
      "pmid": "20338069",
      "pmcid": "PMC2859392",
      "title": "Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults",
      "benchmarks": {
        "drug_annotations": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "unmatched_ground_truth": [
            {
              "Variant Annotation ID": 1448993666,
              "Variant/Haplotypes": "rs3745274",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz",
              "PMID": 20338069,
              "Phenotype Category": "Efficacy",
              "Significance": "no",
              "Notes": "No significant difference in median CD4 T cell counts of each genotype at different time points was seen in efavirenz group (p = 0.818, 0.838, 0.783, 0.753 and 0.587 for baseline, weeks 12, 24, 36 and 48 of ART, respectively).",
              "Sentence": "Genotype TT is not associated with response to efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.",
              "Alleles": "TT",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease, Disease:Tuberculosis",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "GG + GT",
              "Comparison Metabolizer types": null,
              "PMID_norm": "20338069",
              "Variant Annotation ID_norm": "1448993666"
            },
            {
              "Variant Annotation ID": 1184988061,
              "Variant/Haplotypes": "rs3745274",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz",
              "PMID": 20338069,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "Association with significantly increased efavirenz plasma levels. Was significant at week 6, 12 of treatment and 1 month after rifampicin discontinuation.",
              "Sentence": "Genotype TT is associated with decreased metabolism of efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.",
              "Alleles": "TT",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "metabolism of",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease, Disease:Tuberculosis",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "GG + GT",
              "Comparison Metabolizer types": null,
              "PMID_norm": "20338069",
              "Variant Annotation ID_norm": "1184988061"
            }
          ],
          "unmatched_predictions": [
            {
              "Variant/Haplotypes": "CYP2B6-G516T",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz, nevirapine",
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "Patients with TT genotype had significantly higher plasma efavirenz concentrations compared to GT and GG genotypes (p < 0.0001).",
              "Sentence": "Genotype TT is associated with increased plasma efavirenz concentrations in HIV/TB co-infected Thai adults.",
              "Alleles": "TT",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "GT, GG",
              "Comparison Metabolizer types": "intermediate metabolizer",
              "Specialty Population": "",
              "Population types": "in people with HIV/TB co-infection",
              "Population Phenotypes or diseases": "Disease:HIV/TB co-infection",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "concentrations of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "The mean 12-hour post-dose plasma efavirenz concentration in patients with TT genotype at weeks 6 and 12 of ART and 1 month after rifampicin discontinuation (10.97 \u00b1 2.32, 13.62 \u00b1 4.21 and 8.48 \u00b1 1.30 mg/L, respectively) were significantly higher than those with GT (3.43 \u00b1 0.29, 3.35 \u00b1 0.27 and 3.21 \u00b1 0.22 mg/L, respectively) (p < 0.0001) or GG genotypes (2.88 \u00b1 0.33, 2.45 \u00b1 0.26 and 2.08 \u00b1 0.16 mg/L, respectively) (p < 0.0001).",
                "This is the first report to demonstrate the effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine concentrations when co-administered with rifampicin in HIV/TB co-infected Thai adults."
              ]
            },
            {
              "Variant/Haplotypes": "CYP2B6-G516T",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz, nevirapine",
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "Plasma efavirenz concentrations were higher in patients with the TT genotype at all time points measured (weeks 6 and 12) compared to GT and GG genotypes.",
              "Sentence": "Genotype TT is associated with increased plasma nevirapine concentrations in HIV/TB co-infected Thai adults.",
              "Alleles": "TT",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "GT, GG",
              "Comparison Metabolizer types": "intermediate metabolizer",
              "Specialty Population": "",
              "Population types": "in people with HIV/TB co-infection",
              "Population Phenotypes or diseases": "Disease:HIV/TB co-infection",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "concentrations of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "The mean 12-hour post-dose plasma efavirenz concentration in patients with TT genotype at weeks 6 and 12 of ART... were significantly higher than those with GT... or GG genotypes (p < 0.0001).",
                "Likewise, the mean 12-hour post-dose plasma nevirapine concentration in patients carrying TT genotype at weeks 6 and 12 of ART... tended to be higher than those carrying GT... or GG genotypes (p = 0.003).",
                "This is the first report to demonstrate the effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine concentrations when co-administered with rifampicin in HIV/TB co-infected Thai adults."
              ]
            }
          ]
        },
        "phenotype_annotations": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": []
        },
        "functional_analysis": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "status": "missing_var_fa_ann"
        },
        "study_parameters": {
          "total_samples": 2,
          "field_scores": {
            "Study Type": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Study Cases": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Study Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Characteristics": {
              "mean_score": 0.9128793478012085,
              "scores": [
                0.9128793478012085,
                0.9128793478012085
              ]
            },
            "Characteristics Type": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Frequency In Cases": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Allele Of Frequency In Cases": {
              "mean_score": 0.9094638526439667,
              "scores": [
                0.9258627891540527,
                0.8930649161338806
              ]
            },
            "Frequency In Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Allele Of Frequency In Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "P Value": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                0.0
              ]
            },
            "Ratio Stat Type": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Ratio Stat": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Confidence Interval Start": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Confidence Interval Stop": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Biogeographical Groups": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.6881562133630117,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.9128793478012085,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 0.0,
                "Allele Of Frequency In Cases": 0.9258627891540527,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 1.0,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1184988079,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1184988061,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "cohort",
                  "prediction": null
                },
                "Study Cases": {
                  "ground_truth": 65.0,
                  "prediction": 65.0
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "HIV-1/TB co-infected receiving efavirenz-based ART and an anti-TB drug regimen.",
                  "prediction": "efavirenz group (CYP2B6-G516T genotypes)"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": 0.62,
                  "prediction": 0.3846
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": "G",
                  "prediction": "GG"
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "< 0.0001",
                  "prediction": "< 0.0001"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "Unknown"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "East Asian",
                  "prediction": "Asian"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.9128793478012085,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 0.0,
                "Allele Of Frequency In Cases": 0.8930649161338806,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.0,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1448993668,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1448993666,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "cohort",
                  "prediction": null
                },
                "Study Cases": {
                  "ground_truth": 65.0,
                  "prediction": 65.0
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "HIV-1/TB co-infected receiving efavirenz-based ART and an anti-TB drug regimen.",
                  "prediction": "efavirenz group (CYP2B6-G516T genotypes)"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": 0.62,
                  "prediction": 0.4769
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": "G",
                  "prediction": "GT"
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "> 0.05",
                  "prediction": "< 0.0001"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "Unknown"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "East Asian",
                  "prediction": "Asian"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            }
          ],
          "aligned_variants": [
            "cohort:HIV-1/TB co-infected",
            "cohort:HIV-1/TB co-infected"
          ],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 124.0,
              "Study Controls": null,
              "Characteristics": "HIV/TB co-infected Thai adults receiving efavirenz or nevirapine",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "< 0.0001",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Asian",
              "Variant Annotation ID_norm": null
            },
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": null,
              "Study Cases": 65.0,
              "Study Controls": null,
              "Characteristics": "efavirenz group (CYP2B6-G516T genotypes)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": 0.1385,
              "Allele Of Frequency In Cases": "TT",
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "< 0.0001",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Asian",
              "Variant Annotation ID_norm": null
            },
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": null,
              "Study Cases": 59.0,
              "Study Controls": null,
              "Characteristics": "nevirapine group (CYP2B6-G516T genotypes)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": 0.4407,
              "Allele Of Frequency In Cases": "GG",
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Asian",
              "Variant Annotation ID_norm": null
            },
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": null,
              "Study Cases": 59.0,
              "Study Controls": null,
              "Characteristics": "nevirapine group (CYP2B6-G516T genotypes)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": 0.5254,
              "Allele Of Frequency In Cases": "GT",
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Asian",
              "Variant Annotation ID_norm": null
            },
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": null,
              "Study Cases": 59.0,
              "Study Controls": null,
              "Characteristics": "nevirapine group (CYP2B6-G516T genotypes)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": 0.0339,
              "Allele Of Frequency In Cases": "TT",
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Asian",
              "Variant Annotation ID_norm": null
            },
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": null,
              "Study Cases": 124.0,
              "Study Controls": null,
              "Characteristics": "CYP2B6-TT genotype's impact on plasma efavirenz concentration",
              "Characteristics Type": "disease",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.025",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Asian",
              "Variant Annotation ID_norm": null
            },
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": null,
              "Study Cases": 124.0,
              "Study Controls": null,
              "Characteristics": "CYP2B6-TT genotype's impact on plasma nevirapine concentration",
              "Characteristics Type": "disease",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.003",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Asian",
              "Variant Annotation ID_norm": null
            }
          ]
        }
      },
      "overall_score": 0.13763124267260235,
      "num_benchmarks": 4
    },
    {
      "pmid": "21428769",
      "pmcid": "PMC3113609",
      "title": "HLA-A\u26053101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans",
      "benchmarks": {
        "drug_annotations": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Variant/Haplotypes": "HLA-A\u26053101",
              "Gene": "HLA-A",
              "Drug(s)": "carbamazepine",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Association confirmed with odds ratio of 12.41 for hypersensitivity syndrome.",
              "Standardized Sentence": "HLA-A\u26053101 is associated with increased hypersensitivity reactions carbamazepine in people of European descent.",
              "Alleles": "HLA-A\u26053101",
              "Metabolizer types": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "Specialty Population": null,
              "Population types": "in people of European descent",
              "Population Phenotypes or diseases": "Side Effect:hypersensitivity reactions",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Multiple phenotypes or diseases And/or": null,
              "Citations": [
                "The HLA-A\u26053101 allele, which has a prevalence of 2 to 5% in Northern European populations, was significantly associated with the hypersensitivity syndrome (P = 3.5x10\u22128).",
                "Follow-up genotyping confirmed the variant as a risk factor for the hypersensitivity syndrome (odds ratio, 12.41; 95% confidence interval [CI], 1.27 to 121.03), maculopapular exanthema (odds ratio, 8.33; 95% CI, 3.59 to 19.36), and SJS-TEN (odds ratio, 25.93; 95% CI, 4.93 to 116.18).",
                "The presence of the HLA-A\u26053101 allele increased the risk from 5.0% to 26.0%, whereas its absence reduced the risk from 5.0% to 3.8%."
              ]
            }
          ]
        },
        "phenotype_annotations": {
          "total_samples": 3,
          "field_scores": {
            "Variant/Haplotypes": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0
              ]
            },
            "Gene": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                0.0,
                0.0
              ]
            },
            "Drug(s)": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                0.0,
                0.0
              ]
            },
            "Phenotype Category": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                0.0,
                0.0
              ]
            },
            "Alleles": {
              "mean_score": 0.2964734236399333,
              "scores": [
                0.8894202709197998,
                0.0,
                0.0
              ]
            },
            "Is/Is Not associated": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                0.0,
                0.0
              ]
            },
            "Direction of effect": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                0.0,
                0.0
              ]
            },
            "Phenotype": {
              "mean_score": 0.3047775626182556,
              "scores": [
                0.9143326878547668,
                0.0,
                0.0
              ]
            },
            "When treated with/exposed to/when assayed with": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                0.0,
                0.0
              ]
            },
            "Comparison Allele(s) or Genotype(s)": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.2961887717247009,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Variant/Haplotypes": 0.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 1.0,
                "Alleles": 0.8894202709197998,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.9143326878547668,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 1.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "HLA-A*31:01",
                  "prediction": "HLA-A\u26053101"
                },
                "Gene": {
                  "ground_truth": "HLA-A",
                  "prediction": "HLA-A"
                },
                "Drug(s)": {
                  "ground_truth": "carbamazepine",
                  "prediction": "carbamazepine"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "*31:01",
                  "prediction": "HLA-A*3101"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Disease:Severe Cutaneous Adverse Reactions",
                  "prediction": "hypersensitivity syndrome, maculopapular exanthema, Stevens-Johnson Syndrome"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": null,
                  "prediction": null
                }
              },
              "dependency_issues": []
            }
          ],
          "aligned_variants": [
            "hla-a+carbamazepine"
          ],
          "unmatched_ground_truth": [
            {
              "Variant Annotation ID": 1184466916,
              "Variant/Haplotypes": "HLA-A*31:01",
              "Gene": "HLA-A",
              "Drug(s)": "carbamazepine",
              "PMID": 21428769,
              "Phenotype Category": "Toxicity",
              "Significance": "yes",
              "Notes": "Patients with carbamazepine-induced maculopapular exanthema had an increased frequency of *31:01, as compared to carbamazepine-tolerant controls.",
              "Sentence": "HLA-A *31:01 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine.",
              "Alleles": "*31:01",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Disease:Maculopapular Exanthema",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": null,
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "21428769",
              "Variant Annotation ID_norm": "1184466916"
            },
            {
              "Variant Annotation ID": 1184466909,
              "Variant/Haplotypes": "HLA-A*31:01",
              "Gene": "HLA-A",
              "Drug(s)": "carbamazepine",
              "PMID": 21428769,
              "Phenotype Category": "Toxicity",
              "Significance": "yes",
              "Notes": "Hypersensitivity syndrome defined as the presence of a rash or liver involvement within 3 months after initiation of carbamazepine treatment, along with a minimum of two of the following manifestations: prolonged recovery phase despite drug withdrawal, fever, involvement of other internal organs, or presence of hematologic abnormalities. Patients who experienced carbamazepine-induced hypersensitivity syndrome had an increased frequency of *31:01, as compared to carbamazepine-tolerant controls.",
              "Sentence": "HLA-A *31:01 is associated with increased risk of Drug Hypersensitivity when treated with carbamazepine.",
              "Alleles": "*31:01",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Disease:Drug Hypersensitivity",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": null,
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "21428769",
              "Variant Annotation ID_norm": "1184466909"
            }
          ],
          "unmatched_predictions": []
        },
        "functional_analysis": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "status": "missing_var_fa_ann"
        },
        "study_parameters": {
          "total_samples": 3,
          "field_scores": {
            "Study Type": {
              "mean_score": 0.6666666666666666,
              "scores": [
                0.0,
                1.0,
                1.0
              ]
            },
            "Study Cases": {
              "mean_score": 0.3333333333333333,
              "scores": [
                0.0,
                1.0,
                0.0
              ]
            },
            "Study Controls": {
              "mean_score": 0.6666666666666666,
              "scores": [
                1.0,
                1.0,
                0.0
              ]
            },
            "Characteristics": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0
              ]
            },
            "Characteristics Type": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0
              ]
            },
            "Frequency In Cases": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                0.0,
                0.0
              ]
            },
            "Allele Of Frequency In Cases": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                0.0,
                0.0
              ]
            },
            "Frequency In Controls": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                0.0,
                0.0
              ]
            },
            "Allele Of Frequency In Controls": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                0.0,
                0.0
              ]
            },
            "P Value": {
              "mean_score": 0.5,
              "scores": [
                0.5,
                0.5,
                0.5
              ]
            },
            "Ratio Stat Type": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            },
            "Ratio Stat": {
              "mean_score": 0.9333333333333332,
              "scores": [
                0.8,
                1.0,
                1.0
              ]
            },
            "Confidence Interval Start": {
              "mean_score": 0.6666666666666666,
              "scores": [
                0.0,
                1.0,
                1.0
              ]
            },
            "Confidence Interval Stop": {
              "mean_score": 0.9333333333333332,
              "scores": [
                0.8,
                1.0,
                1.0
              ]
            },
            "Biogeographical Groups": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            }
          },
          "overall_score": 0.5355555555555556,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 0.0,
                "Study Controls": 1.0,
                "Characteristics": 0.0,
                "Characteristics Type": 0.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.5,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 0.8,
                "Confidence Interval Start": 0.0,
                "Confidence Interval Stop": 0.8,
                "Biogeographical Groups": 1.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1184466918,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1184466916,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "case/control",
                  "prediction": null
                },
                "Study Cases": {
                  "ground_truth": 106.0,
                  "prediction": 145
                },
                "Study Controls": {
                  "ground_truth": 257.0,
                  "prediction": 257
                },
                "Characteristics": {
                  "ground_truth": null,
                  "prediction": "Carbamazepine-induced hypersensitivity reactions (pooled analysis)"
                },
                "Characteristics Type": {
                  "ground_truth": "Unknown",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 8.0E-7",
                  "prediction": "= 1.0x10^\u22127"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": 8.33,
                  "prediction": 9.12
                },
                "Confidence Interval Start": {
                  "ground_truth": 3.59,
                  "prediction": 4.03
                },
                "Confidence Interval Stop": {
                  "ground_truth": 19.36,
                  "prediction": 20.65
                },
                "Biogeographical Groups": {
                  "ground_truth": "European",
                  "prediction": "European"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 1.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.0,
                "Characteristics Type": 0.0,
                "Frequency In Cases": 0.0,
                "Allele Of Frequency In Cases": 0.0,
                "Frequency In Controls": 0.0,
                "Allele Of Frequency In Controls": 0.0,
                "P Value": 0.5,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 1.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1184466924,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1184466922,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "case/control",
                  "prediction": "case/control"
                },
                "Study Cases": {
                  "ground_truth": 12.0,
                  "prediction": 12
                },
                "Study Controls": {
                  "ground_truth": 257.0,
                  "prediction": 257
                },
                "Characteristics": {
                  "ground_truth": null,
                  "prediction": "SJS-TEN (Stevens-Johnson syndrome and toxic epidermal necrolysis)"
                },
                "Characteristics Type": {
                  "ground_truth": "Unknown",
                  "prediction": "disease"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": 0.417
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": "A"
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": 0.039
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": "A"
                },
                "P Value": {
                  "ground_truth": "= 8.0E-5",
                  "prediction": "= 8.0x10^\u22125"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": 25.93,
                  "prediction": 25.93
                },
                "Confidence Interval Start": {
                  "ground_truth": 4.93,
                  "prediction": 4.93
                },
                "Confidence Interval Stop": {
                  "ground_truth": 116.18,
                  "prediction": 116.18
                },
                "Biogeographical Groups": {
                  "ground_truth": "European",
                  "prediction": "European"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 2,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 1.0,
                "Study Cases": 0.0,
                "Study Controls": 0.0,
                "Characteristics": 0.0,
                "Characteristics Type": 0.0,
                "Frequency In Cases": 0.0,
                "Allele Of Frequency In Cases": 0.0,
                "Frequency In Controls": 0.0,
                "Allele Of Frequency In Controls": 0.0,
                "P Value": 0.5,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 1.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1184466915,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1184466909,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "case/control",
                  "prediction": "case/control"
                },
                "Study Cases": {
                  "ground_truth": 27.0,
                  "prediction": 22
                },
                "Study Controls": {
                  "ground_truth": 257.0,
                  "prediction": 2691
                },
                "Characteristics": {
                  "ground_truth": null,
                  "prediction": "Carbamazepine-induced hypersensitivity syndrome"
                },
                "Characteristics Type": {
                  "ground_truth": "Unknown",
                  "prediction": "disease"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": 0.4
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": "A"
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": 0.049
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": "A"
                },
                "P Value": {
                  "ground_truth": "= 0.03",
                  "prediction": "= 3.5x10\u22128"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": 12.41,
                  "prediction": 12.41
                },
                "Confidence Interval Start": {
                  "ground_truth": 1.27,
                  "prediction": 1.27
                },
                "Confidence Interval Stop": {
                  "ground_truth": 121.03,
                  "prediction": 121.03
                },
                "Biogeographical Groups": {
                  "ground_truth": "European",
                  "prediction": "European"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            }
          ],
          "aligned_variants": [
            "case/control",
            "case/control",
            "case/control"
          ],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 106,
              "Study Controls": 257,
              "Characteristics": "Maculopapular exanthema",
              "Characteristics Type": "disease",
              "Frequency In Cases": 0.27,
              "Allele Of Frequency In Cases": "A",
              "Frequency In Controls": 0.04,
              "Allele Of Frequency In Controls": "A",
              "P Value": "= 8.0x10^\u22127",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 8.33,
              "Confidence Interval Start": 3.59,
              "Confidence Interval Stop": 19.36,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          ]
        }
      },
      "overall_score": 0.1959677426285214,
      "num_benchmarks": 4
    },
    {
      "pmid": "21505298",
      "pmcid": "PMC3387531",
      "title": "Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent",
      "benchmarks": {
        "drug_annotations": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Variant/Haplotypes": "CYP2B6",
              "Gene": "CYP2B6",
              "Drug(s)": "nevirapine",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Cutaneous adverse events were associated with CYP2B6 516G\u2192T (OR 1.66, all).",
              "Sentence": "CYP2B6 516G\u2192T is associated with increased cutaneous adverse events nevirapine among HIV-infected adults.",
              "Alleles": "TT",
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "adverse events",
              "Multiple drugs And/or": "",
              "Population types": "in people with",
              "Population Phenotypes or diseases": "other:HIV-1",
              "Comparison Allele(s) or Genotype(s)": "",
              "Comparison Metabolizer types": "",
              "Specialty Population": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Cutaneous adverse events were associated with CYP2B6 516G\u2192T (OR 1.66, all)...",
                "The association with 516G\u2192T was particularly strong in Blacks, in whom the OR for 516TT homozygosity relative to 516GG homozygosity was 5.92 [95% confidence interval (CI) 1.53-26.8].",
                "Among patients with at least 150 CD4 T cells/\u03bcl, polymorphisms in drug metabolism and immune response pathways were associated with greater likelihood of risk for nevirapine-related adverse events."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "516G\u2192T",
              "Gene": "CYP2B6",
              "Drug(s)": "nevirapine",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Cutaneous adverse events were associated with CYP2B6 516G\u2192T (OR 1.66, all).",
              "Sentence": "CYP2B6 516G\u2192T is associated with increased cutaneous adverse events nevirapine among HIV-infected adults.",
              "Alleles": "TT",
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "adverse events",
              "Multiple drugs And/or": "",
              "Population types": "in people with",
              "Population Phenotypes or diseases": "other:HIV-1",
              "Comparison Allele(s) or Genotype(s)": "",
              "Comparison Metabolizer types": "",
              "Specialty Population": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Cutaneous adverse events were associated with CYP2B6 516G\u2192T (OR 1.66, all)...",
                "The association with 516G\u2192T was particularly strong in Blacks, in whom the OR for 516TT homozygosity relative to 516GG homozygosity was 5.92 [95% confidence interval (CI) 1.53-26.8].",
                "Among patients with at least 150 CD4 T cells/\u03bcl, polymorphisms in drug metabolism and immune response pathways were associated with greater likelihood of risk for nevirapine-related adverse events."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "HLA-Cw*04",
              "Gene": "HLA-C",
              "Drug(s)": "nevirapine",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "HLA-Cw*04 was significantly associated with cutaneous adverse events among all study participants, most notably in Blacks and Asians (OR 2.51, all).",
              "Sentence": "HLA-Cw*04 is associated with increased cutaneous adverse events nevirapine among HIV-infected adults.",
              "Alleles": "",
              "Metabolizer types": "",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "adverse events",
              "Multiple drugs And/or": "",
              "Population types": "in people with",
              "Population Phenotypes or diseases": "other:HIV-1",
              "Comparison Allele(s) or Genotype(s)": "",
              "Comparison Metabolizer types": "",
              "Specialty Population": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Cutaneous adverse events were associated with CYP2B6 516G\u2192T (OR 1.66, all), HLA-Cw*04 (OR 2.51, all), and HLA-B*35 (OR 3.47, Asians; 5.65, Thais).",
                "HLA-Cw*04 was significantly associated with cutaneous adverse events among all study participants, most notably among Blacks and Asians (OR 2.51, all).",
                "Risk for cutaneous adverse events was particularly high among Blacks with CYP2B6 516TT and HLA-Cw*04 (OR 18.90) and Asians with HLA-B*35 and HLA-Cw*04 (OR 18.34)."
              ]
            },
            {
              "Variant/Haplotypes": "HLA-B*35",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "HLA-B*35 was strongly associated with cutaneous adverse events in Asian and Thai participants (OR 3.47, Asians; 5.65, Thais).",
              "Sentence": "HLA-B*35 is associated with increased cutaneous adverse events nevirapine among HIV-infected adults.",
              "Alleles": "",
              "Metabolizer types": "",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "adverse events",
              "Multiple drugs And/or": "",
              "Population types": "in people with",
              "Population Phenotypes or diseases": "other:HIV-1",
              "Comparison Allele(s) or Genotype(s)": "",
              "Comparison Metabolizer types": "",
              "Specialty Population": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Cutaneous adverse events were associated with CYP2B6 516G\u2192T (OR 1.66, all), HLA-Cw*04 (OR 2.51, all), and HLA-B*35 (OR 3.47, Asians; 5.65, Thais).",
                "Among Asians, but not Blacks or Whites, the OR for cutaneous adverse events was markedly increased among those carrying both HLA-Cw*04 and HLA-B*35 (OR 18.34, 95% CI 5.10-65.99).",
                "This study confirmed strong associations between HLA-B*35, HLA-Cw*04, and cutaneous adverse events among Asians, particularly in Thai participants."
              ]
            },
            {
              "Variant/Haplotypes": "HLA-DRB*01",
              "Gene": "HLA-DRB",
              "Drug(s)": "nevirapine",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "HLA-DRB*01 was significantly associated with hepatic adverse events in Whites (OR 3.02, Whites).",
              "Sentence": "HLA-DRB*01 is associated with increased hepatic adverse events nevirapine among HIV-infected adults.",
              "Alleles": "",
              "Metabolizer types": "",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "adverse events",
              "Multiple drugs And/or": "",
              "Population types": "in people with",
              "Population Phenotypes or diseases": "other:HIV-1",
              "Comparison Allele(s) or Genotype(s)": "",
              "Comparison Metabolizer types": "",
              "Specialty Population": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Hepatic adverse events were associated with HLA-DRB*01 (OR 3.02, Whites), but not CYP2B6 genotypes.",
                "*HLA-DRB1*01* was significantly associated with hepatic adverse events in Whites.",
                "In analyses that excluded individuals with coincident cutaneous and hepatic adverse events, OR for hepatic adverse events among Whites increased from 3.02 to 3.63 for *HLA-DRB1*01.*\"]}   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User. Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.   Assistant has stopped speaking, and hands back control to the User.  Assistant has stopped speaking, and hands back control to the User.    "
              ]
            }
          ]
        },
        "phenotype_annotations": {
          "total_samples": 6,
          "field_scores": {
            "Variant/Haplotypes": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Gene": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Drug(s)": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Phenotype Category": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Alleles": {
              "mean_score": 0.3033205270767212,
              "scores": [
                0.9099615812301636,
                0.9099615812301636,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Is/Is Not associated": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Direction of effect": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Phenotype": {
              "mean_score": 0.2943449020385742,
              "scores": [
                0.8830347061157227,
                0.8830347061157227,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "When treated with/exposed to/when assayed with": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Comparison Allele(s) or Genotype(s)": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.2675281051132414,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Variant/Haplotypes": 0.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 1.0,
                "Alleles": 0.9099615812301636,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.8830347061157227,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "rs3745274",
                  "prediction": "CYP2B6"
                },
                "Gene": {
                  "ground_truth": "CYP2B6",
                  "prediction": "CYP2B6"
                },
                "Drug(s)": {
                  "ground_truth": "nevirapine",
                  "prediction": "nevirapine"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "T",
                  "prediction": "TT"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:Drug Toxicity",
                  "prediction": "cutaneous adverse events"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": null,
                  "prediction": "GG"
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Variant/Haplotypes": 0.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 1.0,
                "Alleles": 0.9099615812301636,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.8830347061157227,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "rs3745274",
                  "prediction": "516G\u2192T"
                },
                "Gene": {
                  "ground_truth": "CYP2B6",
                  "prediction": "CYP2B6"
                },
                "Drug(s)": {
                  "ground_truth": "nevirapine",
                  "prediction": "nevirapine"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "T",
                  "prediction": "TT"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:Drug Toxicity",
                  "prediction": "cutaneous adverse events"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": null,
                  "prediction": "GG"
                }
              },
              "dependency_issues": []
            }
          ],
          "aligned_variants": [
            "cyp2b6+nevirapine",
            "cyp2b6+nevirapine"
          ],
          "unmatched_ground_truth": [
            {
              "Variant Annotation ID": 1185002091,
              "Variant/Haplotypes": "HLA-B*35:01",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 21505298,
              "Phenotype Category": "Toxicity",
              "Significance": "yes",
              "Notes": "The frequency of the HLA-B*35 allele was greater in those with nevirapine-related hepatic adverse events as compared to healthy controls when considering a Thai population. No significant results were seen for Asians (non-Thai), Blacks or Whites (p corrected = 0.053, 1.0, 1.0, respectively). Note that this annotation was done on HLA-B*35:01:01:01 because this was the first *35 allele discovered. p-value corrected for multiple testing.",
              "Sentence": "HLA-B *35:01 is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*35:01",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Drug Toxicity",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "21505298",
              "Variant Annotation ID_norm": "1185002091"
            },
            {
              "Variant Annotation ID": 1185002083,
              "Variant/Haplotypes": "HLA-DRB1*01:01",
              "Gene": "HLA-DRB1",
              "Drug(s)": "nevirapine",
              "PMID": 21505298,
              "Phenotype Category": "Toxicity",
              "Significance": "yes",
              "Notes": "The frequency of the HLA-DRB1*01 allele was greater in those with nevirapine-related hepatic adverse events as compared to healthy controls when considering a White population. No significant results were seen for Asians or Blacks. Note that this annotation was done on HLA-DRB1*01:01:01 because this was the first *01 allele discovered. p-value corrected for multiple testing.",
              "Sentence": "HLA-DRB1 *01:01 is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*01:01",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Drug Toxicity",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "21505298",
              "Variant Annotation ID_norm": "1185002083"
            },
            {
              "Variant Annotation ID": 1185002071,
              "Variant/Haplotypes": "HLA-C*04:01",
              "Gene": "HLA-C",
              "Drug(s)": "nevirapine",
              "PMID": 21505298,
              "Phenotype Category": "Toxicity",
              "Significance": "yes",
              "Notes": "The frequency of the HLA-Cw*04 allele was greater in those with nevirapine-related cutaneous adverse events as compared to healthy controls. Note that this annotation was done on HLA-C*04:01:01:01 because this was the first *04 allele discovered. p-value corrected for multiple testing.",
              "Sentence": "HLA-C *04:01 is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*04:01",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Drug Toxicity",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "21505298",
              "Variant Annotation ID_norm": "1185002071"
            },
            {
              "Variant Annotation ID": 1185002114,
              "Variant/Haplotypes": "rs3786547",
              "Gene": "CYP2B6",
              "Drug(s)": "nevirapine",
              "PMID": 21505298,
              "Phenotype Category": "Toxicity",
              "Significance": "yes",
              "Notes": "The frequency of the C allele was greater in those with nevirapine-related cutaneous adverse events as compared to healthy controls. This SNP was in LD with rs2054674 (r2 = 0.982) and rs3745274 (r2 > 0.90). p-value corrected for multiple testing. This SNP was not associated with hepatic adverse events after correcting for multiple comparisons.",
              "Sentence": "Allele C is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.",
              "Alleles": "C",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Drug Toxicity",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "21505298",
              "Variant Annotation ID_norm": "1185002114"
            }
          ],
          "unmatched_predictions": []
        },
        "functional_analysis": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "status": "missing_var_fa_ann"
        },
        "study_parameters": {
          "total_samples": 6,
          "field_scores": {
            "Study Type": {
              "mean_score": 0.6666666666666666,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0
              ]
            },
            "Study Cases": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Study Controls": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Characteristics": {
              "mean_score": 0.6026524206002554,
              "scores": [
                0.9308112859725952,
                0.9007943272590637,
                0.8877597451210022,
                0.8965491652488708,
                0.0,
                0.0
              ]
            },
            "Characteristics Type": {
              "mean_score": 0.16666666666666666,
              "scores": [
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Frequency In Cases": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Allele Of Frequency In Cases": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Frequency In Controls": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Allele Of Frequency In Controls": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "P Value": {
              "mean_score": 0.39166666666666666,
              "scores": [
                0.5,
                0.5,
                0.5,
                0.85,
                0.0,
                0.0
              ]
            },
            "Ratio Stat Type": {
              "mean_score": 0.6666666666666666,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0
              ]
            },
            "Ratio Stat": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                0.0,
                0.0,
                1.0,
                0.0,
                0.0
              ]
            },
            "Confidence Interval Start": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Confidence Interval Stop": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Biogeographical Groups": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.35517682804001705,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 1.0,
                "Study Cases": 0.0,
                "Study Controls": 1.0,
                "Characteristics": 0.9308112859725952,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.5,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 0.0,
                "Confidence Interval Stop": 0.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1185002122,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1185002120,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "case/control",
                  "prediction": "case/control"
                },
                "Study Cases": {
                  "ground_truth": 175.0,
                  "prediction": 276
                },
                "Study Controls": {
                  "ground_truth": 587.0,
                  "prediction": 587
                },
                "Characteristics": {
                  "ground_truth": "Severe cutaneous toxicity - grade III or IV on NIAID Division of AIDS criteria.",
                  "prediction": "Symptomatic nevirapine-associated severe (grade III/IV) cutaneous and/or hepatic adverse events"
                },
                "Characteristics Type": {
                  "ground_truth": "Disease",
                  "prediction": "disease"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.13",
                  "prediction": "= 0.0025"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": 1.66,
                  "prediction": 1.66
                },
                "Confidence Interval Start": {
                  "ground_truth": 1.29,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": 2.15,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "Multiple groups, Asian, Black, White",
                  "prediction": "African, Asian, European"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 1.0,
                "Study Cases": 0.0,
                "Study Controls": 1.0,
                "Characteristics": 0.9007943272590637,
                "Characteristics Type": 0.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.5,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 0.0,
                "Confidence Interval Start": 0.0,
                "Confidence Interval Stop": 0.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1185002101,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1185002099,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "case/control",
                  "prediction": "case/control"
                },
                "Study Cases": {
                  "ground_truth": 175.0,
                  "prediction": 276
                },
                "Study Controls": {
                  "ground_truth": 587.0,
                  "prediction": 587
                },
                "Characteristics": {
                  "ground_truth": "Severe cutaneous toxicity - grade III or IV on NIAID Division of AIDS criteria.",
                  "prediction": "HLA-B*35 associated with cutaneous adverse events"
                },
                "Characteristics Type": {
                  "ground_truth": "Disease",
                  "prediction": "drug"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.019",
                  "prediction": "= 0.01"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": 1.76,
                  "prediction": 3.47
                },
                "Confidence Interval Start": {
                  "ground_truth": 1.36,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": 2.27,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "Multiple groups, Asian, Black, White",
                  "prediction": "Asians"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 2,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 1.0,
                "Study Cases": 0.0,
                "Study Controls": 1.0,
                "Characteristics": 0.8877597451210022,
                "Characteristics Type": 0.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.5,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 0.0,
                "Confidence Interval Start": 0.0,
                "Confidence Interval Stop": 0.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1185002116,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1185002114,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "case/control",
                  "prediction": "case/control"
                },
                "Study Cases": {
                  "ground_truth": 175.0,
                  "prediction": 276
                },
                "Study Controls": {
                  "ground_truth": 587.0,
                  "prediction": 587
                },
                "Characteristics": {
                  "ground_truth": "Severe cutaneous toxicity - grade III or IV on NIAID Division of AIDS criteria.",
                  "prediction": "HLA-Cw*04 associated with cutaneous adverse events"
                },
                "Characteristics Type": {
                  "ground_truth": "Disease",
                  "prediction": "drug"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.029",
                  "prediction": "= 0.025"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": 1.74,
                  "prediction": 2.51
                },
                "Confidence Interval Start": {
                  "ground_truth": 1.34,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": 2.25,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "Multiple groups, Asian, Black, White",
                  "prediction": "All races"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 3,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 1.0,
                "Study Cases": 0.0,
                "Study Controls": 0.0,
                "Characteristics": 0.8965491652488708,
                "Characteristics Type": 0.0,
                "Frequency In Cases": 0.0,
                "Allele Of Frequency In Cases": 0.0,
                "Frequency In Controls": 0.0,
                "Allele Of Frequency In Controls": 0.0,
                "P Value": 0.85,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 0.0,
                "Confidence Interval Stop": 0.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1185002085,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1185002083,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "case/control",
                  "prediction": "case/control"
                },
                "Study Cases": {
                  "ground_truth": 57.0,
                  "prediction": 276
                },
                "Study Controls": {
                  "ground_truth": 277.0,
                  "prediction": 587
                },
                "Characteristics": {
                  "ground_truth": "Symptomatic grade >= 3 hepatic transaminase elevation (ALT or AST >5x ULN) or acute hepatic failure",
                  "prediction": "HLA-DRB*01 associated with hepatic adverse events"
                },
                "Characteristics Type": {
                  "ground_truth": "Disease",
                  "prediction": "drug"
                },
                "Frequency In Cases": {
                  "ground_truth": 0.439,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": "*01:01",
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": 0.208,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": "*01:01",
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.0074",
                  "prediction": "= 0.007"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": 3.02,
                  "prediction": 3.02
                },
                "Confidence Interval Start": {
                  "ground_truth": 1.66,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": 5.49,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "Multiple groups, Caucasian and Hispanic/Latino patients",
                  "prediction": "Whites"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            }
          ],
          "aligned_variants": [
            "case/control:Severe cutaneous tox",
            "case/control:Severe cutaneous tox",
            "case/control:Severe cutaneous tox",
            "case/control:Symptomatic grade >="
          ],
          "unmatched_ground_truth": [
            {
              "Study Parameters ID": 1185002093,
              "Variant Annotation ID": 1185002091,
              "Study Type": "case/control",
              "Study Cases": 52.0,
              "Study Controls": 173.0,
              "Characteristics": "Severe cutaneous toxicity - grade III or IV on NIAID Division of AIDS criteria.",
              "Characteristics Type": "Disease",
              "Frequency In Cases": 0.192,
              "Allele Of Frequency In Cases": "*35:01",
              "Frequency In Controls": 0.043,
              "Allele Of Frequency In Controls": "*35:01",
              "P Value": "= 0.022",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 5.65,
              "Confidence Interval Start": 2.03,
              "Confidence Interval Stop": 15.71,
              "Biogeographical Groups": "East Asian",
              "Variant Annotation ID_norm": "1185002091"
            },
            {
              "Study Parameters ID": 1185002079,
              "Variant Annotation ID": 1185002071,
              "Study Type": "case/control",
              "Study Cases": 175.0,
              "Study Controls": 587.0,
              "Characteristics": "Severe cutaneous toxicity - grade III or IV on NIAID Division of AIDS criteria.",
              "Characteristics Type": "Disease",
              "Frequency In Cases": 0.377,
              "Allele Of Frequency In Cases": "*04:01",
              "Frequency In Controls": 0.194,
              "Allele Of Frequency In Controls": "*04:01",
              "P Value": "= 8.7E-6",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.51,
              "Confidence Interval Start": 1.73,
              "Confidence Interval Stop": 3.62,
              "Biogeographical Groups": "Multiple groups, Asian, Thai, Black, White",
              "Variant Annotation ID_norm": "1185002071"
            }
          ],
          "unmatched_predictions": [
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 276,
              "Study Controls": 587,
              "Characteristics": "CYP2B6 516G\u2192T associated with cutaneous adverse events",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "< 0.001",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 18.9,
              "Confidence Interval Start": 1.53,
              "Confidence Interval Stop": 26.8,
              "Biogeographical Groups": "Black",
              "Variant Annotation ID_norm": null
            }
          ]
        }
      },
      "overall_score": 0.15129379714197583,
      "num_benchmarks": 4
    },
    {
      "pmid": "23213055",
      "pmcid": "PMC3548984",
      "title": "CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8",
      "benchmarks": {
        "drug_annotations": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Variant/Haplotypes": "CYP2D6*3",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen, anastrozole",
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "In Arm A during the first 5 years of therapy, women with 2 poor alleles had a higher likelihood of an event than women with two extensive alleles. In years 3-5, PM/PM tended towards a higher likelihood of a disease event relative to EM/EM among women on Arm A but not among women on Arm B.",
              "Sentence": "Genotype PM/PM is associated with increased odds of a disease event during tamoxifen treatment in postmenopausal women with estrogen receptor positive breast cancer.",
              "Alleles": "PM/PM",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Specialty Population": "Geriatric",
              "Population types": "in postmenopausal women",
              "Population Phenotypes or diseases": "Disease:breast cancer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "response to",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "In Arm A during the first 5 years of therapy, women with 2 poor alleles (PM/PM: OR=2.45, 95% CI: 1.05-5.73, p=0.04) had a higher likelihood of an event than women with two extensive alleles (EM/EM).",
                "In years 3-5 when patients remained on tamoxifen (Arm A), PM/PM tended towards a higher likelihood of a disease event relative to EM/EM (OR= 2.40, 95% CI: 0.86-6.66, p=0.09) among women on Arm A but not among women on Arm B.",
                "The negative effects of reduced CYP2D6 metabolism were observed only during the period of tamoxifen administration, and not after switching to anastrozole."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "CYP2D6*4",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen, anastrozole",
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "In Arm A during the first 5 years of therapy, women with 2 poor alleles had a higher likelihood of an event than women with two extensive alleles. In years 3-5, PM/PM tended towards a higher likelihood of a disease event relative to EM/EM among women on Arm A but not among women on Arm B.",
              "Sentence": "Genotype PM/PM is associated with increased odds of a disease event during tamoxifen treatment in postmenopausal women with estrogen receptor positive breast cancer.",
              "Alleles": "PM/PM",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Specialty Population": "Geriatric",
              "Population types": "in postmenopausal women",
              "Population Phenotypes or diseases": "Disease:breast cancer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "response to",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "In Arm A during the first 5 years of therapy, women with 2 poor alleles (PM/PM: OR=2.45, 95% CI: 1.05-5.73, p=0.04) had a higher likelihood of an event than women with two extensive alleles (EM/EM).",
                "In years 3-5 when patients remained on tamoxifen (Arm A), PM/PM tended towards a higher likelihood of a disease event relative to EM/EM (OR= 2.40, 95% CI: 0.86-6.66, p=0.09) among women on Arm A but not among women on Arm B.",
                "The negative effects of reduced CYP2D6 metabolism were observed only during the period of tamoxifen administration, and not after switching to anastrozole."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "CYP2D6*6",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen, anastrozole",
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "In Arm A during the first 5 years of therapy, women with 2 poor alleles had a higher likelihood of an event than women with two extensive alleles. In years 3-5, PM/PM tended towards a higher likelihood of a disease event relative to EM/EM among women on Arm A but not among women on Arm B.",
              "Sentence": "Genotype PM/PM is associated with increased odds of a disease event during tamoxifen treatment in postmenopausal women with estrogen receptor positive breast cancer.",
              "Alleles": "PM/PM",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Specialty Population": "Geriatric",
              "Population types": "in postmenopausal women",
              "Population Phenotypes or diseases": "Disease:breast cancer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "response to",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "In Arm A during the first 5 years of therapy, women with 2 poor alleles (PM/PM: OR=2.45, 95% CI: 1.05-5.73, p=0.04) had a higher likelihood of an event than women with two extensive alleles (EM/EM).",
                "In years 3-5 when patients remained on tamoxifen (Arm A), PM/PM tended towards a higher likelihood of a disease event relative to EM/EM (OR= 2.40, 95% CI: 0.86-6.66, p=0.09) among women on Arm A but not among women on Arm B.",
                "The negative effects of reduced CYP2D6 metabolism were observed only during the period of tamoxifen administration, and not after switching to anastrozole."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "CYP2D6*10",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen, anastrozole",
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "In Arm A during the first 5 years of therapy, women with 2 poor alleles had a higher likelihood of an event than women with two extensive alleles. In years 3-5, PM/PM tended towards a higher likelihood of a disease event relative to EM/EM among women on Arm A but not among women on Arm B.",
              "Sentence": "Genotype PM/PM is associated with increased odds of a disease event during tamoxifen treatment in postmenopausal women with estrogen receptor positive breast cancer.",
              "Alleles": "PM/PM",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Specialty Population": "Geriatric",
              "Population types": "in postmenopausal women",
              "Population Phenotypes or diseases": "Disease:breast cancer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "response to",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "In Arm A during the first 5 years of therapy, women with 2 poor alleles (PM/PM: OR=2.45, 95% CI: 1.05-5.73, p=0.04) had a higher likelihood of an event than women with two extensive alleles (EM/EM).",
                "In years 3-5 when patients remained on tamoxifen (Arm A), PM/PM tended towards a higher likelihood of a disease event relative to EM/EM (OR= 2.40, 95% CI: 0.86-6.66, p=0.09) among women on Arm A but not among women on Arm B.",
                "The negative effects of reduced CYP2D6 metabolism were observed only during the period of tamoxifen administration, and not after switching to anastrozole."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "CYP2D6*41",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen, anastrozole",
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "In Arm A during the first 5 years of therapy, women with 2 poor alleles had a higher likelihood of an event than women with two extensive alleles. In years 3-5, PM/PM tended towards a higher likelihood of a disease event relative to EM/EM among women on Arm A but not among women on Arm B.",
              "Sentence": "Genotype PM/PM is associated with increased odds of a disease event during tamoxifen treatment in postmenopausal women with estrogen receptor positive breast cancer.",
              "Alleles": "PM/PM",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Specialty Population": "Geriatric",
              "Population types": "in postmenopausal women",
              "Population Phenotypes or diseases": "Disease:breast cancer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "response to",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "In Arm A during the first 5 years of therapy, women with 2 poor alleles (PM/PM: OR=2.45, 95% CI: 1.05-5.73, p=0.04) had a higher likelihood of an event than women with two extensive alleles (EM/EM).",
                "In years 3-5 when patients remained on tamoxifen (Arm A), PM/PM tended towards a higher likelihood of a disease event relative to EM/EM (OR= 2.40, 95% CI: 0.86-6.66, p=0.09) among women on Arm A but not among women on Arm B.",
                "The negative effects of reduced CYP2D6 metabolism were observed only during the period of tamoxifen administration, and not after switching to anastrozole."
              ],
              "_expanded_from_multi_variant": true
            }
          ]
        },
        "phenotype_annotations": {
          "total_samples": 10,
          "field_scores": {
            "Variant/Haplotypes": {
              "mean_score": 0.2,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Gene": {
              "mean_score": 0.2,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Drug(s)": {
              "mean_score": 0.2,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Phenotype Category": {
              "mean_score": 0.2,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Alleles": {
              "mean_score": 0.1787563681602478,
              "scores": [
                0.893781840801239,
                0.893781840801239,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Is/Is Not associated": {
              "mean_score": 0.2,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Direction of effect": {
              "mean_score": 0.2,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Phenotype": {
              "mean_score": 0.1697877049446106,
              "scores": [
                0.848938524723053,
                0.848938524723053,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "When treated with/exposed to/when assayed with": {
              "mean_score": 0.2,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Comparison Allele(s) or Genotype(s)": {
              "mean_score": 0.17524878978729247,
              "scores": [
                0.8762439489364624,
                0.8762439489364624,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.19024656265974046,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 1.0,
                "Alleles": 0.893781840801239,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.848938524723053,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.8762439489364624
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "CYP2D6*1",
                  "prediction": "CYP2D6"
                },
                "Gene": {
                  "ground_truth": "CYP2D6",
                  "prediction": "CYP2D6"
                },
                "Drug(s)": {
                  "ground_truth": "tamoxifen",
                  "prediction": "tamoxifen"
                },
                "Phenotype Category": {
                  "ground_truth": "Efficacy",
                  "prediction": "efficacy"
                },
                "Alleles": {
                  "ground_truth": "*3/*3 + *4/*4",
                  "prediction": "PM/PM, EM/EM"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Efficacy:Recurrence",
                  "prediction": "disease events"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "*1/*1",
                  "prediction": "EM/EM"
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 1.0,
                "Alleles": 0.893781840801239,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.848938524723053,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.8762439489364624
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "CYP2D6*4",
                  "prediction": "*4"
                },
                "Gene": {
                  "ground_truth": "CYP2D6",
                  "prediction": "CYP2D6"
                },
                "Drug(s)": {
                  "ground_truth": "tamoxifen",
                  "prediction": "tamoxifen"
                },
                "Phenotype Category": {
                  "ground_truth": "Efficacy",
                  "prediction": "efficacy"
                },
                "Alleles": {
                  "ground_truth": "*3/*3 + *4/*4",
                  "prediction": "PM/PM, EM/EM"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Efficacy:Recurrence",
                  "prediction": "disease events"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "*1/*1",
                  "prediction": "EM/EM"
                }
              },
              "dependency_issues": []
            }
          ],
          "aligned_variants": [
            "cyp2d6*1",
            "cyp2d6*4"
          ],
          "unmatched_ground_truth": [
            {
              "Variant Annotation ID": 1444933926,
              "Variant/Haplotypes": "CYP2D6*3",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "Efficacy",
              "Significance": "yes",
              "Notes": "Note: article did not report all genotypes; only *1/variant allele and homozygous variant allele but no combinations of variant alleles e.g. PM/IM even if phenotype grouping exist. Genotyped for null alleles [*3 (2549 del A),*4(1846G>A), and *6(1707T>del)] reduced alleles [*10 (100 C>T and 1846 G>A) and *41 (2988 G>A)] with Applied Biosystems Taqman assay; duplicated alleles could not be assayed. \"extensive\" metabolizers do not carry a null or reduced allele (EM/EM); those with 1 to 2 reduced alleles without a null allele (EM/IM, IM/IM); one null allele (PM/IM, PM/EM), and \"poor\" metabolizers, those with 2 null alleles (PM/PM). Post-menopausal women with estrogen receptor positive breast cancer were treated 5 years with tamoxifen only. The study grouped cases (cancer recurrence) and controls (no recurrence). In a second study arm (tamoxifen+ anastrozole) the higher risk did not persist after switching to anastrozole. [postmenopausal] [adjuvant] [DNA source: paraffin-embedded tissue] [HWE: yes for *4, *6, *10; no for *3, *41]",
              "Sentence": "CYP2D6 *3/*3 + *4/*4 are associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.",
              "Alleles": "*3/*3 + *4/*4",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Efficacy:Recurrence",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in women with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "23213055",
              "Variant Annotation ID_norm": "1444933926",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1444933959,
              "Variant/Haplotypes": "CYP2D6*1",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "Efficacy",
              "Significance": "no",
              "Notes": "Note: PM/IM genotypes are missing; article did not report all genotypes; only *1/variant allele and homozygous variant allele but no combinations of variant alleles e.g. PM/IM even if phenotype grouping exist.Genotyped for null alleles [*3 (2549 del A),*4(1846G>A), and *6(1707T>del)] reduced alleles [*10 (100 C>T and 1846 G>A) and *41 (2988 G>A)] with Applied Biosystems Taqman assay; duplicated alleles could not be assayed. \"extensive\" metabolizers do not carry a null or reduced allele (EM/EM); those with 1 to 2 reduced alleles without a null allele (EM/IM, IM/IM); one null allele (PM/IM, PM/EM), and \"poor\" metabolizers, those with 2 null alleles (PM/PM). Post-menopausal women with estrogen receptor positive breast cancer were treated 5 years with tamoxifen only. The study grouped cases (cancer recurrence) and controls (no recurrence). In a second study arm (tamoxifen+ anastrozole) the higher risk did not persist after switching to anastrozole. [postmenopausal] [adjuvant] [DNA source: paraffin-embedded tissue] [HWE: yes for *4, *6, *10; no for *3, *41]",
              "Sentence": "CYP2D6 *1/*3 + *1/*4 + *1/*6 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.",
              "Alleles": "*1/*3 + *1/*4 + *1/*6",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Efficacy:Recurrence",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in women with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "23213055",
              "Variant Annotation ID_norm": "1444933959",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1444933959,
              "Variant/Haplotypes": "CYP2D6*3",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "Efficacy",
              "Significance": "no",
              "Notes": "Note: PM/IM genotypes are missing; article did not report all genotypes; only *1/variant allele and homozygous variant allele but no combinations of variant alleles e.g. PM/IM even if phenotype grouping exist.Genotyped for null alleles [*3 (2549 del A),*4(1846G>A), and *6(1707T>del)] reduced alleles [*10 (100 C>T and 1846 G>A) and *41 (2988 G>A)] with Applied Biosystems Taqman assay; duplicated alleles could not be assayed. \"extensive\" metabolizers do not carry a null or reduced allele (EM/EM); those with 1 to 2 reduced alleles without a null allele (EM/IM, IM/IM); one null allele (PM/IM, PM/EM), and \"poor\" metabolizers, those with 2 null alleles (PM/PM). Post-menopausal women with estrogen receptor positive breast cancer were treated 5 years with tamoxifen only. The study grouped cases (cancer recurrence) and controls (no recurrence). In a second study arm (tamoxifen+ anastrozole) the higher risk did not persist after switching to anastrozole. [postmenopausal] [adjuvant] [DNA source: paraffin-embedded tissue] [HWE: yes for *4, *6, *10; no for *3, *41]",
              "Sentence": "CYP2D6 *1/*3 + *1/*4 + *1/*6 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.",
              "Alleles": "*1/*3 + *1/*4 + *1/*6",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Efficacy:Recurrence",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in women with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "23213055",
              "Variant Annotation ID_norm": "1444933959",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1444933959,
              "Variant/Haplotypes": "CYP2D6*4",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "Efficacy",
              "Significance": "no",
              "Notes": "Note: PM/IM genotypes are missing; article did not report all genotypes; only *1/variant allele and homozygous variant allele but no combinations of variant alleles e.g. PM/IM even if phenotype grouping exist.Genotyped for null alleles [*3 (2549 del A),*4(1846G>A), and *6(1707T>del)] reduced alleles [*10 (100 C>T and 1846 G>A) and *41 (2988 G>A)] with Applied Biosystems Taqman assay; duplicated alleles could not be assayed. \"extensive\" metabolizers do not carry a null or reduced allele (EM/EM); those with 1 to 2 reduced alleles without a null allele (EM/IM, IM/IM); one null allele (PM/IM, PM/EM), and \"poor\" metabolizers, those with 2 null alleles (PM/PM). Post-menopausal women with estrogen receptor positive breast cancer were treated 5 years with tamoxifen only. The study grouped cases (cancer recurrence) and controls (no recurrence). In a second study arm (tamoxifen+ anastrozole) the higher risk did not persist after switching to anastrozole. [postmenopausal] [adjuvant] [DNA source: paraffin-embedded tissue] [HWE: yes for *4, *6, *10; no for *3, *41]",
              "Sentence": "CYP2D6 *1/*3 + *1/*4 + *1/*6 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.",
              "Alleles": "*1/*3 + *1/*4 + *1/*6",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Efficacy:Recurrence",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in women with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "23213055",
              "Variant Annotation ID_norm": "1444933959",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1444933959,
              "Variant/Haplotypes": "CYP2D6*6",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "Efficacy",
              "Significance": "no",
              "Notes": "Note: PM/IM genotypes are missing; article did not report all genotypes; only *1/variant allele and homozygous variant allele but no combinations of variant alleles e.g. PM/IM even if phenotype grouping exist.Genotyped for null alleles [*3 (2549 del A),*4(1846G>A), and *6(1707T>del)] reduced alleles [*10 (100 C>T and 1846 G>A) and *41 (2988 G>A)] with Applied Biosystems Taqman assay; duplicated alleles could not be assayed. \"extensive\" metabolizers do not carry a null or reduced allele (EM/EM); those with 1 to 2 reduced alleles without a null allele (EM/IM, IM/IM); one null allele (PM/IM, PM/EM), and \"poor\" metabolizers, those with 2 null alleles (PM/PM). Post-menopausal women with estrogen receptor positive breast cancer were treated 5 years with tamoxifen only. The study grouped cases (cancer recurrence) and controls (no recurrence). In a second study arm (tamoxifen+ anastrozole) the higher risk did not persist after switching to anastrozole. [postmenopausal] [adjuvant] [DNA source: paraffin-embedded tissue] [HWE: yes for *4, *6, *10; no for *3, *41]",
              "Sentence": "CYP2D6 *1/*3 + *1/*4 + *1/*6 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.",
              "Alleles": "*1/*3 + *1/*4 + *1/*6",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Efficacy:Recurrence",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in women with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "23213055",
              "Variant Annotation ID_norm": "1444933959",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1444933987,
              "Variant/Haplotypes": "CYP2D6*1",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "Efficacy",
              "Significance": "no",
              "Notes": "Genotyped for null alleles [*3 (2549 del A),*4(1846G>A), and *6(1707T>del)] reduced alleles [*10 (100 C>T and 1846 G>A) and *41 (2988 G>A)] with Applied Biosystems Taqman assay; duplicated alleles could not be assayed. \"extensive\" metabolizers do not carry a null or reduced allele (EM/EM); those with 1 to 2 reduced alleles without a null allele (EM/IM, IM/IM); one null allele (PM/IM, PM/EM), and \"poor\" metabolizers, those with 2 null alleles (PM/PM). Post-menopausal women with estrogen receptor positive breast cancer were treated 5 years with tamoxifen only. The study grouped cases (cancer recurrence) and controls (no recurrence). In a second study arm (tamoxifen+ anastrozole) the higher risk did not persist after switching to anastrozole. [postmenopausal] [adjuvant] [DNA source: paraffin-embedded tissue] [HWE: yes for *4, *6, *10; no for *3, *41]",
              "Sentence": "CYP2D6 *1/*10 + *1/*41 + *10/*10 + *41/*41 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.",
              "Alleles": "*1/*10 + *1/*41 + *10/*10 + *41/*41",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Efficacy:Recurrence",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in women with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "23213055",
              "Variant Annotation ID_norm": "1444933987",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1444933987,
              "Variant/Haplotypes": "CYP2D6*10",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "Efficacy",
              "Significance": "no",
              "Notes": "Genotyped for null alleles [*3 (2549 del A),*4(1846G>A), and *6(1707T>del)] reduced alleles [*10 (100 C>T and 1846 G>A) and *41 (2988 G>A)] with Applied Biosystems Taqman assay; duplicated alleles could not be assayed. \"extensive\" metabolizers do not carry a null or reduced allele (EM/EM); those with 1 to 2 reduced alleles without a null allele (EM/IM, IM/IM); one null allele (PM/IM, PM/EM), and \"poor\" metabolizers, those with 2 null alleles (PM/PM). Post-menopausal women with estrogen receptor positive breast cancer were treated 5 years with tamoxifen only. The study grouped cases (cancer recurrence) and controls (no recurrence). In a second study arm (tamoxifen+ anastrozole) the higher risk did not persist after switching to anastrozole. [postmenopausal] [adjuvant] [DNA source: paraffin-embedded tissue] [HWE: yes for *4, *6, *10; no for *3, *41]",
              "Sentence": "CYP2D6 *1/*10 + *1/*41 + *10/*10 + *41/*41 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.",
              "Alleles": "*1/*10 + *1/*41 + *10/*10 + *41/*41",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Efficacy:Recurrence",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in women with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "23213055",
              "Variant Annotation ID_norm": "1444933987",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1444933987,
              "Variant/Haplotypes": "CYP2D6*41",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "Efficacy",
              "Significance": "no",
              "Notes": "Genotyped for null alleles [*3 (2549 del A),*4(1846G>A), and *6(1707T>del)] reduced alleles [*10 (100 C>T and 1846 G>A) and *41 (2988 G>A)] with Applied Biosystems Taqman assay; duplicated alleles could not be assayed. \"extensive\" metabolizers do not carry a null or reduced allele (EM/EM); those with 1 to 2 reduced alleles without a null allele (EM/IM, IM/IM); one null allele (PM/IM, PM/EM), and \"poor\" metabolizers, those with 2 null alleles (PM/PM). Post-menopausal women with estrogen receptor positive breast cancer were treated 5 years with tamoxifen only. The study grouped cases (cancer recurrence) and controls (no recurrence). In a second study arm (tamoxifen+ anastrozole) the higher risk did not persist after switching to anastrozole. [postmenopausal] [adjuvant] [DNA source: paraffin-embedded tissue] [HWE: yes for *4, *6, *10; no for *3, *41]",
              "Sentence": "CYP2D6 *1/*10 + *1/*41 + *10/*10 + *41/*41 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.",
              "Alleles": "*1/*10 + *1/*41 + *10/*10 + *41/*41",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Efficacy:Recurrence",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in women with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "23213055",
              "Variant Annotation ID_norm": "1444933987",
              "_expanded_from_multi_variant": true
            }
          ],
          "unmatched_predictions": []
        },
        "functional_analysis": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "status": "missing_var_fa_ann"
        },
        "study_parameters": {
          "total_samples": 3,
          "field_scores": {
            "Study Type": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0
              ]
            },
            "Study Cases": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0
              ]
            },
            "Study Controls": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0
              ]
            },
            "Characteristics": {
              "mean_score": 0.9042763113975525,
              "scores": [
                0.9060873985290527,
                0.9055020213127136,
                0.9012395143508911
              ]
            },
            "Characteristics Type": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0
              ]
            },
            "Frequency In Cases": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            },
            "Allele Of Frequency In Cases": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            },
            "Frequency In Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            },
            "Allele Of Frequency In Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            },
            "P Value": {
              "mean_score": 0.8333333333333334,
              "scores": [
                1.0,
                1.0,
                0.5
              ]
            },
            "Ratio Stat Type": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            },
            "Ratio Stat": {
              "mean_score": 0.6666666666666666,
              "scores": [
                1.0,
                1.0,
                0.0
              ]
            },
            "Confidence Interval Start": {
              "mean_score": 0.6666666666666666,
              "scores": [
                1.0,
                1.0,
                0.0
              ]
            },
            "Confidence Interval Stop": {
              "mean_score": 0.6666666666666666,
              "scores": [
                1.0,
                1.0,
                0.0
              ]
            },
            "Biogeographical Groups": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            }
          },
          "overall_score": 0.6491739763153924,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 0.0,
                "Study Controls": 0.0,
                "Characteristics": 0.9060873985290527,
                "Characteristics Type": 0.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 1.0,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 1.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1444933951,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1444933926,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "prospective",
                  "prediction": "case/control"
                },
                "Study Cases": {
                  "ground_truth": 166.0,
                  "prediction": 319
                },
                "Study Controls": {
                  "ground_truth": 287.0,
                  "prediction": 557
                },
                "Characteristics": {
                  "ground_truth": "endpoint: event (disease recurrence, contralateral breast cancer, second non-breast cancer, or death); PM/PM vs EM/EM",
                  "prediction": "CYP2D6 genotype and treatment with tamoxifen or anastrozole in post-menopausal women with ER positive breast cancer"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "drug"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.04",
                  "prediction": "= 0.04"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": 2.45,
                  "prediction": 2.45
                },
                "Confidence Interval Start": {
                  "ground_truth": 1.05,
                  "prediction": 1.05
                },
                "Confidence Interval Stop": {
                  "ground_truth": 5.73,
                  "prediction": 5.73
                },
                "Biogeographical Groups": {
                  "ground_truth": "European",
                  "prediction": "European"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 0.0,
                "Study Controls": 0.0,
                "Characteristics": 0.9055020213127136,
                "Characteristics Type": 0.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 1.0,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 1.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1444933961,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1444933959,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "prospective",
                  "prediction": "case/control"
                },
                "Study Cases": {
                  "ground_truth": 166.0,
                  "prediction": 319
                },
                "Study Controls": {
                  "ground_truth": 287.0,
                  "prediction": 557
                },
                "Characteristics": {
                  "ground_truth": "endpoint: event (disease recurrence, contralateral breast cancer, second non-breast cancer, or death); PM/IM and EM/PM vs EM/EM",
                  "prediction": "CYP2D6 genotype and treatment with tamoxifen or anastrozole in post-menopausal women with ER positive breast cancer"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "drug"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.07",
                  "prediction": "= 0.07"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": 1.67,
                  "prediction": 1.67
                },
                "Confidence Interval Start": {
                  "ground_truth": 0.95,
                  "prediction": 0.95
                },
                "Confidence Interval Stop": {
                  "ground_truth": 2.93,
                  "prediction": 2.93
                },
                "Biogeographical Groups": {
                  "ground_truth": "European",
                  "prediction": "European"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 2,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 0.0,
                "Study Controls": 0.0,
                "Characteristics": 0.9012395143508911,
                "Characteristics Type": 0.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.5,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 0.0,
                "Confidence Interval Start": 0.0,
                "Confidence Interval Stop": 0.0,
                "Biogeographical Groups": 1.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1444933989,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1444933987,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "prospective",
                  "prediction": "case/control"
                },
                "Study Cases": {
                  "ground_truth": 166.0,
                  "prediction": 319
                },
                "Study Controls": {
                  "ground_truth": 287.0,
                  "prediction": 557
                },
                "Characteristics": {
                  "ground_truth": "endpoint: event (disease recurrence, contralateral breast cancer, second non-breast cancer, or death); IM/IM and EM/IM vs EM/EM",
                  "prediction": "CYP2D6 genotype and treatment with tamoxifen or anastrozole in post-menopausal women with ER positive breast cancer"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "drug"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.6",
                  "prediction": "= 0.09"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": 1.23,
                  "prediction": 2.4
                },
                "Confidence Interval Start": {
                  "ground_truth": 0.58,
                  "prediction": 0.86
                },
                "Confidence Interval Stop": {
                  "ground_truth": 2.61,
                  "prediction": 6.66
                },
                "Biogeographical Groups": {
                  "ground_truth": "European",
                  "prediction": "European"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            }
          ],
          "aligned_variants": [
            "prospective:endpoint: event (dis",
            "prospective:endpoint: event (dis",
            "prospective:endpoint: event (dis"
          ],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 319,
              "Study Controls": 557,
              "Characteristics": "CYP2D6 genotype and treatment with tamoxifen or anastrozole in post-menopausal women with ER positive breast cancer",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "> 0.05",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.28,
              "Confidence Interval Start": 0.03,
              "Confidence Interval Stop": 2.3,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          ]
        }
      },
      "overall_score": 0.18690876406100063,
      "num_benchmarks": 4
    },
    {
      "pmid": "23476897",
      "pmcid": "PMC3584248",
      "title": "CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer",
      "benchmarks": {
        "drug_annotations": {
          "total_samples": 10,
          "field_scores": {
            "Variant/Haplotypes": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Gene": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "PMID": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Phenotype Category": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Significance": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Alleles": {
              "mean_score": 0.47338154911994934,
              "scores": [
                0.9467630982398987,
                0.9467630982398987,
                0.9467630982398987,
                0.9467630982398987,
                0.9467630982398987,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Specialty Population": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Metabolizer types": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "isPlural": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Is/Is Not associated": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Direction of effect": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "PD/PK terms": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Multiple drugs And/or": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Population types": {
              "mean_score": 0.43749579787254333,
              "scores": [
                0.8749915957450867,
                0.8749915957450867,
                0.8749915957450867,
                0.8749915957450867,
                0.8749915957450867,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Population Phenotypes or diseases": {
              "mean_score": 0.4714471101760864,
              "scores": [
                0.9428942203521729,
                0.9428942203521729,
                0.9428942203521729,
                0.9428942203521729,
                0.9428942203521729,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Multiple phenotypes or diseases And/or": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Comparison Allele(s) or Genotype(s)": {
              "mean_score": 0.4849123954772949,
              "scores": [
                0.9698247909545898,
                0.9698247909545898,
                0.9698247909545898,
                0.9698247909545898,
                0.9698247909545898,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Comparison Metabolizer types": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Drug(s)": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.28248615013925654,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "PMID": 0.0,
                "Phenotype Category": 1.0,
                "Significance": 1.0,
                "Alleles": 0.9467630982398987,
                "Specialty Population": 0.0,
                "Metabolizer types": 0.0,
                "isPlural": 1.0,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 0.0,
                "PD/PK terms": 1.0,
                "Multiple drugs And/or": 0.0,
                "Population types": 0.8749915957450867,
                "Population Phenotypes or diseases": 0.9428942203521729,
                "Multiple phenotypes or diseases And/or": 0.0,
                "Comparison Allele(s) or Genotype(s)": 0.9698247909545898,
                "Comparison Metabolizer types": 0.0,
                "Drug(s)": 0.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "CYP2D6*1",
                  "prediction": "CYP2D6*1"
                },
                "Gene": {
                  "ground_truth": "CYP2D6",
                  "prediction": "CYP2D6"
                },
                "PMID": {
                  "ground_truth": 23476897,
                  "prediction": null
                },
                "Phenotype Category": {
                  "ground_truth": "Metabolism/PK",
                  "prediction": "metabolism/PK"
                },
                "Significance": {
                  "ground_truth": "yes",
                  "prediction": "yes"
                },
                "Alleles": {
                  "ground_truth": "*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10",
                  "prediction": "CYP2D6*1/*10, CYP2D6*1/*2, CYP2D6*10/*10, *1/*41, CYP2D6*2/*10"
                },
                "Specialty Population": {
                  "ground_truth": null,
                  "prediction": ""
                },
                "Metabolizer types": {
                  "ground_truth": null,
                  "prediction": "intermediate metabolizer"
                },
                "isPlural": {
                  "ground_truth": "Are",
                  "prediction": "Are"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "decreased",
                  "prediction": "increased"
                },
                "PD/PK terms": {
                  "ground_truth": "concentrations of",
                  "prediction": "concentrations of"
                },
                "Multiple drugs And/or": {
                  "ground_truth": null,
                  "prediction": ""
                },
                "Population types": {
                  "ground_truth": "in women with",
                  "prediction": "in people with operable breast cancer"
                },
                "Population Phenotypes or diseases": {
                  "ground_truth": "Disease:Breast Neoplasms",
                  "prediction": "Disease:breast cancer"
                },
                "Multiple phenotypes or diseases And/or": {
                  "ground_truth": null,
                  "prediction": ""
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "*1/*1 + *1/*2 + *2/*2",
                  "prediction": "*1/*1; *1/*10"
                },
                "Comparison Metabolizer types": {
                  "ground_truth": null,
                  "prediction": "normal metabolizer"
                },
                "Drug(s)": {
                  "ground_truth": "endoxifen",
                  "prediction": "tamoxifen"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "PMID": 0.0,
                "Phenotype Category": 1.0,
                "Significance": 1.0,
                "Alleles": 0.9467630982398987,
                "Specialty Population": 0.0,
                "Metabolizer types": 0.0,
                "isPlural": 1.0,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 0.0,
                "PD/PK terms": 1.0,
                "Multiple drugs And/or": 0.0,
                "Population types": 0.8749915957450867,
                "Population Phenotypes or diseases": 0.9428942203521729,
                "Multiple phenotypes or diseases And/or": 0.0,
                "Comparison Allele(s) or Genotype(s)": 0.9698247909545898,
                "Comparison Metabolizer types": 0.0,
                "Drug(s)": 0.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "CYP2D6*2",
                  "prediction": "CYP2D6*2"
                },
                "Gene": {
                  "ground_truth": "CYP2D6",
                  "prediction": "CYP2D6"
                },
                "PMID": {
                  "ground_truth": 23476897,
                  "prediction": null
                },
                "Phenotype Category": {
                  "ground_truth": "Metabolism/PK",
                  "prediction": "metabolism/PK"
                },
                "Significance": {
                  "ground_truth": "yes",
                  "prediction": "yes"
                },
                "Alleles": {
                  "ground_truth": "*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10",
                  "prediction": "CYP2D6*1/*10, CYP2D6*1/*2, CYP2D6*10/*10, *1/*41, CYP2D6*2/*10"
                },
                "Specialty Population": {
                  "ground_truth": null,
                  "prediction": ""
                },
                "Metabolizer types": {
                  "ground_truth": null,
                  "prediction": "intermediate metabolizer"
                },
                "isPlural": {
                  "ground_truth": "Are",
                  "prediction": "Are"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "decreased",
                  "prediction": "increased"
                },
                "PD/PK terms": {
                  "ground_truth": "concentrations of",
                  "prediction": "concentrations of"
                },
                "Multiple drugs And/or": {
                  "ground_truth": null,
                  "prediction": ""
                },
                "Population types": {
                  "ground_truth": "in women with",
                  "prediction": "in people with operable breast cancer"
                },
                "Population Phenotypes or diseases": {
                  "ground_truth": "Disease:Breast Neoplasms",
                  "prediction": "Disease:breast cancer"
                },
                "Multiple phenotypes or diseases And/or": {
                  "ground_truth": null,
                  "prediction": ""
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "*1/*1 + *1/*2 + *2/*2",
                  "prediction": "*1/*1; *1/*10"
                },
                "Comparison Metabolizer types": {
                  "ground_truth": null,
                  "prediction": "normal metabolizer"
                },
                "Drug(s)": {
                  "ground_truth": "endoxifen",
                  "prediction": "tamoxifen"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 2,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "PMID": 0.0,
                "Phenotype Category": 1.0,
                "Significance": 1.0,
                "Alleles": 0.9467630982398987,
                "Specialty Population": 0.0,
                "Metabolizer types": 0.0,
                "isPlural": 1.0,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 0.0,
                "PD/PK terms": 1.0,
                "Multiple drugs And/or": 0.0,
                "Population types": 0.8749915957450867,
                "Population Phenotypes or diseases": 0.9428942203521729,
                "Multiple phenotypes or diseases And/or": 0.0,
                "Comparison Allele(s) or Genotype(s)": 0.9698247909545898,
                "Comparison Metabolizer types": 0.0,
                "Drug(s)": 0.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "CYP2D6*5",
                  "prediction": "CYP2D6*5"
                },
                "Gene": {
                  "ground_truth": "CYP2D6",
                  "prediction": "CYP2D6"
                },
                "PMID": {
                  "ground_truth": 23476897,
                  "prediction": null
                },
                "Phenotype Category": {
                  "ground_truth": "Metabolism/PK",
                  "prediction": "metabolism/PK"
                },
                "Significance": {
                  "ground_truth": "yes",
                  "prediction": "yes"
                },
                "Alleles": {
                  "ground_truth": "*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10",
                  "prediction": "CYP2D6*1/*10, CYP2D6*1/*2, CYP2D6*10/*10, *1/*41, CYP2D6*2/*10"
                },
                "Specialty Population": {
                  "ground_truth": null,
                  "prediction": ""
                },
                "Metabolizer types": {
                  "ground_truth": null,
                  "prediction": "intermediate metabolizer"
                },
                "isPlural": {
                  "ground_truth": "Are",
                  "prediction": "Are"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "decreased",
                  "prediction": "increased"
                },
                "PD/PK terms": {
                  "ground_truth": "concentrations of",
                  "prediction": "concentrations of"
                },
                "Multiple drugs And/or": {
                  "ground_truth": null,
                  "prediction": ""
                },
                "Population types": {
                  "ground_truth": "in women with",
                  "prediction": "in people with operable breast cancer"
                },
                "Population Phenotypes or diseases": {
                  "ground_truth": "Disease:Breast Neoplasms",
                  "prediction": "Disease:breast cancer"
                },
                "Multiple phenotypes or diseases And/or": {
                  "ground_truth": null,
                  "prediction": ""
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "*1/*1 + *1/*2 + *2/*2",
                  "prediction": "*1/*1; *1/*10"
                },
                "Comparison Metabolizer types": {
                  "ground_truth": null,
                  "prediction": "normal metabolizer"
                },
                "Drug(s)": {
                  "ground_truth": "endoxifen",
                  "prediction": "tamoxifen"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 3,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "PMID": 0.0,
                "Phenotype Category": 1.0,
                "Significance": 1.0,
                "Alleles": 0.9467630982398987,
                "Specialty Population": 0.0,
                "Metabolizer types": 0.0,
                "isPlural": 1.0,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 0.0,
                "PD/PK terms": 1.0,
                "Multiple drugs And/or": 0.0,
                "Population types": 0.8749915957450867,
                "Population Phenotypes or diseases": 0.9428942203521729,
                "Multiple phenotypes or diseases And/or": 0.0,
                "Comparison Allele(s) or Genotype(s)": 0.9698247909545898,
                "Comparison Metabolizer types": 0.0,
                "Drug(s)": 0.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "CYP2D6*10",
                  "prediction": "CYP2D6*10"
                },
                "Gene": {
                  "ground_truth": "CYP2D6",
                  "prediction": "CYP2D6"
                },
                "PMID": {
                  "ground_truth": 23476897,
                  "prediction": null
                },
                "Phenotype Category": {
                  "ground_truth": "Metabolism/PK",
                  "prediction": "metabolism/PK"
                },
                "Significance": {
                  "ground_truth": "yes",
                  "prediction": "yes"
                },
                "Alleles": {
                  "ground_truth": "*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10",
                  "prediction": "CYP2D6*1/*10, CYP2D6*1/*2, CYP2D6*10/*10, *1/*41, CYP2D6*2/*10"
                },
                "Specialty Population": {
                  "ground_truth": null,
                  "prediction": ""
                },
                "Metabolizer types": {
                  "ground_truth": null,
                  "prediction": "intermediate metabolizer"
                },
                "isPlural": {
                  "ground_truth": "Are",
                  "prediction": "Are"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "decreased",
                  "prediction": "increased"
                },
                "PD/PK terms": {
                  "ground_truth": "concentrations of",
                  "prediction": "concentrations of"
                },
                "Multiple drugs And/or": {
                  "ground_truth": null,
                  "prediction": ""
                },
                "Population types": {
                  "ground_truth": "in women with",
                  "prediction": "in people with operable breast cancer"
                },
                "Population Phenotypes or diseases": {
                  "ground_truth": "Disease:Breast Neoplasms",
                  "prediction": "Disease:breast cancer"
                },
                "Multiple phenotypes or diseases And/or": {
                  "ground_truth": null,
                  "prediction": ""
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "*1/*1 + *1/*2 + *2/*2",
                  "prediction": "*1/*1; *1/*10"
                },
                "Comparison Metabolizer types": {
                  "ground_truth": null,
                  "prediction": "normal metabolizer"
                },
                "Drug(s)": {
                  "ground_truth": "endoxifen",
                  "prediction": "tamoxifen"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 4,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "PMID": 0.0,
                "Phenotype Category": 1.0,
                "Significance": 1.0,
                "Alleles": 0.9467630982398987,
                "Specialty Population": 0.0,
                "Metabolizer types": 0.0,
                "isPlural": 1.0,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 0.0,
                "PD/PK terms": 1.0,
                "Multiple drugs And/or": 0.0,
                "Population types": 0.8749915957450867,
                "Population Phenotypes or diseases": 0.9428942203521729,
                "Multiple phenotypes or diseases And/or": 0.0,
                "Comparison Allele(s) or Genotype(s)": 0.9698247909545898,
                "Comparison Metabolizer types": 0.0,
                "Drug(s)": 0.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "CYP2D6*41",
                  "prediction": "CYP2D6*41"
                },
                "Gene": {
                  "ground_truth": "CYP2D6",
                  "prediction": "CYP2D6"
                },
                "PMID": {
                  "ground_truth": 23476897,
                  "prediction": null
                },
                "Phenotype Category": {
                  "ground_truth": "Metabolism/PK",
                  "prediction": "metabolism/PK"
                },
                "Significance": {
                  "ground_truth": "yes",
                  "prediction": "yes"
                },
                "Alleles": {
                  "ground_truth": "*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10",
                  "prediction": "CYP2D6*1/*10, CYP2D6*1/*2, CYP2D6*10/*10, *1/*41, CYP2D6*2/*10"
                },
                "Specialty Population": {
                  "ground_truth": null,
                  "prediction": ""
                },
                "Metabolizer types": {
                  "ground_truth": null,
                  "prediction": "intermediate metabolizer"
                },
                "isPlural": {
                  "ground_truth": "Are",
                  "prediction": "Are"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "decreased",
                  "prediction": "increased"
                },
                "PD/PK terms": {
                  "ground_truth": "concentrations of",
                  "prediction": "concentrations of"
                },
                "Multiple drugs And/or": {
                  "ground_truth": null,
                  "prediction": ""
                },
                "Population types": {
                  "ground_truth": "in women with",
                  "prediction": "in people with operable breast cancer"
                },
                "Population Phenotypes or diseases": {
                  "ground_truth": "Disease:Breast Neoplasms",
                  "prediction": "Disease:breast cancer"
                },
                "Multiple phenotypes or diseases And/or": {
                  "ground_truth": null,
                  "prediction": ""
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "*1/*1 + *1/*2 + *2/*2",
                  "prediction": "*1/*1; *1/*10"
                },
                "Comparison Metabolizer types": {
                  "ground_truth": null,
                  "prediction": "normal metabolizer"
                },
                "Drug(s)": {
                  "ground_truth": "endoxifen",
                  "prediction": "tamoxifen"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            }
          ],
          "aligned_variants": [
            "cyp2d6*1",
            "cyp2d6*2",
            "cyp2d6*5",
            "cyp2d6*10",
            "cyp2d6*41"
          ],
          "unmatched_ground_truth": [
            {
              "Variant Annotation ID": 1444930474,
              "Variant/Haplotypes": "CYP2D6*1",
              "Gene": "CYP2D6",
              "Drug(s)": "4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen",
              "PMID": 23476897,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "no",
              "Notes": "No information on menopausal status or if tamoxifen only treatment. No co-treatment with CYP2D6 inhibitors CYP2D6 alleles *2, *3, *4, *5, *6, *10, and *41 are genotyped with predeveloped TaqMan Genotyping Assays. Genotypes were categorized as normal (fully functional CYP2D6 alleles: *1 and *2 -*1/*1, *1/*2, *2/*2), intermediate (alleles associated with reduced enzyme activity: heterozygous for *10 and *41-*1/*10, *2/*10, *1/*41), and slow (homozygous for *10, *41 variants and one or more non-functional null alleles: *3-*6-*10/*10, *10/*41, *1/*5, *2/*5, *5/*10). [pre-menopausal][post-menopausal] [adjuvant]  [DNA source: leukocytes] [HWE: Vietnamese *1, 2, 4, 5, 10, 41 yes Filipino *1 and *2 no rest yes]",
              "Sentence": "CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are not associated with decreased concentrations of 4-hydroxytamoxifen, n-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.",
              "Alleles": "*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "concentrations of",
              "Multiple drugs And/or": "and",
              "Population types": "in women with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1 + *1/*2 + *2/*2",
              "Comparison Metabolizer types": null,
              "PMID_norm": "23476897",
              "Variant Annotation ID_norm": "1444930474",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1444930474,
              "Variant/Haplotypes": "CYP2D6*2",
              "Gene": "CYP2D6",
              "Drug(s)": "4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen",
              "PMID": 23476897,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "no",
              "Notes": "No information on menopausal status or if tamoxifen only treatment. No co-treatment with CYP2D6 inhibitors CYP2D6 alleles *2, *3, *4, *5, *6, *10, and *41 are genotyped with predeveloped TaqMan Genotyping Assays. Genotypes were categorized as normal (fully functional CYP2D6 alleles: *1 and *2 -*1/*1, *1/*2, *2/*2), intermediate (alleles associated with reduced enzyme activity: heterozygous for *10 and *41-*1/*10, *2/*10, *1/*41), and slow (homozygous for *10, *41 variants and one or more non-functional null alleles: *3-*6-*10/*10, *10/*41, *1/*5, *2/*5, *5/*10). [pre-menopausal][post-menopausal] [adjuvant]  [DNA source: leukocytes] [HWE: Vietnamese *1, 2, 4, 5, 10, 41 yes Filipino *1 and *2 no rest yes]",
              "Sentence": "CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are not associated with decreased concentrations of 4-hydroxytamoxifen, n-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.",
              "Alleles": "*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "concentrations of",
              "Multiple drugs And/or": "and",
              "Population types": "in women with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1 + *1/*2 + *2/*2",
              "Comparison Metabolizer types": null,
              "PMID_norm": "23476897",
              "Variant Annotation ID_norm": "1444930474",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1444930474,
              "Variant/Haplotypes": "CYP2D6*5",
              "Gene": "CYP2D6",
              "Drug(s)": "4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen",
              "PMID": 23476897,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "no",
              "Notes": "No information on menopausal status or if tamoxifen only treatment. No co-treatment with CYP2D6 inhibitors CYP2D6 alleles *2, *3, *4, *5, *6, *10, and *41 are genotyped with predeveloped TaqMan Genotyping Assays. Genotypes were categorized as normal (fully functional CYP2D6 alleles: *1 and *2 -*1/*1, *1/*2, *2/*2), intermediate (alleles associated with reduced enzyme activity: heterozygous for *10 and *41-*1/*10, *2/*10, *1/*41), and slow (homozygous for *10, *41 variants and one or more non-functional null alleles: *3-*6-*10/*10, *10/*41, *1/*5, *2/*5, *5/*10). [pre-menopausal][post-menopausal] [adjuvant]  [DNA source: leukocytes] [HWE: Vietnamese *1, 2, 4, 5, 10, 41 yes Filipino *1 and *2 no rest yes]",
              "Sentence": "CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are not associated with decreased concentrations of 4-hydroxytamoxifen, n-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.",
              "Alleles": "*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "concentrations of",
              "Multiple drugs And/or": "and",
              "Population types": "in women with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1 + *1/*2 + *2/*2",
              "Comparison Metabolizer types": null,
              "PMID_norm": "23476897",
              "Variant Annotation ID_norm": "1444930474",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1444930474,
              "Variant/Haplotypes": "CYP2D6*10",
              "Gene": "CYP2D6",
              "Drug(s)": "4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen",
              "PMID": 23476897,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "no",
              "Notes": "No information on menopausal status or if tamoxifen only treatment. No co-treatment with CYP2D6 inhibitors CYP2D6 alleles *2, *3, *4, *5, *6, *10, and *41 are genotyped with predeveloped TaqMan Genotyping Assays. Genotypes were categorized as normal (fully functional CYP2D6 alleles: *1 and *2 -*1/*1, *1/*2, *2/*2), intermediate (alleles associated with reduced enzyme activity: heterozygous for *10 and *41-*1/*10, *2/*10, *1/*41), and slow (homozygous for *10, *41 variants and one or more non-functional null alleles: *3-*6-*10/*10, *10/*41, *1/*5, *2/*5, *5/*10). [pre-menopausal][post-menopausal] [adjuvant]  [DNA source: leukocytes] [HWE: Vietnamese *1, 2, 4, 5, 10, 41 yes Filipino *1 and *2 no rest yes]",
              "Sentence": "CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are not associated with decreased concentrations of 4-hydroxytamoxifen, n-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.",
              "Alleles": "*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "concentrations of",
              "Multiple drugs And/or": "and",
              "Population types": "in women with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1 + *1/*2 + *2/*2",
              "Comparison Metabolizer types": null,
              "PMID_norm": "23476897",
              "Variant Annotation ID_norm": "1444930474",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1444930474,
              "Variant/Haplotypes": "CYP2D6*41",
              "Gene": "CYP2D6",
              "Drug(s)": "4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen",
              "PMID": 23476897,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "no",
              "Notes": "No information on menopausal status or if tamoxifen only treatment. No co-treatment with CYP2D6 inhibitors CYP2D6 alleles *2, *3, *4, *5, *6, *10, and *41 are genotyped with predeveloped TaqMan Genotyping Assays. Genotypes were categorized as normal (fully functional CYP2D6 alleles: *1 and *2 -*1/*1, *1/*2, *2/*2), intermediate (alleles associated with reduced enzyme activity: heterozygous for *10 and *41-*1/*10, *2/*10, *1/*41), and slow (homozygous for *10, *41 variants and one or more non-functional null alleles: *3-*6-*10/*10, *10/*41, *1/*5, *2/*5, *5/*10). [pre-menopausal][post-menopausal] [adjuvant]  [DNA source: leukocytes] [HWE: Vietnamese *1, 2, 4, 5, 10, 41 yes Filipino *1 and *2 no rest yes]",
              "Sentence": "CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are not associated with decreased concentrations of 4-hydroxytamoxifen, n-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.",
              "Alleles": "*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "concentrations of",
              "Multiple drugs And/or": "and",
              "Population types": "in women with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1 + *1/*2 + *2/*2",
              "Comparison Metabolizer types": null,
              "PMID_norm": "23476897",
              "Variant Annotation ID_norm": "1444930474",
              "_expanded_from_multi_variant": true
            }
          ],
          "unmatched_predictions": [
            {
              "Variant/Haplotypes": "CYP2D6*3",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "High endoxifen concentrations were associated with higher risk of recurrence; significant association found with p-value of 0.002.",
              "Standardized Sentence": "CYP2D6*10 is associated with decreased endoxifen concentrations in Filipino and Vietnamese women receiving tamoxifen for breast cancer.",
              "Alleles": "CYP2D6*1/*10, CYP2D6*1/*2, CYP2D6*10/*10, *1/*41, CYP2D6*2/*10",
              "Metabolizer types": "intermediate metabolizer",
              "Comparison Allele(s) or Genotype(s)": "*1/*1; *1/*10",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "",
              "Population types": "in people with operable breast cancer",
              "Population Phenotypes or diseases": "Disease:breast cancer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "concentrations of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "We found a significant association of reduced endoxifen plasma concentrations with functionally important CYP2D6 genotypes.",
                "High endoxifen concentrations were associated with higher risk of recurrence; with a quadratic trend fitted to a stratified Cox proportional hazards regression model, the likelihood ratio p-value was 0.002.",
                "The trend also showed that in 8 out of 9 pairs with low endoxifen concentrations, the recurrent case had lower endoxifen levels than the matched control."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "CYP2D6*4",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "High endoxifen concentrations were associated with higher risk of recurrence; significant association found with p-value of 0.002.",
              "Standardized Sentence": "CYP2D6*10 is associated with decreased endoxifen concentrations in Filipino and Vietnamese women receiving tamoxifen for breast cancer.",
              "Alleles": "CYP2D6*1/*10, CYP2D6*1/*2, CYP2D6*10/*10, *1/*41, CYP2D6*2/*10",
              "Metabolizer types": "intermediate metabolizer",
              "Comparison Allele(s) or Genotype(s)": "*1/*1; *1/*10",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "",
              "Population types": "in people with operable breast cancer",
              "Population Phenotypes or diseases": "Disease:breast cancer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "concentrations of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "We found a significant association of reduced endoxifen plasma concentrations with functionally important CYP2D6 genotypes.",
                "High endoxifen concentrations were associated with higher risk of recurrence; with a quadratic trend fitted to a stratified Cox proportional hazards regression model, the likelihood ratio p-value was 0.002.",
                "The trend also showed that in 8 out of 9 pairs with low endoxifen concentrations, the recurrent case had lower endoxifen levels than the matched control."
              ],
              "_expanded_from_multi_variant": true
            }
          ]
        },
        "phenotype_annotations": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": []
        },
        "functional_analysis": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "status": "missing_var_fa_ann"
        },
        "study_parameters": {
          "total_samples": 4,
          "field_scores": {
            "Study Type": {
              "mean_score": 0.25,
              "scores": [
                1.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Study Cases": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0
              ]
            },
            "Study Controls": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0
              ]
            },
            "Characteristics": {
              "mean_score": 0.6683181673288345,
              "scores": [
                0.8825568556785583,
                0.9262558817863464,
                0.8644599318504333,
                0.0
              ]
            },
            "Characteristics Type": {
              "mean_score": 0.75,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0
              ]
            },
            "Frequency In Cases": {
              "mean_score": 0.75,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0
              ]
            },
            "Allele Of Frequency In Cases": {
              "mean_score": 0.75,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0
              ]
            },
            "Frequency In Controls": {
              "mean_score": 0.75,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0
              ]
            },
            "Allele Of Frequency In Controls": {
              "mean_score": 0.75,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0
              ]
            },
            "P Value": {
              "mean_score": 0.25,
              "scores": [
                0.5,
                0.0,
                0.5,
                0.0
              ]
            },
            "Ratio Stat Type": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Ratio Stat": {
              "mean_score": 0.75,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0
              ]
            },
            "Confidence Interval Start": {
              "mean_score": 0.75,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0
              ]
            },
            "Confidence Interval Stop": {
              "mean_score": 0.75,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0
              ]
            },
            "Biogeographical Groups": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.544554544488589,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 1.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.8825568556785583,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.5,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1444930476,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1444930474,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "clinical trial",
                  "prediction": "clinical trial"
                },
                "Study Cases": {
                  "ground_truth": 224.0,
                  "prediction": 224.0
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "endpoint: tamoxifen concentration after 4 month; slow vs normal metabolizer; p = 0.39 for trend: normal > intermediate > slow",
                  "prediction": "Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.39",
                  "prediction": "= 0.002"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "HR"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "East Asian",
                  "prediction": "Multiple Groups"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.9262558817863464,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.0,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1444930473,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1444930388,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "clinical trial",
                  "prediction": null
                },
                "Study Cases": {
                  "ground_truth": 224.0,
                  "prediction": 224.0
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "endpoint: endoxifen concentration after 4 month; slow vs normal metabolizer; p = 0.0001 for trend: normal > intermediate > slow",
                  "prediction": "Endoxifen concentrations associated with likelihood of recurrence among participants"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.0001",
                  "prediction": null
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": null
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "East Asian",
                  "prediction": "Multiple Groups"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 2,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 0.0,
                "Study Controls": 0.0,
                "Characteristics": 0.8644599318504333,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.5,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1444930499,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1444930474,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "clinical trial",
                  "prediction": null
                },
                "Study Cases": {
                  "ground_truth": 224.0,
                  "prediction": 48.0
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": 48.0
                },
                "Characteristics": {
                  "ground_truth": "endpoint: N-desmethyltamoxifen concentration after 4 month; slow vs normal metabolizer; p = 0.06 for trend: normal > intermediate > slow",
                  "prediction": "Nested case-control study of women with and without disease recurrence"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.06",
                  "prediction": "= 0.002"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "Unknown"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "East Asian",
                  "prediction": "Multiple Groups"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            }
          ],
          "aligned_variants": [
            "clinical trial:endpoint: tamoxifen ",
            "clinical trial:endpoint: endoxifen ",
            "clinical trial:endpoint: N-desmethy"
          ],
          "unmatched_ground_truth": [
            {
              "Study Parameters ID": 1444930497,
              "Variant Annotation ID": 1444930474,
              "Study Type": "clinical trial",
              "Study Cases": 224.0,
              "Study Controls": null,
              "Characteristics": "endpoint: 4-hydroxytamoxifen concentration after 4 month; slow vs normal metabolizer; p = 0.13 for trend: normal > intermediate > slow",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.13",
              "Ratio Stat Type": "OR",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "East Asian",
              "Variant Annotation ID_norm": "1444930474"
            }
          ],
          "unmatched_predictions": []
        }
      },
      "overall_score": 0.19365675393949475,
      "num_benchmarks": 4
    },
    {
      "pmid": "23588310",
      "pmcid": "PMC3839910",
      "title": "HLA-A*31:01 and HLA-B*15:02 as genetic markers for carbamazepine hypersensitivity in children",
      "benchmarks": {
        "drug_annotations": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Variant/Haplotypes": "HLA-A*31:01",
              "Gene": "HLA-A",
              "Drug(s)": "carbamazepine",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Significantly associated with HSS (OR: 26.4, p=0.0025) and maculopapular exanthems (OR: 8.6, p=0.0037).",
              "Sentence": "HLA-A*31:01 is associated with increased hypersensitivity reactions carbamazepine in children with diverse ancestries.",
              "Alleles": "HLA-A*31:01",
              "Metabolizer types": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "Specialty Population": "Pediatric",
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Side Effect:Hypersensitivity",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Multiple phenotypes or diseases And/or": null,
              "Citations": [
                "HLA-A*31:01 was significantly associated with CBZ-HSS (odds ratio (OR): 26.4, p=0.0025) and maculopapular exanthems (OR: 8.6, p=0.0037)",
                "This study aimed to address these gaps by investigating HLA-B*15:02 and HLA-A*31:01, two important pharmacogenetic markers with consistent evidence from adult-based studies, in Canadian children with diverse ancestries.",
                "We replicated important associations of two genetic risk factors, HLA-B*15:02 and HLA-A*31:01, in pediatric patients."
              ]
            },
            {
              "Variant/Haplotypes": "HLA-B*15:02",
              "Gene": "HLA-B",
              "Drug(s)": "carbamazepine",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Associated with SJS (OR: 38.6, p=0.002).",
              "Sentence": "HLA-B*15:02 is associated with increased risk of Stevens-Johnson syndrome carbamazepine in children of Asian origin.",
              "Alleles": "HLA-B*15:02",
              "Metabolizer types": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "Specialty Population": "Pediatric",
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Side Effect:Stevens-Johnson syndrome",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of",
              "Multiple drugs And/or": null,
              "Multiple phenotypes or diseases And/or": null,
              "Citations": [
                "HLA-B*15:02 was associated with CBZ-SJS (OR: 38.6, p=0.002)\".",
                "Three of the nine patients with CBZ-SJS/TEN were carriers of HLA-B*15:02, resulting in a significant association of HLA-B*15:02 with CBZ-SJS/TEN (OR: 38.6; P=0.002; [Table 2](#T2)).",
                "All three HLA-B*15:02-positive patients with CBZ-SJS/TEN were of Asian origin."
              ]
            },
            {
              "Variant/Haplotypes": "rs1061235",
              "Gene": "HLA-A",
              "Drug(s)": "carbamazepine",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Strong association with CBZ-HSS (OR: 26.4, P=0.0025) and MPE (OR: 8.6, P=0.0037) also observed.",
              "Sentence": "The rs1061235 T allele is associated with increased hypersensitivity reactions carbamazepine in children with diverse ancestries.",
              "Alleles": "rs1061235 T",
              "Metabolizer types": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "Specialty Population": "Pediatric",
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Side Effect:Hypersensitivity",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Multiple phenotypes or diseases And/or": null,
              "Citations": [
                "HLA-A*31:01 was significantly associated with CBZ-HSS (odds ratio (OR): 26.4, p=0.0025) and maculopapular exanthems (OR: 8.6, p=0.0037)",
                "Overall, 20 (15%) children treated with CBZ carried the T allele of rs1061235... HLA-A*31:01 was not observed in any of the children not carrying rs1061235T.",
                "...rs1061235 was also overrepresented in hypersensitivity cases after excluding HLA-A*31:01-positive children (OR: 5.83; P=0.033)"
              ]
            }
          ]
        },
        "phenotype_annotations": {
          "total_samples": 6,
          "field_scores": {
            "Variant/Haplotypes": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Gene": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Drug(s)": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Phenotype Category": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Alleles": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Is/Is Not associated": {
              "mean_score": 0.16666666666666666,
              "scores": [
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Direction of effect": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Phenotype": {
              "mean_score": 0.311708003282547,
              "scores": [
                0.9858836531639099,
                0.8843643665313721,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "When treated with/exposed to/when assayed with": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Comparison Allele(s) or Genotype(s)": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.3158402227693134,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 1.0,
                "Alleles": 1.0,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.9858836531639099,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 1.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "HLA-B*15:02",
                  "prediction": "HLA-B*15:02"
                },
                "Gene": {
                  "ground_truth": "HLA-B",
                  "prediction": "HLA-B"
                },
                "Drug(s)": {
                  "ground_truth": "carbamazepine",
                  "prediction": "carbamazepine"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "*15:02",
                  "prediction": "*15:02"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Disease:Stevens-Johnson Syndrome",
                  "prediction": "Stevens-Johnson Syndrome"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": null,
                  "prediction": null
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 1.0,
                "Alleles": 1.0,
                "Is/Is Not associated": 0.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.8843643665313721,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 1.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "HLA-A*31:01",
                  "prediction": "HLA-A*31:01"
                },
                "Gene": {
                  "ground_truth": "HLA-A",
                  "prediction": "HLA-A"
                },
                "Drug(s)": {
                  "ground_truth": "carbamazepine",
                  "prediction": "carbamazepine"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "*31:01",
                  "prediction": "*31:01"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Not associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Disease:Stevens-Johnson Syndrome",
                  "prediction": "hypersensitivity syndrome"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": null,
                  "prediction": null
                }
              },
              "dependency_issues": []
            }
          ],
          "aligned_variants": [
            "hla-b*15:02",
            "hla-a*31:01"
          ],
          "unmatched_ground_truth": [
            {
              "Variant Annotation ID": 994531642,
              "Variant/Haplotypes": "HLA-B*15:02",
              "Gene": "HLA-B",
              "Drug(s)": "carbamazepine",
              "PMID": 23588310,
              "Phenotype Category": "Toxicity",
              "Significance": "no",
              "Notes": null,
              "Sentence": "HLA-B *15:02 is not associated with increased risk of Maculopapular Exanthema when treated with carbamazepine in children.",
              "Alleles": "*15:02",
              "Specialty Population": "Pediatric",
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Disease:Maculopapular Exanthema",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in children",
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "23588310",
              "Variant Annotation ID_norm": "994531642"
            },
            {
              "Variant Annotation ID": 993813998,
              "Variant/Haplotypes": "HLA-A*31:01",
              "Gene": "HLA-A",
              "Drug(s)": "carbamazepine",
              "PMID": 23588310,
              "Phenotype Category": "Toxicity",
              "Significance": "yes",
              "Notes": null,
              "Sentence": "HLA-A *31:01 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine in children.",
              "Alleles": "*31:01",
              "Specialty Population": "Pediatric",
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Disease:Maculopapular Exanthema",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in children",
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "23588310",
              "Variant Annotation ID_norm": "993813998"
            },
            {
              "Variant Annotation ID": 992282434,
              "Variant/Haplotypes": "HLA-A*31:01",
              "Gene": "HLA-A",
              "Drug(s)": "carbamazepine",
              "PMID": 23588310,
              "Phenotype Category": "Toxicity",
              "Significance": "yes",
              "Notes": null,
              "Sentence": "HLA-A *31:01 is associated with increased risk of Carbamazepine-induced hypersensitivity syndrome when treated with carbamazepine in children.",
              "Alleles": "*31:01",
              "Specialty Population": "Pediatric",
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Carbamazepine-induced hypersensitivity syndrome",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in children",
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "23588310",
              "Variant Annotation ID_norm": "992282434"
            },
            {
              "Variant Annotation ID": 994398056,
              "Variant/Haplotypes": "HLA-B*15:02",
              "Gene": "HLA-B",
              "Drug(s)": "carbamazepine",
              "PMID": 23588310,
              "Phenotype Category": "Toxicity",
              "Significance": "no",
              "Notes": null,
              "Sentence": "HLA-B *15:02 is not associated with increased risk of Carbamazepine-induced hypersensitivity syndrome (HSS) when treated with carbamazepine in children.",
              "Alleles": "*15:02",
              "Specialty Population": "Pediatric",
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Carbamazepine-induced hypersensitivity syndrome (HSS)",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in children",
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "23588310",
              "Variant Annotation ID_norm": "994398056"
            }
          ],
          "unmatched_predictions": []
        },
        "functional_analysis": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "status": "missing_var_fa_ann"
        },
        "study_parameters": {
          "total_samples": 6,
          "field_scores": {
            "Study Type": {
              "mean_score": 0.8333333333333334,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0
              ]
            },
            "Study Cases": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Study Controls": {
              "mean_score": 0.8333333333333334,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0
              ]
            },
            "Characteristics": {
              "mean_score": 0.9033698240915934,
              "scores": [
                0.9173091053962708,
                0.9117952585220337,
                0.9119175672531128,
                0.9092235565185547,
                0.8552606701850891,
                0.9147127866744995
              ]
            },
            "Characteristics Type": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Frequency In Cases": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Allele Of Frequency In Cases": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Frequency In Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Allele Of Frequency In Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "P Value": {
              "mean_score": 0.6666666666666666,
              "scores": [
                1.0,
                0.5,
                1.0,
                0.5,
                0.5,
                0.5
              ]
            },
            "Ratio Stat Type": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Ratio Stat": {
              "mean_score": 0.4666666666666666,
              "scores": [
                1.0,
                0.8,
                1.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Confidence Interval Start": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Confidence Interval Stop": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Biogeographical Groups": {
              "mean_score": 0.8333333333333334,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0
              ]
            }
          },
          "overall_score": 0.724669099383884,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 1.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.9173091053962708,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 1.0,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 0.0,
                "Confidence Interval Stop": 0.0,
                "Biogeographical Groups": 1.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 993728141,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 992282434,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "case/control",
                  "prediction": "case/control"
                },
                "Study Cases": {
                  "ground_truth": 42.0,
                  "prediction": 42
                },
                "Study Controls": {
                  "ground_truth": 91.0,
                  "prediction": 91
                },
                "Characteristics": {
                  "ground_truth": "pediatric patients from North America with a diverse ethnic background, 42 children with CBZ hypersensitivity and 91 CBZ-tolerant children from across Canada.",
                  "prediction": "Children with carbamazepine hypersensitivity reactions"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.0025",
                  "prediction": "= 0.0025"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": 26.4,
                  "prediction": 26.4
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": 2.53
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": 307.89
                },
                "Biogeographical Groups": {
                  "ground_truth": "Multiple groups",
                  "prediction": "Multiple Groups"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 1.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.9117952585220337,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.5,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 0.8,
                "Confidence Interval Start": 0.0,
                "Confidence Interval Stop": 0.0,
                "Biogeographical Groups": 1.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 993818102,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 993813998,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "case/control",
                  "prediction": "case/control"
                },
                "Study Cases": {
                  "ground_truth": 42.0,
                  "prediction": 42
                },
                "Study Controls": {
                  "ground_truth": 91.0,
                  "prediction": 91
                },
                "Characteristics": {
                  "ground_truth": "pediatric patients from North America with a diverse ethnic background, 42 children with CBZ hypersensitivity and 91 CBZ-tolerant children from across Canada.",
                  "prediction": "All CBZ cases"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.0037",
                  "prediction": "= 2.6x10^\u22124"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": 8.6,
                  "prediction": 8.14
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": 2.25
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": 37.34
                },
                "Biogeographical Groups": {
                  "ground_truth": "Multiple groups",
                  "prediction": "Multiple Groups"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 2,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 1.0,
                "Study Cases": 0.0,
                "Study Controls": 1.0,
                "Characteristics": 0.9119175672531128,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 1.0,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 0.0,
                "Confidence Interval Stop": 0.0,
                "Biogeographical Groups": 1.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 994166721,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 994166507,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "case/control",
                  "prediction": "case/control"
                },
                "Study Cases": {
                  "ground_truth": 42.0,
                  "prediction": 9
                },
                "Study Controls": {
                  "ground_truth": 91.0,
                  "prediction": 91
                },
                "Characteristics": {
                  "ground_truth": "pediatric patients from North America with a diverse ethnic background, 42 children with CBZ hypersensitivity and 91 CBZ-tolerant children from across Canada.",
                  "prediction": "Children with CBZ-SJS/TEN"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.002",
                  "prediction": "= 0.002"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": 38.6,
                  "prediction": 38.6
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": 2.68
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": 2239.5
                },
                "Biogeographical Groups": {
                  "ground_truth": "Multiple groups",
                  "prediction": "Multiple Groups"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 3,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 1.0,
                "Study Cases": 0.0,
                "Study Controls": 1.0,
                "Characteristics": 0.9092235565185547,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.5,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 0.0,
                "Confidence Interval Start": 0.0,
                "Confidence Interval Stop": 0.0,
                "Biogeographical Groups": 1.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 994531644,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 994531642,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "case/control",
                  "prediction": "case/control"
                },
                "Study Cases": {
                  "ground_truth": 42.0,
                  "prediction": 32
                },
                "Study Controls": {
                  "ground_truth": 91.0,
                  "prediction": 91
                },
                "Characteristics": {
                  "ground_truth": "pediatric patients from North America with a diverse ethnic background, 42 children with CBZ hypersensitivity and 91 CBZ-tolerant children from across Canada.",
                  "prediction": "Children with hypersensitivity reactions"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 1.0",
                  "prediction": "= 2.6x10^\u22124"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": 1.09,
                  "prediction": 11.2
                },
                "Confidence Interval Start": {
                  "ground_truth": 0.04,
                  "prediction": 2.53
                },
                "Confidence Interval Stop": {
                  "ground_truth": 27.5,
                  "prediction": 69.27
                },
                "Biogeographical Groups": {
                  "ground_truth": "Multiple groups",
                  "prediction": "Multiple Groups"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 4,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 1.0,
                "Study Cases": 0.0,
                "Study Controls": 1.0,
                "Characteristics": 0.8552606701850891,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.5,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 0.0,
                "Confidence Interval Start": 0.0,
                "Confidence Interval Stop": 0.0,
                "Biogeographical Groups": 1.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 993944507,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 993944301,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "case/control",
                  "prediction": "case/control"
                },
                "Study Cases": {
                  "ground_truth": 42.0,
                  "prediction": 26
                },
                "Study Controls": {
                  "ground_truth": 91.0,
                  "prediction": 91
                },
                "Characteristics": {
                  "ground_truth": "pediatric patients from North America with a diverse ethnic background, 42 children with CBZ hypersensitivity and 91 CBZ-tolerant children from across Canada.",
                  "prediction": "Children with maculopapular exanthems"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 1.0",
                  "prediction": "= 0.0037"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": 1.33,
                  "prediction": 8.6
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": 1.67
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": 57.5
                },
                "Biogeographical Groups": {
                  "ground_truth": "Multiple groups",
                  "prediction": "Multiple Groups"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 5,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 0.0,
                "Study Controls": 0.0,
                "Characteristics": 0.9147127866744995,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.5,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 0.0,
                "Confidence Interval Start": 0.0,
                "Confidence Interval Stop": 0.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 994398281,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 994398056,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "case/control",
                  "prediction": "cohort"
                },
                "Study Cases": {
                  "ground_truth": 42.0,
                  "prediction": 20
                },
                "Study Controls": {
                  "ground_truth": 91.0,
                  "prediction": 65
                },
                "Characteristics": {
                  "ground_truth": "pediatric patients from North America with a diverse ethnic background, 42 children with CBZ hypersensitivity and 91 CBZ-tolerant children from across Canada.",
                  "prediction": "European CBZ cases"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 1.0",
                  "prediction": "= 0.025"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": 4.44,
                  "prediction": 7.62
                },
                "Confidence Interval Start": {
                  "ground_truth": 0.16,
                  "prediction": 0.99
                },
                "Confidence Interval Stop": {
                  "ground_truth": 120.0,
                  "prediction": 91.4
                },
                "Biogeographical Groups": {
                  "ground_truth": "Multiple groups",
                  "prediction": "European"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            }
          ],
          "aligned_variants": [
            "case/control:pediatric patients f",
            "case/control:pediatric patients f",
            "case/control:pediatric patients f",
            "case/control:pediatric patients f",
            "case/control:pediatric patients f",
            "case/control:pediatric patients f"
          ],
          "unmatched_ground_truth": [],
          "unmatched_predictions": []
        }
      },
      "overall_score": 0.2396858867075708,
      "num_benchmarks": 4
    },
    {
      "pmid": "15024131",
      "pmcid": "PMC384715",
      "title": "Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant",
      "benchmarks": {
        "drug_annotations": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Variant/Haplotypes": "HLA-B*5701",
              "Gene": "HLA-B",
              "Drug(s)": "abacavir",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "HLA-B*5701 was present in 94.4% of hypersensitive cases compared with 1.7% of controls (odds ratio, 960; P < 0.00001).",
              "Sentence": "HLA-B*5701 is associated with increased risk of abacavir hypersensitivity in people with HIV.",
              "Alleles": "HLA-B*5701, Hsp70-Hom M493T",
              "Metabolizer types": "",
              "Comparison Allele(s) or Genotype(s": "",
              "Comparison Metabolizer types": "",
              "Specialty Population": "",
              "Population types": "in people with HIV",
              "Population Phenotypes or diseases": "Disease:Abacavir Hypersensitivity",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "response to",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "HLA-B*5701 was present in 94.4% of hypersensitive cases compared with 1.7% of controls (odds ratio, 960; P < 0.00001).",
                "A haplotypic nonsynonymous polymorphism of Hsp70-Hom (HspA1L, resulting from the substitution of residue M493T in the peptide-binding subunit) was found in combination with HLA-B*5701 in 94.4% of hypersensitive cases and 0.4% of controls (odds ratio, 3,893; P < 0.00001).",
                "These data indicate that the concurrence of HLA-B*5701 and Hsp70-Hom M493T alleles is necessary for the development of abacavir hypersensitivity, which is likely to be mediated by an HLA-B*5701-restricted immune response to abacavir."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "Hsp70-Hom",
              "Gene": "HLA-B",
              "Drug(s)": "abacavir",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "HLA-B*5701 was present in 94.4% of hypersensitive cases compared with 1.7% of controls (odds ratio, 960; P < 0.00001).",
              "Sentence": "HLA-B*5701 is associated with increased risk of abacavir hypersensitivity in people with HIV.",
              "Alleles": "HLA-B*5701, Hsp70-Hom M493T",
              "Metabolizer types": "",
              "Comparison Allele(s) or Genotype(s": "",
              "Comparison Metabolizer types": "",
              "Specialty Population": "",
              "Population types": "in people with HIV",
              "Population Phenotypes or diseases": "Disease:Abacavir Hypersensitivity",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "response to",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "HLA-B*5701 was present in 94.4% of hypersensitive cases compared with 1.7% of controls (odds ratio, 960; P < 0.00001).",
                "A haplotypic nonsynonymous polymorphism of Hsp70-Hom (HspA1L, resulting from the substitution of residue M493T in the peptide-binding subunit) was found in combination with HLA-B*5701 in 94.4% of hypersensitive cases and 0.4% of controls (odds ratio, 3,893; P < 0.00001).",
                "These data indicate that the concurrence of HLA-B*5701 and Hsp70-Hom M493T alleles is necessary for the development of abacavir hypersensitivity, which is likely to be mediated by an HLA-B*5701-restricted immune response to abacavir."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "M493T",
              "Gene": "HLA-B",
              "Drug(s)": "abacavir",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "HLA-B*5701 was present in 94.4% of hypersensitive cases compared with 1.7% of controls (odds ratio, 960; P < 0.00001).",
              "Sentence": "HLA-B*5701 is associated with increased risk of abacavir hypersensitivity in people with HIV.",
              "Alleles": "HLA-B*5701, Hsp70-Hom M493T",
              "Metabolizer types": "",
              "Comparison Allele(s) or Genotype(s": "",
              "Comparison Metabolizer types": "",
              "Specialty Population": "",
              "Population types": "in people with HIV",
              "Population Phenotypes or diseases": "Disease:Abacavir Hypersensitivity",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "response to",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "HLA-B*5701 was present in 94.4% of hypersensitive cases compared with 1.7% of controls (odds ratio, 960; P < 0.00001).",
                "A haplotypic nonsynonymous polymorphism of Hsp70-Hom (HspA1L, resulting from the substitution of residue M493T in the peptide-binding subunit) was found in combination with HLA-B*5701 in 94.4% of hypersensitive cases and 0.4% of controls (odds ratio, 3,893; P < 0.00001).",
                "These data indicate that the concurrence of HLA-B*5701 and Hsp70-Hom M493T alleles is necessary for the development of abacavir hypersensitivity, which is likely to be mediated by an HLA-B*5701-restricted immune response to abacavir."
              ],
              "_expanded_from_multi_variant": true
            }
          ]
        },
        "phenotype_annotations": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "unmatched_ground_truth": [
            {
              "Variant Annotation ID": 1444876870,
              "Variant/Haplotypes": "HLA-B*57:01",
              "Gene": "HLA-B",
              "Drug(s)": "abacavir",
              "PMID": 15024131,
              "Phenotype Category": "Toxicity",
              "Significance": "yes",
              "Notes": "The HLA-B*57:01 allele was present in 94.4% of cases of definite abacavir hypersensitivity compared with 1.7% of abacavir-tolerant controls. When in combination with the rs2227956 T allele (Hsp70-Hom M493T), the strength of the association increased, with this combination being present in 94.4% of cases of abacavir hypersensitivity, compared with 0.43% of controls.",
              "Sentence": "HLA-B *57:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV Infections.",
              "Alleles": "*57:01",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Drug Hypersensitivity",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "15024131",
              "Variant Annotation ID_norm": "1444876870"
            }
          ],
          "unmatched_predictions": [
            {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "HLA-B*5701",
              "Gene": "HLA-B, HSP70",
              "Drug(s)": "abacavir",
              "PMID": 15024131,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "HLA-B*5701 present in 94.4% of hypersensitive cases; odds ratio 960; significant p < 0.00001.",
              "Sentence": "HLA-B*5701 and Hsp70-Hom M493T are associated with increased risk of abacavir hypersensitivity when treated with abacavir in people of Western Australian descent.",
              "Alleles": "HLA-B*5701, Hsp70-Hom M493T",
              "Specialty Population": "Pediatric",
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "abacavir hypersensitivity",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people of Western Australian descent",
              "Population Phenotypes or diseases": "HIV",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "15024131",
              "Variant Annotation ID_norm": "1",
              "Citations": [
                "HLA-B*5701 was present in 94.4% of hypersensitive cases compared with 1.7% of controls (odds ratio, 960; P < 0.00001).",
                "A haplotypic nonsynonymous polymorphism of Hsp70-Hom (HspA1L, resulting from the substitution of residue M493T in the peptide-binding subunit) was found in combination with HLA-B*5701 in 94.4% of hypersensitive cases and 0.4% of controls (odds ratio, 3,893; P < 0.00001).",
                "These data indicate that the concurrence of HLA-B*5701 and Hsp70-Hom M493T alleles is necessary for the development of abacavir hypersensitivity."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "Hsp70-Hom",
              "Gene": "HLA-B, HSP70",
              "Drug(s)": "abacavir",
              "PMID": 15024131,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "HLA-B*5701 present in 94.4% of hypersensitive cases; odds ratio 960; significant p < 0.00001.",
              "Sentence": "HLA-B*5701 and Hsp70-Hom M493T are associated with increased risk of abacavir hypersensitivity when treated with abacavir in people of Western Australian descent.",
              "Alleles": "HLA-B*5701, Hsp70-Hom M493T",
              "Specialty Population": "Pediatric",
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "abacavir hypersensitivity",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people of Western Australian descent",
              "Population Phenotypes or diseases": "HIV",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "15024131",
              "Variant Annotation ID_norm": "1",
              "Citations": [
                "HLA-B*5701 was present in 94.4% of hypersensitive cases compared with 1.7% of controls (odds ratio, 960; P < 0.00001).",
                "A haplotypic nonsynonymous polymorphism of Hsp70-Hom (HspA1L, resulting from the substitution of residue M493T in the peptide-binding subunit) was found in combination with HLA-B*5701 in 94.4% of hypersensitive cases and 0.4% of controls (odds ratio, 3,893; P < 0.00001).",
                "These data indicate that the concurrence of HLA-B*5701 and Hsp70-Hom M493T alleles is necessary for the development of abacavir hypersensitivity."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "M493T",
              "Gene": "HLA-B, HSP70",
              "Drug(s)": "abacavir",
              "PMID": 15024131,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "HLA-B*5701 present in 94.4% of hypersensitive cases; odds ratio 960; significant p < 0.00001.",
              "Sentence": "HLA-B*5701 and Hsp70-Hom M493T are associated with increased risk of abacavir hypersensitivity when treated with abacavir in people of Western Australian descent.",
              "Alleles": "HLA-B*5701, Hsp70-Hom M493T",
              "Specialty Population": "Pediatric",
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "abacavir hypersensitivity",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people of Western Australian descent",
              "Population Phenotypes or diseases": "HIV",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "15024131",
              "Variant Annotation ID_norm": "1",
              "Citations": [
                "HLA-B*5701 was present in 94.4% of hypersensitive cases compared with 1.7% of controls (odds ratio, 960; P < 0.00001).",
                "A haplotypic nonsynonymous polymorphism of Hsp70-Hom (HspA1L, resulting from the substitution of residue M493T in the peptide-binding subunit) was found in combination with HLA-B*5701 in 94.4% of hypersensitive cases and 0.4% of controls (odds ratio, 3,893; P < 0.00001).",
                "These data indicate that the concurrence of HLA-B*5701 and Hsp70-Hom M493T alleles is necessary for the development of abacavir hypersensitivity."
              ],
              "_expanded_from_multi_variant": true
            }
          ],
          "status": "no_overlap_after_alignment"
        },
        "functional_analysis": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "status": "missing_var_fa_ann"
        },
        "study_parameters": {
          "total_samples": 2,
          "field_scores": {
            "Study Type": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Study Cases": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Study Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Characteristics": {
              "mean_score": 0.8813773691654205,
              "scores": [
                0.851554811000824,
                0.9111999273300171
              ]
            },
            "Characteristics Type": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Frequency In Cases": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Allele Of Frequency In Cases": {
              "mean_score": 0.8706721067428589,
              "scores": [
                0.9137797355651855,
                0.8275644779205322
              ]
            },
            "Frequency In Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Allele Of Frequency In Controls": {
              "mean_score": 0.8706721067428589,
              "scores": [
                0.9137797355651855,
                0.8275644779205322
              ]
            },
            "P Value": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Ratio Stat Type": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Ratio Stat": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Confidence Interval Start": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Confidence Interval Stop": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Biogeographical Groups": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.8415147721767425,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.851554811000824,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 0.9137797355651855,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 0.9137797355651855,
                "P Value": 1.0,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1444877014,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1444876870,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "case/control",
                  "prediction": "retrospective"
                },
                "Study Cases": {
                  "ground_truth": 18.0,
                  "prediction": 18
                },
                "Study Controls": {
                  "ground_truth": 230.0,
                  "prediction": 230
                },
                "Characteristics": {
                  "ground_truth": "Western Australian HIV Cohort Study; HLA-B*57:01 alone.",
                  "prediction": "Definite abacavir hypersensitivity cases"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": 0.944,
                  "prediction": 0.944
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": "*57:01",
                  "prediction": "HLA-B*5701"
                },
                "Frequency In Controls": {
                  "ground_truth": 0.017,
                  "prediction": 0.017
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": "*57:01",
                  "prediction": "HLA-B*5701"
                },
                "P Value": {
                  "ground_truth": "< 0.00001",
                  "prediction": "< 0.00001"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": 960.0,
                  "prediction": 960
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "Multiple groups, European, Asian Indian, African, indigenous Australian, Asian",
                  "prediction": "European"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.9111999273300171,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 0.8275644779205322,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 0.8275644779205322,
                "P Value": 1.0,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1444877110,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1444876870,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "case/control",
                  "prediction": "retrospective"
                },
                "Study Cases": {
                  "ground_truth": 18.0,
                  "prediction": 18
                },
                "Study Controls": {
                  "ground_truth": 230.0,
                  "prediction": 230
                },
                "Characteristics": {
                  "ground_truth": "Western Australian HIV Cohort Study; HLA-B*57:01 in combination with rs2227956.",
                  "prediction": "Haplotype combination of HLA-B*5701 and Hsp70-Hom M493T"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": 0.944,
                  "prediction": 0.944
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": "*57:01",
                  "prediction": "Hsp70-Hom M493T"
                },
                "Frequency In Controls": {
                  "ground_truth": 0.004,
                  "prediction": 0.004
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": "*57:01",
                  "prediction": "Hsp70-Hom M493T"
                },
                "P Value": {
                  "ground_truth": "< 0.00001",
                  "prediction": "< 0.00001"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": 3893.0,
                  "prediction": 3893
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "Multiple groups, European, Asian Indian, African, indigenous Australian, Asian",
                  "prediction": "European"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            }
          ],
          "aligned_variants": [
            "case/control:Western Australian H",
            "case/control:Western Australian H"
          ],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "prospective",
              "Study Cases": 2,
              "Study Controls": 46,
              "Characteristics": "Abacavir hypersensitivity in HLA-B*5701 negative individuals",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": 0.0,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": null,
              "Ratio Stat": null,
              "Confidence Interval Start": 0,
              "Confidence Interval Stop": 0.075,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            },
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "retrospective",
              "Study Cases": 18,
              "Study Controls": 230,
              "Characteristics": "Combined presence of HLA-B*5701 and C4A6",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": 0.778,
              "Allele Of Frequency In Cases": "C4A6",
              "Frequency In Controls": 0.03,
              "Allele Of Frequency In Controls": "C4A6",
              "P Value": "< 0.00001",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 111,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          ]
        }
      },
      "overall_score": 0.1683029544353485,
      "num_benchmarks": 4
    },
    {
      "pmid": "26745506",
      "pmcid": "PMC4706412",
      "title": "A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics",
      "benchmarks": {
        "drug_annotations": {
          "total_samples": 8,
          "field_scores": {
            "Variant/Haplotypes": {
              "mean_score": 0.375,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Gene": {
              "mean_score": 0.375,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "PMID": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Phenotype Category": {
              "mean_score": 0.375,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Significance": {
              "mean_score": 0.375,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Alleles": {
              "mean_score": 0.35985463857650757,
              "scores": [
                1.0,
                0.9458000063896179,
                0.9330371022224426,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Specialty Population": {
              "mean_score": 0.375,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Metabolizer types": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "isPlural": {
              "mean_score": 0.125,
              "scores": [
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Is/Is Not associated": {
              "mean_score": 0.375,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Direction of effect": {
              "mean_score": 0.375,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "PD/PK terms": {
              "mean_score": 0.375,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Multiple drugs And/or": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Population types": {
              "mean_score": 0.375,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Population Phenotypes or diseases": {
              "mean_score": 0.375,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Multiple phenotypes or diseases And/or": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Comparison Allele(s) or Genotype(s)": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Comparison Metabolizer types": {
              "mean_score": 0.375,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Drug(s)": {
              "mean_score": 0.375,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.2623607704513951,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "PMID": 0.0,
                "Phenotype Category": 1.0,
                "Significance": 1.0,
                "Alleles": 1.0,
                "Specialty Population": 1.0,
                "Metabolizer types": 0.0,
                "isPlural": 1.0,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "PD/PK terms": 1.0,
                "Multiple drugs And/or": 0.0,
                "Population types": 1.0,
                "Population Phenotypes or diseases": 1.0,
                "Multiple phenotypes or diseases And/or": 0.0,
                "Comparison Allele(s) or Genotype(s)": 0.0,
                "Comparison Metabolizer types": 1.0,
                "Drug(s)": 1.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "CYP4F2*3",
                  "prediction": "CYP4F2*3"
                },
                "Gene": {
                  "ground_truth": "CYP4F2",
                  "prediction": "CYP4F2"
                },
                "PMID": {
                  "ground_truth": 26745506,
                  "prediction": null
                },
                "Phenotype Category": {
                  "ground_truth": "Dosage",
                  "prediction": "dosage"
                },
                "Significance": {
                  "ground_truth": "yes",
                  "prediction": "yes"
                },
                "Alleles": {
                  "ground_truth": "*3",
                  "prediction": "*3"
                },
                "Specialty Population": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Metabolizer types": {
                  "ground_truth": null,
                  "prediction": "normal metabolizer"
                },
                "isPlural": {
                  "ground_truth": "Is",
                  "prediction": "Is"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "PD/PK terms": {
                  "ground_truth": "dose of",
                  "prediction": "dose of"
                },
                "Multiple drugs And/or": {
                  "ground_truth": null,
                  "prediction": ""
                },
                "Population types": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Population Phenotypes or diseases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Multiple phenotypes or diseases And/or": {
                  "ground_truth": null,
                  "prediction": ""
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "*1",
                  "prediction": null
                },
                "Comparison Metabolizer types": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Drug(s)": {
                  "ground_truth": "warfarin",
                  "prediction": "warfarin"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "PMID": 0.0,
                "Phenotype Category": 1.0,
                "Significance": 1.0,
                "Alleles": 0.9458000063896179,
                "Specialty Population": 1.0,
                "Metabolizer types": 0.0,
                "isPlural": 0.0,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "PD/PK terms": 1.0,
                "Multiple drugs And/or": 0.0,
                "Population types": 1.0,
                "Population Phenotypes or diseases": 1.0,
                "Multiple phenotypes or diseases And/or": 0.0,
                "Comparison Allele(s) or Genotype(s)": 0.0,
                "Comparison Metabolizer types": 1.0,
                "Drug(s)": 1.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "CYP2C9*2",
                  "prediction": "CYP2C9*2"
                },
                "Gene": {
                  "ground_truth": "CYP2C9",
                  "prediction": "CYP2C9"
                },
                "PMID": {
                  "ground_truth": 26745506,
                  "prediction": null
                },
                "Phenotype Category": {
                  "ground_truth": "Dosage",
                  "prediction": "dosage"
                },
                "Significance": {
                  "ground_truth": "yes",
                  "prediction": "yes"
                },
                "Alleles": {
                  "ground_truth": "*2 + *3 + *8",
                  "prediction": "*2"
                },
                "Specialty Population": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Metabolizer types": {
                  "ground_truth": null,
                  "prediction": "poor metabolizer"
                },
                "isPlural": {
                  "ground_truth": "Are",
                  "prediction": "Is"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "decreased",
                  "prediction": "decreased"
                },
                "PD/PK terms": {
                  "ground_truth": "dose of",
                  "prediction": "dose of"
                },
                "Multiple drugs And/or": {
                  "ground_truth": null,
                  "prediction": ""
                },
                "Population types": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Population Phenotypes or diseases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Multiple phenotypes or diseases And/or": {
                  "ground_truth": null,
                  "prediction": ""
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "*1",
                  "prediction": null
                },
                "Comparison Metabolizer types": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Drug(s)": {
                  "ground_truth": "warfarin",
                  "prediction": "warfarin"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 2,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "PMID": 0.0,
                "Phenotype Category": 1.0,
                "Significance": 1.0,
                "Alleles": 0.9330371022224426,
                "Specialty Population": 1.0,
                "Metabolizer types": 0.0,
                "isPlural": 0.0,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "PD/PK terms": 1.0,
                "Multiple drugs And/or": 0.0,
                "Population types": 1.0,
                "Population Phenotypes or diseases": 1.0,
                "Multiple phenotypes or diseases And/or": 0.0,
                "Comparison Allele(s) or Genotype(s)": 0.0,
                "Comparison Metabolizer types": 1.0,
                "Drug(s)": 1.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "CYP2C9*3",
                  "prediction": "CYP2C9*3"
                },
                "Gene": {
                  "ground_truth": "CYP2C9",
                  "prediction": "CYP2C9"
                },
                "PMID": {
                  "ground_truth": 26745506,
                  "prediction": null
                },
                "Phenotype Category": {
                  "ground_truth": "Dosage",
                  "prediction": "dosage"
                },
                "Significance": {
                  "ground_truth": "yes",
                  "prediction": "yes"
                },
                "Alleles": {
                  "ground_truth": "*2 + *3 + *8",
                  "prediction": "*3"
                },
                "Specialty Population": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Metabolizer types": {
                  "ground_truth": null,
                  "prediction": "poor metabolizer"
                },
                "isPlural": {
                  "ground_truth": "Are",
                  "prediction": "Is"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "decreased",
                  "prediction": "decreased"
                },
                "PD/PK terms": {
                  "ground_truth": "dose of",
                  "prediction": "dose of"
                },
                "Multiple drugs And/or": {
                  "ground_truth": null,
                  "prediction": ""
                },
                "Population types": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Population Phenotypes or diseases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Multiple phenotypes or diseases And/or": {
                  "ground_truth": null,
                  "prediction": ""
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "*1",
                  "prediction": null
                },
                "Comparison Metabolizer types": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Drug(s)": {
                  "ground_truth": "warfarin",
                  "prediction": "warfarin"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            }
          ],
          "aligned_variants": [
            "cyp4f2*3",
            "cyp2c9*2",
            "cyp2c9*3"
          ],
          "unmatched_ground_truth": [
            {
              "Variant Annotation ID": 1447682700,
              "Variant/Haplotypes": "CYP4F2*1",
              "Gene": "CYP4F2",
              "Drug(s)": "warfarin",
              "PMID": 26745506,
              "Phenotype Category": "Dosage",
              "Significance": "yes",
              "Notes": "The authors aimed to develop an admixture-adjusted (genetic ancestry) PGx dosing algorithm for warfarin in Caribbean Hispanics from Puerto Rico. [Algorithm R sq.=0.70, MAE = 0.72 mg/day]. When externally validated with 55 individuals from an independent cohort the novel algorithm predicted 58% of the warfarin dose variance [MAE = 0.89 mg/day, 24% mean bias]. Please note: the derivation cohort was 99% male.",
              "Sentence": "CYP4F2 *3 is associated with increased dose of warfarin as compared to CYP4F2 *1.",
              "Alleles": "*3",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "dose of",
              "Multiple drugs And/or": null,
              "Population types": null,
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "26745506",
              "Variant Annotation ID_norm": "1447682700",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1447682605,
              "Variant/Haplotypes": "CYP2C9*1",
              "Gene": "CYP2C9",
              "Drug(s)": "warfarin",
              "PMID": 26745506,
              "Phenotype Category": "Dosage",
              "Significance": "yes",
              "Notes": "The authors aimed to develop an admixture-adjusted (genetic ancestry) PGx dosing algorithm for warfarin in Caribbean Hispanics from Puerto Rico. [Algorithm R sq.=0.70, MAE = 0.72 mg/day]. When externally validated with 55 individuals from an independent cohort the novel algorithm predicted 58% of the warfarin dose variance [MAE = 0.89 mg/day, 24% mean bias]. Please note: the derivation cohort was 99% male and  \"variables were included in final lin. reg model if p<0.05 or if association with daily warfarin dose was marginally significant 0.05 = p = 0.20 with strong biological plausibility\".",
              "Sentence": "CYP2C9 *2 + *3 + *8 are associated with decreased dose of warfarin as compared to CYP2C9 *1.",
              "Alleles": "*2 + *3 + *8",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "dose of",
              "Multiple drugs And/or": null,
              "Population types": null,
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "26745506",
              "Variant Annotation ID_norm": "1447682605",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1447682605,
              "Variant/Haplotypes": "CYP2C9*8",
              "Gene": "CYP2C9",
              "Drug(s)": "warfarin",
              "PMID": 26745506,
              "Phenotype Category": "Dosage",
              "Significance": "yes",
              "Notes": "The authors aimed to develop an admixture-adjusted (genetic ancestry) PGx dosing algorithm for warfarin in Caribbean Hispanics from Puerto Rico. [Algorithm R sq.=0.70, MAE = 0.72 mg/day]. When externally validated with 55 individuals from an independent cohort the novel algorithm predicted 58% of the warfarin dose variance [MAE = 0.89 mg/day, 24% mean bias]. Please note: the derivation cohort was 99% male and  \"variables were included in final lin. reg model if p<0.05 or if association with daily warfarin dose was marginally significant 0.05 = p = 0.20 with strong biological plausibility\".",
              "Sentence": "CYP2C9 *2 + *3 + *8 are associated with decreased dose of warfarin as compared to CYP2C9 *1.",
              "Alleles": "*2 + *3 + *8",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "dose of",
              "Multiple drugs And/or": null,
              "Population types": null,
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "26745506",
              "Variant Annotation ID_norm": "1447682605",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1447682688,
              "Variant/Haplotypes": "rs9923231",
              "Gene": "VKORC1",
              "Drug(s)": "warfarin",
              "PMID": 26745506,
              "Phenotype Category": "Dosage",
              "Significance": "yes",
              "Notes": "The authors aimed to develop an admixture-adjusted (genetic ancestry) PGx dosing algorithm for warfarin in Caribbean Hispanics from Puerto Rico. [Algorithm R sq.=0.70, MAE = 0.72 mg/day]. When externally validated with 55 individuals from an independent cohort the novel algorithm predicted 58% of the warfarin dose variance [MAE = 0.89 mg/day, 24% mean bias]. Please note: the derivation cohort was 99% male.",
              "Sentence": "Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.",
              "Alleles": "CT + TT",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "dose of",
              "Multiple drugs And/or": null,
              "Population types": null,
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "CC",
              "Comparison Metabolizer types": null,
              "PMID_norm": "26745506",
              "Variant Annotation ID_norm": "1447682688"
            },
            {
              "Variant Annotation ID": 1447682722,
              "Variant/Haplotypes": "rs1800566",
              "Gene": "NQO1",
              "Drug(s)": "warfarin",
              "PMID": 26745506,
              "Phenotype Category": "Dosage",
              "Significance": "yes",
              "Notes": "The authors aimed to develop an admixture-adjusted (genetic ancestry) PGx dosing algorithm for warfarin in Caribbean Hispanics from Puerto Rico. [Algorithm R sq.=0.70, MAE = 0.72 mg/day]. When externally validated with 55 individuals from an independent cohort the novel algorithm predicted 58% of the warfarin dose variance [MAE = 0.89 mg/day, 24% mean bias]. Please note: 1) the derivation cohort was 99% male 2) alleles have been complemented to the + chromosomal strand and 3) \"variables were included in final lin. reg model if p<0.05 or if association with daily warfarin dose was marginally significant 0.05 = p = 0.20 with strong biological plausability\".",
              "Sentence": "Genotypes AA + AG are associated with increased dose of warfarin as compared to genotype GG.",
              "Alleles": "AA + AG",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "dose of",
              "Multiple drugs And/or": null,
              "Population types": null,
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "GG",
              "Comparison Metabolizer types": null,
              "PMID_norm": "26745506",
              "Variant Annotation ID_norm": "1447682722"
            }
          ],
          "unmatched_predictions": [
            {
              "Variant/Haplotypes": "VKORC1-1639A",
              "Gene": "VKORC1",
              "Drug(s)": "warfarin",
              "Phenotype Category": "dosage",
              "Significance": "yes",
              "Notes": "Carriers of the VKORC1-1639AA genotype had reduced warfarin dose requirements.",
              "Sentence": "VKORC1-1639A is associated with decreased warfarin dose in Caribbean Hispanics.",
              "Alleles": "A",
              "Metabolizer types": "normal metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "dose of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Combined VKORC1-1639AA and GA genotypes explained approximately 2.1% of the dose variability in this population. Moreover, this covariate was associated with a 13% reduction in the therapeutic warfarin dose per number of A alleles.",
                "The mean absolute error (MAE, mg/day, defined as the mean of the absolute values for the difference between the predicted and actual doses) was used to evaluate the model's predictive accuracy. We selected the final model as the one that had the lowest predictive MAE.",
                "For patients at the highest risk who required either \u22643mg (~19.2% of the study cohorts) or \u22657 mg/day of warfarin per day (~11% of the study cohorts), 54.5% of the dose predictions using our developed model resulted within 20% of the actual dose ('ideal dose') as compared with only 29% when using the clinical non-genetic algorithm (p<0.001)."
              ]
            },
            {
              "Variant/Haplotypes": "NQO1*2",
              "Gene": "NQO1",
              "Drug(s)": "warfarin",
              "Phenotype Category": "dosage",
              "Significance": "yes",
              "Notes": "Presence of NQO1*2 variant has an effect on warfarin metabolism, requiring dosage adjustment.",
              "Sentence": "NQO1*2 is associated with increased warfarin dose in Caribbean Hispanics.",
              "Alleles": "*2",
              "Metabolizer types": "normal metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "dose of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "NQO1*2 variant has an effect on warfarin metabolism, requiring dosage adjustment.",
                "The CYP4F2*3 and NQO1*2 variants were independently associated with a 17% and 10% increase of the dose per variant allele, respectively; whereas, the admixed status of the admixture index decreases the dose by 7%.",
                "Combined VKORC1-1639AA and GA genotypes explained approximately 2.1% of the dose variability in this population."
              ]
            }
          ]
        },
        "phenotype_annotations": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": []
        },
        "functional_analysis": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "status": "missing_var_fa_ann"
        },
        "study_parameters": {
          "total_samples": 7,
          "field_scores": {
            "Study Type": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Study Cases": {
              "mean_score": 0.5714285714285714,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Study Controls": {
              "mean_score": 0.42857142857142855,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Characteristics": {
              "mean_score": 0.4811199648039682,
              "scores": [
                0.8469297885894775,
                0.8017519116401672,
                0.8670436143875122,
                0.8521144390106201,
                0.0,
                0.0,
                0.0
              ]
            },
            "Characteristics Type": {
              "mean_score": 0.5714285714285714,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Frequency In Cases": {
              "mean_score": 0.2857142857142857,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Allele Of Frequency In Cases": {
              "mean_score": 0.2857142857142857,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Frequency In Controls": {
              "mean_score": 0.2857142857142857,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Allele Of Frequency In Controls": {
              "mean_score": 0.2857142857142857,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "P Value": {
              "mean_score": 0.07142857142857142,
              "scores": [
                0.5,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Ratio Stat Type": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Ratio Stat": {
              "mean_score": 0.5714285714285714,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Confidence Interval Start": {
              "mean_score": 0.5714285714285714,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Confidence Interval Stop": {
              "mean_score": 0.5714285714285714,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Biogeographical Groups": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.3320746643202645,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.8469297885894775,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.5,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1447682693,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1447682688,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "cohort, retrospective",
                  "prediction": null
                },
                "Study Cases": {
                  "ground_truth": 255.0,
                  "prediction": 255
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "NCT01318057; VKORC1 rs9923231 AA partial reg. coeff. -0.896 (SE 0.2169), adj R sq .0.641",
                  "prediction": "Patients at highest risk of adverse events"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "< 0.0001",
                  "prediction": "< 0.001"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "Unknown"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "Latino",
                  "prediction": "Multiple Groups"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.8017519116401672,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.0,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1447682695,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1447682688,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "cohort, retrospective",
                  "prediction": "retrospective"
                },
                "Study Cases": {
                  "ground_truth": 255.0,
                  "prediction": 255
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "NCT01318057; VKORC1 rs9923231 AG partial reg. coeff. -0.379 (SE 0.1391), adj R sq .0.659",
                  "prediction": "Caribbean Hispanic patients"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.007",
                  "prediction": "< 0.001"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "HR"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "Unknown",
                  "prediction": "Multiple Groups"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 2,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.8670436143875122,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 0.0,
                "Allele Of Frequency In Cases": 0.0,
                "Frequency In Controls": 0.0,
                "Allele Of Frequency In Controls": 0.0,
                "P Value": 0.0,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1447682724,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1447682722,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "cohort, retrospective",
                  "prediction": "retrospective"
                },
                "Study Cases": {
                  "ground_truth": 255.0,
                  "prediction": 255
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "NCT01318057; NQO1 rs1800566 A allele partial reg. coeff. 0.346 (SE 0.2246), adj R sq .0.689",
                  "prediction": "Admixture-driven pharmacogenetic model used"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": 0.098,
                  "prediction": 0.58
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": "A",
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": 0.902,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": "G",
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.125",
                  "prediction": null
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "Unknown"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "Latino",
                  "prediction": "Multiple Groups"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 3,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 1.0,
                "Study Controls": 0.0,
                "Characteristics": 0.8521144390106201,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 0.0,
                "Allele Of Frequency In Cases": 0.0,
                "Frequency In Controls": 0.0,
                "Allele Of Frequency In Controls": 0.0,
                "P Value": 0.0,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1447682664,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1447682605,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "cohort, retrospective",
                  "prediction": "retrospective"
                },
                "Study Cases": {
                  "ground_truth": 255.0,
                  "prediction": 255
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": 55
                },
                "Characteristics": {
                  "ground_truth": "Study Cohort: NCT01318057; CYP2C9 *3 partial reg. coeff. -0.544 (SE 0.2224), adj R sq 0.625",
                  "prediction": "External validation cohort from Hartford Hospital"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": 0.05,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": "*3",
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": 0.83,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": "*1",
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.015",
                  "prediction": "< 0.001"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "Unknown"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "Latino",
                  "prediction": "Multiple Groups"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            }
          ],
          "aligned_variants": [
            "cohort, retrospective:NCT01318057; VKORC1 ",
            "cohort, retrospective:NCT01318057; VKORC1 ",
            "cohort, retrospective:NCT01318057; NQO1 rs",
            "cohort, retrospective:Study Cohort: NCT013"
          ],
          "unmatched_ground_truth": [
            {
              "Study Parameters ID": 1447682702,
              "Variant Annotation ID": 1447682700,
              "Study Type": "cohort, retrospective",
              "Study Cases": 255.0,
              "Study Controls": null,
              "Characteristics": "NCT01318057; CYP4F3 *3 partial reg. coeff. 0.560 (SE 0.2274), adj R sq0.0.673",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": 0.115,
              "Allele Of Frequency In Cases": "*3",
              "Frequency In Controls": 0.885,
              "Allele Of Frequency In Controls": "*1",
              "P Value": "= 0.014",
              "Ratio Stat Type": "OR",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Latino",
              "Variant Annotation ID_norm": "1447682700"
            },
            {
              "Study Parameters ID": 1447682655,
              "Variant Annotation ID": 1447682605,
              "Study Type": "cohort, retrospective",
              "Study Cases": 255.0,
              "Study Controls": null,
              "Characteristics": "NCT01318057; CYP2C9 *2 partial reg. coeff. -0.245 (SE 0.1654), adj R sq0.613",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": 0.09,
              "Allele Of Frequency In Cases": "*2",
              "Frequency In Controls": 0.83,
              "Allele Of Frequency In Controls": "*1",
              "P Value": "= 0.014",
              "Ratio Stat Type": "OR",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Latino",
              "Variant Annotation ID_norm": "1447682605"
            },
            {
              "Study Parameters ID": 1447682687,
              "Variant Annotation ID": 1447682605,
              "Study Type": "cohort, retrospective",
              "Study Cases": 255.0,
              "Study Controls": null,
              "Characteristics": "NCT01318057; CYP2C9 *8 partial reg. coeff. -1.00 (SE 0.6014), adj R sq 0.638",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": 0.006,
              "Allele Of Frequency In Cases": "*8",
              "Frequency In Controls": 0.83,
              "Allele Of Frequency In Controls": "*1",
              "P Value": "= 0.098",
              "Ratio Stat Type": "OR",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Latino",
              "Variant Annotation ID_norm": "1447682605"
            }
          ],
          "unmatched_predictions": []
        }
      },
      "overall_score": 0.14512316399947145,
      "num_benchmarks": 4
    },
    {
      "pmid": "26715213",
      "pmcid": "PMC4916189",
      "title": "Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Nai\u0308ve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study",
      "benchmarks": {
        "drug_annotations": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Variant/Haplotypes": "CYP2B6",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Lower risk of CNS-related adverse events was associated with CYP2B6 983TC/CC (OR 0.35, 95 % CI 0.15-0.81, p = 0.015).",
              "Sentence": "CYP2B6 983TC/CC is associated with decreased CNS-related adverse events efavirenz treated individuals.",
              "Alleles": "TC/CC",
              "Metabolizer types": "intermediate metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "CNS-related adverse events",
              "Multiple drugs And/or": "",
              "Population types": "",
              "Population Phenotypes or diseases": "",
              "Comparison Allele(s) or Genotype(s)": "CYP2B6 983TT",
              "Comparison Metabolizer types": "",
              "Specialty Population": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Lower risk of CNS-related adverse events was associated with CYP2B6 983TC/CC (OR 0.35, 95 % CI 0.15-0.81, p = 0.015) and higher risk was associated with CYP2B6 15582CT/TT and ABCB1 3435TT (OR 1.46, 95 % CI 1.02-2.09, p = 0.040; OR 2.31, 95 % CI 1.33-4.02, p = 0.003, respectively).",
                "A decreased risk of CNS adverse events (Stocrin\u00ae product information) was associated with CYP2B6 983TC or CC carriers (OR 0.30, 95 % CI 0.12-0.75, p = 0.010) but an increased risk in patients with CYP2B6 15582CT or TT and ABCB1 3435TT carriers was observed (OR 1.59, 95 % CI 1.11-2.27, p = 0.011; and OR 2.14, 95 % CI 1.25-3.67, p = 0.006, respectively)."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "983TC/CC",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Lower risk of CNS-related adverse events was associated with CYP2B6 983TC/CC (OR 0.35, 95 % CI 0.15-0.81, p = 0.015).",
              "Sentence": "CYP2B6 983TC/CC is associated with decreased CNS-related adverse events efavirenz treated individuals.",
              "Alleles": "TC/CC",
              "Metabolizer types": "intermediate metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "CNS-related adverse events",
              "Multiple drugs And/or": "",
              "Population types": "",
              "Population Phenotypes or diseases": "",
              "Comparison Allele(s) or Genotype(s)": "CYP2B6 983TT",
              "Comparison Metabolizer types": "",
              "Specialty Population": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Lower risk of CNS-related adverse events was associated with CYP2B6 983TC/CC (OR 0.35, 95 % CI 0.15-0.81, p = 0.015) and higher risk was associated with CYP2B6 15582CT/TT and ABCB1 3435TT (OR 1.46, 95 % CI 1.02-2.09, p = 0.040; OR 2.31, 95 % CI 1.33-4.02, p = 0.003, respectively).",
                "A decreased risk of CNS adverse events (Stocrin\u00ae product information) was associated with CYP2B6 983TC or CC carriers (OR 0.30, 95 % CI 0.12-0.75, p = 0.010) but an increased risk in patients with CYP2B6 15582CT or TT and ABCB1 3435TT carriers was observed (OR 1.59, 95 % CI 1.11-2.27, p = 0.011; and OR 2.14, 95 % CI 1.25-3.67, p = 0.006, respectively)."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "CYP2B6",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Higher risk of CNS-related adverse events was associated with CYP2B6 15582CT/TT (OR 1.46, 95 % CI 1.02-2.09, p = 0.040).",
              "Sentence": "CYP2B6 15582CT/TT is associated with increased CNS-related adverse events efavirenz treated individuals.",
              "Alleles": "CT/TT",
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "CNS-related adverse events",
              "Multiple drugs And/or": "",
              "Population types": "",
              "Population Phenotypes or diseases": "",
              "Comparison Allele(s) or Genotype(s)": "CYP2B6 15582CC",
              "Comparison Metabolizer types": "",
              "Specialty Population": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "higher risk was associated with CYP2B6 15582CT/TT and ABCB1 3435TT (OR 1.46, 95 % CI 1.02-2.09, p = 0.040; OR 2.31, 95 % CI 1.33-4.02, p = 0.003, respectively)",
                "CNS adverse events were similar between doses (42 % EFV400 vs. 46 % EFV600, p = 0.287)",
                "A higher rate of EFV-related adverse events and discontinuations due to these events for EFV600 were not driven by polymorphisms assessed."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "15582CT/TT",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Higher risk of CNS-related adverse events was associated with CYP2B6 15582CT/TT (OR 1.46, 95 % CI 1.02-2.09, p = 0.040).",
              "Sentence": "CYP2B6 15582CT/TT is associated with increased CNS-related adverse events efavirenz treated individuals.",
              "Alleles": "CT/TT",
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "CNS-related adverse events",
              "Multiple drugs And/or": "",
              "Population types": "",
              "Population Phenotypes or diseases": "",
              "Comparison Allele(s) or Genotype(s)": "CYP2B6 15582CC",
              "Comparison Metabolizer types": "",
              "Specialty Population": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "higher risk was associated with CYP2B6 15582CT/TT and ABCB1 3435TT (OR 1.46, 95 % CI 1.02-2.09, p = 0.040; OR 2.31, 95 % CI 1.33-4.02, p = 0.003, respectively)",
                "CNS adverse events were similar between doses (42 % EFV400 vs. 46 % EFV600, p = 0.287)",
                "A higher rate of EFV-related adverse events and discontinuations due to these events for EFV600 were not driven by polymorphisms assessed."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "ABCB1",
              "Gene": "ABCB1",
              "Drug(s)": "efavirenz",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Higher risk of CNS-related adverse events was associated with ABCB1 3435TT (OR 2.31, 95 % CI 1.33-4.02, p = 0.003).",
              "Sentence": "ABCB1 3435TT is associated with increased CNS-related adverse events efavirenz treated individuals.",
              "Alleles": "TT",
              "Metabolizer types": "",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "CNS-related adverse events",
              "Multiple drugs And/or": "",
              "Population types": "",
              "Population Phenotypes or diseases": "",
              "Comparison Allele(s) or Genotype(s)": "ABCB1 3435CC",
              "Comparison Metabolizer types": "",
              "Specialty Population": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "...higher risk was associated with CYP2B6 15582CT/TT and ABCB1 3435TT (OR 1.46, 95 % CI 1.02-2.09, p = 0.040; OR 2.31, 95 % CI 1.33-4.02, p = 0.003, respectively).",
                "CNS adverse events were similar between doses (42 % EFV400 vs. 46 % EFV600, p = 0.287).",
                "Despite concerns regarding lower plasma concentrations obtained with efavirenz 400 mg (EFV400) compared with 600 mg (EFV600) in ENCORE1, virological efficacy was not compromised..."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "3435TT",
              "Gene": "ABCB1",
              "Drug(s)": "efavirenz",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Higher risk of CNS-related adverse events was associated with ABCB1 3435TT (OR 2.31, 95 % CI 1.33-4.02, p = 0.003).",
              "Sentence": "ABCB1 3435TT is associated with increased CNS-related adverse events efavirenz treated individuals.",
              "Alleles": "TT",
              "Metabolizer types": "",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "CNS-related adverse events",
              "Multiple drugs And/or": "",
              "Population types": "",
              "Population Phenotypes or diseases": "",
              "Comparison Allele(s) or Genotype(s)": "ABCB1 3435CC",
              "Comparison Metabolizer types": "",
              "Specialty Population": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "...higher risk was associated with CYP2B6 15582CT/TT and ABCB1 3435TT (OR 1.46, 95 % CI 1.02-2.09, p = 0.040; OR 2.31, 95 % CI 1.33-4.02, p = 0.003, respectively).",
                "CNS adverse events were similar between doses (42 % EFV400 vs. 46 % EFV600, p = 0.287).",
                "Despite concerns regarding lower plasma concentrations obtained with efavirenz 400 mg (EFV400) compared with 600 mg (EFV600) in ENCORE1, virological efficacy was not compromised..."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "CYP2B6",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz",
              "Phenotype Category": "dosage",
              "Significance": "yes",
              "Notes": "Possession of the CYP2B6 516GT and TT variants and CYP2A6*9B CA/AA carriers was associated with a higher risk of overall EFV discontinuation (80, 166 and 100 %, respectively).",
              "Sentence": "CYP2B6 516GT/TT is associated with increased risk of discontinuation of efavirenz in HIV-infected individuals.",
              "Alleles": "GT/TT",
              "Metabolizer types": "extensive metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "discontinuation",
              "Multiple drugs And/or": "",
              "Population types": "",
              "Population Phenotypes or diseases": "",
              "Comparison Allele(s) or Genotype(s)": "CYP2B6 516GG",
              "Comparison Metabolizer types": "",
              "Specialty Population": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Possession of the CYP2B6 516GT and TT variants and CYP2A6*9B CA/AA carriers was associated with a higher risk of overall EFV discontinuation (80, 166 and 100 %, respectively).",
                "Following adjustment for age, sex and dose, and stratifying by country, CYP2B6 516GT, TT and CYP2A6*9B heterozygote or homozygous variant (CA or AA) patients had an 80, 166 and 100 % increased risk of overall discontinuation, respectively."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "516GT/TT",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz",
              "Phenotype Category": "dosage",
              "Significance": "yes",
              "Notes": "Possession of the CYP2B6 516GT and TT variants and CYP2A6*9B CA/AA carriers was associated with a higher risk of overall EFV discontinuation (80, 166 and 100 %, respectively).",
              "Sentence": "CYP2B6 516GT/TT is associated with increased risk of discontinuation of efavirenz in HIV-infected individuals.",
              "Alleles": "GT/TT",
              "Metabolizer types": "extensive metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "discontinuation",
              "Multiple drugs And/or": "",
              "Population types": "",
              "Population Phenotypes or diseases": "",
              "Comparison Allele(s) or Genotype(s)": "CYP2B6 516GG",
              "Comparison Metabolizer types": "",
              "Specialty Population": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Possession of the CYP2B6 516GT and TT variants and CYP2A6*9B CA/AA carriers was associated with a higher risk of overall EFV discontinuation (80, 166 and 100 %, respectively).",
                "Following adjustment for age, sex and dose, and stratifying by country, CYP2B6 516GT, TT and CYP2A6*9B heterozygote or homozygous variant (CA or AA) patients had an 80, 166 and 100 % increased risk of overall discontinuation, respectively."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "NR1I2",
              "Gene": "NR1I2",
              "Drug(s)": "efavirenz",
              "Phenotype Category": "dosage",
              "Significance": "yes",
              "Notes": "NR1I2 63396TT carriers were at decreased risk of discontinuation by 22 %.",
              "Sentence": "NR1I2 63396TT is associated with decreased risk of discontinuation of efavirenz in HIV-infected individuals.",
              "Alleles": "TT",
              "Metabolizer types": "",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "discontinuation",
              "Multiple drugs And/or": "",
              "Population types": "",
              "Population Phenotypes or diseases": "",
              "Comparison Allele(s) or Genotype(s)": "NR1I2 63396CC",
              "Comparison Metabolizer types": "",
              "Specialty Population": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Posession of the CYP2B6 516GT and TT variants and CYP2A6*9B CA/AA carriers was associated with a higher risk of overall EFV discontinuation (80, 166 and 100 %, respectively), whereas NR1I2 63396TT carriers were at decreased risk (22 %).",
                "Following adjustment for age, sex and dose, and stratifying by country, CYP2B6 516GT, TT and CYP2A6*9B heterozygote or homozygous variant (CA or AA) patients had an 80, 166 and 100 % increased risk of overall discontinuation, respectively, whereas NR1I2 63396TT carriers had a 22 % reduced risk."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "63396TT",
              "Gene": "NR1I2",
              "Drug(s)": "efavirenz",
              "Phenotype Category": "dosage",
              "Significance": "yes",
              "Notes": "NR1I2 63396TT carriers were at decreased risk of discontinuation by 22 %.",
              "Sentence": "NR1I2 63396TT is associated with decreased risk of discontinuation of efavirenz in HIV-infected individuals.",
              "Alleles": "TT",
              "Metabolizer types": "",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "discontinuation",
              "Multiple drugs And/or": "",
              "Population types": "",
              "Population Phenotypes or diseases": "",
              "Comparison Allele(s) or Genotype(s)": "NR1I2 63396CC",
              "Comparison Metabolizer types": "",
              "Specialty Population": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Posession of the CYP2B6 516GT and TT variants and CYP2A6*9B CA/AA carriers was associated with a higher risk of overall EFV discontinuation (80, 166 and 100 %, respectively), whereas NR1I2 63396TT carriers were at decreased risk (22 %).",
                "Following adjustment for age, sex and dose, and stratifying by country, CYP2B6 516GT, TT and CYP2A6*9B heterozygote or homozygous variant (CA or AA) patients had an 80, 166 and 100 % increased risk of overall discontinuation, respectively, whereas NR1I2 63396TT carriers had a 22 % reduced risk."
              ],
              "_expanded_from_multi_variant": true
            }
          ]
        },
        "phenotype_annotations": {
          "total_samples": 8,
          "field_scores": {
            "Variant/Haplotypes": {
              "mean_score": 0.25,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Gene": {
              "mean_score": 0.875,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0
              ]
            },
            "Drug(s)": {
              "mean_score": 0.875,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0
              ]
            },
            "Phenotype Category": {
              "mean_score": 0.5,
              "scores": [
                0.0,
                0.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0
              ]
            },
            "Alleles": {
              "mean_score": 0.7908523082733154,
              "scores": [
                0.8314046263694763,
                0.8348969221115112,
                0.9514200687408447,
                0.9394291639328003,
                0.9394291639328003,
                0.8862298727035522,
                0.9440086483955383,
                0.0
              ]
            },
            "Is/Is Not associated": {
              "mean_score": 0.875,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0
              ]
            },
            "Direction of effect": {
              "mean_score": 0.875,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0
              ]
            },
            "Phenotype": {
              "mean_score": 0.8100174441933632,
              "scores": [
                0.9333196878433228,
                0.865143358707428,
                0.937089204788208,
                0.937089204788208,
                0.937089204788208,
                0.937089204788208,
                0.9333196878433228,
                0.0
              ]
            },
            "When treated with/exposed to/when assayed with": {
              "mean_score": 0.875,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0
              ]
            },
            "Comparison Allele(s) or Genotype(s)": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.7130261125663916,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 0.0,
                "Alleles": 0.8314046263694763,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.9333196878433228,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "CYP2B6*1",
                  "prediction": "CYP2B6"
                },
                "Gene": {
                  "ground_truth": "CYP2B6",
                  "prediction": "CYP2B6"
                },
                "Drug(s)": {
                  "ground_truth": "efavirenz",
                  "prediction": "efavirenz"
                },
                "Phenotype Category": {
                  "ground_truth": "Efficacy",
                  "prediction": "dosage"
                },
                "Alleles": {
                  "ground_truth": "*9",
                  "prediction": "GT/TT"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Efficacy:Discontinuation",
                  "prediction": "overall discontinuation"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "*1/*1",
                  "prediction": null
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 0.0,
                "Alleles": 0.8348969221115112,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.865143358707428,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "CYP2B6*1",
                  "prediction": "CYP2B6"
                },
                "Gene": {
                  "ground_truth": "CYP2B6",
                  "prediction": "CYP2B6"
                },
                "Drug(s)": {
                  "ground_truth": "efavirenz",
                  "prediction": "efavirenz"
                },
                "Phenotype Category": {
                  "ground_truth": "Efficacy",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "*9",
                  "prediction": "CT/TT"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Efficacy:Discontinuation",
                  "prediction": "CNS-related adverse events"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "*1/*1",
                  "prediction": null
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 2,
              "field_scores": {
                "Variant/Haplotypes": 0.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 1.0,
                "Alleles": 0.9514200687408447,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.937089204788208,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "rs4803419",
                  "prediction": "15582CT/TT"
                },
                "Gene": {
                  "ground_truth": "CYP2B6",
                  "prediction": "CYP2B6"
                },
                "Drug(s)": {
                  "ground_truth": "efavirenz",
                  "prediction": "efavirenz"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "CT + TT",
                  "prediction": "CT/TT"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:Central Nervous System Disorder",
                  "prediction": "CNS-related adverse events"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "CC",
                  "prediction": null
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 3,
              "field_scores": {
                "Variant/Haplotypes": 0.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 1.0,
                "Alleles": 0.9394291639328003,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.937089204788208,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "rs28399499",
                  "prediction": "CYP2B6"
                },
                "Gene": {
                  "ground_truth": "CYP2B6",
                  "prediction": "CYP2B6"
                },
                "Drug(s)": {
                  "ground_truth": "efavirenz",
                  "prediction": "efavirenz"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "CC + CT",
                  "prediction": "TC/CC"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "decreased",
                  "prediction": "decreased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:Central Nervous System Disorder",
                  "prediction": "CNS-related adverse events"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "TT",
                  "prediction": null
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 4,
              "field_scores": {
                "Variant/Haplotypes": 0.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 1.0,
                "Alleles": 0.9394291639328003,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.937089204788208,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "rs28399499",
                  "prediction": "983TC/CC"
                },
                "Gene": {
                  "ground_truth": "CYP2B6",
                  "prediction": "CYP2B6"
                },
                "Drug(s)": {
                  "ground_truth": "efavirenz",
                  "prediction": "efavirenz"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "CC + CT",
                  "prediction": "TC/CC"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "decreased",
                  "prediction": "decreased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:Central Nervous System Disorder",
                  "prediction": "CNS-related adverse events"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "TT",
                  "prediction": null
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 5,
              "field_scores": {
                "Variant/Haplotypes": 0.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 1.0,
                "Alleles": 0.8862298727035522,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.937089204788208,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "rs1045642",
                  "prediction": "ABCB1"
                },
                "Gene": {
                  "ground_truth": "ABCB1",
                  "prediction": "ABCB1"
                },
                "Drug(s)": {
                  "ground_truth": "efavirenz",
                  "prediction": "efavirenz"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "AA",
                  "prediction": "TT"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:Central Nervous System Disorder",
                  "prediction": "CNS-related adverse events"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "GG",
                  "prediction": null
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 6,
              "field_scores": {
                "Variant/Haplotypes": 0.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 0.0,
                "Alleles": 0.9440086483955383,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.9333196878433228,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "rs3745274",
                  "prediction": "516GT/TT"
                },
                "Gene": {
                  "ground_truth": "CYP2B6",
                  "prediction": "CYP2B6"
                },
                "Drug(s)": {
                  "ground_truth": "efavirenz",
                  "prediction": "efavirenz"
                },
                "Phenotype Category": {
                  "ground_truth": "Efficacy",
                  "prediction": "dosage"
                },
                "Alleles": {
                  "ground_truth": "GT + TT",
                  "prediction": "GT/TT"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Efficacy:Discontinuation",
                  "prediction": "overall discontinuation"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "GG",
                  "prediction": null
                }
              },
              "dependency_issues": []
            }
          ],
          "aligned_variants": [
            "cyp2b6*1",
            "cyp2b6*9",
            "cyp2b6+efavirenz",
            "cyp2b6+efavirenz",
            "abcb1+efavirenz",
            "cyp2b6+efavirenz",
            "cyp2b6+efavirenz"
          ],
          "unmatched_ground_truth": [
            {
              "Variant Annotation ID": 1448993794,
              "Variant/Haplotypes": "rs2472677",
              "Gene": "NR1I2",
              "Drug(s)": "efavirenz",
              "PMID": 26715213,
              "Phenotype Category": "Efficacy",
              "Significance": "yes",
              "Notes": null,
              "Sentence": "Genotype TT is associated with decreased likelihood of discontinuation when treated with efavirenz in people with HIV Infections as compared to genotypes CC + CT.",
              "Alleles": "TT",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Efficacy:Discontinuation",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "CC + CT",
              "Comparison Metabolizer types": null,
              "PMID_norm": "26715213",
              "Variant Annotation ID_norm": "1448993794"
            }
          ],
          "unmatched_predictions": [
            {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "3435TT",
              "Gene": "ABCB1",
              "Drug(s)": "efavirenz",
              "PMID": 26715213,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Higher risk of CNS-related adverse events found in ABCB1 3435TT carriers.",
              "Sentence": "ABCB1 3435TT is associated with increased risk of CNS-related adverse events when treated with efavirenz in treatment-nai\u0308ve HIV-infected patients.",
              "Alleles": "TT",
              "Specialty Population": null,
              "Metabolizer types": "not stated",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "CNS-related adverse events",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": null,
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": null,
              "Variant Annotation ID_norm": null,
              "Citations": [
                "Lower risk of CNS-related adverse events was associated with CYP2B6 983TC/CC (OR 0.35, 95 % CI 0.15-0.81, p = 0.015) and higher risk was associated with CYP2B6 15582CT/TT and ABCB1 3435TT (OR 1.46, 95 % CI 1.02-2.09, p = 0.040; OR 2.31, 95 % CI 1.33-4.02, p = 0.003, respectively).",
                "Possession of the CYP2B6 516GT and TT variants and CYP2A6*9B CA/AA carriers was associated with a higher risk of overall EFV discontinuation (80, 166 and 100 %, respectively), whereas NR1I2 63396TT carriers were at decreased risk (22 %).",
                "...CNS adverse events were not driven by EFV dose or concentrations; however, CYP2B6 15582CT/TT and ABCB1 3435TT carriers were at higher risk (46 and 131 %, respectively) of CNS-related adverse events compared with 35 % lower risk in CYP2B6 983TC/CC patients."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "Dose",
              "Gene": "N/A",
              "Drug(s)": "efavirenz",
              "PMID": 26715213,
              "Phenotype Category": "dosage",
              "Significance": "yes",
              "Notes": "Discontinuation due to adverse events associated with dosage.",
              "Sentence": "Higher dose (600 mg) is associated with increased discontinuation due to adverse events when treated with efavirenz in treatment-nai\u0308ve HIV-infected patients.",
              "Alleles": null,
              "Specialty Population": null,
              "Metabolizer types": "not stated",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "discontinuation due to adverse events",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": null,
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": null,
              "Variant Annotation ID_norm": null,
              "Citations": [
                "Discontinuation due to adverse events (clinician decision) was independently associated with dose (OR 2.54, 95 % CI 1.19-5.43, p = 0.016).",
                "A higher rate of EFV-related adverse events and discontinuations due to these events for EFV600 were not driven by polymorphisms assessed.",
                "EFV-related adverse events and discontinuations due to these events were increased with dose."
              ]
            }
          ]
        },
        "functional_analysis": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "status": "missing_var_fa_ann"
        },
        "study_parameters": {
          "total_samples": 7,
          "field_scores": {
            "Study Type": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Study Cases": {
              "mean_score": 0.6571428571428571,
              "scores": [
                1.0,
                0.8,
                1.0,
                1.0,
                0.8,
                0.0,
                0.0
              ]
            },
            "Study Controls": {
              "mean_score": 0.7142857142857143,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0
              ]
            },
            "Characteristics": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Characteristics Type": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Frequency In Cases": {
              "mean_score": 0.7142857142857143,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0
              ]
            },
            "Allele Of Frequency In Cases": {
              "mean_score": 0.7142857142857143,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0
              ]
            },
            "Frequency In Controls": {
              "mean_score": 0.7142857142857143,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0
              ]
            },
            "Allele Of Frequency In Controls": {
              "mean_score": 0.7142857142857143,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0
              ]
            },
            "P Value": {
              "mean_score": 0.2857142857142857,
              "scores": [
                0.5,
                0.0,
                0.5,
                0.5,
                0.5,
                0.0,
                0.0
              ]
            },
            "Ratio Stat Type": {
              "mean_score": 0.5714285714285714,
              "scores": [
                1.0,
                0.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0
              ]
            },
            "Ratio Stat": {
              "mean_score": 0.2571428571428572,
              "scores": [
                0.8,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Confidence Interval Start": {
              "mean_score": 0.38571428571428573,
              "scores": [
                0.8,
                1.0,
                0.9,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Confidence Interval Stop": {
              "mean_score": 0.37142857142857144,
              "scores": [
                0.8,
                1.0,
                0.0,
                0.8,
                0.0,
                0.0,
                0.0
              ]
            },
            "Biogeographical Groups": {
              "mean_score": 0.7142857142857143,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.4542857142857143,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.0,
                "Characteristics Type": 0.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.5,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 0.8,
                "Confidence Interval Start": 0.8,
                "Confidence Interval Stop": 0.8,
                "Biogeographical Groups": 1.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1448993822,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1448993820,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "cohort, clinical trial",
                  "prediction": "cohort"
                },
                "Study Cases": {
                  "ground_truth": 606.0,
                  "prediction": 606
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": null,
                  "prediction": "CYP2B6 15582CT/TT and ABCB1 3435TT carriers experiencing CNS-related adverse events"
                },
                "Characteristics Type": {
                  "ground_truth": "Unknown",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.011",
                  "prediction": "= 0.040"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": 1.59,
                  "prediction": 1.46
                },
                "Confidence Interval Start": {
                  "ground_truth": 1.11,
                  "prediction": 1.02
                },
                "Confidence Interval Stop": {
                  "ground_truth": 2.27,
                  "prediction": 2.09
                },
                "Biogeographical Groups": {
                  "ground_truth": "Multiple groups",
                  "prediction": "Multiple Groups"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 0.8,
                "Study Controls": 1.0,
                "Characteristics": 0.0,
                "Characteristics Type": 0.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.0,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 1.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1448993785,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1448993783,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "cohort, clinical trial",
                  "prediction": "cohort"
                },
                "Study Cases": {
                  "ground_truth": 569.0,
                  "prediction": 606
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": null,
                  "prediction": "C12 between 0.47 and 0.76 mg/L achieving pVL <200 copies/mL at 96 weeks"
                },
                "Characteristics Type": {
                  "ground_truth": "Unknown",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.016",
                  "prediction": null
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "Unknown"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "Multiple groups",
                  "prediction": "Multiple Groups"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 2,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.0,
                "Characteristics Type": 0.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.5,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 0.0,
                "Confidence Interval Start": 0.9,
                "Confidence Interval Stop": 0.0,
                "Biogeographical Groups": 1.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1448993833,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1448993831,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "cohort, clinical trial",
                  "prediction": "cohort"
                },
                "Study Cases": {
                  "ground_truth": 606.0,
                  "prediction": 606
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": null,
                  "prediction": "Discontinuation due to adverse events (clinician decision)"
                },
                "Characteristics Type": {
                  "ground_truth": "Unknown",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.006",
                  "prediction": "= 0.016"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": 2.14,
                  "prediction": 2.54
                },
                "Confidence Interval Start": {
                  "ground_truth": 1.25,
                  "prediction": 1.19
                },
                "Confidence Interval Stop": {
                  "ground_truth": 3.67,
                  "prediction": 5.43
                },
                "Biogeographical Groups": {
                  "ground_truth": "Multiple groups",
                  "prediction": "Multiple Groups"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 3,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.0,
                "Characteristics Type": 0.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.5,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 0.0,
                "Confidence Interval Start": 0.0,
                "Confidence Interval Stop": 0.8,
                "Biogeographical Groups": 1.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1448993812,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1448993810,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "cohort, clinical trial",
                  "prediction": "cohort"
                },
                "Study Cases": {
                  "ground_truth": 606.0,
                  "prediction": 606
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": null,
                  "prediction": "CYP2B6 983TC/CC carriers experiencing CNS-related adverse events"
                },
                "Characteristics Type": {
                  "ground_truth": "Unknown",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.01",
                  "prediction": "= 0.015"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": 0.3,
                  "prediction": 0.35
                },
                "Confidence Interval Start": {
                  "ground_truth": 0.12,
                  "prediction": 0.15
                },
                "Confidence Interval Stop": {
                  "ground_truth": 0.75,
                  "prediction": 0.81
                },
                "Biogeographical Groups": {
                  "ground_truth": "Multiple groups",
                  "prediction": "Multiple Groups"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 4,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 0.8,
                "Study Controls": 1.0,
                "Characteristics": 0.0,
                "Characteristics Type": 0.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.5,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 0.0,
                "Confidence Interval Start": 0.0,
                "Confidence Interval Stop": 0.0,
                "Biogeographical Groups": 1.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1448993769,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1448993767,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "cohort, clinical trial",
                  "prediction": "cohort"
                },
                "Study Cases": {
                  "ground_truth": 573.0,
                  "prediction": 606
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": null,
                  "prediction": "Treatment-nai\u0308ve HIV-infected adults, 32% female, 37% African, 33% Asian"
                },
                "Characteristics Type": {
                  "ground_truth": "Unknown",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.01",
                  "prediction": "= 0.204"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": 5.25
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": 0.41
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": 67.9
                },
                "Biogeographical Groups": {
                  "ground_truth": "Multiple groups",
                  "prediction": "Multiple Groups"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            }
          ],
          "aligned_variants": [
            "cohort, clinical trial",
            "cohort, clinical trial",
            "cohort, clinical trial",
            "cohort, clinical trial",
            "cohort, clinical trial"
          ],
          "unmatched_ground_truth": [
            {
              "Study Parameters ID": 1448993796,
              "Variant Annotation ID": 1448993794,
              "Study Type": "cohort, clinical trial",
              "Study Cases": 570.0,
              "Study Controls": null,
              "Characteristics": null,
              "Characteristics Type": "Unknown",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.008",
              "Ratio Stat Type": "OR",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Multiple groups",
              "Variant Annotation ID_norm": "1448993794"
            },
            {
              "Study Parameters ID": 1448993766,
              "Variant Annotation ID": 1448993759,
              "Study Type": "cohort, clinical trial",
              "Study Cases": 546.0,
              "Study Controls": null,
              "Characteristics": null,
              "Characteristics Type": "Unknown",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.42",
              "Ratio Stat Type": "OR",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Multiple groups",
              "Variant Annotation ID_norm": "1448993759"
            }
          ],
          "unmatched_predictions": []
        }
      },
      "overall_score": 0.3047649766270603,
      "num_benchmarks": 4
    },
    {
      "pmid": "28550460",
      "pmcid": "PMC5508045",
      "title": "The impact of non-genetic and genetic factors on a stable warfarin dose in Thai patients",
      "benchmarks": {
        "drug_annotations": {
          "total_samples": 4,
          "field_scores": {
            "Variant/Haplotypes": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0
              ]
            },
            "Gene": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0
              ]
            },
            "PMID": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Phenotype Category": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0
              ]
            },
            "Significance": {
              "mean_score": 0.25,
              "scores": [
                0.0,
                1.0,
                0.0,
                0.0
              ]
            },
            "Alleles": {
              "mean_score": 0.4568524956703186,
              "scores": [
                0.9322953224182129,
                0.8951146602630615,
                0.0,
                0.0
              ]
            },
            "Specialty Population": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0
              ]
            },
            "Metabolizer types": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0
              ]
            },
            "isPlural": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0
              ]
            },
            "Is/Is Not associated": {
              "mean_score": 0.25,
              "scores": [
                0.0,
                1.0,
                0.0,
                0.0
              ]
            },
            "Direction of effect": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "PD/PK terms": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0
              ]
            },
            "Multiple drugs And/or": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Population types": {
              "mean_score": 0.4272996485233307,
              "scores": [
                0.8545992970466614,
                0.8545992970466614,
                0.0,
                0.0
              ]
            },
            "Population Phenotypes or diseases": {
              "mean_score": 0.4465292990207672,
              "scores": [
                0.8930585980415344,
                0.8930585980415344,
                0.0,
                0.0
              ]
            },
            "Multiple phenotypes or diseases And/or": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Comparison Allele(s) or Genotype(s)": {
              "mean_score": 0.44645263254642487,
              "scores": [
                0.9467825293540955,
                0.839028000831604,
                0.0,
                0.0
              ]
            },
            "Comparison Metabolizer types": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0
              ]
            },
            "Drug(s)": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.35669126714530747,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "PMID": 0.0,
                "Phenotype Category": 1.0,
                "Significance": 0.0,
                "Alleles": 0.9322953224182129,
                "Specialty Population": 1.0,
                "Metabolizer types": 1.0,
                "isPlural": 1.0,
                "Is/Is Not associated": 0.0,
                "Direction of effect": 0.0,
                "PD/PK terms": 1.0,
                "Multiple drugs And/or": 0.0,
                "Population types": 0.8545992970466614,
                "Population Phenotypes or diseases": 0.8930585980415344,
                "Multiple phenotypes or diseases And/or": 0.0,
                "Comparison Allele(s) or Genotype(s)": 0.9467825293540955,
                "Comparison Metabolizer types": 1.0,
                "Drug(s)": 1.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "rs2108622",
                  "prediction": "rs2108622"
                },
                "Gene": {
                  "ground_truth": "CYP4F2",
                  "prediction": "CYP4F2"
                },
                "PMID": {
                  "ground_truth": 28550460,
                  "prediction": null
                },
                "Phenotype Category": {
                  "ground_truth": "Dosage",
                  "prediction": "dosage"
                },
                "Significance": {
                  "ground_truth": "yes",
                  "prediction": "no"
                },
                "Alleles": {
                  "ground_truth": "TT",
                  "prediction": "TT, CT, CC"
                },
                "Specialty Population": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Metabolizer types": {
                  "ground_truth": null,
                  "prediction": null
                },
                "isPlural": {
                  "ground_truth": "Is",
                  "prediction": "Is"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Not associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": ""
                },
                "PD/PK terms": {
                  "ground_truth": "dose of",
                  "prediction": "dose of"
                },
                "Multiple drugs And/or": {
                  "ground_truth": null,
                  "prediction": ""
                },
                "Population types": {
                  "ground_truth": "in people with",
                  "prediction": "in Thai patients"
                },
                "Population Phenotypes or diseases": {
                  "ground_truth": "Disease:Atrial Fibrillation, Disease:Heart valve replacement, Disease:Pulmonary Hypertension, Disease:Pulmonary Embolism, Disease:Venous Thrombosis",
                  "prediction": "Disease:warfarin dosing variability"
                },
                "Multiple phenotypes or diseases And/or": {
                  "ground_truth": "and",
                  "prediction": ""
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "CC",
                  "prediction": "CC genotype"
                },
                "Comparison Metabolizer types": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Drug(s)": {
                  "ground_truth": "warfarin",
                  "prediction": "warfarin"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "PMID": 0.0,
                "Phenotype Category": 1.0,
                "Significance": 1.0,
                "Alleles": 0.8951146602630615,
                "Specialty Population": 1.0,
                "Metabolizer types": 1.0,
                "isPlural": 1.0,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 0.0,
                "PD/PK terms": 1.0,
                "Multiple drugs And/or": 0.0,
                "Population types": 0.8545992970466614,
                "Population Phenotypes or diseases": 0.8930585980415344,
                "Multiple phenotypes or diseases And/or": 0.0,
                "Comparison Allele(s) or Genotype(s)": 0.839028000831604,
                "Comparison Metabolizer types": 1.0,
                "Drug(s)": 1.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "rs887829",
                  "prediction": "rs887829"
                },
                "Gene": {
                  "ground_truth": "UGT1A1",
                  "prediction": "UGT1A1"
                },
                "PMID": {
                  "ground_truth": 28550460,
                  "prediction": null
                },
                "Phenotype Category": {
                  "ground_truth": "Dosage",
                  "prediction": "dosage"
                },
                "Significance": {
                  "ground_truth": "no",
                  "prediction": "no"
                },
                "Alleles": {
                  "ground_truth": "C",
                  "prediction": "TT, CT, CC"
                },
                "Specialty Population": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Metabolizer types": {
                  "ground_truth": null,
                  "prediction": null
                },
                "isPlural": {
                  "ground_truth": "Is",
                  "prediction": "Is"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Not associated with",
                  "prediction": "Not associated with"
                },
                "Direction of effect": {
                  "ground_truth": null,
                  "prediction": ""
                },
                "PD/PK terms": {
                  "ground_truth": "dose of",
                  "prediction": "dose of"
                },
                "Multiple drugs And/or": {
                  "ground_truth": null,
                  "prediction": ""
                },
                "Population types": {
                  "ground_truth": "in people with",
                  "prediction": "in Thai patients"
                },
                "Population Phenotypes or diseases": {
                  "ground_truth": "Disease:Atrial Fibrillation, Disease:Heart valve replacement, Disease:Pulmonary Hypertension, Disease:Pulmonary Embolism, Disease:Venous Thrombosis",
                  "prediction": "Disease:warfarin dosing variability"
                },
                "Multiple phenotypes or diseases And/or": {
                  "ground_truth": "and",
                  "prediction": ""
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "T",
                  "prediction": "CC genotype"
                },
                "Comparison Metabolizer types": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Drug(s)": {
                  "ground_truth": "warfarin",
                  "prediction": "warfarin"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            }
          ],
          "aligned_variants": [
            "rs2108622",
            "rs887829"
          ],
          "unmatched_ground_truth": [
            {
              "Variant Annotation ID": 1448624157,
              "Variant/Haplotypes": "rs9923231",
              "Gene": "VKORC1",
              "Drug(s)": "warfarin",
              "PMID": 28550460,
              "Phenotype Category": "Dosage",
              "Significance": "yes",
              "Notes": "Please note: alleles have been complemented to the + strand.",
              "Sentence": "Genotypes CT + TT are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism or Venous Thrombosis as compared to genotype CC.",
              "Alleles": "CT + TT",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "dose of",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:Atrial Fibrillation, Disease:Heart valve replacement, Disease:Pulmonary Hypertension, Disease:Pulmonary Embolism, Disease:Venous Thrombosis",
              "Multiple phenotypes or diseases And/or": "or",
              "Comparison Allele(s) or Genotype(s)": "CC",
              "Comparison Metabolizer types": null,
              "PMID_norm": "28550460",
              "Variant Annotation ID_norm": "1448624157"
            },
            {
              "Variant Annotation ID": 1448624168,
              "Variant/Haplotypes": "rs1057910",
              "Gene": "CYP2C9",
              "Drug(s)": "warfarin",
              "PMID": 28550460,
              "Phenotype Category": "Dosage",
              "Significance": "yes",
              "Notes": null,
              "Sentence": "Genotypes AC + CC are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype AA.",
              "Alleles": "AC + CC",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "dose of",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:Atrial Fibrillation, Disease:Heart valve replacement, Disease:Pulmonary Hypertension, Disease:Pulmonary Embolism, Disease:Venous Thrombosis",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "AA",
              "Comparison Metabolizer types": null,
              "PMID_norm": "28550460",
              "Variant Annotation ID_norm": "1448624168"
            }
          ],
          "unmatched_predictions": [
            {
              "Variant/Haplotypes": "VKORC1",
              "Gene": "VKORC1, CYP2C9",
              "Drug(s)": "warfarin",
              "Phenotype Category": "dosage",
              "Significance": "yes",
              "Notes": "Patients with variant genotypes of VKORC1 \u2212 1639G > A required significantly lower warfarin stable weekly doses (SWDs) than those with wild-type genotype (p < 0.001). Similarly, the patients with CYP2C9*3 variant allele required significantly lower warfarin SWDs than those with homozygous wild-type (p = 0.006).",
              "Sentence": "VKORC1 \u2212 1639G > A, CYP2C9*3 is associated with decreased dosage of warfarin in Thai patients.",
              "Alleles": "AA, GA",
              "Metabolizer types": null,
              "Comparison Allele(s) or Genotype(s)": "GG genotype",
              "Comparison Metabolizer types": null,
              "Specialty Population": null,
              "Population types": "in Thai patients",
              "Population Phenotypes or diseases": "Disease:warfarin dosing variability",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "dose of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "The patients with variant genotypes of VKORC1 \u2212 1639G > A required significantly lower warfarin stable weekly doses (SWDs) than those with wild-type genotype (p < 0.001).",
                "Similarly, the patients with CYP2C9*3 variant allele required significantly lower warfarin SWDs than those with homozygous wild-type (p = 0.006).",
                "VKORC1 \u2212 1639G > A, CYP2C9*3, and CYP4F2 rs2108622 polymorphisms together with age, body mass index, antiplatelet drug use, amiodarone use, and current smoker status explained 51.3% of individual variability in stable warfarin doses."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "\u2212",
              "Gene": "VKORC1, CYP2C9",
              "Drug(s)": "warfarin",
              "Phenotype Category": "dosage",
              "Significance": "yes",
              "Notes": "Patients with variant genotypes of VKORC1 \u2212 1639G > A required significantly lower warfarin stable weekly doses (SWDs) than those with wild-type genotype (p < 0.001). Similarly, the patients with CYP2C9*3 variant allele required significantly lower warfarin SWDs than those with homozygous wild-type (p = 0.006).",
              "Sentence": "VKORC1 \u2212 1639G > A, CYP2C9*3 is associated with decreased dosage of warfarin in Thai patients.",
              "Alleles": "AA, GA",
              "Metabolizer types": null,
              "Comparison Allele(s) or Genotype(s)": "GG genotype",
              "Comparison Metabolizer types": null,
              "Specialty Population": null,
              "Population types": "in Thai patients",
              "Population Phenotypes or diseases": "Disease:warfarin dosing variability",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "dose of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "The patients with variant genotypes of VKORC1 \u2212 1639G > A required significantly lower warfarin stable weekly doses (SWDs) than those with wild-type genotype (p < 0.001).",
                "Similarly, the patients with CYP2C9*3 variant allele required significantly lower warfarin SWDs than those with homozygous wild-type (p = 0.006).",
                "VKORC1 \u2212 1639G > A, CYP2C9*3, and CYP4F2 rs2108622 polymorphisms together with age, body mass index, antiplatelet drug use, amiodarone use, and current smoker status explained 51.3% of individual variability in stable warfarin doses."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "1639G",
              "Gene": "VKORC1, CYP2C9",
              "Drug(s)": "warfarin",
              "Phenotype Category": "dosage",
              "Significance": "yes",
              "Notes": "Patients with variant genotypes of VKORC1 \u2212 1639G > A required significantly lower warfarin stable weekly doses (SWDs) than those with wild-type genotype (p < 0.001). Similarly, the patients with CYP2C9*3 variant allele required significantly lower warfarin SWDs than those with homozygous wild-type (p = 0.006).",
              "Sentence": "VKORC1 \u2212 1639G > A, CYP2C9*3 is associated with decreased dosage of warfarin in Thai patients.",
              "Alleles": "AA, GA",
              "Metabolizer types": null,
              "Comparison Allele(s) or Genotype(s)": "GG genotype",
              "Comparison Metabolizer types": null,
              "Specialty Population": null,
              "Population types": "in Thai patients",
              "Population Phenotypes or diseases": "Disease:warfarin dosing variability",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "dose of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "The patients with variant genotypes of VKORC1 \u2212 1639G > A required significantly lower warfarin stable weekly doses (SWDs) than those with wild-type genotype (p < 0.001).",
                "Similarly, the patients with CYP2C9*3 variant allele required significantly lower warfarin SWDs than those with homozygous wild-type (p = 0.006).",
                "VKORC1 \u2212 1639G > A, CYP2C9*3, and CYP4F2 rs2108622 polymorphisms together with age, body mass index, antiplatelet drug use, amiodarone use, and current smoker status explained 51.3% of individual variability in stable warfarin doses."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": ">",
              "Gene": "VKORC1, CYP2C9",
              "Drug(s)": "warfarin",
              "Phenotype Category": "dosage",
              "Significance": "yes",
              "Notes": "Patients with variant genotypes of VKORC1 \u2212 1639G > A required significantly lower warfarin stable weekly doses (SWDs) than those with wild-type genotype (p < 0.001). Similarly, the patients with CYP2C9*3 variant allele required significantly lower warfarin SWDs than those with homozygous wild-type (p = 0.006).",
              "Sentence": "VKORC1 \u2212 1639G > A, CYP2C9*3 is associated with decreased dosage of warfarin in Thai patients.",
              "Alleles": "AA, GA",
              "Metabolizer types": null,
              "Comparison Allele(s) or Genotype(s)": "GG genotype",
              "Comparison Metabolizer types": null,
              "Specialty Population": null,
              "Population types": "in Thai patients",
              "Population Phenotypes or diseases": "Disease:warfarin dosing variability",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "dose of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "The patients with variant genotypes of VKORC1 \u2212 1639G > A required significantly lower warfarin stable weekly doses (SWDs) than those with wild-type genotype (p < 0.001).",
                "Similarly, the patients with CYP2C9*3 variant allele required significantly lower warfarin SWDs than those with homozygous wild-type (p = 0.006).",
                "VKORC1 \u2212 1639G > A, CYP2C9*3, and CYP4F2 rs2108622 polymorphisms together with age, body mass index, antiplatelet drug use, amiodarone use, and current smoker status explained 51.3% of individual variability in stable warfarin doses."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "A",
              "Gene": "VKORC1, CYP2C9",
              "Drug(s)": "warfarin",
              "Phenotype Category": "dosage",
              "Significance": "yes",
              "Notes": "Patients with variant genotypes of VKORC1 \u2212 1639G > A required significantly lower warfarin stable weekly doses (SWDs) than those with wild-type genotype (p < 0.001). Similarly, the patients with CYP2C9*3 variant allele required significantly lower warfarin SWDs than those with homozygous wild-type (p = 0.006).",
              "Sentence": "VKORC1 \u2212 1639G > A, CYP2C9*3 is associated with decreased dosage of warfarin in Thai patients.",
              "Alleles": "AA, GA",
              "Metabolizer types": null,
              "Comparison Allele(s) or Genotype(s)": "GG genotype",
              "Comparison Metabolizer types": null,
              "Specialty Population": null,
              "Population types": "in Thai patients",
              "Population Phenotypes or diseases": "Disease:warfarin dosing variability",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "dose of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "The patients with variant genotypes of VKORC1 \u2212 1639G > A required significantly lower warfarin stable weekly doses (SWDs) than those with wild-type genotype (p < 0.001).",
                "Similarly, the patients with CYP2C9*3 variant allele required significantly lower warfarin SWDs than those with homozygous wild-type (p = 0.006).",
                "VKORC1 \u2212 1639G > A, CYP2C9*3, and CYP4F2 rs2108622 polymorphisms together with age, body mass index, antiplatelet drug use, amiodarone use, and current smoker status explained 51.3% of individual variability in stable warfarin doses."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "CYP2C9*3",
              "Gene": "VKORC1, CYP2C9",
              "Drug(s)": "warfarin",
              "Phenotype Category": "dosage",
              "Significance": "yes",
              "Notes": "Patients with variant genotypes of VKORC1 \u2212 1639G > A required significantly lower warfarin stable weekly doses (SWDs) than those with wild-type genotype (p < 0.001). Similarly, the patients with CYP2C9*3 variant allele required significantly lower warfarin SWDs than those with homozygous wild-type (p = 0.006).",
              "Sentence": "VKORC1 \u2212 1639G > A, CYP2C9*3 is associated with decreased dosage of warfarin in Thai patients.",
              "Alleles": "AA, GA",
              "Metabolizer types": null,
              "Comparison Allele(s) or Genotype(s)": "GG genotype",
              "Comparison Metabolizer types": null,
              "Specialty Population": null,
              "Population types": "in Thai patients",
              "Population Phenotypes or diseases": "Disease:warfarin dosing variability",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "dose of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "The patients with variant genotypes of VKORC1 \u2212 1639G > A required significantly lower warfarin stable weekly doses (SWDs) than those with wild-type genotype (p < 0.001).",
                "Similarly, the patients with CYP2C9*3 variant allele required significantly lower warfarin SWDs than those with homozygous wild-type (p = 0.006).",
                "VKORC1 \u2212 1639G > A, CYP2C9*3, and CYP4F2 rs2108622 polymorphisms together with age, body mass index, antiplatelet drug use, amiodarone use, and current smoker status explained 51.3% of individual variability in stable warfarin doses."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "CYP4F2",
              "Gene": "CYP4F2",
              "Drug(s)": "warfarin",
              "Phenotype Category": "dosage",
              "Significance": "no",
              "Notes": "There were no significant differences in the SWDs between the patients who carried variant alleles of CYP4F2 rs2108622 and wild-type allele carriers (p=0.172). Multivariate analysis showed that CYP4F2 rs2108622 TT genotype accounted for a modest part of warfarin dose variability (1.2%).",
              "Sentence": "CYP4F2 rs2108622 is not associated with dosage of warfarin in Thai patients.",
              "Alleles": "TT, CT, CC",
              "Metabolizer types": null,
              "Comparison Allele(s) or Genotype(s)": "CC genotype",
              "Comparison Metabolizer types": null,
              "Specialty Population": null,
              "Population types": "in Thai patients",
              "Population Phenotypes or diseases": "Disease:warfarin dosing variability",
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "",
              "PD/PK terms": "dose of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "In contrast, there were no significant differences in the SWDs between the patients who carried variant alleles of CYP4F2 rs2108622 and wild-type allele carriers (p=0.172).",
                "Multivariate analysis, however, showed that CYP4F2 rs2108622 TT genotype accounted for a modest part of warfarin dose variability (1.2%).",
                "...these results showed that the CYP4F2 gene also contributed to warfarin dose requirements in Thais at a modest level..."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "UGT1A1",
              "Gene": "UGT1A1",
              "Drug(s)": "warfarin",
              "Phenotype Category": "dosage",
              "Significance": "no",
              "Notes": "The UGT1A1 rs887829 polymorphism did not contribute to dose variability.",
              "Sentence": "UGT1A1 rs887829 is not associated with dosage of warfarin in Thai patients.",
              "Alleles": "TT, CT, CC",
              "Metabolizer types": null,
              "Comparison Allele(s) or Genotype(s)": "CC genotype",
              "Comparison Metabolizer types": null,
              "Specialty Population": null,
              "Population types": "in Thai patients",
              "Population Phenotypes or diseases": "Disease:warfarin dosing variability",
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "",
              "PD/PK terms": "dose of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "In contrast, there were no significant differences in the SWDs between the patients who carried variant alleles of CYP4F2 rs2108622 and UGT1A1 rs887829 as compared to wild-type allele carriers.",
                "In contrast, the UGT1A1 rs887829 polymorphism did not contribute to dose variability."
              ],
              "_expanded_from_multi_variant": true
            }
          ]
        },
        "phenotype_annotations": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": []
        },
        "functional_analysis": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "status": "missing_var_fa_ann"
        },
        "study_parameters": {
          "total_samples": 4,
          "field_scores": {
            "Study Type": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Study Cases": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Study Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Characteristics": {
              "mean_score": 0.9022846072912216,
              "scores": [
                0.9147093892097473,
                0.9083763360977173,
                0.9082671999931335,
                0.8777855038642883
              ]
            },
            "Characteristics Type": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Frequency In Cases": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Allele Of Frequency In Cases": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Frequency In Controls": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Allele Of Frequency In Controls": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "P Value": {
              "mean_score": 0.875,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.5
              ]
            },
            "Ratio Stat Type": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Ratio Stat": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Confidence Interval Start": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Confidence Interval Stop": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Biogeographical Groups": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.45181897381941477,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.9147093892097473,
                "Characteristics Type": 0.0,
                "Frequency In Cases": 0.0,
                "Allele Of Frequency In Cases": 0.0,
                "Frequency In Controls": 0.0,
                "Allele Of Frequency In Controls": 0.0,
                "P Value": 1.0,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1448624170,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1448624168,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "cohort, retrospective",
                  "prediction": null
                },
                "Study Cases": {
                  "ground_truth": 250.0,
                  "prediction": 250
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "warfarin; CC genotype assoc. w/avg decrease of 25.9 mg, and AC of 7.9 mg vs AA",
                  "prediction": "VKORC1 \u2212 1639G > A genotype group AA"
                },
                "Characteristics Type": {
                  "ground_truth": "Drug",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": 0.976,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": "A",
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": 0.024,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": "C",
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "< 0.001",
                  "prediction": "< 0.001"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "Unknown"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "East Asian",
                  "prediction": "Asian"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.9083763360977173,
                "Characteristics Type": 0.0,
                "Frequency In Cases": 0.0,
                "Allele Of Frequency In Cases": 0.0,
                "Frequency In Controls": 0.0,
                "Allele Of Frequency In Controls": 0.0,
                "P Value": 1.0,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1448624180,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1448624178,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "cohort, retrospective",
                  "prediction": null
                },
                "Study Cases": {
                  "ground_truth": 250.0,
                  "prediction": 250
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "warfarin; TT genotype assoc. w/avg increase of 4.1 mg vs CC",
                  "prediction": "CYP4F2 rs2108622 TT genotype"
                },
                "Characteristics Type": {
                  "ground_truth": "Drug",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": 0.774,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": "C",
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": 0.226,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": "T",
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.016",
                  "prediction": "0.016"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "Unknown"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "East Asian",
                  "prediction": "Asian"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 2,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.9082671999931335,
                "Characteristics Type": 0.0,
                "Frequency In Cases": 0.0,
                "Allele Of Frequency In Cases": 0.0,
                "Frequency In Controls": 0.0,
                "Allele Of Frequency In Controls": 0.0,
                "P Value": 1.0,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1448624167,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1448624157,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "cohort, retrospective",
                  "prediction": null
                },
                "Study Cases": {
                  "ground_truth": 250.0,
                  "prediction": 250
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "warfarin; CT genotype assoc. w/avg decrease of 9.7 mg, and TT of 18.1 mg vs CC",
                  "prediction": "VKORC1 \u2212 1639G > A genotype group GG"
                },
                "Characteristics Type": {
                  "ground_truth": "Drug",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": 0.832,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": "T",
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": 0.168,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": "C",
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "< 0.001",
                  "prediction": "< 0.001"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "Unknown"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "East Asian",
                  "prediction": "Asian"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 3,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.8777855038642883,
                "Characteristics Type": 0.0,
                "Frequency In Cases": 0.0,
                "Allele Of Frequency In Cases": 0.0,
                "Frequency In Controls": 0.0,
                "Allele Of Frequency In Controls": 0.0,
                "P Value": 0.5,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1448624190,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1448624188,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "cohort, retrospective",
                  "prediction": null
                },
                "Study Cases": {
                  "ground_truth": 250.0,
                  "prediction": 250
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "warfarin",
                  "prediction": "CYP2C9 genotype group 1/3"
                },
                "Characteristics Type": {
                  "ground_truth": "Drug",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": 0.88,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": "C",
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": 0.12,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": "T",
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.921",
                  "prediction": "= 0.006"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "Unknown"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "East Asian",
                  "prediction": "Asian"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            }
          ],
          "aligned_variants": [
            "cohort, retrospective:warfarin; CC genotyp",
            "cohort, retrospective:warfarin; TT genotyp",
            "cohort, retrospective:warfarin; CT genotyp",
            "cohort, retrospective:warfarin"
          ],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 250,
              "Study Controls": null,
              "Characteristics": "Thai patients with stable warfarin doses",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "< 0.001",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Asian",
              "Variant Annotation ID_norm": null
            },
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": null,
              "Study Cases": 250,
              "Study Controls": null,
              "Characteristics": "VKORC1 \u2212 1639G > A genotype group GA",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "< 0.001",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Asian",
              "Variant Annotation ID_norm": null
            },
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": null,
              "Study Cases": 250,
              "Study Controls": null,
              "Characteristics": "CYP2C9 genotype group 1/1",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.006",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Asian",
              "Variant Annotation ID_norm": null
            },
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": null,
              "Study Cases": 250,
              "Study Controls": null,
              "Characteristics": "CYP2C9 genotype group 3/3",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.006",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Asian",
              "Variant Annotation ID_norm": null
            }
          ]
        }
      },
      "overall_score": 0.1973711749074752,
      "num_benchmarks": 4
    },
    {
      "pmid": "15743917",
      "pmcid": "PMC554812",
      "title": "HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol",
      "benchmarks": {
        "drug_annotations": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "HLA-B*5801",
              "Gene": "HLA-B",
              "Drug(s)": "allopurinol",
              "PMID": 15743917,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "HLA-B*5801 allele was present in all (100%) 51 patients with allopurinol-SCAR, but only in 20 (15%) of 135 tolerant patients.",
              "Sentence": "Allele HLA-B*5801 is associated with increased risk of severe cutaneous adverse reactions (SCAR) to allopurinol in Han Chinese populations.",
              "Alleles": "HLA-B*5801",
              "Metabolizer types": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "Specialty Population": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:allopurinol-induced SCAR",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of",
              "Multiple drugs And/or": null,
              "Multiple phenotypes or diseases And/or": null,
              "Citations": [
                "The HLA-B*5801 allele was present in all (100%) 51 patients with allopurinol-SCAR, but only in 20 (15%) of 135 tolerant patients",
                "Our results indicated that allopurinol-SCAR is strongly associated with a genetic predisposition in Han Chinese. In particular, HLA-B*5801 allele is an important genetic risk factor for this life-threatening condition.",
                "This association was only seen with allopurinol-SCAR and not with the patients' underlying diseases, such as gout, renal insufficiency, or autoimmune disease, etc."
              ]
            }
          ]
        },
        "phenotype_annotations": {
          "total_samples": 5,
          "field_scores": {
            "Variant/Haplotypes": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Gene": {
              "mean_score": 0.2,
              "scores": [
                1.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Drug(s)": {
              "mean_score": 0.2,
              "scores": [
                1.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Phenotype Category": {
              "mean_score": 0.2,
              "scores": [
                1.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Alleles": {
              "mean_score": 0.18474544286727906,
              "scores": [
                0.9237272143363953,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Is/Is Not associated": {
              "mean_score": 0.2,
              "scores": [
                1.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Direction of effect": {
              "mean_score": 0.2,
              "scores": [
                1.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Phenotype": {
              "mean_score": 0.19686925411224365,
              "scores": [
                0.9843462705612183,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "When treated with/exposed to/when assayed with": {
              "mean_score": 0.2,
              "scores": [
                1.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Comparison Allele(s) or Genotype(s)": {
              "mean_score": 0.2,
              "scores": [
                1.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.18090472271045052,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Variant/Haplotypes": 0.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 1.0,
                "Alleles": 0.9237272143363953,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.9843462705612183,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 1.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "HLA-B*58:01",
                  "prediction": "HLA-B*5801"
                },
                "Gene": {
                  "ground_truth": "HLA-B",
                  "prediction": "HLA-B"
                },
                "Drug(s)": {
                  "ground_truth": "allopurinol",
                  "prediction": "allopurinol"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "*58:01",
                  "prediction": "*5801"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:Severe Cutaneous Adverse Reactions",
                  "prediction": "severe cutaneous adverse reactions"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": null,
                  "prediction": null
                }
              },
              "dependency_issues": []
            }
          ],
          "aligned_variants": [
            "hla-b+allopurinol"
          ],
          "unmatched_ground_truth": [
            {
              "Variant Annotation ID": 1184755073,
              "Variant/Haplotypes": "HLA-DRB1*03:01",
              "Gene": "HLA-DRB1",
              "Drug(s)": "allopurinol",
              "PMID": 15743917,
              "Phenotype Category": "Toxicity",
              "Significance": "yes",
              "Notes": "Note: Alleles HLA-A*3303, HLA-C*0302, HLA-DRB1*0301 were in LD and formed an extended haplotype with HLA-B*5801. Chronic renal insufficiency was seen at a significantly higher frequency in patients with allopurinol-induced SCAR compared to allopurinol-tolerant patients p<0.0001 (OR=4.7 (2.3-9.3)).",
              "Sentence": "HLA-DRB1 *03:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.",
              "Alleles": "*03:01",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": null,
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "15743917",
              "Variant Annotation ID_norm": "1184755073"
            },
            {
              "Variant Annotation ID": 1184755032,
              "Variant/Haplotypes": "HLA-C*03:02",
              "Gene": "HLA-C",
              "Drug(s)": "allopurinol",
              "PMID": 15743917,
              "Phenotype Category": "Toxicity",
              "Significance": "yes",
              "Notes": "Note: Alleles HLA-A*3303, HLA-C*0302, HLA-DRB1*0301 were in LD and formed an extended haplotype with HLA-B*5801. Chronic renal insufficiency was seen at a significantly higher frequency in patients with allopurinol-induced SCAR compared to allopurinol-tolerant patients p<0.0001 (OR=4.7 (2.3-9.3)).",
              "Sentence": "HLA-C *03:02 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.",
              "Alleles": "*03:02",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": null,
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "15743917",
              "Variant Annotation ID_norm": "1184755032"
            },
            {
              "Variant Annotation ID": 1184755056,
              "Variant/Haplotypes": "HLA-A*33:03",
              "Gene": "HLA-A",
              "Drug(s)": "allopurinol",
              "PMID": 15743917,
              "Phenotype Category": "Toxicity",
              "Significance": "yes",
              "Notes": "Note: Alleles HLA-A*3303, HLA-C*0302, HLA-DRB1*0301 were in LD and formed an extended haplotype with HLA-B*5801. Chronic renal insufficiency was seen at a significantly higher frequency in patients with allopurinol-induced SCAR compared to allopurinol-tolerant patients p<0.0001 (OR=4.7 (2.3-9.3)).",
              "Sentence": "HLA-A *33:03 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.",
              "Alleles": "*33:03",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": null,
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "15743917",
              "Variant Annotation ID_norm": "1184755056"
            },
            {
              "Variant Annotation ID": 1184755144,
              "Variant/Haplotypes": "rs1594",
              "Gene": "CFLAR",
              "Drug(s)": "allopurinol",
              "PMID": 15743917,
              "Phenotype Category": "Toxicity",
              "Significance": "yes",
              "Notes": "An initial screen of 823 SNPs in the MHC region or in genes related to drug metabolism and immune response for association with allopurinol-induced SCAR. The direction of the association (i.e. which allele was associated with increased risk of SCARs and which allele was associated with decreased risk) was not clear. Unclear whether this was corrected for multiple comparisons or not.",
              "Sentence": "Allele A is associated with severe cutaneous adverse reactions when treated with allopurinol as compared to allele G.",
              "Alleles": "A",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": null,
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "G",
              "Comparison Metabolizer types": null,
              "PMID_norm": "15743917",
              "Variant Annotation ID_norm": "1184755144"
            }
          ],
          "unmatched_predictions": []
        },
        "functional_analysis": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "status": "missing_var_fa_ann"
        },
        "study_parameters": {
          "total_samples": 14,
          "field_scores": {
            "Study Type": {
              "mean_score": 0.14285714285714285,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Study Cases": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Study Controls": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Characteristics": {
              "mean_score": 0.1228173588003431,
              "scores": [
                0.8186778426170349,
                0.9007651805877686,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Characteristics Type": {
              "mean_score": 0.14285714285714285,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Frequency In Cases": {
              "mean_score": 0.14285714285714285,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Allele Of Frequency In Cases": {
              "mean_score": 0.14285714285714285,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Frequency In Controls": {
              "mean_score": 0.14285714285714285,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Allele Of Frequency In Controls": {
              "mean_score": 0.14285714285714285,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "P Value": {
              "mean_score": 0.07142857142857142,
              "scores": [
                0.5,
                0.5,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Ratio Stat Type": {
              "mean_score": 0.14285714285714285,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Ratio Stat": {
              "mean_score": 0.07142857142857142,
              "scores": [
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Confidence Interval Start": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Confidence Interval Stop": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Biogeographical Groups": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.08437830011049906,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 1.0,
                "Study Cases": 0.0,
                "Study Controls": 0.0,
                "Characteristics": 0.8186778426170349,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.5,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 0.0,
                "Confidence Interval Stop": 0.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1184755147,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1184755144,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "case/control",
                  "prediction": "case/control"
                },
                "Study Cases": {
                  "ground_truth": 21.0,
                  "prediction": 51.0
                },
                "Study Controls": {
                  "ground_truth": 75.0,
                  "prediction": 228.0
                },
                "Characteristics": {
                  "ground_truth": "cases n= 21, controls = 75 general population.",
                  "prediction": "Patients with allopurinol-SCAR"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "< 0.01",
                  "prediction": "< 10-18"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": 393.5,
                  "prediction": 393.5
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": 23.23
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": 6665.26
                },
                "Biogeographical Groups": {
                  "ground_truth": "East Asian",
                  "prediction": "Han Chinese"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 1.0,
                "Study Cases": 0.0,
                "Study Controls": 0.0,
                "Characteristics": 0.9007651805877686,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.5,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 0.0,
                "Confidence Interval Start": 0.0,
                "Confidence Interval Stop": 0.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1184755146,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1184755144,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "case/control",
                  "prediction": "case/control"
                },
                "Study Cases": {
                  "ground_truth": 30.0,
                  "prediction": 51.0
                },
                "Study Controls": {
                  "ground_truth": 60.0,
                  "prediction": 228.0
                },
                "Characteristics": {
                  "ground_truth": "cases n= 30, controls = 60 tolerant to allopurinol.",
                  "prediction": "Patients with allopurinol-SCAR"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "< 0.01",
                  "prediction": "< 10-7"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": 580.3
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": 34.4
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": 9780.9
                },
                "Biogeographical Groups": {
                  "ground_truth": "East Asian",
                  "prediction": "Han Chinese"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            }
          ],
          "aligned_variants": [
            "case/control:cases n= 21, control",
            "case/control:cases n= 30, control"
          ],
          "unmatched_ground_truth": [
            {
              "Study Parameters ID": 981345658,
              "Variant Annotation ID": 981345654,
              "Study Type": "case/control",
              "Study Cases": 51.0,
              "Study Controls": 135.0,
              "Characteristics": "cases n= 51, controls = 135 tolerant to allopurinol",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": "*58:01",
              "Frequency In Controls": 0.15,
              "Allele Of Frequency In Controls": "*58:01",
              "P Value": "= 4.7E-24",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 580.3,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "East Asian",
              "Variant Annotation ID_norm": "981345654"
            },
            {
              "Study Parameters ID": 1184754937,
              "Variant Annotation ID": 981345654,
              "Study Type": "case/control",
              "Study Cases": 51.0,
              "Study Controls": 93.0,
              "Characteristics": "cases n= 51, controls = 93 general population.",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": "*58:01",
              "Frequency In Controls": 0.2,
              "Allele Of Frequency In Controls": "*58:01",
              "P Value": "= 8.1E-18",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 393.5,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "East Asian",
              "Variant Annotation ID_norm": "981345654"
            },
            {
              "Study Parameters ID": 1184755119,
              "Variant Annotation ID": 981345654,
              "Study Type": "case/control",
              "Study Cases": 51.0,
              "Study Controls": 135.0,
              "Characteristics": "Cases n= 51, controls = 135 tolerant to allopurinol. Statistics and allele frequencies here are for the HLA-B*5801 extended haplotype: B*5801-C*0302-A*3303-DRB1*0301.",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": 0.41,
              "Allele Of Frequency In Cases": "*58:01",
              "Frequency In Controls": 0.07,
              "Allele Of Frequency In Controls": "*58:01",
              "P Value": "= 0.039",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 9.8,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "East Asian",
              "Variant Annotation ID_norm": "981345654"
            },
            {
              "Study Parameters ID": 1184755075,
              "Variant Annotation ID": 1184755073,
              "Study Type": "case/control",
              "Study Cases": 51.0,
              "Study Controls": 135.0,
              "Characteristics": "cases n= 51, controls = 135 tolerant to allopurinol",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": 0.65,
              "Allele Of Frequency In Cases": "*03:01",
              "Frequency In Controls": 0.13,
              "Allele Of Frequency In Controls": "*03:01",
              "P Value": "= 2.8E-6",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 12.7,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "East Asian",
              "Variant Annotation ID_norm": "1184755073"
            },
            {
              "Study Parameters ID": 1184755076,
              "Variant Annotation ID": 1184755073,
              "Study Type": "case/control",
              "Study Cases": 51.0,
              "Study Controls": 93.0,
              "Characteristics": "cases n= 51, controls = 93 general population.",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": 0.65,
              "Allele Of Frequency In Cases": "*03:01",
              "Frequency In Controls": 0.15,
              "Allele Of Frequency In Controls": "*03:01",
              "P Value": "= 8.5E-4",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 10.3,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "East Asian",
              "Variant Annotation ID_norm": "1184755073"
            },
            {
              "Study Parameters ID": 1184755134,
              "Variant Annotation ID": 1184755073,
              "Study Type": "case/control",
              "Study Cases": 51.0,
              "Study Controls": 93.0,
              "Characteristics": "Cases n= 51, controls = 135 tolerant to allopurinol. Statistics and allele frequencies here are for the HLA-B*5801 extended haplotype: B*5801-C*0302-A*3303-DRB1*0301.",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": 0.41,
              "Allele Of Frequency In Cases": "*03:01",
              "Frequency In Controls": 0.07,
              "Allele Of Frequency In Controls": "*03:01",
              "P Value": "= 0.039",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 9.8,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "East Asian",
              "Variant Annotation ID_norm": "1184755073"
            },
            {
              "Study Parameters ID": 1184755034,
              "Variant Annotation ID": 1184755032,
              "Study Type": "case/control",
              "Study Cases": 51.0,
              "Study Controls": 135.0,
              "Characteristics": "cases n= 51, controls = 135 tolerant to allopurinol",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": 0.94,
              "Allele Of Frequency In Cases": "*03:02",
              "Frequency In Controls": 0.14,
              "Allele Of Frequency In Controls": "*03:02",
              "P Value": "= 1.4E-19",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 97.7,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "East Asian",
              "Variant Annotation ID_norm": "1184755032"
            },
            {
              "Study Parameters ID": 1184755035,
              "Variant Annotation ID": 1184755032,
              "Study Type": "case/control",
              "Study Cases": 51.0,
              "Study Controls": 93.0,
              "Characteristics": "cases n= 51, controls = 93 general population.",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": 0.94,
              "Allele Of Frequency In Cases": "*03:02",
              "Frequency In Controls": 0.2,
              "Allele Of Frequency In Controls": "*03:02",
              "P Value": "= 2.5E-13",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 62.3,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "East Asian",
              "Variant Annotation ID_norm": "1184755032"
            },
            {
              "Study Parameters ID": 1184755127,
              "Variant Annotation ID": 1184755032,
              "Study Type": "case/control",
              "Study Cases": 51.0,
              "Study Controls": 135.0,
              "Characteristics": "Cases n= 51, controls = 135 tolerant to allopurinol. Statistics and allele frequencies here are for the HLA-B*5801 extended haplotype: B*5801-C*0302-A*3303-DRB1*0301.",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": 0.41,
              "Allele Of Frequency In Cases": "*03:02",
              "Frequency In Controls": 0.07,
              "Allele Of Frequency In Controls": "*03:02",
              "P Value": "= 0.39",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 9.8,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "East Asian",
              "Variant Annotation ID_norm": "1184755032"
            },
            {
              "Study Parameters ID": 1184755058,
              "Variant Annotation ID": 1184755056,
              "Study Type": "case/control",
              "Study Cases": 51.0,
              "Study Controls": 135.0,
              "Characteristics": "cases n= 51, controls = 135 tolerant to allopurinol",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": 0.67,
              "Allele Of Frequency In Cases": "*33:03",
              "Frequency In Controls": 0.18,
              "Allele Of Frequency In Controls": "*33:03",
              "P Value": "= 2.2E-4",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 9.3,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "East Asian",
              "Variant Annotation ID_norm": "1184755056"
            },
            {
              "Study Parameters ID": 1184755113,
              "Variant Annotation ID": 1184755056,
              "Study Type": "case/control",
              "Study Cases": 51.0,
              "Study Controls": 135.0,
              "Characteristics": "cases n= 51, controls = 135 tolerant to allopurinol. Statistics and allele frequencies here are for the HLA-B*5801 extended haplotype: B*5801-C*0302-A*3303-DRB1*0301.",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": 0.41,
              "Allele Of Frequency In Cases": "*33:03",
              "Frequency In Controls": 0.07,
              "Allele Of Frequency In Controls": "*33:03",
              "P Value": "= 0.039",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 9.8,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "East Asian",
              "Variant Annotation ID_norm": "1184755056"
            },
            {
              "Study Parameters ID": 1184755059,
              "Variant Annotation ID": 1184755056,
              "Study Type": "case/control",
              "Study Cases": 51.0,
              "Study Controls": 93.0,
              "Characteristics": "cases n= 51, controls = 93 general population.",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": 0.67,
              "Allele Of Frequency In Cases": "*33:03",
              "Frequency In Controls": 0.22,
              "Allele Of Frequency In Controls": "*33:03",
              "P Value": "= 4.7E-2",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 7.3,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "East Asian",
              "Variant Annotation ID_norm": "1184755056"
            }
          ],
          "unmatched_predictions": []
        }
      },
      "overall_score": 0.07114707683523497,
      "num_benchmarks": 4
    },
    {
      "pmid": "28819312",
      "pmcid": "PMC5561238",
      "title": "Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles",
      "benchmarks": {
        "drug_annotations": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Variant/Haplotypes": "HLA-C*04:01",
              "Gene": "HLA-C",
              "Drug(s)": "nevirapine",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Carriage of HLA-C*04:01 vs non-carriage: Odds ratio 3.06 (adjusted for ethnicity), P < 0.0001, indicating a significant association with severe hypersensitivity reactions.",
              "Standardized Sentence": "HLA-C*04:01 is associated with increased cutaneous nevirapine hypersensitivity in individuals of multiple ethnicities.",
              "Alleles": "*04:01",
              "Metabolizer types": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "Specialty Population": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Other:cutaneous nevirapine hypersensitivity",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": null,
              "Multiple drugs And/or": null,
              "Multiple phenotypes or diseases And/or": null,
              "Citations": [
                "Carriage of HLA-C*04:01 vs non-carriage: Odds ratio 3.06 (adjusted for ethnicity), P < 0.0001;",
                "The HLA alleles most often associated with cutaneous manifestations of NVP HSR are *HLA-C*04*, commonly carried across ethnicities.",
                "Four digit HLA typing was available for 151 cases and 413 controls. In single allele logistic regression analyses *HLA-C*04:01* was the only allele for which a consistent, significant predisposing relationship for cutaneous manifestations of NVP HSR was observed across all ancestral groups."
              ]
            },
            {
              "Variant/Haplotypes": "HLA-C*05:01",
              "Gene": "HLA-C",
              "Drug(s)": "nevirapine",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Inspection of HLA-C*05:01 shows an odds ratio of 2.84, indicating a significant predisposition to nevirapine hypersensitivity in Caucasians (P = 0.002).",
              "Standardized Sentence": "HLA-C*05:01 is associated with increased cutaneous nevirapine hypersensitivity in Caucasian patients.",
              "Alleles": "*05:01",
              "Metabolizer types": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "Specialty Population": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Other:cutaneous nevirapine hypersensitivity",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": null,
              "Multiple drugs And/or": null,
              "Multiple phenotypes or diseases And/or": null,
              "Citations": [
                "However, analyses specific to ancestral groups also revealed several other HLA-C allelic associations indicative of HSR predisposition, namely HLA-C*05:01 in Caucasians (versus non-HLA-C*05:01 carriers: OR = 2.84, P = 0.002)",
                "These HSRs are also noted in patients treated with NVP for HIV post-exposure prophylaxis... Cutaneous reactions range in severity from mild rash through to severe diseases with high morbidity and mortality such as Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS)...",
                "[The alleles most often associated with cutaneous manifestations of NVP HSR are HLA-C*04, commonly carried across ethnicities, as well as HLA-B*35 in Asians and Caucasian patients]"
              ]
            },
            {
              "Variant/Haplotypes": "HLA-C*18:01",
              "Gene": "HLA-C",
              "Drug(s)": "nevirapine",
              "Phenotype Category": "toxicity",
              "Significance": "not stated",
              "Notes": "HLA-C*18:01 shows an odds ratio of 2.67 in people of African ancestry, which is indicative of increased risk, albeit not statistically significant (P = 0.2).",
              "Standardized Sentence": "HLA-C*18:01 is associated with increased cutaneous nevirapine hypersensitivity in individuals of African ancestry.",
              "Alleles": "*18:01",
              "Metabolizer types": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "Specialty Population": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Other:cutaneous nevirapine hypersensitivity",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": null,
              "Multiple drugs And/or": null,
              "Multiple phenotypes or diseases And/or": null,
              "Citations": [
                "*HLA-C*18:01 in patients with African ancestry (versus non-*HLA-C*18:01 carriers: OR = 2.67, *P* = 0.2; vs non-*HLA-C*04:01/*-C*18:01 carriers: OR = 4.71, *P* = 0.06.",
                "validating the association of *HLA-C* alleles with nevirapine hypersensitivity across different populations."
              ]
            },
            {
              "Variant/Haplotypes": "HLA-B*15:01",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Associated with protection from nevirapine hypersensitivity with an odds ratio showing significant protective qualities. Carriage of this allele shows odds ratio 0.18, P < 0.0001.",
              "Standardized Sentence": "HLA-B*15:01 is associated with decreased cutaneous nevirapine hypersensitivity in individuals.",
              "Alleles": "*15:01",
              "Metabolizer types": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "Specialty Population": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Other:cutaneous nevirapine hypersensitivity",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": null,
              "Multiple drugs And/or": null,
              "Multiple phenotypes or diseases And/or": null,
              "Citations": [
                "In contrast, NVP HSR protection is afforded by a cluster of HLA-B alleles defined by a characteristic peptide binding groove B pocket.",
                "The most prominent secondary effect is protection associated with the HLA-B B pocket, which is independent of HLA-C risk (OR = 0.18, p = 0.0001 and OR = 0.20, p = 0.0003 for models with and without adjustment for the primary HLA-C cluster).",
                "It appears that the protective property of this HLA B62 sub-group is driven by the common B pocket structure of the binding groove."
              ]
            },
            {
              "Variant/Haplotypes": "HLA-DRB1*01:01",
              "Gene": "HLA-DRB1",
              "Drug(s)": "nevirapine",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "A secondary association showing an odds ratio of 2.00 (P = 0.01) indicating a risk for cutaneous nevirapine hypersensitivity.",
              "Standardized Sentence": "HLA-DRB1*01:01 is associated with increased cutaneous nevirapine hypersensitivity in individuals.",
              "Alleles": "*01:01",
              "Metabolizer types": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "Specialty Population": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Other:cutaneous nevirapine hypersensitivity",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": null,
              "Multiple drugs And/or": null,
              "Multiple phenotypes or diseases And/or": null,
              "Citations": [
                "The HLA alleles most often associated with cutaneous manifestations of NVP HSR are *HLA-C*04*, commonly carried across ethnicities, as well as *HLA-B*35* in Asians and Caucasian patients.",
                "Having established that *HLA-C* alleles sharing the HLA-C*04:01 F pocket have a primary predisposing impact on the development of cutaneous NVP HSR, we next sought to elucidate the role of secondary HLA class I and class II effects.",
                "Risk *HLA-B* and *HLA-DRB1* alleles are shared across several *HLA-C* allele groups in addition to the *HLA-C*04:01* F pocket risk group and there is little support for any dominant haplotypic effect in cutaneous NVP HSR risk with the exception of *HLA-B*35:05* carried with *HLA-C*04:01* in Asians which display strong linkage disequilibrium."
              ]
            }
          ]
        },
        "phenotype_annotations": {
          "total_samples": 43,
          "field_scores": {
            "Variant/Haplotypes": {
              "mean_score": 0.11627906976744186,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Gene": {
              "mean_score": 0.11627906976744186,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Drug(s)": {
              "mean_score": 0.11627906976744186,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Phenotype Category": {
              "mean_score": 0.11627906976744186,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Alleles": {
              "mean_score": 0.10703705355178478,
              "scores": [
                0.939811110496521,
                0.9135308265686035,
                0.9258627891540527,
                0.9192909002304077,
                0.9040976762771606,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Is/Is Not associated": {
              "mean_score": 0.06976744186046512,
              "scores": [
                0.0,
                0.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Direction of effect": {
              "mean_score": 0.046511627906976744,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Phenotype": {
              "mean_score": 0.10206664024397384,
              "scores": [
                0.877773106098175,
                0.877773106098175,
                0.877773106098175,
                0.877773106098175,
                0.877773106098175,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "When treated with/exposed to/when assayed with": {
              "mean_score": 0.11627906976744186,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Comparison Allele(s) or Genotype(s)": {
              "mean_score": 0.11627906976744186,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.09725120351758115,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 1.0,
                "Alleles": 0.939811110496521,
                "Is/Is Not associated": 0.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.877773106098175,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 1.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "HLA-B*15:01",
                  "prediction": "HLA-B*15:01"
                },
                "Gene": {
                  "ground_truth": "HLA-B",
                  "prediction": "HLA-B"
                },
                "Drug(s)": {
                  "ground_truth": "nevirapine",
                  "prediction": "nevirapine"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "*15:01",
                  "prediction": "HLA-B*15:01"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Not associated with"
                },
                "Direction of effect": {
                  "ground_truth": "decreased",
                  "prediction": "decreased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                  "prediction": "cutaneous hypersensitivity"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": null,
                  "prediction": null
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 1.0,
                "Alleles": 0.9135308265686035,
                "Is/Is Not associated": 0.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.877773106098175,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 1.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "HLA-DRB1*04:04",
                  "prediction": "HLA-DRB1*04:04"
                },
                "Gene": {
                  "ground_truth": "HLA-DRB1",
                  "prediction": "HLA-DRB1"
                },
                "Drug(s)": {
                  "ground_truth": "nevirapine",
                  "prediction": "nevirapine"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "*04:04",
                  "prediction": "HLA-DRB1*04:04"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Not associated with"
                },
                "Direction of effect": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                  "prediction": "cutaneous hypersensitivity"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": null,
                  "prediction": null
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 2,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 1.0,
                "Alleles": 0.9258627891540527,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 0.0,
                "Phenotype": 0.877773106098175,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 1.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "HLA-C*04:01",
                  "prediction": "HLA-C*04:01"
                },
                "Gene": {
                  "ground_truth": "HLA-C",
                  "prediction": "HLA-C"
                },
                "Drug(s)": {
                  "ground_truth": "nevirapine",
                  "prediction": "nevirapine"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "*04:01",
                  "prediction": "HLA-C*04:01"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": null,
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                  "prediction": "cutaneous hypersensitivity"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": null,
                  "prediction": null
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 3,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 1.0,
                "Alleles": 0.9192909002304077,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 0.0,
                "Phenotype": 0.877773106098175,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 1.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "HLA-C*05:01",
                  "prediction": "HLA-C*05:01"
                },
                "Gene": {
                  "ground_truth": "HLA-C",
                  "prediction": "HLA-C"
                },
                "Drug(s)": {
                  "ground_truth": "nevirapine",
                  "prediction": "nevirapine"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "*05:01",
                  "prediction": "HLA-C*05:01"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": null,
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                  "prediction": "cutaneous hypersensitivity"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": null,
                  "prediction": null
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 4,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 1.0,
                "Alleles": 0.9040976762771606,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 0.0,
                "Phenotype": 0.877773106098175,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 1.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "HLA-DRB1*01:01",
                  "prediction": "HLA-DRB1*01:01"
                },
                "Gene": {
                  "ground_truth": "HLA-DRB1",
                  "prediction": "HLA-DRB1"
                },
                "Drug(s)": {
                  "ground_truth": "nevirapine",
                  "prediction": "nevirapine"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "*01:01",
                  "prediction": "HLA-DRB1*01:01"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": null,
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                  "prediction": "cutaneous hypersensitivity"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": null,
                  "prediction": null
                }
              },
              "dependency_issues": []
            }
          ],
          "aligned_variants": [
            "hla-c*05:01",
            "hla-drb1*04:04",
            "hla-b*15:01",
            "hla-drb1*01:01",
            "hla-c*04:01"
          ],
          "unmatched_ground_truth": [
            {
              "Variant Annotation ID": 1448926055,
              "Variant/Haplotypes": "HLA-B*67:01",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-N*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
              "Sentence": "HLA-B *67:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*67:01",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926055"
            },
            {
              "Variant Annotation ID": 1448926065,
              "Variant/Haplotypes": "HLA-B*78:01",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-N*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
              "Sentence": "HLA-B *78:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*78:01",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926065"
            },
            {
              "Variant Annotation ID": 1448925992,
              "Variant/Haplotypes": "HLA-B*51:02",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-N*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
              "Sentence": "HLA-B *51:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*51:02",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448925992"
            },
            {
              "Variant Annotation ID": 1448926045,
              "Variant/Haplotypes": "HLA-B*56:06",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-N*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
              "Sentence": "HLA-B *56:06 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*56:06",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926045"
            },
            {
              "Variant Annotation ID": 1448926109,
              "Variant/Haplotypes": "HLA-B*39:01",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles which the authors do not distinguish between and is why the OR is the same for the following: HLA-B*13:02, HLA-B*38:01/02, HLA-B*39:01/05/06/09, HLA-B*51:07.",
              "Sentence": "HLA-B *39:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*39:01",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926109"
            },
            {
              "Variant Annotation ID": 1448925913,
              "Variant/Haplotypes": "HLA-C*05:09",
              "Gene": "HLA-C",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Primary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-C alleles that share a common \"binding groove F pocket\" with HLA-C*04:01. The authors do not distinguish between the following HLA-C alleles, which is why the OR is the same: HLA-C*04:03/06/07, HLA-C*05:01/09, HLA-C*18:0.",
              "Sentence": "HLA-C *05:09 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*05:09",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448925913"
            },
            {
              "Variant Annotation ID": 1448926229,
              "Variant/Haplotypes": "HLA-B*15:32",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary risk protection to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-B*15:01/12/24/25/27/32/35, HLA-B*52:01",
              "Sentence": "HLA-B *15:32 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*15:32",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926229"
            },
            {
              "Variant Annotation ID": 1448925982,
              "Variant/Haplotypes": "HLA-B*51:01",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-N*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
              "Sentence": "HLA-B *51:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*51:01",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448925982"
            },
            {
              "Variant Annotation ID": 1448926239,
              "Variant/Haplotypes": "HLA-B*15:35",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary risk protection to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-B*15:01/12/24/25/27/32/35, HLA-B*52:01",
              "Sentence": "HLA-B *15:35 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*15:35",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926239"
            },
            {
              "Variant Annotation ID": 1448926169,
              "Variant/Haplotypes": "HLA-B*15:12",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary risk protection to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-B*15:01/12/24/25/27/32/35, HLA-B*52:01",
              "Sentence": "HLA-B *15:12 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*15:12",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926169"
            },
            {
              "Variant Annotation ID": 1448926299,
              "Variant/Haplotypes": "HLA-DRB1*08:01",
              "Gene": "HLA-DRB1",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary risk of severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-DRB1*01:01/02/03, HLA-DRB1*04:04/05/08/10",
              "Sentence": "HLA-DRB1 *08:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*08:01",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926299"
            },
            {
              "Variant Annotation ID": 1448925972,
              "Variant/Haplotypes": "HLA-B*39:10",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-N*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
              "Sentence": "HLA-B *39:10 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*39:10",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448925972"
            },
            {
              "Variant Annotation ID": 1448926099,
              "Variant/Haplotypes": "HLA-B*38:02",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles which the authors do not distinguish between and is why the OR is the same for the following: HLA-B*13:02, HLA-B*38:01/02, HLA-B*39:01/05/06/09, HLA-B*51:07.",
              "Sentence": "HLA-B *38:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*38:02",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926099"
            },
            {
              "Variant Annotation ID": 1448926089,
              "Variant/Haplotypes": "HLA-B*38:01",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles which the authors do not distinguish between and is why the OR is the same for the following: HLA-B*13:02, HLA-B*38:01/02, HLA-B*39:01/05/06/09, HLA-B*51:07.",
              "Sentence": "HLA-B *38:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*38:01",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926089"
            },
            {
              "Variant Annotation ID": 1448926035,
              "Variant/Haplotypes": "HLA-B*56:01",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-N*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
              "Sentence": "HLA-B *56:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*56:01",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926035"
            },
            {
              "Variant Annotation ID": 1448925958,
              "Variant/Haplotypes": "HLA-B*35:05",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-B*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
              "Sentence": "HLA-B *35:05 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*35:05",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448925958"
            },
            {
              "Variant Annotation ID": 1448926269,
              "Variant/Haplotypes": "HLA-DRB1*01:02",
              "Gene": "HLA-DRB1",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary risk of severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-DRB1*01:01/02/03, HLA-DRB1*04:04/05/08/10",
              "Sentence": "HLA-DRB1 *01:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*01:02",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926269"
            },
            {
              "Variant Annotation ID": 1448926139,
              "Variant/Haplotypes": "HLA-B*39:09",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles which the authors do not distinguish between and is why the OR is the same for the following: HLA-B*13:02, HLA-B*38:01/02, HLA-B*39:01/05/06/09, HLA-B*51:07.",
              "Sentence": "HLA-B *39:09 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*39:09",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926139"
            },
            {
              "Variant Annotation ID": 1448926209,
              "Variant/Haplotypes": "HLA-B*15:27",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary risk protection to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-B*15:01/12/24/25/27/32/35, HLA-B*52:01",
              "Sentence": "HLA-B *15:27 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*15:27",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926209"
            },
            {
              "Variant Annotation ID": 1448998275,
              "Variant/Haplotypes": "HLA-B*35:10",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-B*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
              "Sentence": "HLA-B *35:10 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Severe Cutaneous Adverse Reactions and Drug Reaction with Eosinophilia and Systemic Symptoms when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*35:10",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448998275"
            },
            {
              "Variant Annotation ID": 1448925883,
              "Variant/Haplotypes": "HLA-C*04:06",
              "Gene": "HLA-C",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Primary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-C alleles that share a common \"binding groove F pocket\" with HLA-C*04:01. The authors do not distinguish between the following HLA-C alleles, which is why the OR is the same: HLA-C*04:03/06/07, HLA-C*05:01/09, HLA-C*18:0.",
              "Sentence": "HLA-C *04:06 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*04:06",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448925883"
            },
            {
              "Variant Annotation ID": 1448926149,
              "Variant/Haplotypes": "HLA-B*57:01",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles which the authors do not distinguish between and is why the OR is the same for the following: HLA-B*13:02, HLA-B*38:01/02, HLA-B*39:01/05/06/09, HLA-B*51:07.",
              "Sentence": "HLA-B *57:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*57:01",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926149"
            },
            {
              "Variant Annotation ID": 1448925893,
              "Variant/Haplotypes": "HLA-C*04:07",
              "Gene": "HLA-C",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Primary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-C alleles that share a common \"binding groove F pocket\" with HLA-C*04:01. The authors do not distinguish between the following HLA-C alleles, which is why the OR is the same: HLA-C*04:03/06/07, HLA-C*05:01/09, HLA-C*18:0.",
              "Sentence": "HLA-C *04:07 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Severe Cutaneous Adverse Reactions or Drug Reaction with Eosinophilia and Systemic Symptoms when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*04:07",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448925893"
            },
            {
              "Variant Annotation ID": 1448926022,
              "Variant/Haplotypes": "HLA-B*55:02",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-N*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
              "Sentence": "HLA-B *55:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*55:02",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926022"
            },
            {
              "Variant Annotation ID": 1448926279,
              "Variant/Haplotypes": "HLA-DRB1*01:03",
              "Gene": "HLA-DRB1",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary risk of severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-DRB1*01:01/02/03, HLA-DRB1*04:04/05/08/10",
              "Sentence": "HLA-DRB1 *01:03 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*01:03",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926279"
            },
            {
              "Variant Annotation ID": 1448926012,
              "Variant/Haplotypes": "HLA-B*55:01",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-N*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
              "Sentence": "HLA-B *55:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*55:01",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926012"
            },
            {
              "Variant Annotation ID": 1448926075,
              "Variant/Haplotypes": "HLA-B*13:02",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles which the authors do not distinguish between and is why the OR is the same for the following: HLA-B*13:02, HLA-B*38:01/02, HLA-B*39:01/05/06/09, HLA-B*51:07.",
              "Sentence": "HLA-B *13:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*13:02",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926075"
            },
            {
              "Variant Annotation ID": 1448926199,
              "Variant/Haplotypes": "HLA-B*15:25",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary risk protection to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-B*15:01/12/24/25/27/32/35, HLA-B*52:01",
              "Sentence": "HLA-B *15:25 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*15:25",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926199"
            },
            {
              "Variant Annotation ID": 1448926129,
              "Variant/Haplotypes": "HLA-B*39:06",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles which the authors do not distinguish between and is why the OR is the same for the following: HLA-B*13:02, HLA-B*38:01/02, HLA-B*39:01/05/06/09, HLA-B*51:07.",
              "Sentence": "HLA-B *39:06 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*39:06",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926129"
            },
            {
              "Variant Annotation ID": 1448925873,
              "Variant/Haplotypes": "HLA-C*04:03",
              "Gene": "HLA-C",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Primary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-C alleles that share a common \"binding groove F pocket\" with HLA-C*04:01. The authors do not distinguish between the following HLA-C alleles, which is why the OR is the same: HLA-C*04:03/06/07, HLA-C*05:01/09, HLA-C*18:0.",
              "Sentence": "HLA-C *04:03 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*04:03",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448925873"
            },
            {
              "Variant Annotation ID": 1448926002,
              "Variant/Haplotypes": "HLA-B*54:01",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-N*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
              "Sentence": "HLA-B *54:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*54:01",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926002"
            },
            {
              "Variant Annotation ID": 1448926249,
              "Variant/Haplotypes": "HLA-B*52:01",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary risk protection to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-B*15:01/12/24/25/27/32/35, HLA-B*52:01",
              "Sentence": "HLA-B *52:01 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Severe Cutaneous Adverse Reactions or Drug Reaction with Eosinophilia and Systemic Symptoms when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*52:01",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926249"
            },
            {
              "Variant Annotation ID": 1448926309,
              "Variant/Haplotypes": "HLA-DRB1*10:01",
              "Gene": "HLA-DRB1",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary risk of severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-DRB1*01:01/02/03, HLA-DRB1*04:04/05/08/10",
              "Sentence": "HLA-DRB1 *10:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms and Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*10:01",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926309"
            },
            {
              "Variant Annotation ID": 1448926119,
              "Variant/Haplotypes": "HLA-B*39:05",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles which the authors do not distinguish between and is why the OR is the same for the following: HLA-B*13:02, HLA-B*38:01/02, HLA-B*39:01/05/06/09, HLA-B*51:07.",
              "Sentence": "HLA-B *39:05 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*39:05",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926119"
            },
            {
              "Variant Annotation ID": 1448925923,
              "Variant/Haplotypes": "HLA-C*18:01",
              "Gene": "HLA-C",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Primary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-C alleles that share a common \"binding groove F pocket\" with HLA-C*04:01. The authors do not distinguish between the following HLA-C alleles, which is why the OR is the same: HLA-C*04:03/06/07, HLA-C*05:01/09, HLA-C*18:0.",
              "Sentence": "HLA-C *18:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*18:01",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448925923"
            },
            {
              "Variant Annotation ID": 1448926179,
              "Variant/Haplotypes": "HLA-B*15:24",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary risk protection to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-B*15:01/12/24/25/27/32/35, HLA-B*52:01",
              "Sentence": "HLA-B *15:24 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*15:24",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926179"
            },
            {
              "Variant Annotation ID": 1449155757,
              "Variant/Haplotypes": "rs28399499",
              "Gene": "CYP2B6",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "The authors analyze rs28399499 T>C and rs3745274 G>A/T together as \"slow metabolizer\" genotypes.",
              "Sentence": "Allele C is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms and Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections as compared to allele T.",
              "Alleles": "C",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "T",
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1449155757"
            },
            {
              "Variant Annotation ID": 1449155771,
              "Variant/Haplotypes": "rs3745274",
              "Gene": "CYP2B6",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "The authors analyze rs28399499 T>C and rs3745274 G>A/T together as \"slow metabolizer\" genotypes.",
              "Sentence": "Allele T is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome and Drug Reaction with Eosinophilia and Systemic Symptoms when treated with nevirapine in people with HIV Infections as compared to allele G.",
              "Alleles": "T",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "G",
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1449155771"
            }
          ],
          "unmatched_predictions": []
        },
        "functional_analysis": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "status": "missing_var_fa_ann"
        },
        "study_parameters": {
          "total_samples": 43,
          "field_scores": {
            "Study Type": {
              "mean_score": 0.09302325581395349,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Study Cases": {
              "mean_score": 0.09302325581395349,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Study Controls": {
              "mean_score": 0.09302325581395349,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Characteristics": {
              "mean_score": 0.07945628083029459,
              "scores": [
                0.8460705280303955,
                0.8657017946243286,
                0.8558938503265381,
                0.848953902721405,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Characteristics Type": {
              "mean_score": 0.09302325581395349,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Frequency In Cases": {
              "mean_score": 0.09302325581395349,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Allele Of Frequency In Cases": {
              "mean_score": 0.09302325581395349,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Frequency In Controls": {
              "mean_score": 0.09302325581395349,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Allele Of Frequency In Controls": {
              "mean_score": 0.09302325581395349,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "P Value": {
              "mean_score": 0.023255813953488372,
              "scores": [
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Ratio Stat Type": {
              "mean_score": 0.09302325581395349,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Ratio Stat": {
              "mean_score": 0.020930232558139535,
              "scores": [
                0.0,
                0.9,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Confidence Interval Start": {
              "mean_score": 0.023255813953488372,
              "scores": [
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Confidence Interval Stop": {
              "mean_score": 0.023255813953488372,
              "scores": [
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Biogeographical Groups": {
              "mean_score": 0.023255813953488372,
              "scores": [
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.06870793810186461,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 1.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.8460705280303955,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 1.0,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 0.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 1.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1448925872,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1448925862,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "case/control",
                  "prediction": "case/control"
                },
                "Study Cases": {
                  "ground_truth": 151.0,
                  "prediction": 151
                },
                "Study Controls": {
                  "ground_truth": 413.0,
                  "prediction": 413
                },
                "Characteristics": {
                  "ground_truth": "NCT00310843",
                  "prediction": "Severe cutaneous toxicity (grade 3 or 4) categorized by National Institute of Allergy and Infectious Disease (NIAID) Division of AIDS criteria"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "study cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 1.0E-4",
                  "prediction": "= 0.0001"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": 4.06,
                  "prediction": 3.06
                },
                "Confidence Interval Start": {
                  "ground_truth": 2.39,
                  "prediction": 2.39
                },
                "Confidence Interval Stop": {
                  "ground_truth": 6.88,
                  "prediction": 6.88
                },
                "Biogeographical Groups": {
                  "ground_truth": "Multiple groups",
                  "prediction": "Multiple Groups"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 1.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.8657017946243286,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.0,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 0.9,
                "Confidence Interval Start": 0.0,
                "Confidence Interval Stop": 0.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1448925915,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1448925913,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "case/control",
                  "prediction": "case/control"
                },
                "Study Cases": {
                  "ground_truth": 151.0,
                  "prediction": 151
                },
                "Study Controls": {
                  "ground_truth": 413.0,
                  "prediction": 413
                },
                "Characteristics": {
                  "ground_truth": "NCT00310843)",
                  "prediction": "HLA-C*05:01 association in Caucasian subjects vs non-HLA-C*05:01 carriers"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "study cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": null,
                  "prediction": "= 0.002"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": 2.91,
                  "prediction": 2.84
                },
                "Confidence Interval Start": {
                  "ground_truth": 1.62,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": 5.23,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "Multiple groups",
                  "prediction": "Caucasian"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 2,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 1.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.8558938503265381,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.0,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 0.0,
                "Confidence Interval Start": 0.0,
                "Confidence Interval Stop": 0.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1448926057,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1448926055,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "case/control",
                  "prediction": "case/control"
                },
                "Study Cases": {
                  "ground_truth": 151.0,
                  "prediction": 151
                },
                "Study Controls": {
                  "ground_truth": 413.0,
                  "prediction": 413
                },
                "Characteristics": {
                  "ground_truth": "NCT00310843)",
                  "prediction": "HLA-C*18:01 association in African patients vs non-HLA-C*18:01 carriers"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "study cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": null,
                  "prediction": "= 0.06"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": 2.32,
                  "prediction": 4.71
                },
                "Confidence Interval Start": {
                  "ground_truth": 1.42,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": 3.79,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "Multiple groups",
                  "prediction": "African"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 3,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 1.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.848953902721405,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.0,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 0.0,
                "Confidence Interval Start": 0.0,
                "Confidence Interval Stop": 0.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1448926067,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1448926065,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "case/control",
                  "prediction": "case/control"
                },
                "Study Cases": {
                  "ground_truth": 151.0,
                  "prediction": 151
                },
                "Study Controls": {
                  "ground_truth": 413.0,
                  "prediction": 413
                },
                "Characteristics": {
                  "ground_truth": "NCT00310843)",
                  "prediction": "Symbol allele association analysis: HLA-C0401 vs non-carrier"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "study cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": null,
                  "prediction": "< 0.0001"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": 2.32,
                  "prediction": 5.49
                },
                "Confidence Interval Start": {
                  "ground_truth": 1.42,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": 3.79,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "Multiple groups",
                  "prediction": "Asian"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            }
          ],
          "aligned_variants": [
            "case/control:NCT00310843",
            "case/control:NCT00310843)",
            "case/control:NCT00310843)",
            "case/control:NCT00310843)"
          ],
          "unmatched_ground_truth": [
            {
              "Study Parameters ID": 1448925994,
              "Variant Annotation ID": 1448925992,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.32,
              "Confidence Interval Start": 1.42,
              "Confidence Interval Stop": 3.79,
              "Biogeographical Groups": "Multiple groups",
              "Variant Annotation ID_norm": "1448925992"
            },
            {
              "Study Parameters ID": 1448926047,
              "Variant Annotation ID": 1448926045,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.32,
              "Confidence Interval Start": 1.42,
              "Confidence Interval Stop": 3.79,
              "Biogeographical Groups": "Multiple groups",
              "Variant Annotation ID_norm": "1448926045"
            },
            {
              "Study Parameters ID": 1448926111,
              "Variant Annotation ID": 1448926109,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 1.76,
              "Confidence Interval Start": 1.02,
              "Confidence Interval Stop": 3.02,
              "Biogeographical Groups": "Multiple groups",
              "Variant Annotation ID_norm": "1448926109"
            },
            {
              "Study Parameters ID": 1448926231,
              "Variant Annotation ID": 1448926229,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.18,
              "Confidence Interval Start": 0.07,
              "Confidence Interval Stop": 0.46,
              "Biogeographical Groups": "Multiple groups",
              "Variant Annotation ID_norm": "1448926229"
            },
            {
              "Study Parameters ID": 1448925905,
              "Variant Annotation ID": 1448925903,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.91,
              "Confidence Interval Start": 1.62,
              "Confidence Interval Stop": 5.23,
              "Biogeographical Groups": "Multiple groups",
              "Variant Annotation ID_norm": "1448925903"
            },
            {
              "Study Parameters ID": 1448925984,
              "Variant Annotation ID": 1448925982,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.32,
              "Confidence Interval Start": 1.42,
              "Confidence Interval Stop": 3.79,
              "Biogeographical Groups": "Multiple groups",
              "Variant Annotation ID_norm": "1448925982"
            },
            {
              "Study Parameters ID": 1448926241,
              "Variant Annotation ID": 1448926239,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.18,
              "Confidence Interval Start": 0.07,
              "Confidence Interval Stop": 0.46,
              "Biogeographical Groups": "Multiple groups",
              "Variant Annotation ID_norm": "1448926239"
            },
            {
              "Study Parameters ID": 1448926171,
              "Variant Annotation ID": 1448926169,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.18,
              "Confidence Interval Start": 0.07,
              "Confidence Interval Stop": 0.46,
              "Biogeographical Groups": "Multiple groups",
              "Variant Annotation ID_norm": "1448926169"
            },
            {
              "Study Parameters ID": 1448926301,
              "Variant Annotation ID": 1448926299,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.0,
              "Confidence Interval Start": 1.23,
              "Confidence Interval Stop": 3.24,
              "Biogeographical Groups": "Multiple groups",
              "Variant Annotation ID_norm": "1448926299"
            },
            {
              "Study Parameters ID": 1448925974,
              "Variant Annotation ID": 1448925972,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.32,
              "Confidence Interval Start": 1.42,
              "Confidence Interval Stop": 3.79,
              "Biogeographical Groups": "Multiple groups",
              "Variant Annotation ID_norm": "1448925972"
            },
            {
              "Study Parameters ID": 1448926101,
              "Variant Annotation ID": 1448926099,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 1.76,
              "Confidence Interval Start": 1.02,
              "Confidence Interval Stop": 3.02,
              "Biogeographical Groups": "Multiple groups",
              "Variant Annotation ID_norm": "1448926099"
            },
            {
              "Study Parameters ID": 1448926091,
              "Variant Annotation ID": 1448926089,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 1.76,
              "Confidence Interval Start": 1.02,
              "Confidence Interval Stop": 3.02,
              "Biogeographical Groups": "Multiple groups",
              "Variant Annotation ID_norm": "1448926089"
            },
            {
              "Study Parameters ID": 1448926291,
              "Variant Annotation ID": 1448926289,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.0,
              "Confidence Interval Start": 1.23,
              "Confidence Interval Stop": 3.24,
              "Biogeographical Groups": "Multiple groups",
              "Variant Annotation ID_norm": "1448926289"
            },
            {
              "Study Parameters ID": 1448926037,
              "Variant Annotation ID": 1448926035,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.32,
              "Confidence Interval Start": 1.42,
              "Confidence Interval Stop": 3.79,
              "Biogeographical Groups": "Multiple groups",
              "Variant Annotation ID_norm": "1448926035"
            },
            {
              "Study Parameters ID": 1448925960,
              "Variant Annotation ID": 1448925958,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.32,
              "Confidence Interval Start": 1.42,
              "Confidence Interval Stop": 3.79,
              "Biogeographical Groups": "Multiple groups",
              "Variant Annotation ID_norm": "1448925958"
            },
            {
              "Study Parameters ID": 1448926271,
              "Variant Annotation ID": 1448926269,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.0,
              "Confidence Interval Start": 1.23,
              "Confidence Interval Stop": 3.24,
              "Biogeographical Groups": "Multiple groups",
              "Variant Annotation ID_norm": "1448926269"
            },
            {
              "Study Parameters ID": 1448926141,
              "Variant Annotation ID": 1448926139,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 1.76,
              "Confidence Interval Start": 1.02,
              "Confidence Interval Stop": 3.02,
              "Biogeographical Groups": "Multiple groups",
              "Variant Annotation ID_norm": "1448926139"
            },
            {
              "Study Parameters ID": 1448926161,
              "Variant Annotation ID": 1448926159,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.18,
              "Confidence Interval Start": 0.07,
              "Confidence Interval Stop": 0.46,
              "Biogeographical Groups": "Multiple groups",
              "Variant Annotation ID_norm": "1448926159"
            },
            {
              "Study Parameters ID": 1448926211,
              "Variant Annotation ID": 1448926209,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.18,
              "Confidence Interval Start": 0.07,
              "Confidence Interval Stop": 0.46,
              "Biogeographical Groups": "Multiple groups",
              "Variant Annotation ID_norm": "1448926209"
            },
            {
              "Study Parameters ID": 1448998277,
              "Variant Annotation ID": 1448998275,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.32,
              "Confidence Interval Start": 1.42,
              "Confidence Interval Stop": 3.79,
              "Biogeographical Groups": "Multiple groups",
              "Variant Annotation ID_norm": "1448998275"
            },
            {
              "Study Parameters ID": 1448925885,
              "Variant Annotation ID": 1448925883,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.91,
              "Confidence Interval Start": 1.62,
              "Confidence Interval Stop": 5.23,
              "Biogeographical Groups": "Multiple groups",
              "Variant Annotation ID_norm": "1448925883"
            },
            {
              "Study Parameters ID": 1448926151,
              "Variant Annotation ID": 1448926149,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 1.76,
              "Confidence Interval Start": 1.02,
              "Confidence Interval Stop": 3.02,
              "Biogeographical Groups": "Multiple groups",
              "Variant Annotation ID_norm": "1448926149"
            },
            {
              "Study Parameters ID": 1448925895,
              "Variant Annotation ID": 1448925893,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.91,
              "Confidence Interval Start": 1.62,
              "Confidence Interval Stop": 5.23,
              "Biogeographical Groups": "Multiple groups",
              "Variant Annotation ID_norm": "1448925893"
            },
            {
              "Study Parameters ID": 1448926024,
              "Variant Annotation ID": 1448926022,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.32,
              "Confidence Interval Start": 1.42,
              "Confidence Interval Stop": 3.79,
              "Biogeographical Groups": "Multiple groups",
              "Variant Annotation ID_norm": "1448926022"
            },
            {
              "Study Parameters ID": 1448926281,
              "Variant Annotation ID": 1448926279,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.0,
              "Confidence Interval Start": 1.23,
              "Confidence Interval Stop": 3.24,
              "Biogeographical Groups": "Multiple groups",
              "Variant Annotation ID_norm": "1448926279"
            },
            {
              "Study Parameters ID": 1448926014,
              "Variant Annotation ID": 1448926012,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.32,
              "Confidence Interval Start": 1.42,
              "Confidence Interval Stop": 3.79,
              "Biogeographical Groups": "Multiple groups",
              "Variant Annotation ID_norm": "1448926012"
            },
            {
              "Study Parameters ID": 1448926077,
              "Variant Annotation ID": 1448926075,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 1.76,
              "Confidence Interval Start": 1.02,
              "Confidence Interval Stop": 3.02,
              "Biogeographical Groups": "Multiple groups",
              "Variant Annotation ID_norm": "1448926075"
            },
            {
              "Study Parameters ID": 1448926201,
              "Variant Annotation ID": 1448926199,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.18,
              "Confidence Interval Start": 0.07,
              "Confidence Interval Stop": 0.46,
              "Biogeographical Groups": "Multiple groups",
              "Variant Annotation ID_norm": "1448926199"
            },
            {
              "Study Parameters ID": 1448926131,
              "Variant Annotation ID": 1448926129,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 1.76,
              "Confidence Interval Start": 1.02,
              "Confidence Interval Stop": 3.02,
              "Biogeographical Groups": "Multiple groups",
              "Variant Annotation ID_norm": "1448926129"
            },
            {
              "Study Parameters ID": 1448925875,
              "Variant Annotation ID": 1448925873,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.91,
              "Confidence Interval Start": 1.62,
              "Confidence Interval Stop": 5.23,
              "Biogeographical Groups": "Multiple groups",
              "Variant Annotation ID_norm": "1448925873"
            },
            {
              "Study Parameters ID": 1448926004,
              "Variant Annotation ID": 1448926002,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.32,
              "Confidence Interval Start": 1.42,
              "Confidence Interval Stop": 3.79,
              "Biogeographical Groups": "Multiple groups",
              "Variant Annotation ID_norm": "1448926002"
            },
            {
              "Study Parameters ID": 1448926261,
              "Variant Annotation ID": 1448926259,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.0,
              "Confidence Interval Start": 1.23,
              "Confidence Interval Stop": 3.24,
              "Biogeographical Groups": "Multiple groups",
              "Variant Annotation ID_norm": "1448926259"
            },
            {
              "Study Parameters ID": 1448926251,
              "Variant Annotation ID": 1448926249,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.18,
              "Confidence Interval Start": 0.07,
              "Confidence Interval Stop": 0.46,
              "Biogeographical Groups": "Multiple groups",
              "Variant Annotation ID_norm": "1448926249"
            },
            {
              "Study Parameters ID": 1448926311,
              "Variant Annotation ID": 1448926309,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.0,
              "Confidence Interval Start": 1.23,
              "Confidence Interval Stop": 3.24,
              "Biogeographical Groups": "Multiple groups",
              "Variant Annotation ID_norm": "1448926309"
            },
            {
              "Study Parameters ID": 1448926121,
              "Variant Annotation ID": 1448926119,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 1.76,
              "Confidence Interval Start": 1.02,
              "Confidence Interval Stop": 3.02,
              "Biogeographical Groups": "Multiple groups",
              "Variant Annotation ID_norm": "1448926119"
            },
            {
              "Study Parameters ID": 1448925925,
              "Variant Annotation ID": 1448925923,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.91,
              "Confidence Interval Start": 1.62,
              "Confidence Interval Stop": 5.23,
              "Biogeographical Groups": "Multiple groups",
              "Variant Annotation ID_norm": "1448925923"
            },
            {
              "Study Parameters ID": 1448926181,
              "Variant Annotation ID": 1448926179,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.18,
              "Confidence Interval Start": 0.07,
              "Confidence Interval Stop": 0.46,
              "Biogeographical Groups": "Multiple groups",
              "Variant Annotation ID_norm": "1448926179"
            },
            {
              "Study Parameters ID": 1449155766,
              "Variant Annotation ID": 1449155757,
              "Study Type": "case/control, clinical trial",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "Study Cohort: NCT00310843",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.07,
              "Confidence Interval Start": 1.12,
              "Confidence Interval Stop": 3.82,
              "Biogeographical Groups": "Unknown",
              "Variant Annotation ID_norm": "1449155757"
            },
            {
              "Study Parameters ID": 1449155773,
              "Variant Annotation ID": 1449155771,
              "Study Type": "case/control, clinical trial",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "Study Cohort: NCT00310843",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.07,
              "Confidence Interval Start": 1.12,
              "Confidence Interval Stop": 3.82,
              "Biogeographical Groups": "Unknown",
              "Variant Annotation ID_norm": "1449155771"
            }
          ],
          "unmatched_predictions": []
        }
      },
      "overall_score": 0.04291694867564727,
      "num_benchmarks": 4
    },
    {
      "pmid": "30661084",
      "pmcid": "PMC6435416",
      "title": "CYP2D6 genotype and adverse events to risperidone in children and adolescents",
      "benchmarks": {
        "drug_annotations": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Variant/Haplotypes": "CYP2D6",
              "Gene": "CYP2D6",
              "Drug(s)": "risperidone",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Poor/intermediate metabolizers had increased adverse event risk (adjusted odds ratio 2.4, 95% CI 1.1-5.1, P=0.03) during risperidone treatment.",
              "Sentence": "CYP2D6 poor metabolizers are associated with increased adverse events during risperidone treatment in children.",
              "Alleles": "",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "Comparison Allele(s) or Genotype(s)": "",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "pediatric",
              "Population types": "in children",
              "Population Phenotypes or diseases": "Side Effect:adverse events",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "adverse events from",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "In multivariate analysis adjusting for age, sex, race, and initial dose, poor/intermediate metabolizers had increased AE risk (adjusted odds ratio 2.4, 95% confidence interval 1.1-5.1, P=0.03).",
                "AEs were more common in poor/intermediate versus normal/ultrarapid metabolizers (15/33, 46% vs. 61/224, 27%, P=0.04).",
                "Children with CYP2D6 poor or intermediate metabolizer phenotypes are at greater risk for risperidone AEs."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "poor",
              "Gene": "CYP2D6",
              "Drug(s)": "risperidone",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Poor/intermediate metabolizers had increased adverse event risk (adjusted odds ratio 2.4, 95% CI 1.1-5.1, P=0.03) during risperidone treatment.",
              "Sentence": "CYP2D6 poor metabolizers are associated with increased adverse events during risperidone treatment in children.",
              "Alleles": "",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "Comparison Allele(s) or Genotype(s)": "",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "pediatric",
              "Population types": "in children",
              "Population Phenotypes or diseases": "Side Effect:adverse events",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "adverse events from",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "In multivariate analysis adjusting for age, sex, race, and initial dose, poor/intermediate metabolizers had increased AE risk (adjusted odds ratio 2.4, 95% confidence interval 1.1-5.1, P=0.03).",
                "AEs were more common in poor/intermediate versus normal/ultrarapid metabolizers (15/33, 46% vs. 61/224, 27%, P=0.04).",
                "Children with CYP2D6 poor or intermediate metabolizer phenotypes are at greater risk for risperidone AEs."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "metabolizers",
              "Gene": "CYP2D6",
              "Drug(s)": "risperidone",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Poor/intermediate metabolizers had increased adverse event risk (adjusted odds ratio 2.4, 95% CI 1.1-5.1, P=0.03) during risperidone treatment.",
              "Sentence": "CYP2D6 poor metabolizers are associated with increased adverse events during risperidone treatment in children.",
              "Alleles": "",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "Comparison Allele(s) or Genotype(s)": "",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "pediatric",
              "Population types": "in children",
              "Population Phenotypes or diseases": "Side Effect:adverse events",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "adverse events from",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "In multivariate analysis adjusting for age, sex, race, and initial dose, poor/intermediate metabolizers had increased AE risk (adjusted odds ratio 2.4, 95% confidence interval 1.1-5.1, P=0.03).",
                "AEs were more common in poor/intermediate versus normal/ultrarapid metabolizers (15/33, 46% vs. 61/224, 27%, P=0.04).",
                "Children with CYP2D6 poor or intermediate metabolizer phenotypes are at greater risk for risperidone AEs."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "CYP2D6",
              "Gene": "CYP2D6",
              "Drug(s)": "risperidone",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Poor/intermediate metabolizers had increased adverse event risk (adjusted odds ratio 2.4, 95% CI 1.1-5.1, P=0.03) during risperidone treatment.",
              "Sentence": "CYP2D6 poor metabolizers are associated with increased adverse events during risperidone treatment in children.",
              "Alleles": "",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "Comparison Allele(s) or Genotype(s)": "",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "pediatric",
              "Population types": "in children",
              "Population Phenotypes or diseases": "Side Effect:adverse events",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "adverse events from",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "In multivariate analysis adjusting for age, sex, race, and initial dose, poor/intermediate metabolizers had increased AE risk (adjusted odds ratio 2.4, 95% confidence interval 1.1-5.1, P=0.03).",
                "AEs were more common in poor/intermediate versus normal/ultrarapid metabolizers (15/33, 46% vs. 61/224, 27%, P=0.04).",
                "Children with CYP2D6 poor or intermediate metabolizer phenotypes are at greater risk for risperidone AEs."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "intermediate",
              "Gene": "CYP2D6",
              "Drug(s)": "risperidone",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Poor/intermediate metabolizers had increased adverse event risk (adjusted odds ratio 2.4, 95% CI 1.1-5.1, P=0.03) during risperidone treatment.",
              "Sentence": "CYP2D6 poor metabolizers are associated with increased adverse events during risperidone treatment in children.",
              "Alleles": "",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "Comparison Allele(s) or Genotype(s)": "",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "pediatric",
              "Population types": "in children",
              "Population Phenotypes or diseases": "Side Effect:adverse events",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "adverse events from",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "In multivariate analysis adjusting for age, sex, race, and initial dose, poor/intermediate metabolizers had increased AE risk (adjusted odds ratio 2.4, 95% confidence interval 1.1-5.1, P=0.03).",
                "AEs were more common in poor/intermediate versus normal/ultrarapid metabolizers (15/33, 46% vs. 61/224, 27%, P=0.04).",
                "Children with CYP2D6 poor or intermediate metabolizer phenotypes are at greater risk for risperidone AEs."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "metabolizers",
              "Gene": "CYP2D6",
              "Drug(s)": "risperidone",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Poor/intermediate metabolizers had increased adverse event risk (adjusted odds ratio 2.4, 95% CI 1.1-5.1, P=0.03) during risperidone treatment.",
              "Sentence": "CYP2D6 poor metabolizers are associated with increased adverse events during risperidone treatment in children.",
              "Alleles": "",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "Comparison Allele(s) or Genotype(s)": "",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "pediatric",
              "Population types": "in children",
              "Population Phenotypes or diseases": "Side Effect:adverse events",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "adverse events from",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "In multivariate analysis adjusting for age, sex, race, and initial dose, poor/intermediate metabolizers had increased AE risk (adjusted odds ratio 2.4, 95% confidence interval 1.1-5.1, P=0.03).",
                "AEs were more common in poor/intermediate versus normal/ultrarapid metabolizers (15/33, 46% vs. 61/224, 27%, P=0.04).",
                "Children with CYP2D6 poor or intermediate metabolizer phenotypes are at greater risk for risperidone AEs."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "CYP2D6",
              "Gene": "CYP2D6",
              "Drug(s)": "risperidone",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Poor/intermediate metabolizers had increased adverse event risk (adjusted odds ratio 2.4, 95% CI 1.1-5.1, P=0.03) during risperidone treatment.",
              "Sentence": "CYP2D6 poor metabolizers are associated with increased adverse events during risperidone treatment in children.",
              "Alleles": "",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "Comparison Allele(s) or Genotype(s)": "",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "pediatric",
              "Population types": "in children",
              "Population Phenotypes or diseases": "Side Effect:adverse events",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "adverse events from",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "In multivariate analysis adjusting for age, sex, race, and initial dose, poor/intermediate metabolizers had increased AE risk (adjusted odds ratio 2.4, 95% confidence interval 1.1-5.1, P=0.03).",
                "AEs were more common in poor/intermediate versus normal/ultrarapid metabolizers (15/33, 46% vs. 61/224, 27%, P=0.04).",
                "Children with CYP2D6 poor or intermediate metabolizer phenotypes are at greater risk for risperidone AEs."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "normal",
              "Gene": "CYP2D6",
              "Drug(s)": "risperidone",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Poor/intermediate metabolizers had increased adverse event risk (adjusted odds ratio 2.4, 95% CI 1.1-5.1, P=0.03) during risperidone treatment.",
              "Sentence": "CYP2D6 poor metabolizers are associated with increased adverse events during risperidone treatment in children.",
              "Alleles": "",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "Comparison Allele(s) or Genotype(s)": "",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "pediatric",
              "Population types": "in children",
              "Population Phenotypes or diseases": "Side Effect:adverse events",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "adverse events from",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "In multivariate analysis adjusting for age, sex, race, and initial dose, poor/intermediate metabolizers had increased AE risk (adjusted odds ratio 2.4, 95% confidence interval 1.1-5.1, P=0.03).",
                "AEs were more common in poor/intermediate versus normal/ultrarapid metabolizers (15/33, 46% vs. 61/224, 27%, P=0.04).",
                "Children with CYP2D6 poor or intermediate metabolizer phenotypes are at greater risk for risperidone AEs."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "metabolizers",
              "Gene": "CYP2D6",
              "Drug(s)": "risperidone",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Poor/intermediate metabolizers had increased adverse event risk (adjusted odds ratio 2.4, 95% CI 1.1-5.1, P=0.03) during risperidone treatment.",
              "Sentence": "CYP2D6 poor metabolizers are associated with increased adverse events during risperidone treatment in children.",
              "Alleles": "",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "Comparison Allele(s) or Genotype(s)": "",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "pediatric",
              "Population types": "in children",
              "Population Phenotypes or diseases": "Side Effect:adverse events",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "adverse events from",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "In multivariate analysis adjusting for age, sex, race, and initial dose, poor/intermediate metabolizers had increased AE risk (adjusted odds ratio 2.4, 95% confidence interval 1.1-5.1, P=0.03).",
                "AEs were more common in poor/intermediate versus normal/ultrarapid metabolizers (15/33, 46% vs. 61/224, 27%, P=0.04).",
                "Children with CYP2D6 poor or intermediate metabolizer phenotypes are at greater risk for risperidone AEs."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "CYP2D6",
              "Gene": "CYP2D6",
              "Drug(s)": "risperidone",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Poor/intermediate metabolizers had increased adverse event risk (adjusted odds ratio 2.4, 95% CI 1.1-5.1, P=0.03) during risperidone treatment.",
              "Sentence": "CYP2D6 poor metabolizers are associated with increased adverse events during risperidone treatment in children.",
              "Alleles": "",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "Comparison Allele(s) or Genotype(s)": "",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "pediatric",
              "Population types": "in children",
              "Population Phenotypes or diseases": "Side Effect:adverse events",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "adverse events from",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "In multivariate analysis adjusting for age, sex, race, and initial dose, poor/intermediate metabolizers had increased AE risk (adjusted odds ratio 2.4, 95% confidence interval 1.1-5.1, P=0.03).",
                "AEs were more common in poor/intermediate versus normal/ultrarapid metabolizers (15/33, 46% vs. 61/224, 27%, P=0.04).",
                "Children with CYP2D6 poor or intermediate metabolizer phenotypes are at greater risk for risperidone AEs."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "ultrarapid",
              "Gene": "CYP2D6",
              "Drug(s)": "risperidone",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Poor/intermediate metabolizers had increased adverse event risk (adjusted odds ratio 2.4, 95% CI 1.1-5.1, P=0.03) during risperidone treatment.",
              "Sentence": "CYP2D6 poor metabolizers are associated with increased adverse events during risperidone treatment in children.",
              "Alleles": "",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "Comparison Allele(s) or Genotype(s)": "",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "pediatric",
              "Population types": "in children",
              "Population Phenotypes or diseases": "Side Effect:adverse events",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "adverse events from",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "In multivariate analysis adjusting for age, sex, race, and initial dose, poor/intermediate metabolizers had increased AE risk (adjusted odds ratio 2.4, 95% confidence interval 1.1-5.1, P=0.03).",
                "AEs were more common in poor/intermediate versus normal/ultrarapid metabolizers (15/33, 46% vs. 61/224, 27%, P=0.04).",
                "Children with CYP2D6 poor or intermediate metabolizer phenotypes are at greater risk for risperidone AEs."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "metabolizers",
              "Gene": "CYP2D6",
              "Drug(s)": "risperidone",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Poor/intermediate metabolizers had increased adverse event risk (adjusted odds ratio 2.4, 95% CI 1.1-5.1, P=0.03) during risperidone treatment.",
              "Sentence": "CYP2D6 poor metabolizers are associated with increased adverse events during risperidone treatment in children.",
              "Alleles": "",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "Comparison Allele(s) or Genotype(s)": "",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "pediatric",
              "Population types": "in children",
              "Population Phenotypes or diseases": "Side Effect:adverse events",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "adverse events from",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "In multivariate analysis adjusting for age, sex, race, and initial dose, poor/intermediate metabolizers had increased AE risk (adjusted odds ratio 2.4, 95% confidence interval 1.1-5.1, P=0.03).",
                "AEs were more common in poor/intermediate versus normal/ultrarapid metabolizers (15/33, 46% vs. 61/224, 27%, P=0.04).",
                "Children with CYP2D6 poor or intermediate metabolizer phenotypes are at greater risk for risperidone AEs."
              ],
              "_expanded_from_multi_variant": true
            }
          ]
        },
        "phenotype_annotations": {
          "total_samples": 15,
          "field_scores": {
            "Variant/Haplotypes": {
              "mean_score": 0.2,
              "scores": [
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Gene": {
              "mean_score": 0.6,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Drug(s)": {
              "mean_score": 0.6,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Phenotype Category": {
              "mean_score": 0.6,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Alleles": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Is/Is Not associated": {
              "mean_score": 0.4,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Direction of effect": {
              "mean_score": 0.4,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Phenotype": {
              "mean_score": 0.5828566074371337,
              "scores": [
                0.9714276790618896,
                0.9714276790618896,
                0.9714276790618896,
                0.9714276790618896,
                0.9714276790618896,
                0.9714276790618896,
                0.9714276790618896,
                0.9714276790618896,
                0.9714276790618896,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "When treated with/exposed to/when assayed with": {
              "mean_score": 0.5221225261688233,
              "scores": [
                0.8702042102813721,
                0.8702042102813721,
                0.8702042102813721,
                0.8702042102813721,
                0.8702042102813721,
                0.8702042102813721,
                0.8702042102813721,
                0.8702042102813721,
                0.8702042102813721,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Comparison Allele(s) or Genotype(s)": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.3855645398298899,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 1.0,
                "Alleles": 0.0,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.9714276790618896,
                "When treated with/exposed to/when assayed with": 0.8702042102813721,
                "Comparison Allele(s) or Genotype(s)": 0.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "CYP2D6*1",
                  "prediction": "CYP2D6"
                },
                "Gene": {
                  "ground_truth": "CYP2D6",
                  "prediction": "CYP2D6"
                },
                "Drug(s)": {
                  "ground_truth": "risperidone",
                  "prediction": "risperidone"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17",
                  "prediction": null
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:adverse events",
                  "prediction": "adverse events"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "due to",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "*1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1",
                  "prediction": null
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 1.0,
                "Alleles": 0.0,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.9714276790618896,
                "When treated with/exposed to/when assayed with": 0.8702042102813721,
                "Comparison Allele(s) or Genotype(s)": 0.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "CYP2D6*1",
                  "prediction": "CYP2D6"
                },
                "Gene": {
                  "ground_truth": "CYP2D6",
                  "prediction": "CYP2D6"
                },
                "Drug(s)": {
                  "ground_truth": "risperidone",
                  "prediction": "risperidone"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17",
                  "prediction": null
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:adverse events",
                  "prediction": "adverse events"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "due to",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "*1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1",
                  "prediction": null
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 2,
              "field_scores": {
                "Variant/Haplotypes": 0.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 1.0,
                "Alleles": 0.0,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.9714276790618896,
                "When treated with/exposed to/when assayed with": 0.8702042102813721,
                "Comparison Allele(s) or Genotype(s)": 0.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "CYP2D6*1",
                  "prediction": "poor"
                },
                "Gene": {
                  "ground_truth": "CYP2D6",
                  "prediction": "CYP2D6"
                },
                "Drug(s)": {
                  "ground_truth": "risperidone",
                  "prediction": "risperidone"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17",
                  "prediction": null
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:adverse events",
                  "prediction": "adverse events"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "due to",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "*1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1",
                  "prediction": null
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 3,
              "field_scores": {
                "Variant/Haplotypes": 0.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 1.0,
                "Alleles": 0.0,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.9714276790618896,
                "When treated with/exposed to/when assayed with": 0.8702042102813721,
                "Comparison Allele(s) or Genotype(s)": 0.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "CYP2D6*1",
                  "prediction": "metabolizer"
                },
                "Gene": {
                  "ground_truth": "CYP2D6",
                  "prediction": "CYP2D6"
                },
                "Drug(s)": {
                  "ground_truth": "risperidone",
                  "prediction": "risperidone"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17",
                  "prediction": null
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:adverse events",
                  "prediction": "adverse events"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "due to",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "*1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1",
                  "prediction": null
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 4,
              "field_scores": {
                "Variant/Haplotypes": 0.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 1.0,
                "Alleles": 0.0,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.9714276790618896,
                "When treated with/exposed to/when assayed with": 0.8702042102813721,
                "Comparison Allele(s) or Genotype(s)": 0.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "CYP2D6*1",
                  "prediction": "intermediate"
                },
                "Gene": {
                  "ground_truth": "CYP2D6",
                  "prediction": "CYP2D6"
                },
                "Drug(s)": {
                  "ground_truth": "risperidone",
                  "prediction": "risperidone"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17",
                  "prediction": null
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:adverse events",
                  "prediction": "adverse events"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "due to",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "*1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1",
                  "prediction": null
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 5,
              "field_scores": {
                "Variant/Haplotypes": 0.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 1.0,
                "Alleles": 0.0,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.9714276790618896,
                "When treated with/exposed to/when assayed with": 0.8702042102813721,
                "Comparison Allele(s) or Genotype(s)": 0.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "CYP2D6*1",
                  "prediction": "metabolizer"
                },
                "Gene": {
                  "ground_truth": "CYP2D6",
                  "prediction": "CYP2D6"
                },
                "Drug(s)": {
                  "ground_truth": "risperidone",
                  "prediction": "risperidone"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17",
                  "prediction": null
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:adverse events",
                  "prediction": "adverse events"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "due to",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "*1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1",
                  "prediction": null
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 6,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 1.0,
                "Alleles": 0.0,
                "Is/Is Not associated": 0.0,
                "Direction of effect": 0.0,
                "Phenotype": 0.9714276790618896,
                "When treated with/exposed to/when assayed with": 0.8702042102813721,
                "Comparison Allele(s) or Genotype(s)": 0.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "CYP2D6*1",
                  "prediction": "CYP2D6"
                },
                "Gene": {
                  "ground_truth": "CYP2D6",
                  "prediction": "CYP2D6"
                },
                "Drug(s)": {
                  "ground_truth": "risperidone",
                  "prediction": "risperidone"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17",
                  "prediction": null
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Not associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "decreased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:adverse events",
                  "prediction": "adverse events"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "due to",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "*1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1",
                  "prediction": null
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 7,
              "field_scores": {
                "Variant/Haplotypes": 0.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 1.0,
                "Alleles": 0.0,
                "Is/Is Not associated": 0.0,
                "Direction of effect": 0.0,
                "Phenotype": 0.9714276790618896,
                "When treated with/exposed to/when assayed with": 0.8702042102813721,
                "Comparison Allele(s) or Genotype(s)": 0.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "CYP2D6*1",
                  "prediction": "normal/ultrarapid"
                },
                "Gene": {
                  "ground_truth": "CYP2D6",
                  "prediction": "CYP2D6"
                },
                "Drug(s)": {
                  "ground_truth": "risperidone",
                  "prediction": "risperidone"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17",
                  "prediction": null
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Not associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "decreased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:adverse events",
                  "prediction": "adverse events"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "due to",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "*1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1",
                  "prediction": null
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 8,
              "field_scores": {
                "Variant/Haplotypes": 0.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 1.0,
                "Alleles": 0.0,
                "Is/Is Not associated": 0.0,
                "Direction of effect": 0.0,
                "Phenotype": 0.9714276790618896,
                "When treated with/exposed to/when assayed with": 0.8702042102813721,
                "Comparison Allele(s) or Genotype(s)": 0.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "CYP2D6*1",
                  "prediction": "metabolizer"
                },
                "Gene": {
                  "ground_truth": "CYP2D6",
                  "prediction": "CYP2D6"
                },
                "Drug(s)": {
                  "ground_truth": "risperidone",
                  "prediction": "risperidone"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17",
                  "prediction": null
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Not associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "decreased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:adverse events",
                  "prediction": "adverse events"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "due to",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "*1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1",
                  "prediction": null
                }
              },
              "dependency_issues": []
            }
          ],
          "aligned_variants": [
            "cyp2d6*1",
            "cyp2d6*1xn",
            "cyp2d6*2",
            "cyp2d6+risperidone",
            "cyp2d6+risperidone",
            "cyp2d6+risperidone",
            "cyp2d6+risperidone",
            "cyp2d6+risperidone",
            "cyp2d6+risperidone"
          ],
          "unmatched_ground_truth": [
            {
              "Variant Annotation ID": 1450932846,
              "Variant/Haplotypes": "CYP2D6*9",
              "Gene": "CYP2D6",
              "Drug(s)": "risperidone",
              "PMID": 30661084,
              "Phenotype Category": "Toxicity",
              "Significance": "yes",
              "Notes": "Normal metabolizer also included: *35/*35 + *2/*9 + *2/*3 + *2/*29 + *2/*10 + *1xN/*4 + *10/*46 + *10/*35 + *1/*6 + *1/*33 + *1/*10 + *4/*35. Most common AEs were weight change (9%), sedation (6%), and extrapyramidal symptoms (6%). Of the 224 normal/ultrarapid metabolizers, 20 (9%) were taking one or more concomitant drugs that are known strong inhibitors of CYP2D6. The frequency of AEs was not different among those with a strong concomitant CYP2D6 inhibitor (6/20, 30%) vs. those without (55/204, 27%, P= 0.8). CYP2D6 phenoconversion not considered in the PM+IM vs NM+UM analysis.",
              "Sentence": "CYP2D6 *4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with increased likelihood of adverse events due to risperidone in children as compared to CYP2D6 *1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) .",
              "Alleles": "*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17",
              "Specialty Population": "Pediatric",
              "Metabolizer types": "intermediate metabolizer and poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Side Effect:adverse events",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "due to",
              "Multiple drugs And/or": null,
              "Population types": "in children",
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1",
              "Comparison Metabolizer types": "normal metabolizer and ultrarapid metabolizer",
              "PMID_norm": "30661084",
              "Variant Annotation ID_norm": "1450932846",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1450932846,
              "Variant/Haplotypes": "CYP2D6*10",
              "Gene": "CYP2D6",
              "Drug(s)": "risperidone",
              "PMID": 30661084,
              "Phenotype Category": "Toxicity",
              "Significance": "yes",
              "Notes": "Normal metabolizer also included: *35/*35 + *2/*9 + *2/*3 + *2/*29 + *2/*10 + *1xN/*4 + *10/*46 + *10/*35 + *1/*6 + *1/*33 + *1/*10 + *4/*35. Most common AEs were weight change (9%), sedation (6%), and extrapyramidal symptoms (6%). Of the 224 normal/ultrarapid metabolizers, 20 (9%) were taking one or more concomitant drugs that are known strong inhibitors of CYP2D6. The frequency of AEs was not different among those with a strong concomitant CYP2D6 inhibitor (6/20, 30%) vs. those without (55/204, 27%, P= 0.8). CYP2D6 phenoconversion not considered in the PM+IM vs NM+UM analysis.",
              "Sentence": "CYP2D6 *4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with increased likelihood of adverse events due to risperidone in children as compared to CYP2D6 *1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) .",
              "Alleles": "*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17",
              "Specialty Population": "Pediatric",
              "Metabolizer types": "intermediate metabolizer and poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Side Effect:adverse events",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "due to",
              "Multiple drugs And/or": null,
              "Population types": "in children",
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1",
              "Comparison Metabolizer types": "normal metabolizer and ultrarapid metabolizer",
              "PMID_norm": "30661084",
              "Variant Annotation ID_norm": "1450932846",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1450932846,
              "Variant/Haplotypes": "CYP2D6*17",
              "Gene": "CYP2D6",
              "Drug(s)": "risperidone",
              "PMID": 30661084,
              "Phenotype Category": "Toxicity",
              "Significance": "yes",
              "Notes": "Normal metabolizer also included: *35/*35 + *2/*9 + *2/*3 + *2/*29 + *2/*10 + *1xN/*4 + *10/*46 + *10/*35 + *1/*6 + *1/*33 + *1/*10 + *4/*35. Most common AEs were weight change (9%), sedation (6%), and extrapyramidal symptoms (6%). Of the 224 normal/ultrarapid metabolizers, 20 (9%) were taking one or more concomitant drugs that are known strong inhibitors of CYP2D6. The frequency of AEs was not different among those with a strong concomitant CYP2D6 inhibitor (6/20, 30%) vs. those without (55/204, 27%, P= 0.8). CYP2D6 phenoconversion not considered in the PM+IM vs NM+UM analysis.",
              "Sentence": "CYP2D6 *4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with increased likelihood of adverse events due to risperidone in children as compared to CYP2D6 *1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) .",
              "Alleles": "*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17",
              "Specialty Population": "Pediatric",
              "Metabolizer types": "intermediate metabolizer and poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Side Effect:adverse events",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "due to",
              "Multiple drugs And/or": null,
              "Population types": "in children",
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1",
              "Comparison Metabolizer types": "normal metabolizer and ultrarapid metabolizer",
              "PMID_norm": "30661084",
              "Variant Annotation ID_norm": "1450932846",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1450932846,
              "Variant/Haplotypes": "CYP2D6*29",
              "Gene": "CYP2D6",
              "Drug(s)": "risperidone",
              "PMID": 30661084,
              "Phenotype Category": "Toxicity",
              "Significance": "yes",
              "Notes": "Normal metabolizer also included: *35/*35 + *2/*9 + *2/*3 + *2/*29 + *2/*10 + *1xN/*4 + *10/*46 + *10/*35 + *1/*6 + *1/*33 + *1/*10 + *4/*35. Most common AEs were weight change (9%), sedation (6%), and extrapyramidal symptoms (6%). Of the 224 normal/ultrarapid metabolizers, 20 (9%) were taking one or more concomitant drugs that are known strong inhibitors of CYP2D6. The frequency of AEs was not different among those with a strong concomitant CYP2D6 inhibitor (6/20, 30%) vs. those without (55/204, 27%, P= 0.8). CYP2D6 phenoconversion not considered in the PM+IM vs NM+UM analysis.",
              "Sentence": "CYP2D6 *4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with increased likelihood of adverse events due to risperidone in children as compared to CYP2D6 *1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) .",
              "Alleles": "*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17",
              "Specialty Population": "Pediatric",
              "Metabolizer types": "intermediate metabolizer and poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Side Effect:adverse events",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "due to",
              "Multiple drugs And/or": null,
              "Population types": "in children",
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1",
              "Comparison Metabolizer types": "normal metabolizer and ultrarapid metabolizer",
              "PMID_norm": "30661084",
              "Variant Annotation ID_norm": "1450932846",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1450932846,
              "Variant/Haplotypes": "CYP2D6*35",
              "Gene": "CYP2D6",
              "Drug(s)": "risperidone",
              "PMID": 30661084,
              "Phenotype Category": "Toxicity",
              "Significance": "yes",
              "Notes": "Normal metabolizer also included: *35/*35 + *2/*9 + *2/*3 + *2/*29 + *2/*10 + *1xN/*4 + *10/*46 + *10/*35 + *1/*6 + *1/*33 + *1/*10 + *4/*35. Most common AEs were weight change (9%), sedation (6%), and extrapyramidal symptoms (6%). Of the 224 normal/ultrarapid metabolizers, 20 (9%) were taking one or more concomitant drugs that are known strong inhibitors of CYP2D6. The frequency of AEs was not different among those with a strong concomitant CYP2D6 inhibitor (6/20, 30%) vs. those without (55/204, 27%, P= 0.8). CYP2D6 phenoconversion not considered in the PM+IM vs NM+UM analysis.",
              "Sentence": "CYP2D6 *4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with increased likelihood of adverse events due to risperidone in children as compared to CYP2D6 *1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) .",
              "Alleles": "*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17",
              "Specialty Population": "Pediatric",
              "Metabolizer types": "intermediate metabolizer and poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Side Effect:adverse events",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "due to",
              "Multiple drugs And/or": null,
              "Population types": "in children",
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1",
              "Comparison Metabolizer types": "normal metabolizer and ultrarapid metabolizer",
              "PMID_norm": "30661084",
              "Variant Annotation ID_norm": "1450932846",
              "_expanded_from_multi_variant": true
            },
            {
              "Variant Annotation ID": 1450932846,
              "Variant/Haplotypes": "CYP2D6*41",
              "Gene": "CYP2D6",
              "Drug(s)": "risperidone",
              "PMID": 30661084,
              "Phenotype Category": "Toxicity",
              "Significance": "yes",
              "Notes": "Normal metabolizer also included: *35/*35 + *2/*9 + *2/*3 + *2/*29 + *2/*10 + *1xN/*4 + *10/*46 + *10/*35 + *1/*6 + *1/*33 + *1/*10 + *4/*35. Most common AEs were weight change (9%), sedation (6%), and extrapyramidal symptoms (6%). Of the 224 normal/ultrarapid metabolizers, 20 (9%) were taking one or more concomitant drugs that are known strong inhibitors of CYP2D6. The frequency of AEs was not different among those with a strong concomitant CYP2D6 inhibitor (6/20, 30%) vs. those without (55/204, 27%, P= 0.8). CYP2D6 phenoconversion not considered in the PM+IM vs NM+UM analysis.",
              "Sentence": "CYP2D6 *4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with increased likelihood of adverse events due to risperidone in children as compared to CYP2D6 *1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) .",
              "Alleles": "*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17",
              "Specialty Population": "Pediatric",
              "Metabolizer types": "intermediate metabolizer and poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Side Effect:adverse events",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "due to",
              "Multiple drugs And/or": null,
              "Population types": "in children",
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1",
              "Comparison Metabolizer types": "normal metabolizer and ultrarapid metabolizer",
              "PMID_norm": "30661084",
              "Variant Annotation ID_norm": "1450932846",
              "_expanded_from_multi_variant": true
            }
          ],
          "unmatched_predictions": []
        },
        "functional_analysis": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "status": "missing_var_fa_ann"
        },
        "study_parameters": {
          "total_samples": 1,
          "field_scores": {
            "Study Type": {
              "mean_score": 0.0,
              "scores": [
                0.0
              ]
            },
            "Study Cases": {
              "mean_score": 1.0,
              "scores": [
                1.0
              ]
            },
            "Study Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0
              ]
            },
            "Characteristics": {
              "mean_score": 0.9157626628875732,
              "scores": [
                0.9157626628875732
              ]
            },
            "Characteristics Type": {
              "mean_score": 1.0,
              "scores": [
                1.0
              ]
            },
            "Frequency In Cases": {
              "mean_score": 1.0,
              "scores": [
                1.0
              ]
            },
            "Allele Of Frequency In Cases": {
              "mean_score": 1.0,
              "scores": [
                1.0
              ]
            },
            "Frequency In Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0
              ]
            },
            "Allele Of Frequency In Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0
              ]
            },
            "P Value": {
              "mean_score": 1.0,
              "scores": [
                1.0
              ]
            },
            "Ratio Stat Type": {
              "mean_score": 1.0,
              "scores": [
                1.0
              ]
            },
            "Ratio Stat": {
              "mean_score": 1.0,
              "scores": [
                1.0
              ]
            },
            "Confidence Interval Start": {
              "mean_score": 1.0,
              "scores": [
                1.0
              ]
            },
            "Confidence Interval Stop": {
              "mean_score": 1.0,
              "scores": [
                1.0
              ]
            },
            "Biogeographical Groups": {
              "mean_score": 0.0,
              "scores": [
                0.0
              ]
            }
          },
          "overall_score": 0.8610508441925049,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.9157626628875732,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 1.0,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1450932850,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1450932846,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "cohort, retrospective",
                  "prediction": "cohort"
                },
                "Study Cases": {
                  "ground_truth": 257.0,
                  "prediction": 257
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "multivariate analysis adjusted for age, sex, race, and initial risperidone dose",
                  "prediction": "Children \u226418 years treated with risperidone for at least four weeks"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.03",
                  "prediction": "= 0.03"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": 2.4,
                  "prediction": 2.4
                },
                "Confidence Interval Start": {
                  "ground_truth": 1.1,
                  "prediction": 1.1
                },
                "Confidence Interval Stop": {
                  "ground_truth": 5.1,
                  "prediction": 5.1
                },
                "Biogeographical Groups": {
                  "ground_truth": "Multiple groups, White Hispanic, White non-Hispanic, African American, Asian/Pacific Islander, Native American or 'Unknown' ethnicities",
                  "prediction": "Unknown"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            }
          ],
          "aligned_variants": [
            "cohort, retrospective:multivariate analysi"
          ],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 257,
              "Study Controls": null,
              "Characteristics": "Children \u226418 years treated with risperidone for at least four weeks",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": 0.46,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": 0.27,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.04",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.4,
              "Confidence Interval Start": 1.1,
              "Confidence Interval Stop": 5.1,
              "Biogeographical Groups": "Unknown",
              "Variant Annotation ID_norm": null
            }
          ]
        }
      },
      "overall_score": 0.287879530787468,
      "num_benchmarks": 4
    },
    {
      "pmid": "31024313",
      "pmcid": "PMC6465603",
      "title": "NUDT15 Polymorphism Confer Increased Susceptibility to Thiopurine-Induced Leukopenia in Patients With Autoimmune Hepatitis and Related Cirrhosis",
      "benchmarks": {
        "drug_annotations": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Variant/Haplotypes": "rs116855232",
              "Gene": "NUDT15",
              "Drug(s)": "azathioprine",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "The T risk allele in NUDT15 is significantly associated with thiopurine-induced leukopenia in Chinese patients (P < 0.00001, odds ratio = 20.41).",
              "Sentence": "The T allele is associated with increased risk of leukopenia in azathioprine context in Chinese patients with autoimmune hepatitis.",
              "Alleles": "CC, CT, TT",
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of",
              "Multiple drugs And/or": null,
              "Population types": "in patients with autoimmune hepatitis",
              "Population Phenotypes or diseases": "Other:autoimmune hepatitis",
              "Specialty Population": null,
              "Comparison Allele(s) or Genotype(s)": "CC",
              "Comparison Metabolizer types": null,
              "PMID": 31024313,
              "Variant Annotation ID": 1,
              "Variant Annotation ID_norm": "1",
              "Citations": [
                "the T risk allele in NUDT15 is significantly associated with thiopurine-induced leukopenia in Chinese patients (P < 0.00001, odds ratio = 20.41)",
                "the rs116855232 variant allele resulted in a 7.86-fold (P < 0.00001, 95% confidence interval (CI): 6.13-10.08) increased risk of developing leukopenia",
                "When evaluated by rs116855232 genotype, leukopenia was significantly associated with the T allele [P < 0.00001, odds ratio = 20.41; 95% CI (7.84, 53.13)]"
              ]
            }
          ]
        },
        "phenotype_annotations": {
          "total_samples": 2,
          "field_scores": {
            "Variant/Haplotypes": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                0.0
              ]
            },
            "Gene": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                0.0
              ]
            },
            "Drug(s)": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                0.0
              ]
            },
            "Phenotype Category": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                0.0
              ]
            },
            "Alleles": {
              "mean_score": 0.4781634509563446,
              "scores": [
                0.9563269019126892,
                0.0
              ]
            },
            "Is/Is Not associated": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                0.0
              ]
            },
            "Direction of effect": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                0.0
              ]
            },
            "Phenotype": {
              "mean_score": 0.4786461889743805,
              "scores": [
                0.957292377948761,
                0.0
              ]
            },
            "When treated with/exposed to/when assayed with": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                0.0
              ]
            },
            "Comparison Allele(s) or Genotype(s)": {
              "mean_score": 0.47086411714553833,
              "scores": [
                0.9417282342910767,
                0.0
              ]
            }
          },
          "overall_score": 0.49128347262740135,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 1.0,
                "Alleles": 0.9563269019126892,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.957292377948761,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.9417282342910767
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "rs116855232",
                  "prediction": "rs116855232"
                },
                "Gene": {
                  "ground_truth": "NUDT15",
                  "prediction": "NUDT15"
                },
                "Drug(s)": {
                  "ground_truth": "azathioprine",
                  "prediction": "azathioprine"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "CT + TT",
                  "prediction": "CC, CT, TT"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:Leukopenia",
                  "prediction": "leukopenia"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "CC",
                  "prediction": "CC (wild-type)"
                }
              },
              "dependency_issues": []
            }
          ],
          "aligned_variants": [
            "rs116855232"
          ],
          "unmatched_ground_truth": [
            {
              "Variant Annotation ID": 1451237464,
              "Variant/Haplotypes": "rs1142345",
              "Gene": "TPMT",
              "Drug(s)": "azathioprine",
              "PMID": 31024313,
              "Phenotype Category": "Toxicity",
              "Significance": "no",
              "Notes": "TPMT\u22173C alleles were only observed in four subjects including 3 patients who were heterozygotes (TC) and 1 patient who was homozygous (CC).Authors state in discussion \"the lack of significance observed for rs1142345 in the present study is likely due to its low prevalence in East Asian populations and the small sample size of our cohort.",
              "Sentence": "Allele C is not associated with increased likelihood of Leukopenia when treated with azathioprine in people with Hepatitis, Autoimmune as compared to allele T.",
              "Alleles": "C",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Side Effect:Leukopenia",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Other:Autoimmune hepatitis",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "T",
              "Comparison Metabolizer types": null,
              "PMID_norm": "31024313",
              "Variant Annotation ID_norm": "1451237464"
            }
          ],
          "unmatched_predictions": []
        },
        "functional_analysis": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "status": "missing_var_fa_ann"
        },
        "study_parameters": {
          "total_samples": 2,
          "field_scores": {
            "Study Type": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Study Cases": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Study Controls": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Characteristics": {
              "mean_score": 0.4570173919200897,
              "scores": [
                0.9140347838401794,
                0.0
              ]
            },
            "Characteristics Type": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                0.0
              ]
            },
            "Frequency In Cases": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                0.0
              ]
            },
            "Allele Of Frequency In Cases": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                0.0
              ]
            },
            "Frequency In Controls": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                0.0
              ]
            },
            "Allele Of Frequency In Controls": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                0.0
              ]
            },
            "P Value": {
              "mean_score": 0.25,
              "scores": [
                0.5,
                0.0
              ]
            },
            "Ratio Stat Type": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                0.0
              ]
            },
            "Ratio Stat": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Confidence Interval Start": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Confidence Interval Stop": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Biogeographical Groups": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.24713449279467264,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 0.0,
                "Study Controls": 0.0,
                "Characteristics": 0.9140347838401794,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.5,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 0.0,
                "Confidence Interval Start": 0.0,
                "Confidence Interval Stop": 0.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1451237506,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1451237500,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "case/control",
                  "prediction": "retrospective"
                },
                "Study Cases": {
                  "ground_truth": 12.0,
                  "prediction": 149.0
                },
                "Study Controls": {
                  "ground_truth": 137.0,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "AZA-induced leukopenia in Chinese patients with AIH",
                  "prediction": "Leukopenia observed in patients with NUDT15 CT genotype"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "< 0.0001",
                  "prediction": "< 0.00001"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": 89.47,
                  "prediction": 20.41
                },
                "Confidence Interval Start": {
                  "ground_truth": 10.78,
                  "prediction": 7.84
                },
                "Confidence Interval Stop": {
                  "ground_truth": 742.53,
                  "prediction": 53.13
                },
                "Biogeographical Groups": {
                  "ground_truth": null,
                  "prediction": "Asian"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            }
          ],
          "aligned_variants": [
            "case/control:AZA-induced leukopen"
          ],
          "unmatched_ground_truth": [
            {
              "Study Parameters ID": 1451237470,
              "Variant Annotation ID": 1451237464,
              "Study Type": "case/control",
              "Study Cases": 12.0,
              "Study Controls": 137.0,
              "Characteristics": "AZA-induced leukopenia in Chinese patients with AIH",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": 0.042,
              "Allele Of Frequency In Cases": "C",
              "Frequency In Controls": 0.015,
              "Allele Of Frequency In Controls": "C",
              "P Value": "= 0.283",
              "Ratio Stat Type": null,
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": null,
              "Variant Annotation ID_norm": "1451237464"
            }
          ],
          "unmatched_predictions": [
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "retrospective",
              "Study Cases": 149.0,
              "Study Controls": null,
              "Characteristics": "Patients with autoimmune hepatitis treated with azathioprine",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "< 0.00001",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 20.41,
              "Confidence Interval Start": 7.84,
              "Confidence Interval Stop": 53.13,
              "Biogeographical Groups": "Asian",
              "Variant Annotation ID_norm": null
            },
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "retrospective",
              "Study Cases": 149.0,
              "Study Controls": null,
              "Characteristics": "Patients with rs116855232 CC and CT genotypes",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.028",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": 0.95,
              "Confidence Interval Stop": 1.53,
              "Biogeographical Groups": "Asian",
              "Variant Annotation ID_norm": null
            }
          ]
        }
      },
      "overall_score": 0.19681194034715493,
      "num_benchmarks": 4
    },
    {
      "pmid": "30336686",
      "pmcid": "PMC6714829",
      "title": "Associations of the SLCO1B1 Polymorphisms With Hepatic Function, Baseline Lipid Levels, and Lipid-lowering Response to Simvastatin in Patients With Hyperlipidemia",
      "benchmarks": {
        "drug_annotations": {
          "total_samples": 2,
          "field_scores": {
            "Variant/Haplotypes": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Gene": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "PMID": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Phenotype Category": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Significance": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Alleles": {
              "mean_score": 0.9422865509986877,
              "scores": [
                0.9347140192985535,
                0.949859082698822
              ]
            },
            "Specialty Population": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Metabolizer types": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "isPlural": {
              "mean_score": 0.5,
              "scores": [
                0.0,
                1.0
              ]
            },
            "Is/Is Not associated": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Direction of effect": {
              "mean_score": 0.5,
              "scores": [
                0.0,
                1.0
              ]
            },
            "PD/PK terms": {
              "mean_score": 0.8478798270225525,
              "scores": [
                0.8478798270225525,
                0.8478798270225525
              ]
            },
            "Multiple drugs And/or": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Population types": {
              "mean_score": 0.8947808146476746,
              "scores": [
                0.8947808146476746,
                0.8947808146476746
              ]
            },
            "Population Phenotypes or diseases": {
              "mean_score": 0.9049822688102722,
              "scores": [
                0.9049822688102722,
                0.9049822688102722
              ]
            },
            "Multiple phenotypes or diseases And/or": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Comparison Allele(s) or Genotype(s)": {
              "mean_score": 0.4450344443321228,
              "scores": [
                0.0,
                0.8900688886642456
              ]
            },
            "Comparison Metabolizer types": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Drug(s)": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            }
          },
          "overall_score": 0.580787573990069,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "PMID": 0.0,
                "Phenotype Category": 0.0,
                "Significance": 0.0,
                "Alleles": 0.9347140192985535,
                "Specialty Population": 1.0,
                "Metabolizer types": 1.0,
                "isPlural": 0.0,
                "Is/Is Not associated": 0.0,
                "Direction of effect": 0.0,
                "PD/PK terms": 0.8478798270225525,
                "Multiple drugs And/or": 0.0,
                "Population types": 0.8947808146476746,
                "Population Phenotypes or diseases": 0.9049822688102722,
                "Multiple phenotypes or diseases And/or": 0.0,
                "Comparison Allele(s) or Genotype(s)": 0.0,
                "Comparison Metabolizer types": 1.0,
                "Drug(s)": 1.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "rs4149056",
                  "prediction": "(rs4149056)"
                },
                "Gene": {
                  "ground_truth": "SLCO1B1",
                  "prediction": "SLCO1B1"
                },
                "PMID": {
                  "ground_truth": 30336686,
                  "prediction": null
                },
                "Phenotype Category": {
                  "ground_truth": "Efficacy",
                  "prediction": "metabolism/PK"
                },
                "Significance": {
                  "ground_truth": "yes",
                  "prediction": "no"
                },
                "Alleles": {
                  "ground_truth": "TT",
                  "prediction": "TT, TC, CC"
                },
                "Specialty Population": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Metabolizer types": {
                  "ground_truth": null,
                  "prediction": null
                },
                "isPlural": {
                  "ground_truth": "Is",
                  "prediction": "Are"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Not associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": null
                },
                "PD/PK terms": {
                  "ground_truth": "response to",
                  "prediction": "levels of"
                },
                "Multiple drugs And/or": {
                  "ground_truth": null,
                  "prediction": ""
                },
                "Population types": {
                  "ground_truth": "in people with",
                  "prediction": "in patients with hyperlipidemia"
                },
                "Population Phenotypes or diseases": {
                  "ground_truth": "Other:Hypercholesterolemia",
                  "prediction": "Disease:hyperlipidemia"
                },
                "Multiple phenotypes or diseases And/or": {
                  "ground_truth": null,
                  "prediction": ""
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "CC + CT",
                  "prediction": null
                },
                "Comparison Metabolizer types": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Drug(s)": {
                  "ground_truth": "simvastatin",
                  "prediction": "simvastatin"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "PMID": 0.0,
                "Phenotype Category": 0.0,
                "Significance": 0.0,
                "Alleles": 0.949859082698822,
                "Specialty Population": 1.0,
                "Metabolizer types": 1.0,
                "isPlural": 1.0,
                "Is/Is Not associated": 0.0,
                "Direction of effect": 1.0,
                "PD/PK terms": 0.8478798270225525,
                "Multiple drugs And/or": 0.0,
                "Population types": 0.8947808146476746,
                "Population Phenotypes or diseases": 0.9049822688102722,
                "Multiple phenotypes or diseases And/or": 0.0,
                "Comparison Allele(s) or Genotype(s)": 0.8900688886642456,
                "Comparison Metabolizer types": 1.0,
                "Drug(s)": 1.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "rs2306283",
                  "prediction": "(rs2306283)"
                },
                "Gene": {
                  "ground_truth": "SLCO1B1",
                  "prediction": "SLCO1B1"
                },
                "PMID": {
                  "ground_truth": 30336686,
                  "prediction": null
                },
                "Phenotype Category": {
                  "ground_truth": "Efficacy",
                  "prediction": "metabolism/PK"
                },
                "Significance": {
                  "ground_truth": "no",
                  "prediction": "yes"
                },
                "Alleles": {
                  "ground_truth": "AG + GG",
                  "prediction": "AA, AG, GG"
                },
                "Specialty Population": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Metabolizer types": {
                  "ground_truth": null,
                  "prediction": null
                },
                "isPlural": {
                  "ground_truth": "Are",
                  "prediction": "Are"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Not associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "PD/PK terms": {
                  "ground_truth": "response to",
                  "prediction": "levels of"
                },
                "Multiple drugs And/or": {
                  "ground_truth": null,
                  "prediction": ""
                },
                "Population types": {
                  "ground_truth": "in people with",
                  "prediction": "in patients with hyperlipidemia"
                },
                "Population Phenotypes or diseases": {
                  "ground_truth": "Other:Hypercholesterolemia",
                  "prediction": "Disease:hyperlipidemia"
                },
                "Multiple phenotypes or diseases And/or": {
                  "ground_truth": null,
                  "prediction": ""
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "AA",
                  "prediction": "AG, GG"
                },
                "Comparison Metabolizer types": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Drug(s)": {
                  "ground_truth": "simvastatin",
                  "prediction": "simvastatin"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            }
          ],
          "aligned_variants": [
            "rs4149056",
            "rs2306283"
          ],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Variant/Haplotypes": "388A>G",
              "Gene": "SLCO1B1",
              "Drug(s)": "simvastatin",
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "Individuals with the 388AA genotype had higher ALT and AST levels than those with the 388AG or 388GG genotypes (P = .037 and P = .002, respectively). The interaction between the SLCO1B1 388A>G and 521T>C polymorphisms could be an important genetic determinant of hepatic function and the therapeutic efficiency of simvastatin.",
              "Standardized Sentence": "Genotype AA is associated with increased ALT and AST levels in response to simvastatin in patients with hyperlipidemia.",
              "Alleles": "AA, AG, GG",
              "Metabolizer types": null,
              "Comparison Allele(s) or Genotype(s)": "AG, GG",
              "Comparison Metabolizer types": null,
              "Specialty Population": null,
              "Population types": "in patients with hyperlipidemia",
              "Population Phenotypes or diseases": "Disease:hyperlipidemia",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "levels of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "Individuals with the 388AA genotype had higher ALT and AST levels than those with the 388AG or 388GG genotypes (P = .037 and P = .002, respectively).",
                "the interaction between the SLCO1B1 388A>G and 521T>C polymorphisms could be an important genetic determinant of hepatic function and the therapeutic efficiency of simvastatin.",
                "Our conclusion suggests that the interaction between the SLCO1B1 388A>G and 521T>C polymorphisms could be an important genetic determinant of hepatic function and the therapeutic efficiency of simvastatin in Chinese patients with hyperlipidemia."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "521T>C",
              "Gene": "SLCO1B1",
              "Drug(s)": "simvastatin",
              "Phenotype Category": "metabolism/PK",
              "Significance": "no",
              "Notes": "No significant associations found between the 521T>C polymorphism and baseline ALT and AST levels",
              "Standardized Sentence": "Genotype TT is not associated with altered ALT and AST levels in response to simvastatin in patients with hyperlipidemia.",
              "Alleles": "TT, TC, CC",
              "Metabolizer types": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "Specialty Population": null,
              "Population types": "in patients with hyperlipidemia",
              "Population Phenotypes or diseases": "Disease:hyperlipidemia",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "levels of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "However, no significant relationships between the baseline plasma compounds measuring hepatic function and lipid levels and the SLCO1B1 521T>C polymorphism were found in either the unadjusted or the adjusted models (data not shown).",
                "Compared to the participants in the normal subgroup of baseline AST levels, the adjusted odds of carrying the 388G allele (388AG or 388GG genotype) among the participants in the abnormal subgroup was 0.5 (95% CI, 0.2-1.0). However, no significant associations between the 521T>C polymorphism and baseline ALT and AST levels were found in either the unadjusted or adjusted models (data not shown).",
                "In conclusion, our study revealed that the SLCO1B1 polymorphisms were related with ALT and AST concentrations and could further influence the efficacy of simvastatin treatment."
              ],
              "_expanded_from_multi_variant": true
            }
          ]
        },
        "phenotype_annotations": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": []
        },
        "functional_analysis": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "status": "missing_var_fa_ann"
        },
        "study_parameters": {
          "total_samples": 2,
          "field_scores": {
            "Study Type": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Study Cases": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Study Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Characteristics": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Characteristics Type": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Frequency In Cases": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Allele Of Frequency In Cases": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Frequency In Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Allele Of Frequency In Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "P Value": {
              "mean_score": 0.25,
              "scores": [
                0.5,
                0.0
              ]
            },
            "Ratio Stat Type": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Ratio Stat": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Confidence Interval Start": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Confidence Interval Stop": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Biogeographical Groups": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.6833333333333333,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 1.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.0,
                "Characteristics Type": 0.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.5,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1451226980,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1451226960,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "cohort",
                  "prediction": "cohort"
                },
                "Study Cases": {
                  "ground_truth": 542.0,
                  "prediction": 542
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": null,
                  "prediction": "Patients with hyperlipidemia, experiencing lipid-lowering efficacy post-simvastatin."
                },
                "Characteristics Type": {
                  "ground_truth": "Unknown",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.016",
                  "prediction": "= 0.049"
                },
                "Ratio Stat Type": {
                  "ground_truth": null,
                  "prediction": "Unknown"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "East Asian",
                  "prediction": "Chinese"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 1.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.0,
                "Characteristics Type": 0.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.0,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1451227040,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1451227020,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "cohort",
                  "prediction": "cohort"
                },
                "Study Cases": {
                  "ground_truth": 542.0,
                  "prediction": 542
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": null,
                  "prediction": "Individuals with the 388A/521T genotypes showed higher concentrations of ALT and AST post-simvastatin treatment."
                },
                "Characteristics Type": {
                  "ground_truth": "Unknown",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 0.52",
                  "prediction": "< 0.001"
                },
                "Ratio Stat Type": {
                  "ground_truth": null,
                  "prediction": "Unknown"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "East Asian",
                  "prediction": "Chinese"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            }
          ],
          "aligned_variants": [
            "cohort",
            "cohort"
          ],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 542,
              "Study Controls": null,
              "Characteristics": "Patients with hyperlipidemia, including 166 men and 376 women.",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": 0.28,
              "Allele Of Frequency In Cases": "A",
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.419",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Chinese",
              "Variant Annotation ID_norm": null
            },
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 542,
              "Study Controls": null,
              "Characteristics": "Patients with hyperlipidemia, with baseline ALT levels divided into normal and abnormal subgroups.",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.001",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.4,
              "Confidence Interval Start": 0.2,
              "Confidence Interval Stop": 0.9,
              "Biogeographical Groups": "Chinese",
              "Variant Annotation ID_norm": null
            },
            {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 542,
              "Study Controls": null,
              "Characteristics": "Patients with hyperlipidemia, with baseline AST levels divided into normal and abnormal subgroups.",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.038",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.5,
              "Confidence Interval Start": 0.2,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": "Chinese",
              "Variant Annotation ID_norm": null
            }
          ]
        }
      },
      "overall_score": 0.31090293886368736,
      "num_benchmarks": 4
    },
    {
      "pmid": "33768542",
      "pmcid": "PMC8790808",
      "title": "Class II HLA Variants Associate with Risk of Pegaspargase Hypersensitivity",
      "benchmarks": {
        "drug_annotations": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Variant/Haplotypes": "HLA-DQB1*02:02",
              "Gene": "HLA-DQB1, HLA-DRB1, HLA-DQA1",
              "Drug(s)": "pegaspargase",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "HLA alleles DQB1*02:02, DRB1*07:01, and DQA1*02:01 had the strongest associations with pegaspargase hypersensitivity (P < 5.0x10\u22125) in patients with primarily European ancestry.",
              "Standardized Sentence": "Genotype HLA-DQB1*02:02, HLA-DRB1*07:01, HLA-DQA1*02:01 is associated with increased risk of hypersensitivity reactions to pegaspargase in pediatric patients with leukemia.",
              "Alleles": "HLA-DQB1*02:02, HLA-DRB1*07:01, HLA-DQA1*02:01",
              "Metabolizer types": "",
              "Comparison Allele(s) or Genotype(s": "",
              "Comparison Metabolizer types": "",
              "Specialty Population": "Pediatric",
              "Population types": "in people with leukemia",
              "Population Phenotypes or diseases": "Disease:Acute Lymphoblastic Leukemia",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of hypersensitivity reactions to",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "HLA alleles DQB1*02:02, DRB1*07:01, and DQA1*02:01 had the strongest associations with pegaspargase hypersensitivity (P < 5.0x10\u22125) in patients with primarily European ancestry (EA), with the three alleles associating in a single haplotype.",
                "Although predominantly mediated by antibodies against PEG, not the asparaginase protein, hypersensitivity reactions to pegaspargase were strongly associated with the same HLA haplotype as in the case of ASNase.",
                "In a meta-analysis combining results from the three cohorts, among 97 HLA alleles, HLA-DQB1*02:02*, HLA-DRB1*07:01*, HLA-DQA1*02:01, and HLA-DRB1*04:02* had the strongest association with reactions to pegaspargase (P_meta_ = 3.8x10^\u22129^ OR 2.13, P_meta_ = 2.2x10^\u22125^ OR 1.96, P_meta_ = 2.7x10^\u22125^ OR 1.96, and P_meta_ = 6.3x10^\u22125^ OR 4.61 respectively)."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "HLA-DRB1*07:01",
              "Gene": "HLA-DQB1, HLA-DRB1, HLA-DQA1",
              "Drug(s)": "pegaspargase",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "HLA alleles DQB1*02:02, DRB1*07:01, and DQA1*02:01 had the strongest associations with pegaspargase hypersensitivity (P < 5.0x10\u22125) in patients with primarily European ancestry.",
              "Standardized Sentence": "Genotype HLA-DQB1*02:02, HLA-DRB1*07:01, HLA-DQA1*02:01 is associated with increased risk of hypersensitivity reactions to pegaspargase in pediatric patients with leukemia.",
              "Alleles": "HLA-DQB1*02:02, HLA-DRB1*07:01, HLA-DQA1*02:01",
              "Metabolizer types": "",
              "Comparison Allele(s) or Genotype(s": "",
              "Comparison Metabolizer types": "",
              "Specialty Population": "Pediatric",
              "Population types": "in people with leukemia",
              "Population Phenotypes or diseases": "Disease:Acute Lymphoblastic Leukemia",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of hypersensitivity reactions to",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "HLA alleles DQB1*02:02, DRB1*07:01, and DQA1*02:01 had the strongest associations with pegaspargase hypersensitivity (P < 5.0x10\u22125) in patients with primarily European ancestry (EA), with the three alleles associating in a single haplotype.",
                "Although predominantly mediated by antibodies against PEG, not the asparaginase protein, hypersensitivity reactions to pegaspargase were strongly associated with the same HLA haplotype as in the case of ASNase.",
                "In a meta-analysis combining results from the three cohorts, among 97 HLA alleles, HLA-DQB1*02:02*, HLA-DRB1*07:01*, HLA-DQA1*02:01, and HLA-DRB1*04:02* had the strongest association with reactions to pegaspargase (P_meta_ = 3.8x10^\u22129^ OR 2.13, P_meta_ = 2.2x10^\u22125^ OR 1.96, P_meta_ = 2.7x10^\u22125^ OR 1.96, and P_meta_ = 6.3x10^\u22125^ OR 4.61 respectively)."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "HLA-DQA1*02:01",
              "Gene": "HLA-DQB1, HLA-DRB1, HLA-DQA1",
              "Drug(s)": "pegaspargase",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "HLA alleles DQB1*02:02, DRB1*07:01, and DQA1*02:01 had the strongest associations with pegaspargase hypersensitivity (P < 5.0x10\u22125) in patients with primarily European ancestry.",
              "Standardized Sentence": "Genotype HLA-DQB1*02:02, HLA-DRB1*07:01, HLA-DQA1*02:01 is associated with increased risk of hypersensitivity reactions to pegaspargase in pediatric patients with leukemia.",
              "Alleles": "HLA-DQB1*02:02, HLA-DRB1*07:01, HLA-DQA1*02:01",
              "Metabolizer types": "",
              "Comparison Allele(s) or Genotype(s": "",
              "Comparison Metabolizer types": "",
              "Specialty Population": "Pediatric",
              "Population types": "in people with leukemia",
              "Population Phenotypes or diseases": "Disease:Acute Lymphoblastic Leukemia",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of hypersensitivity reactions to",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "HLA alleles DQB1*02:02, DRB1*07:01, and DQA1*02:01 had the strongest associations with pegaspargase hypersensitivity (P < 5.0x10\u22125) in patients with primarily European ancestry (EA), with the three alleles associating in a single haplotype.",
                "Although predominantly mediated by antibodies against PEG, not the asparaginase protein, hypersensitivity reactions to pegaspargase were strongly associated with the same HLA haplotype as in the case of ASNase.",
                "In a meta-analysis combining results from the three cohorts, among 97 HLA alleles, HLA-DQB1*02:02*, HLA-DRB1*07:01*, HLA-DQA1*02:01, and HLA-DRB1*04:02* had the strongest association with reactions to pegaspargase (P_meta_ = 3.8x10^\u22129^ OR 2.13, P_meta_ = 2.2x10^\u22125^ OR 1.96, P_meta_ = 2.7x10^\u22125^ OR 1.96, and P_meta_ = 6.3x10^\u22125^ OR 4.61 respectively)."
              ],
              "_expanded_from_multi_variant": true
            },
            {
              "Variant/Haplotypes": "rs9958628",
              "Gene": "ARHGAP28",
              "Drug(s)": "pegaspargase",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "The rs9958628 variant had the strongest genetic association (P = 8.9x10\u22129) in non-EAs.",
              "Standardized Sentence": "Variant rs9958628 is associated with increased risk of hypersensitivity reactions to pegaspargase in non-European ancestry patients with leukemia.",
              "Alleles": "",
              "Metabolizer types": "",
              "Comparison Allele(s) or Genotype(s": "",
              "Comparison Metabolizer types": "",
              "Specialty Population": "",
              "Population types": "in non-EA patients",
              "Population Phenotypes or diseases": "Disease:Acute Lymphoblastic Leukemia",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of hypersensitivity reactions to",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "The rs9958628 variant, in ARHGAP28 (previously linked to immune response in children) had the strongest genetic association (P = 8.9x10\u22129) in non-EAs.",
                "Among non-EAs, rs9958628, located in the 5'-UTR of the Rho GTPase activating protein 28 (ARHGAP28) gene transcript, was the top genetic variant and reached genome-wide significance in its association with hypersensitivity (P_meta_ = 8.9x10\u22129, OR 3.69).",
                "This study demonstrated for the first time the association between a non-HLA locus (ARHGAP28) and pegaspargase hypersensitivity with genome-wide significance in non-EAs."
              ]
            }
          ]
        },
        "phenotype_annotations": {
          "total_samples": 4,
          "field_scores": {
            "Variant/Haplotypes": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Gene": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Drug(s)": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Phenotype Category": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Alleles": {
              "mean_score": 0.890499010682106,
              "scores": [
                0.9215661287307739,
                0.9184015393257141,
                0.9164229035377502,
                0.8056054711341858
              ]
            },
            "Is/Is Not associated": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Direction of effect": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Phenotype": {
              "mean_score": 0.9564039707183838,
              "scores": [
                0.9564039707183838,
                0.9564039707183838,
                0.9564039707183838,
                0.9564039707183838
              ]
            },
            "When treated with/exposed to/when assayed with": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0
              ]
            },
            "Comparison Allele(s) or Genotype(s)": {
              "mean_score": 0.75,
              "scores": [
                1.0,
                1.0,
                1.0,
                0.0
              ]
            }
          },
          "overall_score": 0.9582130381216606,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 1.0,
                "Alleles": 0.9215661287307739,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.9564039707183838,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 1.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "HLA-DQB1*02:02",
                  "prediction": "HLA-DQB1*02:02"
                },
                "Gene": {
                  "ground_truth": "HLA-DQB1",
                  "prediction": "HLA-DQB1"
                },
                "Drug(s)": {
                  "ground_truth": "pegaspargase",
                  "prediction": "pegaspargase"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "*02:02",
                  "prediction": "HLA-DQB1*02:02"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:Hypersensitivity",
                  "prediction": "hypersensitivity reactions"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": null,
                  "prediction": null
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 1.0,
                "Alleles": 0.9184015393257141,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.9564039707183838,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 1.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "HLA-DRB1*07:01",
                  "prediction": "HLA-DRB1*07:01"
                },
                "Gene": {
                  "ground_truth": "HLA-DRB1",
                  "prediction": "HLA-DRB1"
                },
                "Drug(s)": {
                  "ground_truth": "pegaspargase",
                  "prediction": "pegaspargase"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "*07:01",
                  "prediction": "HLA-DRB1*07:01"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:Hypersensitivity",
                  "prediction": "hypersensitivity reactions"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": null,
                  "prediction": null
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 2,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 1.0,
                "Alleles": 0.9164229035377502,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.9564039707183838,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 1.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "HLA-DQA1*02:01",
                  "prediction": "HLA-DQA1*02:01"
                },
                "Gene": {
                  "ground_truth": "HLA-DQA1",
                  "prediction": "HLA-DQA1"
                },
                "Drug(s)": {
                  "ground_truth": "pegaspargase",
                  "prediction": "pegaspargase"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "*02:01",
                  "prediction": "HLA-DQA1*02:01"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:Hypersensitivity",
                  "prediction": "hypersensitivity reactions"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": null,
                  "prediction": null
                }
              },
              "dependency_issues": []
            },
            {
              "sample_id": 3,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 1.0,
                "Alleles": 0.8056054711341858,
                "Is/Is Not associated": 1.0,
                "Direction of effect": 1.0,
                "Phenotype": 0.9564039707183838,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "rs9958628",
                  "prediction": "rs9958628"
                },
                "Gene": {
                  "ground_truth": "ARHGAP28",
                  "prediction": "ARHGAP28"
                },
                "Drug(s)": {
                  "ground_truth": "pegaspargase",
                  "prediction": "pegaspargase"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "T",
                  "prediction": "ARHGAP28 rs9958628"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Associated with"
                },
                "Direction of effect": {
                  "ground_truth": "increased",
                  "prediction": "increased"
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:Hypersensitivity",
                  "prediction": "hypersensitivity reactions"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "A",
                  "prediction": null
                }
              },
              "dependency_issues": []
            }
          ],
          "aligned_variants": [
            "hla-dqa1*02:01",
            "hla-dqb1*02:02",
            "hla-drb1*07:01",
            "rs9958628"
          ],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Variant Annotation ID": 104,
              "Variant/Haplotypes": "ARHGAP28",
              "Gene": "ARHGAP28",
              "Drug(s)": "pegaspargase",
              "PMID": 33768542,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Top genetic association with pegaspargase hypersensitivity in non-EA patients with genome-wide significance.",
              "Sentence": "ARHGAP28 rs9958628 is associated with increased risk of hypersensitivity reactions when treated with pegaspargase in people with Acute Lymphoblastic Leukemia.",
              "Alleles": "ARHGAP28 rs9958628",
              "Specialty Population": "Non-European Ancestry",
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "hypersensitivity reactions",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Acute Lymphoblastic Leukemia",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "33768542",
              "Variant Annotation ID_norm": "104",
              "Citations": [
                "The rs9958628 variant, in ARHGAP28 (previously linked to immune response in children) had the strongest genetic association (P = 8.9x10\u22129) in non-EAs.",
                "We are the first to interrogate genetic risk factors for asparaginase hypersensitivity reactions in non-EA patients as separate ancestry groups. Our results identified ARHGAP28 rs9958628 as the top genetic variant associated with pegaspargase hypersensitivity in non-EAs with genome-wide significance.",
                "This SNP was also the top non-HLA hit among all evaluable patients (P_meta_ = 1.2x10^\u22127^, OR 3.03)."
              ],
              "_expanded_from_multi_variant": true
            }
          ]
        },
        "functional_analysis": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "status": "missing_var_fa_ann"
        },
        "study_parameters": {
          "total_samples": 8,
          "field_scores": {
            "Study Type": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Study Cases": {
              "mean_score": 0.475,
              "scores": [
                1.0,
                1.0,
                0.8,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Study Controls": {
              "mean_score": 0.625,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Characteristics": {
              "mean_score": 0.5341743007302284,
              "scores": [
                0.814965009689331,
                0.8823869228363037,
                0.8439874053001404,
                0.8577880859375,
                0.8742669820785522,
                0.0,
                0.0,
                0.0
              ]
            },
            "Characteristics Type": {
              "mean_score": 0.5,
              "scores": [
                1.0,
                1.0,
                0.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Frequency In Cases": {
              "mean_score": 0.625,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Allele Of Frequency In Cases": {
              "mean_score": 0.625,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Frequency In Controls": {
              "mean_score": 0.625,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Allele Of Frequency In Controls": {
              "mean_score": 0.625,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "P Value": {
              "mean_score": 0.1875,
              "scores": [
                0.0,
                0.5,
                0.5,
                0.0,
                0.5,
                0.0,
                0.0,
                0.0
              ]
            },
            "Ratio Stat Type": {
              "mean_score": 0.625,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Ratio Stat": {
              "mean_score": 0.2375,
              "scores": [
                0.9,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Confidence Interval Start": {
              "mean_score": 0.625,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Confidence Interval Stop": {
              "mean_score": 0.625,
              "scores": [
                1.0,
                1.0,
                1.0,
                1.0,
                1.0,
                0.0,
                0.0,
                0.0
              ]
            },
            "Biogeographical Groups": {
              "mean_score": 0.25,
              "scores": [
                1.0,
                0.0,
                1.0,
                0.0,
                0.0,
                0.0,
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.47894495338201526,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.814965009689331,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.0,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 0.9,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 1.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1451510920,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1451510886,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "meta-analysis, GWAS",
                  "prediction": "meta-analysis"
                },
                "Study Cases": {
                  "ground_truth": 2168.0,
                  "prediction": 2168
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "meta-analysis",
                  "prediction": "European ancestry patients with hypersensitivity reactions to pegaspargase"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 3.76e-9",
                  "prediction": "< 5.0x10\u22125"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": 2.14,
                  "prediction": 2.13
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "European",
                  "prediction": "European"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.8823869228363037,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.5,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1451510821,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1451510773,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "meta-analysis, GWAS",
                  "prediction": "meta-analysis"
                },
                "Study Cases": {
                  "ground_truth": 1607.0,
                  "prediction": 1607
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "non European ancestry",
                  "prediction": "Non-European ancestry patients with hypersensitivity reactions to pegaspargase"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 8.9e-9",
                  "prediction": "8.9x10\u22129"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": 3.69,
                  "prediction": 3.69
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "Multiple groups",
                  "prediction": "Non-European"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 2,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 0.8,
                "Study Controls": 1.0,
                "Characteristics": 0.8439874053001404,
                "Characteristics Type": 0.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.5,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 0.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 1.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1451510741,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1451510720,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "cohort",
                  "prediction": "case/control"
                },
                "Study Cases": {
                  "ground_truth": 402.0,
                  "prediction": 375
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "TXVI cohort",
                  "prediction": "Male patients treated for B-ALL"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "gender"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 3.28e-5",
                  "prediction": "= 0.025"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": 2.91,
                  "prediction": 1.24
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "European",
                  "prediction": "European"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 3,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.8577880859375,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.0,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 0.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1451510810,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1451510773,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "cohort, meta-analysis",
                  "prediction": "meta-analysis"
                },
                "Study Cases": {
                  "ground_truth": 3897.0,
                  "prediction": 3897
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "all patients",
                  "prediction": "Pediatric leukemia patients with hypersensitivity reactions to pegaspargase"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 1.2e-7",
                  "prediction": "< 5.0x10\u22125"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": 3.03,
                  "prediction": 2.13
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "European",
                  "prediction": "Multiple Groups"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 4,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 0.0,
                "Study Controls": 1.0,
                "Characteristics": 0.8742669820785522,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 0.5,
                "Ratio Stat Type": 1.0,
                "Ratio Stat": 0.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1451510895,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1451510891,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "cohort",
                  "prediction": "case/control"
                },
                "Study Cases": {
                  "ground_truth": 402.0,
                  "prediction": 82
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "TXVI cohort",
                  "prediction": "Patients with hypersensitivity reactions to pegaspargase in TXVI cohort"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "study cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": "= 3.289e-5",
                  "prediction": "= 6.4x10\u22125"
                },
                "Ratio Stat Type": {
                  "ground_truth": "OR",
                  "prediction": "OR"
                },
                "Ratio Stat": {
                  "ground_truth": 2.91,
                  "prediction": 0.73
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "European",
                  "prediction": "Mixed"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            }
          ],
          "aligned_variants": [
            "meta-analysis, GWAS:meta-analysis",
            "meta-analysis, GWAS:non European ancestr",
            "cohort:TXVI cohort",
            "cohort, meta-analysis:all patients",
            "cohort:TXVI cohort"
          ],
          "unmatched_ground_truth": [
            {
              "Study Parameters ID": 1451510724,
              "Variant Annotation ID": 1451510720,
              "Study Type": "meta-analysis, GWAS",
              "Study Cases": 2168.0,
              "Study Controls": null,
              "Characteristics": "meta-analysis",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 2.74e-5",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 1.99,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": "1451510720"
            },
            {
              "Study Parameters ID": 1451510890,
              "Variant Annotation ID": 1451510886,
              "Study Type": "cohort",
              "Study Cases": 593.0,
              "Study Controls": null,
              "Characteristics": "AALL0232 cohort",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 9.29e-5",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 1.94,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": "1451510886"
            },
            {
              "Study Parameters ID": 1451510941,
              "Variant Annotation ID": 1451510891,
              "Study Type": "meta-analysis, GWAS",
              "Study Cases": 2168.0,
              "Study Controls": null,
              "Characteristics": "meta-analysis",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 2.22e-5",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 1.99,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": "1451510891"
            }
          ],
          "unmatched_predictions": []
        }
      },
      "overall_score": 0.38325290211290125,
      "num_benchmarks": 4
    },
    {
      "pmid": "35431360",
      "pmcid": "PMC8973308",
      "title": "Susceptibility to thiopurine toxicity by TPMT and NUDT15 variants in Colombian children with acute lymphoblastic leukemia",
      "benchmarks": {
        "drug_annotations": {
          "total_samples": 2,
          "field_scores": {
            "Variant/Haplotypes": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Gene": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "PMID": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Phenotype Category": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Significance": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Alleles": {
              "mean_score": 0.8854745328426361,
              "scores": [
                0.8984260559082031,
                0.8725230097770691
              ]
            },
            "Specialty Population": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Metabolizer types": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "isPlural": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Is/Is Not associated": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Direction of effect": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "PD/PK terms": {
              "mean_score": 0.8777309060096741,
              "scores": [
                0.8777309060096741,
                0.8777309060096741
              ]
            },
            "Multiple drugs And/or": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Population types": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Population Phenotypes or diseases": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Multiple phenotypes or diseases And/or": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Comparison Allele(s) or Genotype(s)": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0
              ]
            },
            "Comparison Metabolizer types": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            },
            "Drug(s)": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0
              ]
            }
          },
          "overall_score": 0.4085897599395953,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "PMID": 0.0,
                "Phenotype Category": 0.0,
                "Significance": 1.0,
                "Alleles": 0.8984260559082031,
                "Specialty Population": 0.0,
                "Metabolizer types": 0.0,
                "isPlural": 1.0,
                "Is/Is Not associated": 0.0,
                "Direction of effect": 0.0,
                "PD/PK terms": 0.8777309060096741,
                "Multiple drugs And/or": 0.0,
                "Population types": 0.0,
                "Population Phenotypes or diseases": 0.0,
                "Multiple phenotypes or diseases And/or": 0.0,
                "Comparison Allele(s) or Genotype(s)": 0.0,
                "Comparison Metabolizer types": 1.0,
                "Drug(s)": 1.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "rs116855232",
                  "prediction": "rs116855232"
                },
                "Gene": {
                  "ground_truth": "NUDT15",
                  "prediction": "NUDT15"
                },
                "PMID": {
                  "ground_truth": 35431360,
                  "prediction": null
                },
                "Phenotype Category": {
                  "ground_truth": "Dosage",
                  "prediction": "toxicity"
                },
                "Significance": {
                  "ground_truth": "no",
                  "prediction": "no"
                },
                "Alleles": {
                  "ground_truth": "CT",
                  "prediction": "C/T"
                },
                "Specialty Population": {
                  "ground_truth": "Pediatric",
                  "prediction": null
                },
                "Metabolizer types": {
                  "ground_truth": null,
                  "prediction": "poor metabolizer"
                },
                "isPlural": {
                  "ground_truth": "Is",
                  "prediction": "Is"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Not associated with"
                },
                "Direction of effect": {
                  "ground_truth": "decreased",
                  "prediction": null
                },
                "PD/PK terms": {
                  "ground_truth": "dose of",
                  "prediction": "toxicity of"
                },
                "Multiple drugs And/or": {
                  "ground_truth": null,
                  "prediction": ""
                },
                "Population types": {
                  "ground_truth": "in children with",
                  "prediction": null
                },
                "Population Phenotypes or diseases": {
                  "ground_truth": "Other:Acute lymphoblastic leukemia",
                  "prediction": null
                },
                "Multiple phenotypes or diseases And/or": {
                  "ground_truth": null,
                  "prediction": ""
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "CC",
                  "prediction": null
                },
                "Comparison Metabolizer types": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Drug(s)": {
                  "ground_truth": "mercaptopurine",
                  "prediction": "mercaptopurine"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "PMID": 0.0,
                "Phenotype Category": 0.0,
                "Significance": 1.0,
                "Alleles": 0.8725230097770691,
                "Specialty Population": 0.0,
                "Metabolizer types": 0.0,
                "isPlural": 1.0,
                "Is/Is Not associated": 0.0,
                "Direction of effect": 0.0,
                "PD/PK terms": 0.8777309060096741,
                "Multiple drugs And/or": 0.0,
                "Population types": 0.0,
                "Population Phenotypes or diseases": 0.0,
                "Multiple phenotypes or diseases And/or": 0.0,
                "Comparison Allele(s) or Genotype(s)": 0.0,
                "Comparison Metabolizer types": 1.0,
                "Drug(s)": 1.0
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "rs1800460",
                  "prediction": "rs1800460"
                },
                "Gene": {
                  "ground_truth": "TPMT",
                  "prediction": "TPMT"
                },
                "PMID": {
                  "ground_truth": 35431360,
                  "prediction": null
                },
                "Phenotype Category": {
                  "ground_truth": "Dosage",
                  "prediction": "toxicity"
                },
                "Significance": {
                  "ground_truth": "no",
                  "prediction": "no"
                },
                "Alleles": {
                  "ground_truth": "CT",
                  "prediction": "C/G"
                },
                "Specialty Population": {
                  "ground_truth": "Pediatric",
                  "prediction": null
                },
                "Metabolizer types": {
                  "ground_truth": null,
                  "prediction": "intermediate metabolizer"
                },
                "isPlural": {
                  "ground_truth": "Is",
                  "prediction": "Is"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Not associated with"
                },
                "Direction of effect": {
                  "ground_truth": "decreased",
                  "prediction": null
                },
                "PD/PK terms": {
                  "ground_truth": "dose of",
                  "prediction": "toxicity of"
                },
                "Multiple drugs And/or": {
                  "ground_truth": null,
                  "prediction": ""
                },
                "Population types": {
                  "ground_truth": "in children with",
                  "prediction": null
                },
                "Population Phenotypes or diseases": {
                  "ground_truth": "Other:Acute lymphoblastic leukemia",
                  "prediction": null
                },
                "Multiple phenotypes or diseases And/or": {
                  "ground_truth": null,
                  "prediction": ""
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "CC",
                  "prediction": null
                },
                "Comparison Metabolizer types": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Drug(s)": {
                  "ground_truth": "mercaptopurine",
                  "prediction": "mercaptopurine"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            }
          ],
          "aligned_variants": [
            "rs116855232",
            "rs1800460"
          ],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Variant/Haplotypes": "rs1800462",
              "Gene": "TPMT",
              "Drug(s)": "mercaptopurine",
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "No statistically significant association identified between the genetic variants and the outcomes of interest.",
              "Sentence": "rs1800462 is not associated with increased toxicity mercaptopurine in pediatric patients with acute lymphoblastic leukemia.",
              "Alleles": "C/T",
              "Metabolizer types": "intermediate metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "toxicity of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "No statistically significant association was identified between the genetic variants and the outcomes of interest.",
                "Although we are considered as a Latino population, different degrees of Caucasian, Amerindian and African ancestry are found in different regions of Colombia. Although, our findings vary significantly from previous reports regarding the association between variants and outcomes, those studies were carried out in non-Latino population.",
                "Our study did not find any association between the allelic frequencies of each polymorphism or in those 42 cases in which we had the complete typing of TPMT."
              ]
            },
            {
              "Variant/Haplotypes": "rs1142345",
              "Gene": "TPMT",
              "Drug(s)": "mercaptopurine",
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "No statistically significant association identified between the genetic variants and the outcomes of interest.",
              "Sentence": "rs1142345 is not associated with increased toxicity mercaptopurine in pediatric patients with acute lymphoblastic leukemia.",
              "Alleles": "T/C",
              "Metabolizer types": "intermediate metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "toxicity of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "No statistically significant association was identified between the genetic variants and the outcomes of interest.",
                "Although no statistically significant associations were identified, two of the four patients heterozygous for NUDT15 required a decrease in 6-MP during the follow-up period.",
                "Our study did not find any association between the allelic frequencies of each polymorphism or in those 42 cases in which we had the complete typing of TPMT."
              ]
            }
          ]
        },
        "phenotype_annotations": {
          "total_samples": 1,
          "field_scores": {
            "Variant/Haplotypes": {
              "mean_score": 1.0,
              "scores": [
                1.0
              ]
            },
            "Gene": {
              "mean_score": 1.0,
              "scores": [
                1.0
              ]
            },
            "Drug(s)": {
              "mean_score": 1.0,
              "scores": [
                1.0
              ]
            },
            "Phenotype Category": {
              "mean_score": 1.0,
              "scores": [
                1.0
              ]
            },
            "Alleles": {
              "mean_score": 0.8662022948265076,
              "scores": [
                0.8662022948265076
              ]
            },
            "Is/Is Not associated": {
              "mean_score": 0.0,
              "scores": [
                0.0
              ]
            },
            "Direction of effect": {
              "mean_score": 0.0,
              "scores": [
                0.0
              ]
            },
            "Phenotype": {
              "mean_score": 0.888189435005188,
              "scores": [
                0.888189435005188
              ]
            },
            "When treated with/exposed to/when assayed with": {
              "mean_score": 1.0,
              "scores": [
                1.0
              ]
            },
            "Comparison Allele(s) or Genotype(s)": {
              "mean_score": 0.9417282342910767,
              "scores": [
                0.9417282342910767
              ]
            }
          },
          "overall_score": 0.7097842122117678,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Variant/Haplotypes": 1.0,
                "Gene": 1.0,
                "Drug(s)": 1.0,
                "Phenotype Category": 1.0,
                "Alleles": 0.8662022948265076,
                "Is/Is Not associated": 0.0,
                "Direction of effect": 0.0,
                "Phenotype": 0.888189435005188,
                "When treated with/exposed to/when assayed with": 1.0,
                "Comparison Allele(s) or Genotype(s)": 0.9417282342910767
              },
              "field_values": {
                "Variant/Haplotypes": {
                  "ground_truth": "rs1800462",
                  "prediction": "rs1800462"
                },
                "Gene": {
                  "ground_truth": "TPMT",
                  "prediction": "TPMT"
                },
                "Drug(s)": {
                  "ground_truth": "mercaptopurine",
                  "prediction": "mercaptopurine"
                },
                "Phenotype Category": {
                  "ground_truth": "Toxicity",
                  "prediction": "toxicity"
                },
                "Alleles": {
                  "ground_truth": "CG",
                  "prediction": "C/T"
                },
                "Is/Is Not associated": {
                  "ground_truth": "Associated with",
                  "prediction": "Not associated with"
                },
                "Direction of effect": {
                  "ground_truth": "decreased",
                  "prediction": null
                },
                "Phenotype": {
                  "ground_truth": "Side Effect:Febrile neutropenia, Side Effect:Discontinuation",
                  "prediction": "toxicity"
                },
                "When treated with/exposed to/when assayed with": {
                  "ground_truth": "when treated with",
                  "prediction": "when treated with"
                },
                "Comparison Allele(s) or Genotype(s)": {
                  "ground_truth": "CC",
                  "prediction": "CC (wild-type)"
                }
              },
              "dependency_issues": []
            }
          ],
          "aligned_variants": [
            "rs1800462"
          ],
          "unmatched_ground_truth": [],
          "unmatched_predictions": [
            {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "rs1800460",
              "Gene": "TPMT",
              "Drug(s)": "mercaptopurine",
              "PMID": 35431360,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "No statistically significant association identified between TPMT variant rs1800460 and the risk of toxicity outcomes in children with ALL treated with mercaptopurine.",
              "Sentence": "rs1800460 is not associated with increased risk of toxicity when treated with mercaptopurine in pediatric patients with acute lymphoblastic leukemia.",
              "Alleles": "A/G",
              "Specialty Population": "Pediatric",
              "Metabolizer types": "intermediate metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "toxicity",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in children",
              "Population Phenotypes or diseases": "acute lymphoblastic leukemia",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "AA (wild-type)",
              "Comparison Metabolizer types": "normal metabolizer",
              "PMID_norm": "35431360",
              "Variant Annotation ID_norm": "2",
              "Citations": [
                "No statistically significant association was identified between the genetic variants and the outcomes of interest.",
                "No statistically significant associations were identified between genetic variants in TPMT and NUDT15 with toxicity outcomes evaluated (myelotoxicity and liver toxicity, as well as the dose reduction or interruption of 6-MP).",
                "For the case of rs1800460, of the six heterozygous patients, three required a dosage decrease, and two were also heterozygous for rs1142345. Additionally, differences in the median for the lab values taken in the first 6 months of maintenance treatment were evaluated: aminotransferases, total bilirubin, leukocytes, and differential cell counts; based on genetic variants, no statistically significant differences were found."
              ]
            },
            {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "rs1142345",
              "Gene": "TPMT",
              "Drug(s)": "mercaptopurine",
              "PMID": 35431360,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "No statistically significant association found between TPMT variant rs1142345 and toxicity outcomes in the studied population.",
              "Sentence": "rs1142345 is not associated with increased risk of toxicity when treated with mercaptopurine in pediatric patients with acute lymphoblastic leukemia.",
              "Alleles": "G/A",
              "Specialty Population": "Pediatric",
              "Metabolizer types": "intermediate metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "toxicity",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in children",
              "Population Phenotypes or diseases": "acute lymphoblastic leukemia",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "GG (wild-type)",
              "Comparison Metabolizer types": "normal metabolizer",
              "PMID_norm": "35431360",
              "Variant Annotation ID_norm": "3",
              "Citations": [
                "No statistically significant association was identified between the genetic variants and the outcomes of interest.",
                "No statistically significant associations were identified between genetic variants in TPMT and NUDT15 with toxicity outcomes evaluated (myelotoxicity and liver toxicity, as well as the dose reduction or interruption of 6-MP).",
                "We did not find any statistical association with toxicity events for any of the polymorphisms studied."
              ]
            }
          ]
        },
        "functional_analysis": {
          "total_samples": 0,
          "field_scores": {},
          "overall_score": 0.0,
          "detailed_results": [],
          "aligned_variants": [],
          "status": "missing_var_fa_ann"
        },
        "study_parameters": {
          "total_samples": 3,
          "field_scores": {
            "Study Type": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                0.0,
                0.0
              ]
            },
            "Study Cases": {
              "mean_score": 0.6333333333333333,
              "scores": [
                0.9,
                1.0,
                0.0
              ]
            },
            "Study Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            },
            "Characteristics": {
              "mean_score": 0.8522584835688273,
              "scores": [
                0.8838522434234619,
                0.869573712348938,
                0.803349494934082
              ]
            },
            "Characteristics Type": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            },
            "Frequency In Cases": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                0.0,
                0.0
              ]
            },
            "Allele Of Frequency In Cases": {
              "mean_score": 0.3333333333333333,
              "scores": [
                1.0,
                0.0,
                0.0
              ]
            },
            "Frequency In Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            },
            "Allele Of Frequency In Controls": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            },
            "P Value": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            },
            "Ratio Stat Type": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0
              ]
            },
            "Ratio Stat": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            },
            "Confidence Interval Start": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            },
            "Confidence Interval Stop": {
              "mean_score": 1.0,
              "scores": [
                1.0,
                1.0,
                1.0
              ]
            },
            "Biogeographical Groups": {
              "mean_score": 0.0,
              "scores": [
                0.0,
                0.0,
                0.0
              ]
            }
          },
          "overall_score": 0.699039454460144,
          "detailed_results": [
            {
              "sample_id": 0,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 1.0,
                "Study Cases": 0.9,
                "Study Controls": 1.0,
                "Characteristics": 0.8838522434234619,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 1.0,
                "Allele Of Frequency In Cases": 1.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 1.0,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1451769007,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1451769000,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "cohort",
                  "prediction": "cohort"
                },
                "Study Cases": {
                  "ground_truth": 68.0,
                  "prediction": 70.0
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "Pediatric ALL",
                  "prediction": "Pediatric patients with acute lymphoblastic leukemia undergoing maintenance chemotherapy"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": null,
                  "prediction": ""
                },
                "Ratio Stat Type": {
                  "ground_truth": null,
                  "prediction": "Unknown"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "Latino",
                  "prediction": "Multiple Groups"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 1,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 1.0,
                "Study Controls": 1.0,
                "Characteristics": 0.869573712348938,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 0.0,
                "Allele Of Frequency In Cases": 0.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 1.0,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1451768400,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1451768380,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "cohort",
                  "prediction": null
                },
                "Study Cases": {
                  "ground_truth": 68.0,
                  "prediction": 68.0
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "Pediatric ALL",
                  "prediction": "NUDT15 and TPMT genetic analysis in pediatric patients"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": 0.03
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": "T (NUDT15)"
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": null,
                  "prediction": ""
                },
                "Ratio Stat Type": {
                  "ground_truth": null,
                  "prediction": "Unknown"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "Latino",
                  "prediction": "Colombian population"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            },
            {
              "sample_id": 2,
              "field_scores": {
                "Study Parameters ID": 0.0,
                "Variant Annotation ID": 0.0,
                "Study Type": 0.0,
                "Study Cases": 0.0,
                "Study Controls": 1.0,
                "Characteristics": 0.803349494934082,
                "Characteristics Type": 1.0,
                "Frequency In Cases": 0.0,
                "Allele Of Frequency In Cases": 0.0,
                "Frequency In Controls": 1.0,
                "Allele Of Frequency In Controls": 1.0,
                "P Value": 1.0,
                "Ratio Stat Type": 0.0,
                "Ratio Stat": 1.0,
                "Confidence Interval Start": 1.0,
                "Confidence Interval Stop": 1.0,
                "Biogeographical Groups": 0.0
              },
              "field_values": {
                "Study Parameters ID": {
                  "ground_truth": 1451769045,
                  "prediction": null
                },
                "Variant Annotation ID": {
                  "ground_truth": 1451769040,
                  "prediction": null
                },
                "Study Type": {
                  "ground_truth": "cohort",
                  "prediction": null
                },
                "Study Cases": {
                  "ground_truth": 68.0,
                  "prediction": 42.0
                },
                "Study Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Characteristics": {
                  "ground_truth": "Pediatric ALL",
                  "prediction": "TPMT genotyping results"
                },
                "Characteristics Type": {
                  "ground_truth": "Study Cohort",
                  "prediction": "Study Cohort"
                },
                "Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": 0.02
                },
                "Allele Of Frequency In Cases": {
                  "ground_truth": null,
                  "prediction": "G (TPMT)"
                },
                "Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Allele Of Frequency In Controls": {
                  "ground_truth": null,
                  "prediction": null
                },
                "P Value": {
                  "ground_truth": null,
                  "prediction": ""
                },
                "Ratio Stat Type": {
                  "ground_truth": null,
                  "prediction": "Unknown"
                },
                "Ratio Stat": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Start": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Confidence Interval Stop": {
                  "ground_truth": null,
                  "prediction": null
                },
                "Biogeographical Groups": {
                  "ground_truth": "Latino",
                  "prediction": "Colombian population"
                }
              },
              "dependency_issues": [],
              "penalty_info": {
                "total_penalty": 0.0,
                "penalized_fields": {},
                "issues_by_field": {}
              }
            }
          ],
          "aligned_variants": [
            "cohort:Pediatric ALL",
            "cohort:Pediatric ALL",
            "cohort:Pediatric ALL"
          ],
          "unmatched_ground_truth": [],
          "unmatched_predictions": []
        }
      },
      "overall_score": 0.47532008253743774,
      "num_benchmarks": 4
    }
  ],
  "per_benchmark_stats": {
    "drug_annotations": {
      "mean_score": 0.10384266623377539,
      "min_score": 0.0,
      "max_score": 0.8857231547957972,
      "num_files": 32
    },
    "phenotype_annotations": {
      "mean_score": 0.346022358273965,
      "min_score": 0.0,
      "max_score": 0.9582130381216606,
      "num_files": 32
    },
    "functional_analysis": {
      "mean_score": 0.0009725797980239516,
      "min_score": 0.0,
      "max_score": 0.03112255353676645,
      "num_files": 32
    },
    "study_parameters": {
      "mean_score": 0.5465713986326697,
      "min_score": 0.0,
      "max_score": 0.8610508441925049,
      "num_files": 32
    }
  }
}